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Abstract 
CYLD cutaneous syndrome is a rare, autosomal dominant inherited disease in which an 
individual is predisposed to developing multiple cutaneous tumours; namely 
cylindromas, spiradenomas and trichoepitheliomas, due to germline mutations in the 
tumour suppressor gene CYLD. However at present there are no curative treatments 
other than repetitive surgery to control tumour burden. Therefore, an overarching 
theme of this thesis was to identify potential therapeutic targets that could possibly 
translate into treatment strategies in the clinic.  
 
The first strategic target, c-MYB, was explored, as overexpression of c-MYB was 
previously shown in sporadic cylindromas due to the presence of the fusion protein 
MYB-NFIB. It was demonstrated that inherited cylindromas did not express the MYB-
NFIB fusion protein. However, using immunohistochemistry c-MYB was shown to be 
overexpressed in inherited tumours and that gene silencing of MYB caused a reduction 
in cell viability. A novel finding, transcriptomic and protein analysis also revealed that 
keratinocytes expressed the alternate MYB 9B isoform.  
 
A second strategic target, Trk, was explored using RNA-seq of CYLD defective tumours. 
Exploration of Trk signalling in these tumour cells found that the truncated TrkB.T1 
isoform of the TrkB receptor is overexpressed in the tumours, alongside the receptors 
cognate ligand BDNF. Overexpression of TrkB.T1 in the HaCaT, keratinocyte cell line, 
indicated that TrkB.T1 increased cell survival. BDNF stimulation of TrkB.T1 
overexpressing cells caused Stat3 phosphorylation, and in primary cylindroma tumour 
cells BDNF stimulation increased the nuclear localisation of Stat3.  
 
Finally, a three-dimensional spheroid cell culture method was established and 
characterised using immunofluorescence, as 3D in vitro models better reflect the in 
vivo environment. The cultures were found to have an expression pattern similar to 
their in vivo counterparts and were shown to be sensitive to inhibitory Stat3 targeting, 
supporting the translational relevance of this work in the hope of bringing targeted 
therapies for CYLD cutaneous syndrome to the clinic. 
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1 Chapter 1: General Introduction 
1.1 Inheritance of CYLD-defective tumours: an overview 
1.1.1 CYLD-defective tumour syndromes 
Familial cylindromatosis (FC; OMIM 313270) is a rare autosomal dominant inherited 
skin tumour syndrome. First described in 1842 by Henry Ancell (Ancell, 1842), affected 
individuals are predisposed to developing multiple benign tumours, namely 
cylindromas, in the head and neck region (Figure 1-1) (Rajan, Langtry, et al., 2009). Due 
to the development of the tumours at hair bearing sites of the body, it is thought that 
these neoplasms are of hair follicle origin (Massoumi, Podda, et al., 2006; Sellheyer, 
2015), although histogenesis of the tumours is an ongoing debate. In 2000, germline 
mutations in the tumour-suppressor gene, CYLD, were found to be the underlying 
cause of the condition in humans (Bignell et al., 2000) (discussed in more detail in 
section 1.2) 
 
Figure 1-1: Clinical presentation of cylindroma.  
An image of the first patient reported in the medical literature with cylindromas by Henry Ancell in 
1842; a 52-year-old female with a strong family history of cutaneous tumour development (Image on 
left). Alongside a present day image of a female patient from a North East family, who presented with 
multiple cylindromas (Image on right). 
 
Cylindromas are also found in two other inheritable skin tumour predisposition 
syndromes, multiple familial trichoepithelioma (MFT; OMIM 601606) and Brooke-
Spiegler syndrome (BSS; OMIM 605041). Whilst FC is characterized by the presentation 
of multiple cylindromas, lower numbers of cylindroma coexist in patients affected by 
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MFT, with predominantly small, benign facial tumours called trichoepithelioma; hair 
follicle tumours, that are aggregates of basaloid cells and present as skin-coloured 
papules mainly on the perinasal skin (Alsaad et al., 2007; Navarrete-Dechent et al., 
2016; Salhi et al., 2004). Meanwhile BSS is considered an overlap between the two 
conditions, characterized by the development of multiple skin appendage tumours, 
including cylindromas, trichoepitheliomas and spiradenomas; tumours that are related 
to cylindromas that present as blue-black nodules mainly on the trunk and limbs 
(Obaidat et al., 2007; Uede et al., 2004). Patients may also present with tumours that 
have features of both cylindroma and spiradenoma that are called 
spiradenocylindroma, accordingly (Michal et al., 1999; Rajan, Burn, et al., 2011). The 
other tumour variants arising in these conditions have also been found to be 
manifestations of mutated CYLD (Table 1-1), and have recently been reviewed by 
(Rajan and Ashworth, 2015; Verhoeft et al., 2016). In addition, milia are another 
phenotypic variant feature that may arise in carriers of CYLD mutations. These are 
benign, white, small skin cysts, which are seen on the face of affected individuals and 
can be the only presenting feature. However unlike cylindroma, milia are reported in 
other genetic disorders (Rutter and Judge, 2009). Therefore in the absence of other 
factors, they are not a determining indicator of germline CYLD mutations (Rajan and 
Ashworth, 2015).  
 
CYLD cutaneous syndrome has been proposed as an encompassing term for the 
aforementioned syndromes (Rajan, Langtry, et al., 2009). All three diseases are unified 
at the genetic level with the inheritance of germline CYLD mutations, and as such the 
diseases are considered to be clinical manifestations of an overlapping phenotypic 
spectrum of a single disease entity (Lee D. A. et al., 2005; Oranje et al., 2008; Rajan, 
Langtry, et al., 2009; Welch et al., 1968). Indeed based on the current understanding of 
CYLD mutations genotype-phenotype correlations have been difficult to establish 
(Grossmann et al., 2013; Nagy et al., 2015), as all three clinical phenotypes, FC, MFT or 
BSS can develop in affected individuals from within the same family, despite sharing 
the same mutation (Rajan, Langtry, et al., 2009). Tumours of the skin appendages, such 
as cylindromas can also occur sporadically, although they tend to appear as solitary 
tumours in contrast to the multiple lesions that are affiliated with the aforementioned 
hereditary conditions. 
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Table 1-1: Tumour presentation associated with CYLD cutaneous syndrome 
1.1.2 Clinical presentation of CYLD-defective tumours 
The average age of onset for CYLD cutatenous syndrome in patients with germline 
CYLD mutations is 16 years of age (Rajan, Langtry, et al., 2009). Although there are 
reports of the first tumours developing as early as 5 years of age (Almeida et al., 2008) 
and as late as 42 years of age (Martins and Bartolo, 2000). Sporadic, non-inherited 
neoplasms generally develop later in life (Gerretsen et al., 1993). In inherited 
conditions penetrance is estimated to be near 100% (Gerretsen et al., 1995), whilst a 
female preponderance has been described in individuals with CYLD mutations (Sicinska 
et al., 2007; Szepietowski et al., 2001; van Balkom and Hennekam, 1994), analysis of 
large familial pedigrees supports equal penetrance in both males and females 
(Gerretsen et al., 1995; Rajan, Langtry, et al., 2009). However in the study by Rajan et 
al. it was shown that in a cohort of 26 affected individuals with germline CYLD 
mutations, of whom 14 were women and 12 were men, tumour burden of the scalp 
warranted complete scalp excision in 4 females compared to 1 male. This suggests that 
there may be increased expressivity of CYLD mutations presenting as a more severe 
phenotype in females (Rajan and Ashworth, 2015; Rajan, Langtry, et al., 2009). A 
number of observations including: the development of tumours occurring just after 
puberty, when there are significant hormonal changes within the body; the increased 
occurrence of the tumours at hair bearing sites of the body that are susceptible sites 
for hormonal stimulation (Figure 1-2), such as the pubic region and areas of the scalp 
predisposed to androgenic alopecia; report of a women’s condition becoming worse 
during pregnancy and after starting hormone replacement therapy, are all indicators 
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that hormones may influence the underlying mechanisms for tumourigenesis in these 
inherited conditions, and possibly presentation in males and females (Rajan, Langtry, 
et al., 2009). Indeed, although the data is limited due to the small sample numbers, 
immunohistochemical analyses of the oestrogen and progesterone receptors showed 
that in 13 cases of cylindroma, expression was negative (Albores-Saavedra et al., 
2005). Whilst another group reported positive staining of oestrogen receptor- in 2 
out of 3 cases of spiradenoma, the progesterone receptor in 3 out of 3 cases of 
spiradenoma, and androgen receptor positivity in 1 case of spiradenoma (Kariya et al., 
2005). With the present understanding of these rare syndromes being incomplete, 
particularly as to how a loss of CYLD initiates tumour formation, this is an area that 
may require more attention in the future.  
Figure 1-2: Tumour distribution maps.  
Pictograms displaying the location of tumours in 14 female and 12 male patients, illustrating the 
predominance of tumours on the scalp but also at other locations of the body such as the torso and 
groin (Images from (Rajan, Trainer, et al., 2009). 
The distribution of the tumours is predominantly in the head and neck region, mainly 
the scalp for cylindroma and spiradenoma, and on the face for trichoepitheliomas. 
However the tumours also present on the trunk of the body and in the genital area in 
significant numbers (Figure 1-2) (Rajan, Langtry, et al., 2009). With the high incidence 
of tumour formation on the face and scalp others had postulated that ultraviolet (UV) 
radiation could be responsible for tumour initiation (Massoumi, Chmielarska, et al., 
2006; Massoumi and Paus, 2007), due to the DNA damage caused by UV that is 
recognized in other forms of skin cancer (Kim Y. and He, 2014; Narayanan et al., 2010). 
However the frequency with which tumours also arise on sites that are either less 
exposed to ultraviolet rays from the sun such as the torso, or protected skin such as 
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the pubic and perineal region, indicate that mechanisms independent of UV radiation 
are responsible for tumour formation, but that is not to say that it may not have a 
contributory role to malignant transformation of exposed tumours. 
Cylindroma tumours are benign slow growing appendages, but become more frequent 
in number and increase in size over a patient’s lifetime. The tumours appear as pink 
nodules, with blood vessels visible on the tumour surface. They are generally painless 
and can grow to a considerable size, measuring up to 3-5cm in diameter (Dubois et al., 
2017). When a significant number of cylindromas present on the scalp, the tumours 
can coalesce into a confluent mass, hence the historical term for the condition of 
Turban tumour (Evans, 1954). On the other hand spiradenomas are painful nodular 
tumours, which can also be deep-seated within the dermis and are generally 
encapsulated. They can grow to be as large as 5-10cm in their diameter and can 
require a substantial blood supply. In comparison trichoepitheliomas are smaller 
lesions, usually no more than 2-5mm across (images of the described tumours shown 
in Figure 1-3) (Dubois et al., 2017). Cylindromas can develop blue foci within them and 
become painful, which may represent cystic degeneration and associated formation of 
spiradenoma within the same tumour (Rajan and Ashworth, 2015).  
Despite the typically benign nature of CYLD-defective tumours, these skin appendage 
tumours can have a significant impact on the quality of life of patients affected by BSS, 
FC or MFT, both physically and psychologically. Aside from being a highly disfiguring 
condition, with additional scarring from repetitive surgeries, leading to reports of low 
mood and depression (Parren et al., 2014; van Balkom and Hennekam, 1994), CYLD-
defective tumours that develop at pressure points such as on the back are susceptible 
to compression, which is not only painful but can lead to pressure necrosis and 
consequently ulceration, bleeding and chronic discharge. In addition painful tumours 
in the pubic and perineal regions can cause sexual dysfunction whilst growth of the 
tumours on the external ear can occlude the auditory canal and result in deafness 
(Dubois et al., 2017; Rajan, Langtry, et al., 2009). Furthermore aside from the skin, 
there are rare incidences of patients with BSS developing cylindroma of the breast 
(Mahmoud et al., 2009) and lung (Vernon et al., 1988), in addition to an association 
between patients with BSS and the development of salivary gland tumours in a small 
proportion of patients (Jungehulsing et al., 1999) 
  7
Figure 1-3: Histology of CYLD-defective tumours. 
Examples of the three types of CYLD-defective tumours that arise within CYLD cutaneous syndrome, as 
they present in patients and H&E staining showing each of the tumours pathology. (Top) a cylindroma is 
shown with arborizing blood vessels, and the typical island structure of basaloid cells. (Middle) a 
spiradenoma that is characteristically blue-purple colour underneath the skin, and disorganised sheets 
of basophilic cells. (Bottom) trichoepitheliomas arising as skin coloured papules and displaying islands of 
basaloid cells that contain abortive hair cysts. (Images from (Dubois et al., 2017) 
1.1.3 Histology of CYLD-defective tumours 
The term cylindroma was determined by the histological appearance of the tumours; 
well-defined nests of basaloid cells that resemble cylinders when cut in cross-section 
(Figure 1-3) (Rajan and Ashworth, 2015). These tumour cell islands are arranged in a 
jigsaw pattern, and are surrounded by a thick, eosinophilic, hyaline membrane, 
considered a basement membrane-like zone as it consists of extracellular matrix 
proteins such as Collagens IV and VII, and Laminin 5 (Bruckner-Tuderman et al., 1991; 
Tunggal et al., 2002). The tumour islands contain two groups of cells: peripheral 
palisading basophilic cells, with small dark nuclei, representing relatively 
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undifferentiated epithelial tumour cells, whilst centrally the cells are larger and paler 
resembling ductal or secretory cells (Massoumi and Paus, 2007). In between the 
tumour islands thin bands of stroma are occasionally seen. In comparison to 
cylindromas, spiradenomas appear more disorganised in their structure (Figure 1-3), 
and are instead comprised of a dense mass of sheets or cords of epithelial cells, with 
obvious vessel and tubular structures throughout, and globules of basement 
membrane material present within the neoplastic nodules (Obaidat et al., 2007). A 
main difference between the tumour types is the association of a lymphocytic infiltrate 
with spiradenomas (Michal et al., 1999). 
 
Figure 1-4: An overview of the hair follicle. 
The hair follicle is considered a mini organ within the skin. It consists of the hair follicle itself, the 
sebaceous gland (for sebum production) and apocrine gland (for scent at particular body sites (not 
shown). The eccrine gland (sweat gland in image) is distinct from the hair follicle unit and is required for 
thermoregulation. The outer root sheath of the follicle is contiguous with the basal epidermal layer, 
which separates the epidermis and dermis compartments of the skin. The bulge region is where the 
epidermal stem cells reside, which migrate along the outer root sheath to the dermal papilla and give 
rise to transit-amplifying matrix cells that terminally dfferntiate to generate the different cell types of 
the hair follicle. Thus maintaining the hair follicle through its cyclical growth phases.  At the bottom of 
the hair follicle is the hair bulb, which consists of the dermal papilla where interactions between the 
mesenchymal cells and surrounding epithelial matrix cells leads to new hair formation. Adapted from 
(Fuchs and Raghavan, 2002). 
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1.1.4 Cell of origin of CYLD-defective tumours 
There has been much debate over the cell of origin of CYLD-defective tumours, and 
whether the tumours are derived from the follicular, apocrine or eccrine lineages. The 
appendages of the skin (Figure 1-4), which arise from progenitor cells committed to 
such differentiation lineages, such as the hair follicles, sebaceous glands, and sweat 
glands, each contain epidermal stem cells that replenish and maintain these 
compartments, yet these stem cells have been shown to be functionally 
interconvertible (Arwert et al., 2012; Blanpain and Fuchs, 2006). These stem cells 
therefore are prime candidates in which early tumourigenic events may take place, 
such as the loss of CYLD, and consequently lead to tumour development due to 
aberrations in cellular differentiation. 
 
 Both apocrine and eccrine patterns of differentiation in cylindroma and spiradenoma 
have been found (Cotton and Braye, 1984; Crain and Helwig, 1961; Michal, 1996; 
Penneys and Kaiser, 1993; van der Putte, 1995). The striking histological similarity 
between cylindromas and salivary gland cancers such as adenoid cystic carcinoma 
(ACC) (Albores-Saavedra et al., 2005; Crain and Helwig, 1961; Fusco et al., 2016), 
alongside the reported development of salivary gland tumours in BSS patients 
(Headington et al., 1977; Jungehulsing et al., 1999) had led to earlier speculation that 
the tumours were eccrine derivatives. However in more recent years, further 
investigation of CYLD-defective tumours with immunohistochemical analyses of 
cylindromas and spiradenomas, has led Massoumi et al. (Massoumi, Podda, et al., 
2006) and Sellheyer (Sellheyer, 2015) to argue that stem cells of the hair follicle are the 
more likely tumour cell of origin. This is evidenced by the fact that hair-specific 
differentiation markers such as hair Keratins 17, 71 and 75 are expressed in cylindroma 
(Massoumi, Podda, et al., 2006), alongside expression of the hair stem cell marker 
CD200 (Sellheyer, 2015) in cylindromas and spiradenomas, all of which are absent in 
the eccrine glands. Furthermore the multipotent nature of hair follicle stem cells 
(Ohyama, 2007), and the fact that the tumours do not present on the palms or soles of 
the feet, areas of the skin that are recognized to have the highest density of eccrine 
(sweat) glands but are devoid of pilo-sebaceous units (including the hair follicle and 
sebaceous gland) and apocrine glands (Massoumi, Podda, et al., 2006), alongside the 
reported hair defects in a conditional mouse model, with epidermis-targeted 
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expression of catalytically deficient CYLD expression due to K14-Cre-mediated deletion 
of exon 9 (Jin Y. J. et al., 2016), all together provide convincing evidence in support of 
the hair follicle hypothesis. 
1.1.5 Malignant transformation of CYLD-defective tumours 
The majority of CYLD-defective tumours are benign, however there are rare incidences 
(< 50) reported in the literature of cylindroma and spiradenoma undergoing malignant 
transformation to cylindrocarcinoma and spiradenocarcinoma respectively (Bansal et 
al., 2012; Borik et al., 2015; Durani et al., 2001; Gerretsen et al., 1993; Kazakov, Zelger, 
et al., 2009; Kostler et al., 2005). There is a greater tendency for malignant 
transformation in the inherited tumour conditions, like BSS, compared to sporadic 
neoplasms, probably due to the increased number of tumours present (Gerretsen et 
al., 1993). As would be expected malignancy occurs in more elderly patients with an 
age range of 43 -96 years (Durani et al., 2001; Kazakov, Zelger, et al., 2009). Cutaneous 
clinical features that are associated with transformation are ulceration, bleeding, rapid 
growth and an increase in surface vascularity (Durani et al., 2001; Gerretsen et al., 
1993), although it should be acknowledged that these are also features that can be 
seen in benign tumours (Rajan and Ashworth, 2015). Histologically, malignant cells are 
distinct from the residual benign tumour often present within the same specimen 
(Gerretsen et al., 1993). Malignant cylindroma cells lose the defining histological 
characteristics of benign growths such as the jigsaw pattern of growth and hyaline 
sheaths, as well as having high mitotic counts and pleiomorphic cells (Gerretsen et al., 
1993; Kuklani et al., 2009). 
 
Malignant tumours of the scalp have been found to invade locally into the skull plate 
and the brain (Durani et al., 2001; Tripathy et al., 2015). Although local infiltration is 
reported in benign cases too (Serracino and Kleinschmidt-Demasters, 2013). Tumours 
may also metastasise to a variety of organs and tissues including the lungs, liver, 
thyroid, stomach and bone (Bansal et al., 2012; Kazakov, Zelger, et al., 2009; Kuklani et 
al., 2009). One of the largest reviews of malignant cylindromas by Gerretsen et al. 
showed that out of 24 malignant cases, 15 were cylindromas from individuals affected 
by BSS and 9 were sporadic lesions. Furthermore 9 of the 15 inherited cases 
metastasized, most commonly to the lymph nodes and liver, and as a direct result 
caused death in 6 of these patients, demonstrating the aggressive nature of the 
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malignancy (Gerretsen et al., 1993). 
 
Aside from cylindromas and spiradenomas, there have also been a handful of reports 
of malignant transformation of trichoepitheliomas into basal cell carcinomas (BCC) in 
both the inherited and sporadic settings (Kallam et al., 2016; Melly et al., 2012). As BCC 
is the most common form of cancer the occurrence of BCC may be coincidental, as was 
evidenced in one of the cases in which a BCC and trichoepithelioma (TE) were found to 
be separate lesions on the face (Kallam et al., 2016). Meanwhile another rare event in 
these normally benign tumours are reports of a trichoepithelioma variant called 
trichoblastoma also undergoing malignant transformation into a trichoblastic 
carcinoma (Lee K. H. et al., 2008; Schulz et al., 2005). 
1.1.6 Genetics of CYLD-defective tumours 
Initial genetic linkage analysis studies in two families with BSS, which are based on 
tracking the inheritance pattern of specific genetic markers that are matched between 
family members, led to mapping of the locus for the susceptibility gene to 
chromosome 16q12-13 and revealed the likely loss of a tumour suppressor gene as the 
underlying cause for the rare condition (Biggs et al., 1996), with the locus further 
refined in 19 families by Takahashi et al. (Takahashi M. et al., 2000). Subsequently 
germline mutations in a gene encoding for an ubiquitin-specific protease were found in 
21 cylindromatosis families and somatic mutations found in 6 cylindromas, leading to 
the identification of the causative tumour-suppressor gene CYLD (cylindromatosis) 
(Bignell et al., 2000). Four years later the same gene was found to be responsible for 
multiple familial trichoepithelioma (Zhang X. J. et al., 2004).  
 Carriers of CYLD mutations are rare, with an occurrence rate of ~1:100,000, although 
the prevalence is difficult to estimate due to such variation in the phenotypic 
manifestation of the mutations of CYLD (Rajan and Ashworth, 2015). In patients who 
have inherited germline CYLD mutations, tumour formation occurs as a result of a loss 
of heterozygosity (LOH) of the remaining wild-type allele, which is seen in 70% of 
tumours (Bignell et al., 2000), whilst the others have acquired somatic mutations 
(Grossmann et al., 2013). This genetic pattern for the development of these tumours 
follows the principles of Knudson’s two hit hypothesis model for cancer initiation 
(Knudson, 1971), whereby a cell requires a mutation in each allele of a tumour 
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suppressive gene. In inherited conditions a mutated copy of the gene is already 
present in the cells, and the second copy can become mutated or lost through somatic 
events causing a cell to become neoplastic. In BSS, FC and MFT this leads to loss of the 
tumour-suppressor gene CYLD.  
Mutations in the CYLD gene have been identified in patients with BSS, FC and MFT, 
with around 108 germline mutations reported to date (Fujii et al., 2017; Grossmann et 
al., 2013; Verhoeft et al., 2016). There is bias in the location of CYLD mutations, the 
vast majority (99%) of germline mutations having been found in the C terminal two-
thirds of the gene, encompassing exons 9-20, as shown in Figure 1-5 (Nagy et al., 
2015). This includes the catalytic domain of the deubiquitinase protein encoded for by 
CYLD (Blake and Toro, 2009). A mutation has however been reported in exon 5, near 
the start of the coding region of the gene (Nasti et al., 2009). Indeed several hotspot 
mutation sites that have been identified in CYLD: 1112C>A (S371), 2272C>T (R758) and 
2806C>T (R936), which correspond to exons 9, 17 and 20, respectively, and are the 
most frequently reported having been found in 14, 10 and 13 families, respectively 
(Verhoeft et al., 2016). The mutations of CYLD are mainly deleterious consisting of 
frameshift (44%), nonsense (25%), splice site (11%) and missense (11%) mutations, 
with small numbers of germline deletions also occurring (Nagy et al., 2015; Verhoeft et 
al., 2016). The collation of known germline CYLD mutations in a bid to evaluate 
genotype-phenotype correlations in 2015 by Nagy et al. demonstrated that nonsense 
mutations are associated with the most phenotypic diversity, meanwhile missense 
mutations have been associated with the least diversity, as 73% of mutations are 
found only in patients affected by MFT (Nagy et al., 2015).  
The majority of mutations are predicted to encode premature termination codons, 
which consequently result in a truncated protein product and loss of the catalytic 
activity of CYLD (Blake and Toro, 2009). There are incidences in which patients affected 
by BSS and MFT were found to lack mutation of CYLD (Grossmann et al., 2013). This 
may be a reflection of the methods used such as direct sequencing in specific regions, 
which would have meant that some alterations of CYLD would be undetectable. There 
may be rare intronic variants that may effect splicing of CYLD (Kazakov, Thoma-
Uszynski, et al., 2009) or large rearrangements of CYLD including large deletions 
(Vanecek et al., 2014), which may explain an apparent absence of causal mutation for 
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the presented disease in these patients. 
Aside from undetermined CYLD mutations, it may also be that other unidentified 
genetic events may have a role to play in how the condition manifests. This is 
exemplified when a patient’s ancestry is taken into account. Whilst CYLD mutations 
have been described in European, African and Asian populations, there are 
unaccounted for differences in disease severity and phenotypes despite commonality 
in the genetic loss of CYLD. For example the confluent growth of tumours on the scalp 
in those affected by familial cylindromatosis is almost exclusively reported in patients 
of white European origin, meanwhile patients of African or Asian origin suffer a severe 
facial multiple trichoepithelioma phenotype which infrequently affects the scalp; this 
phenotype is more uncommon in white European patients (Rajan and Ashworth, 
2015). Likewise even in those that share the same recurrent mutation there can be a 
vast difference in the severity of the phenotype as demonstrated in two European 
families, where a Romanian pedigree had large tumours compared to a few 
trichoepitheliomas in an unrelated English pedigree (Nagy et al., 2013). This suggests 
that there may also be unknown population specific modifier genes that produce a 
certain phenotype. 
Despite at present not being able to predict a clinical phenotype or disease severity 
from the type of CYLD mutation, there is not yet a single study in which the whole of 
the CYLD gene has been sequenced in the tumours. Therefore as we embark on the 
next-generation sequencing era it is thought that previously undetermined alterations 
to CYLD and other potential genetic changes associated with this disease can be 
detected, which can be used to inform treatment strategies, genetic counselling and 
management of this collection of cutaneous tumour conditions.  
1.1.7 Treatment of CYLD-defective tumours 
At present surgical excision of the tumours is the mainstay treatment strategy to 
control tumour burden; in some cases this can necessitate whole scalp removal (Rajan, 
Trainer, et al., 2009). Some of the surgical techniques include primary excision, 
curettage, and laser resurfacing (Rajan, Trainer, et al., 2009). This means in a condition 
in which multiple tumours are developing throughout an affected individual’s lifetime, 
repetitive surgical procedures are required, which only adds to the morbidity of the 
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disease. Furthermore recurrence rates after excision are around 35% (Crain and 
Helwig, 1961). Therefore alternative non-surgical interventions are warranted; gaining 
further insight into the biology of the tumours and understanding the function of CYLD 
may yield attractive therapeutic targets. To this end a clinical trial with a topical 
treatment of salicylic acid was undertaken (Oosterkamp et al., 2006). As an inhibitor of 
NF-κB activation, by prevention of IκB degradation, it aimed to target the increased 
activity of NF-κB that is caused by the loss of CYLD function (see section 1.2.3.1). 
However the trial showed only modest results with complete remission seen in only 2 
of 12 cylindromas (Oosterkamp et al., 2006). A case report in which a combination of 
oral aspirin and Adalimumab (a TNF- neutralizing antibody) were used in the 
treatment of trichoepithelioma, which additionally blocked TNF activation of NF-κB, 
showed a gradual improvement of the condition (Fisher and Geronemus, 2006). 
However the patient also had concurrent laser resurfacing so it was difficult to 
conclude the extent of the effectiveness of the treatment. More recently tropomyosin 
receptor kinase (Trk) signalling has been identified as a therapeutic target. Evidenced 
by transcriptomic data and the oncogenic dependency of primary cylindroma cultures 
on Trk (Rajan, Elliott, et al., 2011). Therefore with further understanding of perturbed 
signalling pathways alternative treatment options may be found. 
1.2 CYLD 
The human CYLD gene is approximately 56kb in length and is composed of 20 exons, 
the first 3 of which are non-coding. The remaining 17 exons encode for the protein 
product CYLD, a deubiquitinating enzyme, which is 956 (amino acids) in length 
(Bignell et al., 2000). Alternative splicing occurs in non-coding exon 3, and in the small, 
nine-nucleotide, exon 7, which produces a shorter isoform of 953. This splice 
variant, like the full-length transcript, is ubiquitously expressed yet little is known 
about its function (Bignell et al., 2000). However knock-in mouse studies in which the 
short CYLDex7/8 variant, which lacks exons 7 and 8, is selectively expressed, appear to 
suggest that this splice form has regulatory roles in immune responses (Hovelmeyer et 
al., 2007; Srokowski et al., 2009). CYLD is an evolutionarily conserved gene with 
homologues identified in common model organisms such as Drosophila melanogaster 
and Caenorhabditis elegans (Hadweh et al., 2018). CYLD expressed in many tissues, 
including the fetal brain, testis and skeletal muscle, with lower levels observed in the 
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heart, liver, lung, kidney, spleen and ovary (Bignell et al., 2000). Within the skin, the 
highest level of CYLD expression is found in the inner root sheath of the hair follicle 
(Massoumi, Podda, et al., 2006), and it has been shown in mice to be elevated in the 
catagen phase of the hair cycle, in which there is proliferation cessation (Moriwaki et 
al., 2007). Whilst this reinforces the idea that hair follicle stem cells are the cells of 
origin of cylindroma (Massoumi, Podda, et al., 2006), it should be noted that eccrine 
sweat glands also express CYLD, which again brings into debate the origin of the 
tumours (Zuo et al., 2007). The ubiquitous expression of CYLD does bring into question 
why the inherited conditions manifest so specifically in the skin and implies other 
tissue specific events are responsible for tumour formation. 
 
Figure 1-5: An overview of the CYLD gene and protein structure.  
The exons of the CYLD gene are shown (numbered 4-20), starting at exon 4, as this is the exon from 
which translation is initiated. The coloured sticks represent the known mutations of CYLD, with a key for 
the type of mutation shown above (top diagram). The domains of the protein structure are shown 
beneath the exons by which they are encoded. The catalytic domain of CYLD is sub divided into the 
regions labelled. Together these subdomains allow for disruption of ubiquitin bonds and give specificity 
to the types of ubiquitin attachments the protein acts upon. The B-box domain is a unique feature of 
CYLD. 
1.2.1 The structure of CYLD 
The CYLD protein has three main functional motifs (Figure 1-5), these are comprised of 
3 cytoskeleton-associated protein glycine-rich (CAP-Gly) domains at the N terminus, a 
proline rich region that is thought to constitute a Src homology 3 (SH3)-binding 
domain, and a catalytic ubiquitin-specific protease (USP) domain which mediates 
CYLD’s deubiquitinating function (Bignell et al., 2000; Komander et al., 2008). The CAP-
Gly domains are important in the regulation of microtubule dynamics and function, 
with CYLD having been shown to interact directly with microtubules and tubulin, 
implying functions outside of the catalytic domain (Gao et al., 2008; Yang and Zhou, 
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Gly  USP domain 
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5’ 3’ 
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2016). The first CAP-Gly domain in particular was shown to be necessary for cell 
migration (Gao et al., 2008). There are four subdomains that make up the USP of CYLD: 
Thumb, Palm, Fingers, and an important additional insert within the palm domain, the 
zinc-finger-like B box domain (Komander et al., 2008). Highly conserved within the USP 
family of deubiquitinating enzymes, the Thumb and Palm regions are responsible for 
engaging and attacking the bond between ubiquitin moieties and lysine residues, due 
to the palm incorporating the catalytic triad of Cysteine 601, Histidine 871 and Aspartic 
acid 889 (Komander et al., 2008). Whilst for some defined USP motifs homology is 
conserved, the determination of the structure of the USP domain revealed unique 
properties of CYLD within this region, which are highly divergent from other USP family 
members. The most telling being that the Fingers subdomain is much smaller in CYLD 
compared to other USPs, together with secondary structural alterations near to the 
catalytic site underpinning CYLD’s specificity for Lysine (K) 63-linked ubiquitin chains 
over K48-linked chains (Komander et al., 2008). Alongside this the B-box domain was 
shown to be necessary for sub cellular localization of CYLD to the cytoplasm 
(Komander et al., 2008; Xie et al., 2017). 
1.2.2 The function of CYLD 
As demonstrated by the structure of CYLD, the function of this protein is as a 
deubiquitinating enzyme (DUB), intended to hydrolyse and reverse the attachment of 
K63-linked and Met-1 (linear) -linked polyubiquitin moieties from a variety of 
substrates (Komander et al., 2009; Sato Y. et al., 2015). Despite this it is unclear 
whether CYLD is exclusively specific for these ubiquitin linkages, as CYLD has been 
reported to have shown activity towards K48-linked ubiquitn chains also, suggesting 
that specificity may be dependent on the target protein (Reiley W. W. et al., 2006). The 
post-translational modification of ubiquitylation is an important regulatory mechanism 
that influences many cellular processes such as: DNA repair, cell cycle, signal 
transduction, endocytosis of membrane proteins, and protein degradation (Haglund 
and Dikic, 2005). Ubiquitins (Ubs) are small proteins that can attach to substrates as 
single molecules or as polymeric chains that are linked through either of the 7 Lysine 
residues (K6, K11, K27, K29, K33, K48 and K63) or Met1. This ubiquitin code can affect 
the stability and protein-protein interactions of a target substrate depending on the 
number and the residue by which ubiquitin moieties are linked (Ikeda and Dikic, 2008; 
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Komander and Rape, 2012). For example the attachment of K48 linked ubiquitin chains 
are thought to highlight a protein to the proteasome for degradation (Clague and 
Urbe, 2010), on the other hand K63 linked ubiquitin chains are thought to be involved 
in other proteasome-independent functions such as, receptor endocytosis, DNA repair 
and signal transduction (Yau and Rape, 2016). Increasingly proteins tagged with K63 
linked ubiquitin are being recognised to have a role in cancer (Dwane et al., 2017), 
meanwhile linear ubiquitin chains are involved in the regulation of immune and 
apoptotic signalling (Rittinger and Ikeda, 2017). 
 
Figure 1-6: The cycle of ubiquitylation and deubiquitination. 
The process of ubiqutiylation is a reversible process that involves the attachment of ubiquitin moieties 
to a substrate. Depending on the composition and assembly of the ubiquitin molecules, either as single 
entities or in polyubiquitin chains, different fates are determined for the substrate, such as degradation 
or cell signalling interactions. The process requires the activity of three enzymes: E1, the activating 
enzyme, which activates the c-terminus of ubiquitin for nucleophilic attack. E2, the conjugating enzyme, 
that carries activated ubiquitin to the substrate, where it is then transferred by E3, the ligase enzyme, to 
the lysine residue to which it will attach. The E3 ligases displaying specificity in their substrate 
interactions. Deubiquitinating enzymes (DUB) then cleave the bond between ubiquitin moieties and 
substrates to terminate the ubiquitin signal. 
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The conjugation of ubiquitin to its specific substrate is a three-step enzymatic cascade 
that starts with C-terminal activation of the ubiquitin protein via an ubiquitin-
activating enzyme (E1), which then transfers the ubiquitin to an ubiquitin-conjugating 
enzyme (E2), which in turn interacts with an ubiquitin-protein ligase (E3) to bring the 
substrate and ubiquitin moiety together (Figure 1-6) (Pickart and Eddins, 2004). 
Ubiquitination is a reversible process, and CYLD has been shown to regulate various 
signalling pathways via the cleavage of K63 linked polyubiquitin chains (as will be 
discussed in section 1.2.3). The molecular studies of CYLD to date have shown that 
CYLD is a structurally unique DUB, and with the majority of mutations in CYLD found in 
the catalytic USP domain abolishing DUB activity, it is clear that the loss of this specific 
deubiquitinating function of CYLD is important in the initiation of tumourigenesis. 
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Figure 1-7: Signalling pathways associated with CYLD 
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Figure 1-7: Signalling pathways associated with CYLD (from previous page). 
CYLD has been found to negatively regulate the NF- κB, Wnt, JNK and Notch signalling pathways. CYLD 
prevents downstream signalling and activation of target genes via deubiquitylation of target substrates. 
In the Notch pathway in a role independent of its catalytic function CYLD stabilises MIB2 to attenuate 
signalling. Blue arrows indicate nuclear translocation of the substrate. Figure adapted from (Verhoeft et 
al., 2016). 
1.2.3 CYLD regulation of cell signalling 
In efforts to understand the pathogenesis of CYLD-defective tumours, CYLD has been 
found to be involved in the negative regulation of a number of key signalling pathways 
(Figure 1-7), as detailed below. In addition Trk signalling is discussed in results chapter 
3. As many of these pathways have already been defined to have a role in many cancer 
types, these findings reinforced the proteins role as a tumour suppressor, as reviewed 
by (Blake and Toro, 2009; Verhoeft et al., 2016). However despite increased 
knowledge of the mutation status of CYLD and disease linkage, understanding of the 
molecular mechanisms that promote the formation of multiple tumours still remains 
incomplete. 
1.2.3.1 Regulation of NF-B signalling by CYLD 
NF-κB signalling was indicated as a target of CYLD when it was discovered that a loss of 
CYLD resulted in the upregulation of NF-κB in an RNA interference screen of DUB 
enzymes (Brummelkamp et al., 2003). NF-κB is a family of transcription factors, 
consisting of five members: p65/RelA, RelB, c-Rel, p52/p100 and p50/p105, whose 
activation results in the induction of a variety of inflammatory, developmental, cell 
survival and proliferation genes (Shih et al., 2011). The oncogenic potential of this 
signalling pathway is therefore well recognised, with aberrant activation of NF-κB seen 
as a ‘driver’ of oncogenesis in cancers such as diffuse large B-cell lymphoma (DLBCL), 
hepatocellular carcinoma (HCC) and prostate (Karin, 2009). NF-κB can be activated via 
a variety of stimuli, such as tumour-necrosis factor-α (TNF-α), interleukin-1 (IL-1), and 
lipopolysaccharide (LPS), through their corresponding receptors. These signals induce a 
rapid and reversible inflammatory or immune response through activation of the 
canonical pathway, which is dependent on NF-κB essential modulator (NEMO). In 
contrast stimuli such as CD40 and receptor activator for NF-κB (RANK), induce a slower 
and irreversible developmental response typically through the non-canonical pathway, 
which is instead dependent on NF-κB-inducing kinase (NIK) (Shih et al., 2011; Zhang Q. 
et al., 2017).  
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NF-κB is usually kept inactivated in the cytoplasm by inhibitor of NF-κB (IκB) proteins, 
preventing it from entering the nucleus and interacting with the DNA. When 
stimulated, downstream events such as recruitment and auto-ubiquitination of TNF 
receptor-associated factors (TRAFs), TRAF2 and TRAF6, activate the IκB kinase (IKK) 
complex causing phosphorylation of IκB, leading to its subsequent polyubiquitination 
and degradation by the proteasome. Alternatively in non-canonical signalling NIK 
activates an IKK complex, which in turn phosphorylates the IκB domain of p100 for 
proteolytic processing to p52. In both instances this then leaves NF-κB dimers free to 
translocate to the nucleus, where they can activate the transcription of a variety of 
target genes that facilitate cell proliferation and survival (Hoesel and Schmid, 2013; 
Karin et al., 2002). 
CYLD is a negative regulator of the NF-κB signalling pathway and has been found to 
interact with a number of proteins involved in mediating NF-κB activation (Sun S. C., 
2010). These include NEMO (IKKγ), a non-catalytic regulatory subunit of the IKK 
complex, and other upstream activating proteins such as TRAF2 and TRAF6 (Trompouki 
et al., 2003), receptor-interacting protein 1 (RIP1) (Wright et al., 2007), and 
transforming growth factor-β-Activated Kinase 1 (TAK1) (Reiley W. W. et al., 2007). 
Essentially due to the prevention of ubiquitylation by CYLD of K-63 linked polyubiquitin 
chains to substrates that are upstream of IKK, activation of NF-κB cannot occur due to 
a lack of activation of IKK, as the ubiquitin tags facilitate protein interactions and the 
assembly of signalling complexes to transmit the signal (Kovalenko et al., 2003). 
However the negative regulation of IKK by CYLD could be conditional upon the 
stimulating receptor, after it was found that the knockdown of CYLD in HEK293 cells 
and HeLa cells did not promote IKK activation in response to TNF-α stimulation, but IKK 
was activated in response to LPS and IL-1 (Reiley W. et al., 2004). CYLD also interacts 
and negatively regulates TAK1, via the cleavage of unanchored K-63 polyubiquitin 
chains by which TAK1 is activated, preventing subsequent phosphorylation of IKK-β, 
another component of the IKK complex, and inhibiting activation of IKK (Xia et al., 
2009). Also in co-operation with the E3 ubiquitin ligase Itch, the CYLD-Itch complex is 
capable of blocking TAK1 activation via the removal of K-63 ubiquitin by CYLD, and 
catalysing TAK1 degradation via the addition of K-48 ubiquitin by Itch, thus preventing 
the induction of proinflammatory cyotokines and regulating inflammation (Ahmed et 
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al., 2011). 
CYLD has also been implicated in the regulation of non-canonical NF-κB signalling. 
Studies using CYLD-/- mice found that CYLD was required to remove K63-linked 
ubiquitin chains from B- cell lymphoma protein-3 (Bcl-3) (Massoumi, Chmielarska, et 
al., 2006). Bcl-3 is a homolog of IκB, which is a transcriptional co-activator of NF-κB 
p50 and p52 homodimers (Lenardo and Siebenlist, 1994). In normal conditions 
regulatory deubiquitination by CYLD prevents Bcl-3 from entering the nucleus and 
interacting with NF-κB subunits, inhibiting transcription and attenuating NF-κB 
signalling. Conversely, CYLD-/- mice were highly susceptible to chemically or UV light-
induced skin tumours, that were caused by nuclear accumulation of Bcl-3 and 
subsequent CyclinD1 expression leading to increased proliferation (Massoumi, 
Chmielarska, et al., 2006). Further to this Bcl-3 promotion of cell proliferation and 
oncogenesis through activation of CyclinD1 transcription has been shown in a variety 
of tumour types for example breast (Cogswell et al., 2000), melanoma (Massoumi et 
al., 2009) and hepatocellular carcinoma (Tu et al., 2016).  
Therefore it has been postulated that the loss of CYLD regulation may modulate 
different effects by the different NF-κB family members. Indeed TNF- treatment, 
stimulating canonical NF-κB signalling, inhibited the proliferation of both CYLD+/+ and 
CYLD-/- keratinocytes, yet led to significantly higher activation of an NF-κB responsive 
luciferase reporter (Massoumi, Chmielarska, et al., 2006). Hence non-canonical p50-
Bcl-3 and p52-Bcl-3 activation may contribute to tumour formation through increased 
proliferation, whilst canonical TRAF2-dependent NF-κB signalling may instead be 
responsible for immune or inflammatory responses to promote cell survival and 
support tumourigenesis. Interestingly an immune lymphocytic infiltrate is observed in 
spiradenoma tumours (Michal et al., 1999). Although in this CYLD-/- mouse model the 
role of canonical NF-κB signalling requires further clarification, to explain how 
dysregulation of canonical NF-κB signalling contributes to CYLD-defective 
tumourigenesis. 
1.2.3.2 Regulation of MAPK/JNK signalling by CYLD 
CYLD is also a modulator of the c-Jun NH2-terminal Kinase (JNK) signalling pathway. A 
member of the mitogen-activated protein kinase (MAPK) family, the JNK pathway has 
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roles in regulating cell proliferation, survival, and apoptosis. As these processes are 
hallmarks of tumourigenesis, this pathway is constitutively active in many cancers 
(Bubici and Papa, 2014). In response to cytokine activation, a downstream signalling 
cascade through TRAF2 to MAPK kinases, such as MKK7 and MKK4 leads to the 
activation of JNK and subsequent downstream targets such as c-Jun and c-Fos (Davis R. 
J., 2000). MKK7 in particular is required for JNK activation by inflammatory cytokines 
(Tournier et al., 2001). CYLD through its modulation of TRAF2 ubiquitylation negatively 
regulates the activation of MKK7 and thus prevents phosphorylation of JNK, 
attenuating further signalling. It was shown however that this signalling inhibition by 
CYLD is receptor dependent. In CYLD knockdown studies in HEK293 cells, TNF-α 
stimulation showed a preferential activation of JNK instead of IKK. In addition CD40, 
LPS and IL-1 were also capable of more prominent JNK activation in contrast to IKK, 
suggesting JNK is a key downstream target of CYLD (Reiley W. et al., 2004). In addition 
a study by Millani de Marval et al. using a mouse model, in which catalytically deficient 
CYLD expression was driven by the Cytokeratin 14 (CK14) promoter, found that 
JNK/AP-1 (Activator protein-1) activity was essential for chemically induced tumour 
formation in mutant CYLD mice, and that CYLD could also suppress AP-1 activity 
through regulation of c-Jun and c-Fos ubiquitylation (Miliani de Marval et al., 2011).  
TAK1 also has a role in activation of JNK-p38MAPK signalling through phosphorylation 
and activation of MKK6 and is regulated by K63-ubiquitination (Wang C. et al., 2001). 
This pathway is crucial to T-cell development and innate immune responses (Liu H. H. 
et al., 2006). These functions, in addition to the role of TAK1 in the NF-κB pathway, 
may also be mechanisms by which de-regulation of these pathways can contribute to 
the pathogenesis of CYLD-defective tumours. 
1.2.3.3 Regulation of Wnt/-catenin signalling by CYLD 
The Wingless (Wnt)/-catenin pathway is another signalling cascade in which 
components are negatively regulated by CYLD. Wnt/-catenin signalling is critical in 
development and tissue homeostasis, especially for self-renewal of the skin and skin 
appendage formation (Lim X. and Nusse, 2013; Reddy et al., 2001), which again can be 
frequently dysregulated in cancer (as reviewed by (Zhan et al., 2017) and may be 
another way in which a loss of CYLD function can cause tumour formation. Particularly 
as hyperactive Wnt signalling, represented by nuclear -catenin, was demonstrated in 
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tumours from cylindromatosis patients (Tauriello et al., 2010). Dishevelled (Dvl) acts 
directly downstream of the Wnt receptor, Frizzled, and allows for transduction of the 
Wnt signal by disrupting the -catenin inhibitory complex to prevent degradation of -
catenin. Consequently -catenin is free to locate to the nucleus to promote target 
gene transcription. CYLD was found to regulate K63 ubiquitylation of Dvl. In the 
absence of functional CYLD, sustained K-63 ubiquitylation of Dvl facilitates signal 
transduction through polymerization of Dvl, and recruitment of the -catenin 
inhibitory complex to the membrane. This allows for accumulation of the transcription 
factor ß-catenin, leading to enhanced levels of transcription of its target genes 
(Tauriello et al., 2010). Furthermore a study by Rajan et al. found that expression of 
Dickkopf 2 (DKK2), a negative regulator of the Wnt pathway, is reduced in 
spiradenomas possibly due to the methylation of the DKK2 promoter, and correlated 
with the increased tumour disorganisation found in these tumours. The potential 
pathogenic role of this pathway was emulated in vitro with primary cylindroma cells 
conferring a survival advantage when DKK2 was silenced (Rajan, Burn, et al., 2011). 
However the influence of CYLD in this aspect of Wnt signalling regulation is yet to be 
resolved. 
1.2.3.4 Regulation of Notch signalling by CYLD 
Notch signalling is involved in the development and homeostasis of a number of 
tissues including the skin (Williams et al., 2011), mediating a number of cell fate 
decisions such as stem cell self-renewal, differentiation and cell cycle progression 
(Wilson A. and Radtke, 2006). Interestingly Notch receptors and their ligands show a 
restrictive pattern of expression to areas that are undergoing both early and late 
stages of differentiation within the hair follicles and interfollicular epidermis skin 
compartments (Nowell and Radtke, 2013; Powell et al., 1998), indicating that 
perturbations to this pathway could influence the normal differentiation associated 
with the activity of this pathway within these skin compartments. This may result in a 
pathogenic role for this pathway, as has been shown in human cancers such as 
myeloma and leukaemia (Liu N. et al., 2013; Takeuchi et al., 2005). 
 
The Notch signalling cascade functions in a cell-cell contact-dependent manner. 
Signalling is initiated by expression of the Delta-Serrate-Lag (DSL) family of ligands on a 
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signal-sending cell interacting with Notch receptors expressed on a signal-receiving 
cell. This results in cleavage of the Notch receptor and translocation of the intracellular 
part of the receptor to the nucleus where it acts as a transcriptional co-activator to 
drive gene expression. The DSL ligand relies on ubiquitylation to facilitate the signalling 
interaction with a signal-receiving cell (Le Bras et al., 2011). Mind-Bomb homologue 2 
(MIB2)/skeletrophin is an E3 ubiquitin ligase, which specifically interacts with the DSL 
ligand Jagged-2 (JAG2) to enhance Notch signalling by mediating endocytosis of JAG2 
(Takeuchi et al., 2005). CYLD is thought to attenuate Notch signalling by stabilising 
MIB2, in a non-catalytic dependent manner. This stabilisation disrupts 
autoubiquitylation and processing of MIB2 demonstrated by an increase in lower 
molecular weight ubiquitylated MIB2 products in the presence of exogenous CYLD 
expression, and consequently leads to a reduction in JAG2 expression (Rajan et al., 
2014). Indeed Notch signalling was found to be activated in CYLD-defective tumours 
and primary cylindroma cells were sensitive to -secretase inhibitors, which suppress 
Notch signalling through disabling cleavage of the Notch receptor and release of the 
intracellular domain. These results therefore suggest that the cells may have an 
oncogenic dependency on this signalling pathway (Rajan et al., 2014). 
1.2.4 Physiological functions of CYLD 
CYLD is recognised to have diverse physiological functions, which mainly revolve 
around the critical regulatory role of CYLD in NF-κB signalling. Examples include 
negative regulation of innate immune responses to both bacterial and viral infection. 
For instance CYLD was shown to suppress the induction of proinflammatory mediators 
by inhibition of NF-κB activation in response to Escherichia coli pneumonia infection, 
protecting the host from inflammatory tissue damage and sepsis (Lim J. H. et al., 
2008). In a similar manner CYLD was found to deubiquitinate Myeloid differentiation 
factor (MyD88) to regulate immune responses induced by nontypeable Haemophilus 
influenza (NTHi) (Lee B. C. et al., 2016). As MyD88 is an adaptor molecule for Toll-like 
receptors (TLR’s), K63-linked polyubiquitylation of MyD88 is induced by NHTi infection 
to trigger TLR dependent NF-κB signalling and initiate an inflammatory response. In 
addition TLR stimulation promotes upregulation of CYLD in an autoregulatory feedback 
mechanism to deubiquitinate TRAF6 and TRAF7, causing attenuation of NF-κB 
mediated immune responses (Jono et al., 2004; Yoshida et al., 2005). Separately CYLD 
was also shown to negatively regulate virus-induced production of type 1 interferon 
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(IFN) cytokines (Friedman et al., 2008). The proposed mechanism involving CYLD 
deubiquitination of a cytoplasmic viral RNA sensor, retinoic acid-induced gene 1 (RIG-
1), and IKK-related kinases TRAF family member-associated NF-kB activator (TANK) 
binding kinase 1 (TBK1) and IKK-, causing inhibition of the interferon regulatory factor 
3 (IRF3) pathway (Friedman et al., 2008; Zhang M. et al., 2008). 
 
Other regulatory roles for CYLD in spermatogenesis and osteoclastogenesis were 
identified in CYLD knockout mouse studies. The loss of CYLD caused attenuation of the 
early wave of germ cell apoptosis, which is critical to germ cell homeostasis in the 
spermatogenesis process, due to increased activation of NF-κB and consequently 
heightened expression of anti-apoptotic genes (Wright et al., 2007). On the other hand 
in bones the loss of CYLD caused deregulation of the homeostatic control of 
osteoclastogenesis, resulting in over production of osteoclasts, due to the loss of 
negative regulation of RANK ligand (RANKL) induced NF-κB signalling and 
deubiquitination of TRAF6 to inhibit signalling (Jin W. et al., 2008).  
1.2.4.1 Regulation of microtubule dynamics and associated activities by CYLD 
More recently an accumulating body of evidence has demonstrated that CYLD is 
involved in the regulation of a number of cellular processes, independent of NF-kB 
signalling, including cell cycle progression, cell migration and ciliogenesis due to 
interacting with microtubules (as reviewed by (Yang and Zhou, 2016)). Microtubules 
are filamentous structures comprised of tubulin polymers providing a cytoskeleton to 
cells to give the cells shape, as well as mediating activities such as intracellular 
trafficking, cell division and motility. As stated in section 1.2.1 the CAP-Gly domains of 
CYLD are mainly responsible for microtubule interactions (Gao et al., 2008), suggesting 
deubiquitylase independent functions of CYLD that may be important to tumour 
formation. Indeed, CYLD has been found to enhance microtubule stability through 
inhibition of HDAC6 deacetylase activity. Consequently this was found to lead to 
increased acetylation of a-tubulin and a delay in G1/S transition of the cell cycle in both 
melanoma cells and keratinocytes (Wickstrom et al., 2010). Whilst others have shown 
that CYLD is a critical regulator of microtubule dynamics and cell polarization during 
angiogenesis. This was evidenced by silencing of CYLD in human umbilical vein 
endothelial cells (HUVECS) causing microtubules to spend an increased amount of time 
in a paused state, impairing normal switching between growth and shortening phases, 
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and causing randomised centrosome localisation leading to cell migration defects (Gao 
et al., 2010). In addition CYLD interacts with microtubule binding proteins such as End 
binding 1 (EB1) to regulate microtubule-related activities, however this was found to 
be dependent on the deubiqutiylase activity of CYLD and not the CAP-Gly domains (Li 
D. et al., 2014). This therefore indicates that the different domains of CYLD may 
mutually affect each other or act synergistically in their regulation of cellular processes 
especially as microtubule-associated proteins undergo ubiquitylation (Gilberto and 
Peter, 2017; Yang, Liu, et al., 2014). Interplay between these two functional domains 
of CYLD is yet to be clarified, however the regulation of microtubule activity may have 
an underlying role in the pathogenicity of CYLD mutations in CYLD cutaneous 
syndrome, particularly as a cylindroma phenotype has been reported in patients 
harbouring mutations in exon 5 which partly encodes for the Cap-Gly domains (Nasti et 
al., 2009). 
 
Furthermore CYLD has been found to promote ciliogenesis, as several symptoms were 
observed in CYLD knock out mice or mice expressing truncated CYLD that are 
associated with cilia abnormalities, such as male infertility (Wright et al., 2007), 
osteoporosis (Jin W. et al., 2008), impaired lung maturation (Trompouki et al., 2009) 
and polydactyly (extra digits on the foot) and cilia defects in the skin, kidney, trachea 
and sperm (Yang, Ran, et al., 2014). Primary cilia are microtubule-based structures that 
present on the surface of eukaryotic cells to sense chemical and mechanical signals 
from the environment (Goetz and Anderson, 2010). Further investigation found CYLD 
interacted with centrosomal proteins, including Centrosomal protein of 70kDa 
(Cep70), which was deubiquitinated by CYLD (Yang, Liu, et al., 2014), and Centrosome-
associated protein 350 (Cap350) (Eguether et al., 2014). These interactions are 
important for positioning of CYLD at the centrosome and localisation of Cep70 at the 
basal bodies of cilia to promote their organisation and the elongation of microtubules 
for ciliogenesis (Eguether et al., 2014; Yang, Liu, et al., 2014). In addition the inhibition 
of HDAC6 by CYLD is involved in regulation of cililary length (Yang, Liu, et al., 2014). 
  
Cilia formation is intrinsically linked with cell cycle progression, through connections 
with the centrosome, and has been shown to be essential for signal transduction 
through recognised oncogenes and tumour suppressors such as Sonic hedgehog/ 
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Patched 1 (Shh/Ptch1), Platelet-derived growth factor receptor- (PDGFR-), and Von 
Hippel-Landau (VHL) (Michaud and Yoder, 2006; Schneider et al., 2005). Therefore it 
has been postulated by others that defective ciliogenesis and cilia functioning may 
contribute to tumourigenesis due to unrestrained growth, however whether this is due 
to the presence or absence of primary cilia remains contested (Castresana, 2015; 
Michaud and Yoder, 2006; Moser et al., 2009). Intriguingly the Shh/Ptch1 signalling 
pathway, which is a primary driver of basal cell carcinoma (Bonilla et al., 2016), 
another skin tumour that is thought to originate from hair follicle stem cells and is a 
malignancy into which trichoepithelioma has been reported to transform (Kallam et 
al., 2016), has been identified as an upstream regulator of CYLD expression (discussed 
in more detail in section 1.2.5) (Kuphal et al., 2011). In addition a number of the 
pathways that CYLD regulates have also been found to be cilia-related for example, 
Wnt (Gerdes et al., 2007), Notch (Ezratty et al., 2011) and Transforming growth factor-
 (TGF-) (Clement et al., 2013). Therefore it would be interesting to further 
investigate whether perturbation of normal cilia formation and function due to a loss 
of CYLD has pathological implications in CYLD cutaneous syndrome.  
 
CYLD has also been implicated as a regulator of mitotic entry, after it was shown that 
CYLD depletion in HeLa cells caused a premitotic arrest phenotype, which was 
dependent on CYLD deubiquitination, as the arrest phenotype was not restored by a 
catalytically inactive mutant of CYLD (Stegmeier et al., 2007). The fluctuating pattern of 
CYLD protein levels during the cell cycle; reduced on mitosis exit and accumulating 
during S phase, were observed to be similar to other mitotic regulators such as Polo 
like kinase 1 (PLK1). Subsequently it was found that CYLD interacted with PLK1 and the 
authors speculated that K63 deubiquitination regulated PLK1 activity. This result 
therefore implies a paradoxical, tumour promoting function of CYLD, which was 
suggested to be a possibility for the benign nature of CYLD-defective tumours, as the 
loss of functional CYLD would lead to a proliferative disadvantage and restricted 
growth (Stegmeier et al., 2007). Alternatively though other deubiquitinating enzymes 
may afford redundancy in the importance of this cell-cycle regulatory role of CYLD in 
different tissues. Conversely CYLD has been shown to inhibit Aurora-B independently 
of its deubiquitinating function but still requiring the C-terminus (Sun L. et al., 2010). 
As the Aurora-B kinase is important in regulating chromosomal segregation and 
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promotes cell cycle progression, it is frequently found to be over-expressed in cancer 
(Tang et al., 2017). Therefore as a tumour-suppressive mitotic regulatory role of CYLD, 
deregulation by a loss of CYLD could promote tumour growth.  
1.2.5 Regulation of CYLD  
In CYLD-defective tumours mutations cause a loss of CYLD function, however CYLD 
expression and function can be regulated by both transcriptional and post-
translational modifications. At the promoter level CYLD transcription is regulated by 
NF-κB signalling in autoregulatory feedback mechanisms to suppress NF-κB activation; 
supported by genomic sequence analysis, which found NF-κB binding sites in the 
promoter region of CYLD (Jono et al., 2004). Other proteins that are recruited to the 
CYLD promoter include BAF57, an ATP-dependent protein complex required for 
chromatin structure modification, which can be mutated in a vaiety of tumour types. 
In human breast carcinoma cells the overexpression of BAF57 was found to trigger up-
regulation of CYLD by recruitment to the promoter region, to induce apoptosis and cell 
cycle arrest causing reversal of the transformed phenotype (Wang L. et al., 2005). 
Meanwhile in melanoma cells the transcriptional repressor Snail is recruited to the 
CYLD promoter in response to BRAF-mediated activation of extracellular signal-related 
kinase (ERK), to facilitate the growth and metastasis of melanoma (Massoumi et al., 
2009). Similarly in the context of basal cell carcinoma Snail mediated the repression of 
CYLD expression and caused increased cell proliferation, except that in this cell context 
Snail was induced by the transcription factor Glioma-associated onocogene 1 (GLI1) 
downstream of Shh signalling. The loss of CYLD in these cells was rescued by the 
inhibition of GLI1 (Kuphal et al., 2011).  
 
Phosphorylation is another modification that is capable of controlling the activity of 
CYLD. For example in response to cell stimuli such as TNF-, TRAF2 undergoes self-
ubiquitylation to activate JNK signalling. Reiley et al. found that this coincided with 
phosphorylation of CYLD, which required IKK, to inactivate the catalytic activity of 
CYLD to allow for temporary accumulation of ubiquitin chains and subsequent 
downstream signalling (Reiley W. et al., 2005). Furthermore in breast cancer cells the 
phosphorylation of CYLD, at Serine 418, by IKK- again suppressed CYLD activity and in 
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turn increased NF-κB activation. Thus demonstrating a potential mechanism for IKK- 
driven oncogenesis in breast cancer (Hutti et al., 2009)  
 
There is evidence that CYLD itself may be ubiquitylated to promote its degradation. 
The human papilloma virus (HPV) encoded E6 protein was shown under hypoxic 
conditions, to act as an E3 ubiquitin ligase, responsible for Lys48 ubiquitylation of CYLD 
and induction of NF-κB activation to drive HPV-infected malignancies (An et al., 2008). 
Also in the regulation of Notch signalling and the interaction between CYLD and MIB2, 
ubiquitylation of CYLD by MIB2 is thought to target CYLD for degradation as a self- 
regulatory measure to control the autoubiquitylation of MIB2 (Rajan et al., 2014).  
 
Finally the micro-RNA, miR-181b-1 has been shown to target and repress CYLD. In a 
transducible model of cellular transformation, using the mammary epithelial cell line 
MCF-10A, the expression of signal transducer and activator of transcription 3 (STAT3) 
was induced upon transformation. Consequently this led to the establishment of an 
inflammatory feedback loop involving STAT3 mediated upregulation of miR181b-1 
which directly targeted CYLD to suppress it’s expression and cause increased NF-κB 
activation to maintain the inflammatory response required for a sustained 
transformed state (Iliopoulos et al., 2010). 
1.2.6 CYLD and other human malignancies 
Despite the tissue tropism of tumour formation to the skin in CYLD cutaneous 
syndrome, it is evident that CYLD has an effect on cancer pathogenesis outwith of the 
skin, from the aforementioned various roles of CYLD and mechanisms of regulation 
Therefore the study of CYLD biology and the effects of CYLD dysfunction in CYLD-
defective tumours gives us the opportunity to gain greater insight into not just the 
pathology of this rare benign tumour syndrome, but also of more common 
malignancies and the contribution of deubiquitinating enzymes, which could then 
inform on targeted treatment strategies for these cancers. 
 
Although at a low frequency, the loss of CYLD through genetic mutation and a LOH has 
been observed in other tumour types including head and neck squamous cell 
carcinoma, lung adenocarcinoma and stomach adenocarcinoma (Verhoeft et al., 2016) 
human atlas (60)). The two regions in which mutations of CYLD cluster, identified by 
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large-scale studies for cancer sequencing, correspond to coding exons for the 
functional domains of CYLD; the catalytic residues of the C-terminus and the CAP-Gly 
domains at the start of the coding region with mutations predominantly encoding for 
premature stop codons (Rajan and Ashworth, 2015).  
 
The alternative mechanism employed in different cancers to the truncating mutations, 
like those observed in CYLD-defective tumours, is repression of CYLD expression. 
Further to the examples described in section 1.2.5, repression of CYLD is seen in T-cell 
acute lymphoblastic leukaemia (T-ALL), in which crosstalk between Notch and NF-B 
signalling promotes survival of T-ALL cells, with Hes1 the transcriptional repressor 
target of Notch, driving the repression of CYLD and activation of IKK and NF-B 
(Espinosa et al., 2010). Similarly in multiple myeloma mutation or deletion of CYLD was 
associated with enhanced disease aggression due to aberrant Wnt activation (van 
Andel et al., 2017). Finally CYLD expression is downregulated in HCC, which due to 
increased NF-B activity and the ensuing inflammation promotes carcinogenesis 
(Urbanik et al., 2011). Indeed in mouse liver models in which CYLD is lost, constitutive 
activation of TAK1 initially leads to hepatocyte apoptosis, disrupting liver homeostasis 
and causing inflammation and fibrosis as potential compensatory survival mechanisms, 
which results in the development of tumours (Nikolaou et al., 2012). 
1.2.7 CYLD transgenic models  
A number of transgenic mouse models have been developed to aid with the 
characterisation of CYLD (Table 1-2), as demonstrated by the examples given in the 
functions of CYLD section previously. However to date none of the CYLD-deficient 
mouse models spontaneously develop CYLD-defective tumours such as cylindroma. 
Nonetheless these models have provided further insight into CYLD function, and 
intriguingly marked differences in the phenotypes of complete CYLD-knockout mice 
and mice ubiquitously expressing truncating CYLD mutations that closely mimic human 
mutations have been observed. CYLD-knockout mice are viable but show an increased 
susceptibility to chemically induced tumour formation. Indeed the topical application 
of 7, 12-dimethylbenz(a)anthracene (DMBA) followed by 12-O-tetradecanoylphorbol-
13 acetate (TPA) in CYLD-/- mice led to the development of squamous cutaneous 
papillomas, with increases seen in the number, frequency and size of tumours 
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compared to wild-type littermates (Massoumi, Chmielarska, et al., 2006). Likewise the 
treatment of another CYLD-/- mouse model with azoxymethane (AOM) and dextran 
sulphate sodium (DSS), to induce mutations and inflammation in the colon epithelium, 
led to the development of an increased number of colorectal tumours compared to 
wild-type mice (Zhang J. et al., 2006). Conversely the ubiquitous expression of 
truncated CYLD leads to perinatal lethality due to incomplete lung development and 
leads to a lack of oxygenation (Trompouki et al., 2009). This discrepancy between the 
models may possibly be explained by compensatory mechanisms that may exist in 
knockout mice. On the other hand truncated CYLD may act in a dominant-negative 
manner, interfering with compensatory networks and deubiquitylase activities, as it is 
still capable of binding to target substrates and maintains the CAP-Gly domain on 
which some deubiquitylase activities may be dependent. In support of this theory a 
mouse with deletion of exons 7 and 8 of CYLD that abrogates the TRAF2 and NEMO 
binding site is viable, suggesting that this domain may be responsible for mediating 
dominant-negative effects that account for the lethal phenotype (Hovelmeyer et al., 
2007). Further investigation of these models may lead to explanations of the 
pathogenic effects exerted by CYLD truncation.  
 
Due to viability issues with the truncated CYLD mouse models, more recent studies 
have tried to circumvent this by creating conditional knock in models to express 
mutant CYLD in a particular tissue. Intriguingly mouse models in which mutant CYLD 
expression has been targeted to the skin have again shown diverging phenotypes. 
Mice that conditionally expressed a catalytically deficient form of CYLD driven by the 
CK14 promoter (K14-CYLDm) displayed no obvious developmental abnormalities, other 
than mild epidermal hyper-proliferation. However in contrast to CYLD-/- mice, they 
were susceptible to developing highly malignant and metastatic skin tumours, some 
displayed clinical features of SCC when exposed to DMBA/TPA treatment (Miliani de 
Marval et al., 2011). Yet mice that expressed a truncated form of CYLD, due to deletion 
of exon 9, and whose expression of truncated CYLD was exclusive to K14-positive hair 
follicles and basal epidermal cells (CYLD E9/E9) were born alive, but in contrast to K14-
CYLDm mice developed skin, hair and dental abnormalities, as well as being prone to 
developing basaloid tumours and sebaceous adenomas in response to DMBA/TPA 
treatment. The study also identified c-Myc as a potential driver of tumour 
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development (Jin Y. J. et al., 2016). These results importantly highlighted that the 
expression of truncated CYLD by its endogenous promoter must be essential for the 
observed defects within the context of the hair follicle compartment. However the lack 
of spontaneous skin tumour development limits the use of these models for drug 
discovery strategies, and indicates that there may be biological differences between 
humans and mice in the role of CYLD in the hair follicle or that other tumour initiating 
events are required to promote tumour formation. Interestingly cylindromas and 
trichoepitheliomas are reported in a Gli1 over-expressing mouse model (Nilsson et al., 
2000), suggesting interplay between the Shh signalling network and CYLD may be such 
a hair follicle tumour promoting event, especially as this signalling pathway is 
important for hair follicle development (Rishikaysh et al., 2014). However expression 
of Gli1 was under the K5 promoter, which may reflect differences in biology. 
1.3 Research aims and objectives 
A lack of treatment options for CYLD cutaneous syndrome, other than repetitive 
surgery, warrants the need for further understanding of CYLD-defective tumours to 
identify potential therapeutic targets for alternate treatment strategies for patients 
with this genetic condition. Further understanding may also provide molecular insight 
into the promotion of tumorigenesis in other cancers in which CYLD is mutated or 
repressed. Previous work has highlighted the many signalling pathways in which CYLD 
is involved, with MYB and TrkB having been identified as targets of interest due to 
their overexpression in CYLD-defective tumours. The overall aim of this thesis 
therefore, was to identify and characterise targetable downstream targets of signalling 
pathways, such as MYB and TrkB, which are perturbed by a loss of functional CYLD, 
alongside developing a 3D culture model in which to explore these targets with 
compounds that may be therapeutically beneficial to patients. 
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Table 1-2: CYLD transgenic mouse models.  
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2 Chapter 2: Materials and Methods 
2.1 General Principles 
2.1.1 Ethical Approval 
Ethical approval had been granted from the local ethical review board (REC 06/1059) 
and written informed consent obtained from patients for the patient samples used in 
this study. 
2.2 Molecular Biology 
2.2.1 Collection of tissue for extractions 
Surplus skin and tumour tissue taken from patients undergoing routine surgery was 
obtained and snap frozen in liquid nitrogen and stored at -80°C. Tissue was mounted 
with OCT embedding reagent and sectioned on a cryostat (Leica), cutting at a thickness 
of 30μm with 10 sections collected per sample. 
2.2.2 RNA extraction from tissue 
Prior to commencing extractions the working area was prepared to reduce possible 
RNase contamination. All work surfaces and pipettes were wiped with RNAse Zap 
(Ambion) and filter tips were used for all pipetting steps. 
  
Total RNA was extracted from tumour and skin tissue samples using the AllPrep® 
DNA/RNA/miRNA Universal kit (Qiagen) according to the manufacturer’s protocol. 
Tissue sections were lysed in 600μl Buffer RLT containing -mercaptoethanol and 
guanidine isothiocyanate to denature RNAses and DNAses, with disruption of the 
samples using a pestle and homogenisation via repeated pipetting through a 1ml tip. 
Samples were then centrifuged for 1 minute at x13000rpm to pellet the debris and the 
supernatant transferred to a DNA Mini spin column for extraction of DNA. The flow 
through from this column containing the RNA was then transferred to an eppendorf. 
To extract the RNA 150μl of chloroform was added, before centrifugation at 4°C at 
x15000rpm for 3 minutes. The upper aqueous phase was removed and treated with 
80μl Proteinase K in the presence of 350μl of 100% ethanol to remove protein 
contaminants. Samples were left to incubate at room temperature for 10 minutes 
  37
before 750μl of 100% ethanol was added and the sample transferred to an RNeasy 
mini spin column. The columns were centrifuged for 15 seconds at x13000rpm to bind 
the RNA to the column membrane. The columns were washed with Buffer RPE before 
on column DNase digestion, 80μl of DNase I mixed with Buffer RDD was applied and 
the columns were left at room temperature for 15 minutes. The sample columns then 
underwent a series of washes with 500μl of each of Buffer FRN, Buffer RPE and 100% 
ethanol added in turn to the column with centrifugation at x13000rpm for 15 seconds 
in between, before a final centrifugation step for 2 minutes to ensure the removal of 
all ethanol. The RNA was then eluted in 30μl of RNase-free water, with three elutions 
per sample. All samples were stored at-80°C. 
2.2.3 RNA extraction from cells 
Similar to the column based method above, total RNA was extracted directly after 
trypsinisation from cell pellets using the RNeasy® Mini kit (Qiagen) according to the 
manufacturer’s protocol. Briefly, cell pellets were lysed in 600μl Buffer RLT containing 
-mercaptoethanol, before being centrifuged at x15000rpm for 10 minutes and the 
supernatant added to 600μl of 70% ethanol. The mixture was then put through an 
RNeasy spin column, with subsequent washing with 700μl Buffer RWT and 500μl 
Buffer RPE and centrifugation steps at x13000rpm for 1 minute in between, before a 
final centrifugation step for 2 minutes to ensure the removal of all ethanol. The RNA 
was then eluted in 30μl RNase-free water, with three elutions per sample. All samples 
were stored at -80°C. 
2.2.3.1 DNase treatment of RNA 
As the RNA extraction protocol above did not include a DNase digestion step this was 
carried out after extraction using the TURBO DNA-free kit (Ambion). A volume of 
RNA equivalent to 1μg was added to 10X TURBO DNase buffer (x0.1 of RNA volume) 
and 1μl of DNase. The samples were mixed and incubated for 30 minutes at 37°C in a 
thermoshaker. Subsequently 2μl of DNase inactivation reagent was added to also 
remove divalent cations that can catalyse RNA degradation when heated. The samples 
were then left at 26°C for 5 minutes in a thermoshaker, before centrifugation at 
x13000rpm and the RNA supernatant removed and stored at -80°C or taken forward 
for generation of cDNA. 
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2.2.4 Determination of RNA concentration 
The concentration of RNA samples was quantified using a fluorometric quantitation 
method. This works on the principle that a fluorescent dye (specific for the molecule of 
interest) upon binding with RNA in the sample-dye solution produces a fluorescent 
signal, which is directly proportional to the concentration of RNA in the solution. The 
level of fluorescence is then detected by a fluorometer and converted into a 
concentration value using RNA standards of known concentration and a curve-fitting 
algorithm. 
The Qubit RNA Broad Range assay kit was used alongside the Qubit 2.0 
fluorometer (both Life Technologies). Samples were prepared according to the 
manufacturer’s protocol. In brief a buffer/dye working solution was prepared by 
diluting dye reagent 1:200 in assay buffer in a volume appropriate to cover the number 
of samples and standards to be assayed. RNA sample was diluted 1:100 in a buffer/dye 
working solution (2μl to 198μl), alongside two RNA standards (0ng/μl and 10ng/μl) 
diluted 1:20 in the buffer/dye working solution (10μl to 190μl). These were then 
incubated at room temperature for 2 minutes before taking concentration readings. 
2.2.5 Analysis of RNA integrity 
Once extracted the integrity of the RNA was assessed to ensure the samples had not 
degraded and were of a quality suitable for sequencing and other downstream 
applications. The RNA 6000 Nano Kit alongside a 2100 Bioanalyzer instrument was 
used for analysis (both Agilent Technologies). This is an electrophoretic assay, with 1μl 
of RNA sample added to a microfluidic chip primed with a gel containing a fluorescent 
dye. RNA fragments are separated and internal markers of known size are used to 
generate a standard curve of migration time versus fragment size, to which the 
samples are referenced. A digitised image then displays the RNA bands and an 
integrity number (RIN) calculated based on the preservation of the 18S and 28S 
ribosomal bands (Figure 2-1). For sequencing purposes, samples that had a RIN >8 
were included (see section 2.7). 
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Figure 2-1: An example of the digitized gel image or electropherogram showing intact 
18S and 28S ribosomal peaks within the RNA samples after a Bioanalyzer run. 
 
2.2.6 Generation of cDNA by reverse transcription 
cDNA was generated from RNA using the SuperScript II Reverse Transcriptase kit 
(Invitrogen). For each sample 1μg of RNA was reverse transcribed in a total reaction 
volume of 20μl (reaction mix shown in Table 2-1). Firstly sample RNA, RNase-free 
water, Random Primers (Promega) and dNTP mix (Promega) were added together to 
give a total volume of 12μl. The reaction mix was then heated for 5 minutes at 65°C in 
a heat block. Next 5x First Strand Buffer, DTT, and RNase-free water were added, to 
bring the total volume to 19μl. The reaction mix was left at 25°C for 2 minutes in a 
heat block, before finally adding the reverse transcriptase SuperScript II enzyme. The 
reactions were run in a thermal cycler following the programme shown in Table 2-2. 
Once generated the cDNA was diluted 1:50 with water to achieve a working 
concentration. The cDNA was then stored at -20°C. 
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Table 2-1: Reaction mixture composition for cDNA generation 
 
Table 2-2: Thermocycler program for cDNA generation 
 
2.2.7 Polymerase chain reaction (PCR) for TrkB (NTRK2) isoforms for cloning 
The cDNA from a cylindroma tumour and the SHSY-5Y cell-line treated with retinoic 
acid was used for amplification of transcripts of each of the NTRK2 isoforms NTRK2.FL 
and NTRK2.T1 respectively, for cloning purposes (see section 2.6). Primers were 
designed based on sequences obtained from Ensembl (www.ensembl.org) (Table 2-3). 
Each of the NTRK2 transcripts was amplified using a proofreading KOD polymerase 
(Novagen) in a total reaction volume of 20μl (reaction mix shown in Table 2-4) and 
reactions were run in a thermal cycler following the conditions in Table 2-5. 
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Table 2-3: Primers used for amplification of the NTRK2 gene for cloning of TrkB 
isoforms 
Table 2-4: Reaction mixture composition for NTRK2 PCR for cloning of TrkB isoforms 
 
Table 2-5: Thermocycler PCR program for cloning of TrkB isoforms 
 
2.2.8 Agarose gel electrophoresis 
PCR products were run and visualised on a 1% agarose gel containing GelRednucleic 
acid stain. The gel was produced by adding 1g of agarose to 100ml of TAE buffer, 
heating the mixture until bubbling and left to solidify. PCR product samples (20μl) were 
mixed with 6X loading dye (4 μl) prior to loading onto the gel. Gels were run for one 
hour at 100V in 1X TAE buffer to separate the PCR amplicons. A 1Kb ladder (Promega) 
was run alongside the PCR product samples to determine if the correct amplicon size 
was obtained.  
2.2.9 Gel extraction and DNA purification 
DNA was extracted from agarose gels and purified using a QIAquick gel extraction kit 
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(Qiagen) according to the manufacturer’s protocol. DNA fragments were visualised 
using a UV light box and the DNA fragment of interest excised from the gel with a 
scalpel. The gel fragment was placed in an eppendorf and weighed to allow for correct 
calculation of the buffer volume for extraction, with 300μl Buffer QG added per 100mg 
of gel. The agarose gel was incubated in Buffer QG at 50°C for 10 minutes to dissolve 
the gel. For DNA fragments that were less than 500bp and greater than 4kb, 
isopropanol was added to increase the yield. The sample was then added to a QIAquick 
spin column to bind the DNA and centrifuged for 1 minute at x13000rpm (all 
subsequent centrifugation steps carried out in the same way). The column was washed 
with 500μl Buffer QG to remove any residual traces of agarose, before being incubated 
with 750μl Buffer PE for 5 minutes to remove salts that may interfere with 
downstream ligations for cloning. DNA was finally eluted from the column in 30μl of 
Buffer EB and DNA stored at -20°C. 
2.2.10 Quantitative reverse transcription polymerase chain reaction (qPCR) 
2.2.10.1 Principles of qPCR 
Quantitative PCR is a technique that utilises the amplification of specific DNA target 
sequences by traditional PCR, whilst using fluorescent dyes or fluorescently-tagged 
probes to detect and measure the amount of DNA generated during each cycle of the 
PCR reaction. As the amount of fluorescence measured is proportional to the 
accumulation of PCR product as the reaction progresses the amount of DNA can be 
quantified. Therefore the higher the starting level of the target sequence the fewer 
PCR cycles needed to generate a significant level of DNA. 
 
There are two types of fluorescence detection methods that can be used in qPCR. 
Fluorescent dyes, such as SYBR Green I, are non-specific DNA binding dyes that 
intensely fluoresce when they intercalate within the double stranded DNA produced 
during the PCR reaction. Alternatively probe-based chemistry, such as a Taqman 
probe, uses fluorescently tagged oligonucleotide probes that are specifically designed 
for a particular DNA sequence. The 5’ end of the probe contains a fluorophore such as 
6FAM (6-carboxyfluorescein), which when excited by a light source from the thermal 
cycler transfers energy to the quencher such as TAMRA (tetramethylrhodamine) 
attached at the 3’ end leading to suppression of any fluorescence signal. However 
  43
upon binding of the probe to the specific DNA region to which they are designed, 
during the elongation phase the 5’ to 3’ exonuclease activity of the Taq polymerase 
cleaves the fluorophore releasing it from the quencher leading to an increase in 
fluorescence which reflects amplification of the target amplicon. This method 
increases specificity, as it requires hybridization of the probe to the target sequence to 
generate a fluorescent signal. 
2.2.10.2 qPCR with SYBR green 
The primers used (Table 2-6) were designed using Primer3 software (version 4.0.0), 
and targeted the terminal exons unique to each isoform. Sequences that ran across 
the intron-exon boundary were selected to ensure non-amplification of potential 
contaminating genomic DNA, and designed to flank exons unique to the 3’ end of each 
NTRK2 isoform transcript. For NTRK2.FL this was exon 24 and for NTRK2.T1 this was 
exon 16. A master mix was prepared for each set of primers, and individual reactions 
were set-up in a 96 well format with a final volume of 25l. The components of each 
reaction mix are shown in Table 2-7 below. For each sample, each primer pair was run 
in triplicate. 
Table 2-6: Primers used for amplification of the NTRK2 isoforms for qPCR 
 
Table 2-7: Reaction mixture composition for NTRK2 isoforms for qPCR 
Once plates had been set-up and sealed, they were centrifuged at 2000rpm for 1 
minute to ensure all reagents were at the bottom of the well and to remove air 
bubbles. Plates were then run on a Chromo4 Real-Time PCR Detector System 
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(Biorad) with Opticon Monitor software (BioRad), using the thermal cycling 
conditions shown in Table 2-8. 
 
Table 2-8: Thermocycler PCR program for NTRK2 isoforms for qPCR 
PCR products were initially analysed on a 2% agarose gel, to confirm amplification of a 
single product of the correct size, as well as the generation of a melting curve during 
the qPCR run. In the amplification plots a threshold was set and Ct values determined. 
The relative normalized gene expression was calculated using the 2-∆Ct method, and 
gene expression was normalised to GAPDH. Experiments were repeated three times. 
2.2.10.3 qPCR with Taqman probes 
For qPCR using Taqman probes the Taqman Gene Expression Mastermix was used. A 
master mix was prepared for each set of primers (Table 2-9), and individual reactions 
were set-up in a 96 well format with a final volume of 20l. The components of each 
reaction mix are shown in Table 2-10. For each sample, each primer pair was run in 
triplicate. Once plates had been set-up and sealed, they were centrifuged at x2000rpm 
for 1 minute to ensure all reagents were at the bottom of the well and to remove air 
bubbles. Plates were then run on a 7500 Fast Real-Time PCR system (Applied 
Biosystems) with 7500 software v.2.0.5 (Applied Biosystems), using the thermal cycling 
conditions shown in Table 2-11. In the amplification plots a threshold was set and Ct 
values determined. The relative normalized gene expression was calculated using the 
2-∆Ct method and gene expression was normalised to PUM1. Experiments were 
repeated three times. PUM1 was chosen for normalisation due to previous analysis of 
the microarray dataset comparing the expression values of 15 housekeeping genes 
between tumours and perilesional skin. PUM1 was selected due to this gene having 
the smallest standard deviation as a percentage of the mean expression signal value, 
which was consistent between both the tumour and control samples. 
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Table 2-9: Taqman Probes for qPCR 
Table 2-10: Reaction mixture composition for Taqman probe qPCR 
Table 2-11: Thermocycler PCR program for Taqman probe qPCR 
2.3 Cloning 
2.3.1 Preparation of competent cells 
E.coli DH5-alpha cells (Stratagene) were streaked from a glycerol stock onto an LB agar 
plate and incubated at 37C overnight. A single colony was selected and used to 
inoculate 10mls of LB media without any selection antibiotic, which was incubated at 
37C overnight on a shaking platform at 220rpm. 1ml of the starter culture was added 
to 100mls of LB media and incubated at 37C with vigorous shaking and checked over 
a few hours until the absorbance at 600nm gave a reading of 0.6. The cells were 
harvested by firstly placing the cells on ice for 10 minutes before centrifuging at 
x6000rpm for 10 minutes in a pre-chilled centrifuge. Following this cells were 
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resuspended in 25mls of ice-cold, 100mM calcium chloride (CaCl2) and incubated on 
ice for 20 minutes. The cells were again centrifuged as before then resuspended in 
5mls of CaCl2 and 1ml of 100% glycerol added. The cells were divided into 100l 
aliquots and stored at -80C. 
2.3.2 Purification of plasmid DNA 
Plasmid DNA was purified using the QIAprep Spin Miniprep Kit (Qiagen) according to 
the manufacturer’s protocol. In brief, overnight bacterial cultures were pelleted by 
centrifugation at x3000rpm for 5 minutes. Bacterial cells were then resuspended in a 
series of buffers, firstly 250l of Buffer P1 containing RNase A (100g/ml) and LyseBlue 
reagent. The cells are then lysed under alkaline conditions with 250l of Buffer P2 
added which turns the sample blue to ensure a homogenous solution, prior to adding 
350l of Buffer NE to neutralise and precipitate the cellular debris in a high salt 
concentrate buffer, followed by separation of the DNA via centrifugation for 10 
minutes at x13000rpm. The plasmid DNA was then isolated through adsorption onto a 
silica membrane of a spin column, which was subsequently washed with Buffer PB 
then Buffer PE to remove endonucleases and residual salts respectively. The purified 
plasmid DNA was finally eluted in 50l Buffer EB by centrifugation and stored at -20C. 
2.3.3 Glycerol stocks 
From the 5ml overnight bacterial cultures generated from selected colonies, 1ml of 
culture was transferred to an eppendorf and centrifuged at x5000rpm for 1 minute to 
pellet the cells. The supernatant was discarded until and the pellet resuspended in 
50l 100% glycerol to make stocks. These were stored at -80C and used to further 
amplify the plasmids in E.coli DH5-alpha cells for lentiviral transfection into human 
HEK293T and HaCaT cells. 
2.3.4 Generation of mutant pLEX-CYLD 
The lentiviral expression vector pLEX-CYLD was previously generated by Dr Neil Rajan, 
and incorporated wild-type CYLD into the lentiviral vector pLEX-MCS. Glycerol stocks of 
transformed E.coli DH5-alpha were grown and plasmid DNA prepared as explained 
above. 
2.3.4.1 Site-directed mutagenesis 
Site directed mutagenesis is a technique that is used to investigate the relationship 
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between the structure and biological activity of proteins, DNA and RNA, thus helping 
to characterise the mechanisms of known disease causing mutations. It allows for 
targeted alterations, such as base substitutions, insertions or deletions to be made in 
double stranded plasmid DNA, with the use of primers that are designed with the 
desired mutation incorporated and flanked by sequences that are complementary to 
the template DNA. Therefore with thermal cycling the primers anneal to the vector 
DNA and are extended to integrate the mutation into the newly synthesised plasmid 
DNA. The product from this PCR reaction is then subjected to enzymatic digestion, to 
isolate the mutant product from the parental template, using the restriction 
endonuclease Dpn I. This enzyme specifically recognises a methylated GATC sequence 
present on DNA or plasmids isolated from E.coli strains such as the template plasmid. 
The mutant plasmid can then be transformed into competent bacteria (see below).  
Patient specific mutations of CYLD: c.2460delC, c.2290- 2294del, c.2806 C>T and 
p.C601S (which corresponds to a g > c change at position 1803 in the nucleotide 
sequence) were incorporated in to the previously generated expression vector pLEX-
CYLD, using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies). Primer pairs were designed to incorporate the CYLD mutations using 
the QuikChange primer design program and guidelines (available at 
www.agilent.com/genomics/qcpd), and synthesised by Eurofins. The mutations were 
positioned in the middle of the primer sequence (as shown in Table 2-12). The first 
reaction set-up used PCR amplification to incorporate the desired mutations into the 
wild-type template (Tables 2-13 & 2-14). This was followed by incubation of the 
amplified reactions with 2μl of Dpn I restriction enzyme at 37C for 5 minutes, to 
digest the non-mutated DNA template.  
Table 2-12: Primer sequences for site-directed mutagenesis of pLEX-CYLD 
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The letters that are underlined in red represent the bases between which the deletion has occurred. The 
bases in red represent the bases that have been altered for another base. 
Table 2-13: Reaction mixture composition for site-directed mutagenesis 
 
Table 2-14: Thermocycler program for site-directed mutagenesis 
2.3.4.2 Transformation of competent cells with mutant pLEX-CYLD 
XL10-Gold ultracompetent cells (45l aliquot) were thawed on ice, then incubated 
with 2l -mercaptoethanol mix (provided in kit) on ice for 2 minutes. Subsequently 
2l of the Dpn I treated DNA was added to the reaction mix and left on ice for 30 
minutes. The cells were then heat shocked at 42°C for 30 seconds, then returned to ice 
for 2 minutes. The cells were then agitated at 225rpm for an hour at 37C with 500l 
of NZY+ media, before being spread onto agar plates, containing the selective antibiotic 
Ampicillin, and left to incubate at 37C overnight. Single colonies were picked from 
selective agar plates and used to inoculate 5mls of NZY+ media containing ampicillin, 
before being cultured overnight at 37C on a shaking platform at 220rpm. Plasmid DNA 
was extracted from bacterial cultures (section 2.3.2) and DNA sent for sequence 
verification (section 2.3.6). Once verified E.coli DH5-alpha cells were transformed in 
the same manner to generate stocks. 
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2.3.5 Generation of pLEX-TrkB.FL and pLEX-TrkB.T1 
2.3.5.1 Blunt PCR cloning 
Both TrkB.FL and TrkB.T1 isoforms were amplified and the resulting PCR products 
purified (section 2.2.7). The StrataClone blunt PCR cloning kit (Agilent Technologies) 
was used to ligate the TrkB DNA products into the pSC-B-amp/kan vector supplied, by 
exploiting the activity of Topoisomerase I to ligate the PCR product into DNA arms that 
contain loxP recognition sequences on the opposite ends. This linear product, once 
transformed into competent cells expressing Cre recombinase, can undergo Cre-
mediated recombination of the vector and linear molecule containing the PCR product 
to create circular DNA (Figure 2-2). The ligation reaction mix is included in Table 2-15 
and the components were added in the order in which they are displayed. The reaction 
was incubated for 5 minutes at room temperature before being placed onto ice.  
Table 2-15:  Reaction mixture composition for blunt PCR cloning 
StrataClone solopack competent cells (50l aliquot) were thawed on ice, before adding 
2l of the cloning reaction mix and incubating on ice for 20 minutes. The cells were 
then heat shocked at 42°C for 45 seconds, then returned to ice for 2 minutes. The cells 
were then agitated at 225rpm for an hour at 37C with 250l of LB (lysogeny broth) 
media, before being spread onto agar plates containing the selective antibiotic 
Ampicillin, and left to incubate at 37C overnight. Single colonies were picked from 
selective agar plates and used to inoculate 5mls of LB media containing ampicillin, 
before being cultured overnight at 37C on a shaking platform at 220rpm. Plasmid DNA 
was extracted from bacterial cultures (section 2.3.2) and the DNA used for subsequent 
restriction digests and ligations. 
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Figure 2-2:  An overview of the Strataclone Blunt PCR cloning method. 
2.3.5.2 Restriction enzyme digests 
Both the pSC-B-amp/kan and pLEX-MCS vectors carried restriction enzyme sites and 
underwent restriction digests to enable downstream insertion of desired inserts and 
for the analysis of positive clones. A double digest was carried out for all digest 
reactions using the restriction enzymes BamHI and XhoI (New England BioLabs). The 
most compatible buffer for both enzymes was selected for, which for these reactions 
was NEBuffer 3 (New England BioLabs). The reaction mix is shown in Table 2-16. The 
reactions were incubated for 1 hour at 37C, before being resolved on a 1% agarose 
gel. 
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Table 2-16:  Reaction mixture composition for restriction enzyme digests. 
2.3.5.3 Ligation reactions 
The digested DNA underwent agarose gel electrophoresis and the fragments of 
interest were cut out and purified. The purified digested DNA was then ligated in 
different ratios of vector to insert in a 20l ligation reaction mix, which included 1l T4 
DNA ligase (Promega) and 2l of Reaction Buffer (10X). The reaction was left for 20 
minutes at room temperature before being left at 70C for 5 minutes. The ligation 
mixture was then used to transform competent E.coli DH5-alpha cells, which were 
then spread onto agar plates containing the selective antibiotic Ampicillin and left for 
at least 18 hours at 37C. Colonies were numbered, selected and each cultured in 
200l of LB media in a 96 well plate overnight on a shaking platform at 220rpm. The 
cells were pelleted by centrifugation at x1000rpm for 5 minutes before sterile tips 
were dipped into the pellets and transferred into a 96 well plate for PCR screening. The 
recipient PCR plate contained 10l of PCR mastermix in each well, containing primers 
for each of the TrkB isoforms; Exons 15-18 for TrkB.FL and Exons 15-16 for TrkB.T1 
(section 4.2.1). The plate was placed into a thermal cycler to run the PCR reactions and 
the products run on a 1% agarose gel. Colonies that were identified as positive for the 
insert were then used to inoculate 5mls of LB media containing ampicillin, before being 
cultured overnight at 37C on a shaking platform at 220rpm. Plasmid DNA was 
extracted from bacterial cultures (section 2.3.2) and subject to digestion again to 
confirm the presence of the insert. Once confirmed the pLEX-TrkB.FL and pLEX-TrkB.T1 
products were sent for sequence and orientation verification. 
2.3.6 Sequence verification of plasmids and PCR product inserts 
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Plasmid DNA for both CYLD and TrkB was sent for sequencing (Eurofins Genomics) with 
primers that covered the entire gene and flanking sequence from the insertion site of 
the plasmid (primer sequences included in Appendix), to verify the sequence and 
check the orientation of the product before proceeding with cell transduction 
experiments. Sequences were visualised in Sequencher v5.1 (Genecodes Corporation) 
(Figure 2-3). 
Figure 2-3:  Chromatogram examples of sequencing of mutant pLEX-CYLD vectors. 
2.4 Western Blotting 
The levels of protein expression in cell lysates and tissue samples were measured using 
western blotting. The technique has four stages as follows: firstly protein 
denaturation, which involves boiling protein samples in the presence of a reducing 
agent such as -mercaptoethanol or dithiothreitol (DTT) to break down tertiary protein 
structures such as disulphide bonds. Secondly the samples are prepared with sodium 
dodecyl sulphate (SDS), an ionic detergent that covers the protein with a negative 
charge to create a homogenous mass to charge ratio, which allows for electrophoretic 
separation according to molecular weight by SDS-PAGE. Thirdly proteins are 
transferred to a PVDF membrane and probed with antibodies, which are lastly 
visualised with the use of horseradish peroxidase (HRP) conjugated antibodies. The 
peroxidase catalysing the oxidation of luminol in the presence of chemical enhancers 
to produce a chemiluminescence signal that can be detected. 
 CYLD 
Mutant 
CYLD 
 CYLD 
Mutant 
CYLD 
 
c.2290_2294delAAACT  c.2806 C>T 
 
c.2460delC 
 p.C601S 
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2.4.1 Preparation and extraction of protein lysates from tissue 
Tissue samples, snap frozen after surgery in liquid nitrogen, were mounted in OCT 
embedding reagent and sectioned using a cryostat. Samples were cut at a thickness of 
30m, with 10-20 sections collected per sample and placed into a 1.5ml eppendorf on 
dry ice. The tissue sections were firstly washed in 1ml ice cold PBS with phosphatase 
inhibitors, such as PhosSTOP tablets (Roche), then briefly centrifuged at 4°C to pellet 
the tissue. The tissue was lysed in 150-200l of Phosphosafe lysis buffer and samples 
left at room temperature for 5 minutes before being transferred to a Precellys bead 
tube (Bertin). The samples were then homogenized at x6500rpm for 30 seconds using 
the Precellys Evolution homogeniser (Bertin) with the sample lysate then being 
transferred into a 1.5ml eppendorf. The beads were washed with a further 100l of 
lysis buffer, which was added to the homogenized lysate. The samples were then 
centrifuged at 14000rpm for 15 minutes at 4°C. The supernatant was removed and 
samples were either taken forward to determine the protein concentration or stored 
at -80°C. 
2.4.2 Preparation and extraction of protein lysates from cells 
Cells were trypsinised (section 2.6.4) and cell pellets collected. Any surplus media was 
removed before resuspending the cell pellet in 50-200l (dependent on the pellet size 
and the vessel trypsinised) of Phosphosafe lysis buffer. The sample was then 
transferred to an eppendorf and centrifuged at x14000rpm for 15 minutes at 4C. 
Following this the supernatant was collected and both the pellet and lysate were 
stored at -80C or the lysate was taken forward to determine the protein 
concentration. 
2.4.3 Determination of protein concentration- Qubit 
The concentration of protein in sample lysates was quantified using a fluorometric 
quantitation method as explained in section 2.2.4. The level of fluorescence is 
detected by a fluorometer and converted into a concentration value using protein 
standards of known concentration and a curve-fitting algorithm. 
The Qubit Protein Assay kit was used alongside the Qubit 3.0 fluorometer (both 
Life Technologies). Samples were prepared according to the manufacturer’s protocol. 
In brief a buffer/dye working solution was prepared by diluting dye reagent 1:200 in 
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assay buffer in a volume appropriate to cover the number of samples and standards to 
be assayed. Protein lysate was diluted 1:100 in the buffer/dye working solution  (2μl to 
198μl), alongside three protein standards (0ng/μl, 200ng/μl, 400 ng/μl) diluted 1:20 in 
the buffer/dye working solution (10μl to 190μl). These were then incubated at room 
temperature for 15 minutes before taking readings. 
2.4.4 Determination of protein concentration- BCA assay 
Alternatively protein concentrations were quantified using a BCA kit (Pierce, 
ThermoFisher Scientific) according to manufacturer’s instructions. Briefly, sample 
lysates were first diluted 1:20 in distilled water, before 25μl of sample was added to 
200μl of working reagent (50:1, Part A:Part B) in a 96 well microplate, with samples set 
up in duplicate wells. An albumin standard supplied with the kit was serially diluted 
(0.025mg/ml-2mg/ml) with water and a constant proportion of lysis buffer, with each 
standard also included in duplicate on the plate. Plates were incubated for 30 minutes 
at 37°C before determining the colourimetric absorbance at 562nm on a plate reader. 
A standard curve was generated from the mean absorbance values of the standards 
and sample concentrations were interpolated, before correcting for dilution factor. 
2.4.5 SDS-PAGE (Sodium Dodecyl Sulphate-Poly Acrylamide gel electrophoresis) 
and membrane transfer 
Protein samples were prepared with an appropriate volume of lysate that equated to 
25 μg of protein would be run in each lane of a gel. The samples were also prepared 
with 4X LDS (lithium dodecyl sulphate) loading buffer (Invitrogen), 10X reducing agent 
(Invitrogen) and water to make the final volume upto 30μl. Protein samples were 
boiled at 70°C for 10 minutes, then separated under reduced conditions using the 
NuPAGE® gel electrophoresis system on 3-8% Tris-Acetate gels (Invitrogen) in 1X Tris-
Acetate SDS running buffer (Invitrogen). Alongside the samples 7μl of PageRuler Plus 
prestained protein stanadrd was used for molecular weight markers (Thermofisher 
Scientific). Following this proteins were transferred onto PVDF membranes using the 
Trans-Blot® Turbo blotting system (Bio-Rad) according to the manufacturer’s 
protocol. This is a semi-dry rapid transfer system in which the PVDF membranes are 
soaked in 100% methanol before being equilibrated in 1X transfer buffer for a couple 
of minutes. The membrane, protein gel, and sponges are then assembled into a 
transfer cassette and proteins transferred at 25V for 10 minutes. 
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2.4.6 Protein detection 
After protein transfer the membranes were blocked in 5% (w/v) non-fat milk powder 
in Tris buffered saline with Tween 20 (TBST) (50mM Tris pH7.4, 200mM NaCl, 0.1% 
(v/v) Tween 20) for 1 hour at room temperature. Membranes were subsequently 
probed with primary antibody overnight at 4°C with rotary agitation, with all 
antibodies used prepared in 5% (w/v) non-fat milk powder in TBST. Antibodies used 
are listed in Table 2-17. After primary antibody exposure, the blot was washed three 
times, for 5 minutes with TBST. Membranes were then left to incubate with HRP-
conjugated goat anti-rabbit (Cell Signalling Technologies) or goat anti-mouse (Cell 
Signalling Technologies) secondary antibody diluted in 5% (w/v) non-fat milk powder in 
TBST, for 1 hour at room temperature with agitation. Membranes were washed as 
previously described before visualisation using enhanced chemiluminescence (ECL) 
detection reagents (GE Healthcare) and exposure onto photographic film (FujiFilm 
Corporation).  
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Table 2-17:  Antibodies used for Western Blotting. 
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2.5 Histological Techniques 
2.5.1 Tissue processing and sectioning 
2.5.1.1 Tissue fixation and embedding 
Surplus skin and tumour tissue taken from patients undergoing routine surgery was 
obtained and the tissue samples were fixed the in 4% PFA for 2 hours to overnight at 
4°C, depending on the specimen size. Once fixed the tissue samples were washed in 
PBS to remove excess fixative. The tissue was then dehydrated in graded alcohols 
(30%-100%) followed by xylene, before finally being immersed in molten paraffin wax 
at 60°C and the wax changed a further two times. The tissue was then embedded in 
paraffin wax and set into moulds to create a block. 
2.5.1.2 Tissue sectioning (wax) 
Tissue blocks were sectioned using a microtome (Leica) at a thickness of 5-8m and 
orientated onto Superfrost Plus slides (VWR). Tissue sections were floated on water 
atop of the slides, warmed to 37°C using a hotplate, and left to flatten out. Excess 
water was removed and sections were left to dry at 40°C overnight to ensure sections 
adhered well to the slide. 
2.5.1.3 Tissue sectioning (frozen) 
Tissue specimens were embedded in OCT and sectioned using a Cryostat (Leica). Tissue 
sections were cut at 5-8m and mounted onto Superfrost Plus slides (VWR). Slides 
were left to dry on dry ice before being stored short-term at -20°C until required. 
2.5.2 Haematoxylin and Eosin staining 
For analysis of tissue morphology, sections were stained with haematoxylin- a purple 
stain to visualize the nuclei of cells, and eosin- a pink counterstain to visualize the 
cytoplasm. Briefly slides were de-waxed in xylene for 2 x 10 minutes with a change of 
xylene, submerged in graded alcohols (100%-30%) then distilled water, 5 minutes in 
each, to rehydrate the slides, before being put in haematoxylin solution for 30 
seconds. Following this slides were briefly dipped in distilled water, before 3-4 dips in 
the bluing solution Scott’s Tap water. Again the slides were briefly washed in distilled 
water before being submerged in eosin for 30 seconds, followed by a brief wash in 
water and dips back up the graded alcohols, before sitting in 100% Ethanol for 2 x 5 
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mins and then placed in xylene for 2 x 5 minutes. Finally the slides were mounted with 
DPX mounting medium (Fisher) and cover-slipped.  
2.5.3 Immunohistochemistry (IHC) using DAB 
Solutions:  
Sodium Citrate Buffer (pH6.0): 5.84g sodium citrate to 2L of distilled H20 
2.5.3.1 IHC immunostaining protocol 
Tissue section slides were firstly incubated in an oven at 60°C for 30 minutes to melt 
the paraffin wax, the wax was then removed by submerging the slides in fresh xylene 
for 10 minutes, which was then repeated. The sections were then rehydrated in 
graded alcohols (100%-30%) for 5 minutes each and finally immersed in distilled water. 
Tissue sections were placed in sodium citrate buffer (pH6.0) in a pressure cooker, for 
antigen retrieval, with sections left at full pressure for 8-16 minutes. Slides were then 
washed three times in tris buffered saline (TBS) for 3 minutes before the sections were 
circled with a hydrophobic barrier pen, ensuring that the sections were not allowed to 
dry out. The EnVision + Dual Link System-HRP kit (Dako) was applied for 
immunohistochemical staining. Peroxidase blocking solution was applied to the 
sections for 5 minutes to prevent endogenous peroxidase activity, followed by three 
washes in TBS for 3 minutes. Sections were subsequently incubated with primary 
antibody, prepared in antibody diluent (Dako) to the concentrations specified in Table 
2-18,  for 1 hour at room temperature or overnight at 4°C, followed by three washes in 
TBS for 3 minutes. An HRP-labelled polymer conjugated with secondary antibodies was 
then applied to the sections for 1 hour at room temperature before washing three 
times in TBS for 3 minutes. Antibody binding was visualized with liquid DAB (3,3’-
Diaminobenzidine) staining, prepared according to the manufacturer’s instructions 
(Dako). The slides were rinsed in distilled water three times for 3 minutes followed by 
nuclear counterstaining with haematoxylin (diluted 1:5 in distilled water), dehydration 
in graded alcohols and clearing in xylene. The slides were finally mounted under cover 
slips with DPX mounting medium (Thermofisher Scientific) and left to dry overnight.  
2.5.3.2 Analysis and protein quantification of DAB staining 
Slides were inspected under a microscope, before being scanned on a SCN400 slide 
scanner (Leica) (Newcastle Biobank service). For quantification five representative 
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immunohistochemistry images were taken at 20X magnification, of a tissue section 
from each tumour sample and control perilesional skin areas. ImageJ software (v 1.48; 
https://imagej.nih.gov/ij) was used to quantify DAB staining in the images. RGB values 
were restricted to the colour of DAB in the images were used to distinguish areas that 
were DAB-positive and the area quantified. This was then compared to the total area 
of the assessed image to generate a ratio of positive staining. The mean average of the 
ratios was taken from across all 5 images to generate a ratio per sample. This was 
repeated for the control areas for comparison.   
2.5.4 Immunofluorescence (IF) on frozen sections 
Solutions:  
Washing Reagent 1: 1x PBS- 5 PBS tablets (fisher) into 1L distilled H2O) 
Washing Reagent 2: 0.1% Triton X-100- 100ul Triton X-100 (maker), 0.2% BSA- 0.2g 
BSA (fisher) per 100mL 1x PBS  
Block/Antibody diluent: 0.3% Triton X-100- 300ul Triton X-100, 0.5% BSA- 0.5g BSA per 
100mL 1x PBS  
2.5.4.1 IF immunostaining protocol 
Spheroid section slides were initially thawed at room temperature for 5 minutes 
before being placed in sodium citrate buffer (pH6.0) in a pressure cooker, for antigen 
retrieval, with sections left at full pressure for 6-8 minutes. The slides were then 
washed for 10 minutes in PBS before the sections were circled with a hydrophobic 
barrier pen, ensuring that the sections were not allowed to dry out. The sections were 
incubated for an hour at room temperature in 50-100l of blocking solution (0.3% 
Triton X-100, 0.5%BSA in PBS). Primary antibodies were prepared in antibody diluent 
(0.3% Triton X-100, 0.5%BSA in PBS) to the concentrations specified in Table 2-18, and 
sections incubated with 50-100l of primary antibody overnight at 4°C. Subsequently 
slides were washed three times in 0.1% Triton X-100, 0.2% BSA in PBS solution for 10 
minutes, before sections were incubated with 50-100l Alexafluor conjugated 
secondary antibodies (Jackson Laboratories) prepared in the same antibody diluent as 
the primary and filtered. Slides were left to incubate for an hour at room temperature 
in the dark. After which the slides were washed as previously described, then excess 
  60
liquid was removed and sections were mounted with coverslips using 20-30l of 
Vectashield Antifade mounting medium with DAPI included for a nuclear stain (Vector 
Laboratories). Images of the slides were then taken using a UV Zeiss Axioimager 
microscope and images captured with a monochrome digital camera (Zeiss) connected 
to a computer running Zeiss Axiovision 4.7 software. 
Table 2-18:  Antibodies used for Immunohistochemical techniques 
2.5.5 Immunocytochemistry (ICC) on cell culture chamber slides 
Solutions:  
Antibody diluent: 0.1% Triton X-100 - 5l Triton X-100 into 5mls 1x PBS 
Washing Reagent 1: 1x PBS- 5 PBS tablets (fisher) into 1L distilled H2O) 
2.5.5.1 ICC immunostaining protocol 
Storage PBS was removed form each well of the chamber slide and 500l of ice-cold 
methanol added for 10mins to allow for permeabilisation of cell membranes, before 
wells were rinsed with PBS. To each well 500l of 2% normal goat serum in PBS was 
added and left at room temperature for 20 minutes, with agitation on a rocker. 
Following this 200l of primary antibody, diluted in 0.1% Triton X-100 solution (5l 
Triton X-100 in 5mls PBS) to the concentration specified in Table 2-18, was added to 
each of the wells and the slides left overnight at 4 C. Subsequently wells were washed 
three times in PBS for 10 minutes on a rocker, before adding 200l of filtered, 
Alexafluor conjugated secondary antibodies (Jackson Laboratories) diluted in PBS, to 
each well. The slides were then left at room temperature for an hour and kept in the 
dark. After which the slides were washed as previously described, the chamber well 
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casing and excess liquid was removed and sections were mounted with coverslips 
using 20-30l of Vectashield Antifade mounting medium with DAPI included for a 
nuclear stain (Vector Laboratories). Images of the slides were then taken using a UV 
Zeiss Axioimager microscope and images captured with a monochrome digital camera 
(Zeiss) connected to a computer running Zeiss Axiovision 4.7 software. 
2.6 Cell culture 
2.6.1 Cell line maintenance  
All cell culture procedures and experiments were carried out under aseptic conditions 
using a class II vertical laminar flow biological safety cabinet. The HaCaT and HEK-293T 
cell lines were used in this study. HEK293T cells, are a derivative of the human 
embryonic kidney cell line (Graham et al., 1977) but are transformed with SV40 T 
antigen (DuBridge et al., 1987), and are routinely used in research due to their high 
transfection efficiency. HaCaTs are a spontaneously immortalised human keratinocyte 
cell line with a transformed phenotype, but remains non-tumouregenic and maintains 
full epidermal differentiation capacity (Boukamp et al., 1988). Cells lines were 
routinely cultured on standard tissue culture plasticware, flasks and plates, at 37°C in a 
humidified atmosphere in a 5% CO2 incubator. HEK293-T cells were maintained in 
DMEM (with phenol red) (Invitrogen, cat no: 21969-500) supplemented with 10% FBS, 
1% Penicillin (100U/ml) Streptomycin (100μg/ml), 1% L-glutamine (2mM) and 1ml 
Amphotericin B (0.5μg/ml) (all Gibco, Invitrogen). HaCaT cells were maintained in 
EpiLife medium (Gibco, cat no: MEPI500CA) supplemented with 1% 100X human 
keratinocyte growth supplement (containing growth promoting additives including 
recombinant epidermal growth factor, insulin and bovine pituitary extract; cat no: 
S0015), 0.2% Penicillin (20U/ml) Streptomycin (20μg/ml), 1% L-glutamine (2mM) and 
0.2ml Amphotericin B (0.1μg/ml) (all Gibco, Invitrogen). Media was replaced every 48 
hours. 
2.6.2 Cylindroma primary cell culture (CPCC) 
Tumour tissue obtained from surgery was stored in complete DMEM (as above) for 
transport of the samples and processed within 1-2 hours. Firstly any remaining 
overlying epidermis and fat were removed before the cylindroma tumour sample was 
cut up into 1-2mm pieces with scalpels in a petri dish. The tissue pieces were then 
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transferred to a sterile 15ml tube in 2-3mls of complete DMEM and centrifuged at 
x900rpm for 5 minutes. All subsequent centrifugation steps were carried out with 
these settings. Once the media had been decanted the tissue pieces underwent 
enzymatic digestion to gain a single cell suspension; firstly being resuspended in 5mls 
of 2.5% Trypsin (Gibco) for an hour at 37°C, followed by centrifugation and 
resuspension in 5mls of Collagenase (1mg/ml) (Sigma) for 95 minutes at 37°C, with 
periodic agitation of tubes in a waterbath. Tumour samples were centrifuged again 
then resuspended in 10mls of complete DMEM to inhibit any further enzymatic 
digestion. The cells were then filtered through a 40μm filter before being counted with 
a Neubauer chamber haemocytometer (section 2.6.6). Once counted, cells were 
seeded for experiments (see below), and the remaining cells cryopreserved (section 
2.6.5). Cells were seeded onto plasticware that had been coated with Type I collagen 
at a concentration of 0.661μl/cm2 using a collagen coating matrix kit (Gibco cat no: 
R011K). Primary cells cells were maintained in defined Keratinocyte Serum-Free Media 
(K-SFM) (Invitrogen, cat no: 10744-019) supplemented with 1ml 10X growth 
supplement, containing recombinant growth factors but not bovine pituitary extract, 
1ml Penicillin (20U/ml) Streptomycin (20μg/ml), 1% L-glutamine (2mM) and 0.2ml 
Amphotericin B (0.1μg/ml) (all Gibco, Invitrogen). Media was replaced every 48 hours 
with a 50:50 exchange of fresh media. 
2.6.3 Thawing of cell lines and primary cells 
Cells were removed from -80°C storage and thawed in a 37°C bead bath. The cell 
suspension was transferred into a sterile falcon tube and centrifuged at 200xg for 5 
minutes to remove the cryoprotective DMSO media. The pelleted cells were then 
resuspended in 7mls of pre-warmed complete growth media and transferred to a 
75cm2 flask and placed in an 5% CO2 incubator at 37°C. 
2.6.4 Routine passaging of cells 
Cells were passaged every 3-7 days depending on how quickly cells reached 
confluency. The cell growth media was removed and the cell monolayer was washed 
with sterile phosphate buffered saline (PBS) (Gibco). For HaCaTs and primary cells, the 
cells were initially incubated with Versene (an EDTA solution) (Gibco) for 5 minutes at 
37°C. Cells were then incubated with 0.5% Trypsin-EDTA for 5-15 minutes at 37°C. An 
equivalent volume of complete DMEM growth media was then added to neutralise the 
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Trypsin-EDTA and detached cells were collected and centrifuged to pellet the cells. The 
supernatant was discarded before cells were resuspended in complete growth media 
and passaged as required. 
2.6.5 Cryopreservation of cells 
To maintain stocks of cells, cultured cells were routinely cryopreserved in 
cryoprotective media consisting of 90% FBS (v/v) (Gibco) and 10% DMSO (v/v) 
(dimethyl sulphoxide) (ThermoFisher). Cells were trypsinised and resuspended in 
cryoprotective media. The cell suspension was divided into 1ml aliquots in cryogenic 
vials (ThermoFisher) and stored at -80°C for long-term storage. 
2.6.6 Cell counting 
Cells that had been trypsinised were counted prior to experiments using a Neubauer 
chamber haemocytometer. Cell pellets were resuspended in complete DMEM growth 
media and a 10μl aliquot of cell suspension was added to 10μl of trypan blue to 
discount dead cells. This cell suspension was then placed onto the haemocytometer 
and cells were counted in the two central grids; the liquid was of 0.1mm depth 
covering a 1mm square and therefore had a volume of 10-4 ml. The number of cells per 
ml was calculated and the cells then diluted to the required number for seeding. 
2.6.7 Culturing of cells on chamber slides 
Primary cells were counted and seeded onto glass cell culture chamber slides (8 wells 
per slide) (BD Falcon Biosciences) at a density of 10 x 104 cells/well. Wells had been 
collagen coated prior to seeding. Cell slides were cultured for 5- 7 days before cells 
were treated with 100ng/μl BDNF and 25ng/μl IL-6 diluted in 200ul of KSFM media, for 
30 minutes at 37°C in a 5% CO2 incubator. Following treatment of the cells, media was 
removed and cells were fixed in 4% PFA for 30 minutes before being washed with PBS 
and stored in fresh PBS at 4°C until required. 
2.6.8 3D cell culture on scaffolds 
Polystyrene tissue culture scaffolds (Alvetex) were first hydrated with 100% ethanol 
before being alternately washed with 70% ethanol and PBS twice before finally being 
coated with 32.5μl of Type1 collagen and 200μl KSFM. Scaffolds were left for 1 hour in 
the hood. Both primary cells and HaCaTs were seeded onto scaffolds. After cells had 
been counted, 3 x 106 cells were pelleted by centrifugation and resuspended in 200μl 
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of KSFM. Scaffolds were transferred into 6 well plates and the cell suspension was 
added drop wise onto the scaffold until covered. Scaffolds were then incubated for 1 
hour at 37°C in a 5% CO2 incubator. After, the wells were topped up with 5mls KSFM, 
slowly added down the wall of the well to gently flood the scaffold. Scaffolds were 
then left for 4 weeks with media changes every 2-3 days. 
2.6.9 Cell viability assay 
The viability of the cells was assessed using the CellTiterGlo luminescent cell viability 
assay (Promega), which quantitates the amount of ATP present as a marker of 
metabolically active ‘alive’ cells, and thus generates a luminescent signal that is 
directly proportional to the number of cells present. 
Cells that had been transfected were seeded at 1 x 104 cells/well into the central 60 
wells of a 96 well white tissue culture plate, with clear well bases. At least 10 wells 
were seeded per sample. Plates were left in a 5% CO2 incubator at 37C for 72 hours. 
The bottoms of the wells of the plates were taped over before growth media was 
removed and a 1:1 ratio of 40μl of fresh complete media and 40μl of CellTiterGlo 
solution was added to each well. Plates were then run on a Luminoskan (Thermo 
Scientific) to measure luminescence. The machine followed a program of plate shaking 
for 2 minutes followed by incubation for 10 minutes in the dark before taking 
measurements of luminescence as luminescent units (RLU) for each well. Control wells 
with no cells were included (in triplicate) to establish background luminescence. 
Experiments were repeated at least three times. Data was normalised and the mean 
value of the three replicates for each cell type plotted in GraphPad Prism v6.0 
(GraphPad Software Inc).  
Figure 2-4: 96 well set-up for drug assays. 
Drug conc. 
 
 
Drug 1 
Drug 2 
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2.6.10 Drug assays 
Cells that had been grown on 3D tissue scaffolds for 4 weeks had 2mm discs of the 
scaffold punched out, using a 2mm Harris uni-core (GE Healthcare) and placed into the 
inner 60 wells of a 96 well plate. The cells were maintained for 2 weeks in a final 
volume of 280μl of KSFM with inhibitors diluted in DMSO, with a final concentration of 
0.1% DMSO. Each drug was prepared as a 10X stock solution at a range of 
concentrations in KSFM media. 28μl of drug at the specified concentration was added 
per well and media changes were performed every 48 hours. After 2 weeks the cells 
were assayed using CellTiterGlo. Alternatively inhibitors were added to the growth 
media at the desired concentration to treat cells cultured in 6 well plates. Cells were 
incubated for 48 hours before being assayed by Western blot. 
2.6.11 Colony forming assay 
Cells that had been transfected were seeded at 2 x 103 cells per well into 6 well tissue 
culutre plates. Cells were grown for 8 days for colony formation before being fixed 
with 4% PFA for 30 minutes, washed with PBS and stained with 2mls of 0.57% 
sulphorhodamine in 1% acetic acid per well for 30 minutes.  Cells were then washed in 
1% acetic acid three times, left to dry overnight before being scanned. Plate images 
were analysed using Image J software (v 1.48; https://imagej.nih.gov/ij) to quantify 
staining in the images. RGB values were restricted to the colour of sulphorhodamine to 
distinguish areas that were positively stained and colony counts and total cell area 
were determined. Data was normalised and the mean value of the three replicates 
plotted in GraphPad Prism v6.0 (GraphPad Software Inc).  
2.6.12 Lentiviral mediated gene over-expression and silencing 
2.6.12.1 Lentivirus packaging and production 
Lentiviral vectors were used to deliver the pLEX and pGIPz shRNA vectors (Figure 2-5), 
for CYLD (shCYL1 and shCYL2) and TrkB isoforms, to the cell lines. Both pLEX-MCS 
empty vector and non-silencing shRNA vectors were used as controls (Thermo 
Scientific Openbiosystems). Lentiviral vectors were first packaged using a Trans-
Lentiviral packaging mix (Thermo Scientific Openbiosystems), containing the genes 
required for viral particle formation on 5 different vectors. A liposomal transfection 
technique was used to transfect HEK293T cells with a specified ratio of packaging mix 
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vectors to the lentiviral vectors in serum-free DMEM medium, with media changed to 
fully supplemented DMEM the next day. Cells were left for a further 48 hours before 
lentiviral-containing media was harvested. Media was cleared of cell debris by 
centrifugation followed by filtration (0.45M). Polybrene was added (4g/ml final 
concentration) to optimise transfection efficiency, and the lentivirus was aliquoted and 
stored at -80C. 
2.6.12.2 Lentiviral transduction of cell lines 
HaCaT and HEK293T cells were grown to 50%-70% confluence in 6 well plates before 
being transduced with 2mls lentiviral media for 24 hours. The media was then replaced 
with supplemented DMEM for HEK293T or EpiLife for HaCaTs and the cells grown for a 
further 48 hours. Puromycin selection was used (upto 5ug/ml) to obtain successfully 
transduced cells, with the shCYLD vectors also monitored for GFP expression.  
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Figure 2-5: Lentiviral vectors pLEX-MCS and pGIPz. 
The pLEX MCS and pGIPz vectors (both Open Biosystems) contain elements for lentiviral transduction 
and generation of stable cell lines. The gene of interest ligated into pLEX-MCS or a shRNA (shRNAmir) 
expression are under the control of the CMV promoter. Alongside other elements that are common to 
both of the vectors, including 5’LTR (5’ long terminal repeat), ampicillin resistance (bacterial selectable 
marker), IRES-Puro resistance, (mammalian selectable marker), SIN-LTR (3’ self inactivating long 
terminal repeat), WPRE (enhances the level of gene expression) and pUC Ori (high copy replication in 
E.coli). In addition the pGIPz vectors have Turbo GFP (marker to track shRNAmir expression). 
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2.7 RNA-seq 
RNA was extracted from snap frozen CYLD-defective tumours and perilesional control 
skin, quantified and RNA integrity checked as stated in sections 2.2.2 and 2.2.5. The 
samples were then sent to AROS Applied Biotechnology A/S (Denmark) for library 
preparation and RNA sequencing analysis. cDNA libraries were prepared from 200ng of 
RNA using the TruSeq stranded mRNA library prep kit (Illumina). During this procedure 
mRNA species within the samples are purified through poly-A selection, using poly-T 
oligo-attached magnetic beads, followed by fragmentation using divalent cations and 
heat. The RNA fragments were then sequentially subjected to first and second strand 
cDNA synthesis by random priming, 3’ adenylation and adaptor ligation, and finally 
PCR amplification to enrich for DNA fragments with adaptors attached at both ends 
ready for hybridisation of the cDNA library on to a flow cell for sequencing. Paired-end 
sequencing was performed on an Illumina Hiseq 2500 machine using version 4 
chemistry, giving a minimum of 84 million 100 base pair, paired end reads per sample. 
 
RNA-seq FASTQ files were processed and analysed by Mr Robert Stones (Newcastle 
University). The quality of the sequencing reads was checked using FastQC software. 
The reads were then aligned to the human reference genome GRCh38 using TopHat2 
(Kim, 2013). This is a program that is designed to identify exon-exon splice junctions in 
its alignment of reads to the genome. Differential gene expression between tumours 
and perilesional controls was performed using Cufflinks and CuffDiff (Trapnell, 2012). 
This is an algorithm designed to estimate the expression of a transcript by counting the 
number of fragments generated by it and learns how read counts vary for each gene 
across replicates and uses these variance estimates to calculate the significance of 
observed changes in expression (Trapnell, 2012), with outputs tabulated in a 
spreadsheet. BED files generated form this pipeline were visualised in integrated 
genomic viewer v2.3 (IGV) and GTF files were visualised in the UCSC genome browser. 
2.8 Statistical analyses 
All statistical tests were performed using GraphPad Prism Version 6.0 software 
(GraphPad Software Inc.). Paired and unpaired t-tests were used where stated, with a 
p- value of <0.05 considered significant. 
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3 Chapter 3: Investigation of the transcription factor MYB in CYLD-
defective tumours 
3.1 Introduction 
3.1.1 Chapter Aims 
Taking in to consideration the recognised histological similarities of cylindromas and 
adenoid cystic carcinoma (ACC), a salivary gland malignancy in which MYB-NFIB fusion 
expression is considered a molecular hallmark; in addition to MYB-NFIB fusion 
transcripts, and in the absence of fusions activation of MYB, having been identified in 
sporadic cases of cylindroma, the overall objective of the work in this chapter was to 
characterise the expression of MYB, including MYB-NFIB fusion transcripts, in inherited 
CYLD-defective tumours. The main aims were: 
 To assess whether inherited cylindromas express the MYB-NFIB transcript 
 To characterise the expression of MYB in inherited CYLD defective tumours 
 To determine whether CYLD regulates MYB expression using in vitro silencing 
and overexpression assays 
 To explore whether NF-B regulates MYB expression using in vitro drug 
inhibition assays 
3.1.2 The MYB family of transcription factors 
The highly conserved MYB family of genes includes three members A-MYB, B-MYB 
(also known as MYBL1 and MYBL2 respectively), and the most widely studied proto-
oncogene c-MYB (hereafter referred to as MYB for the gene and MYB for the protein). 
Each of the genes encode for nuclear proteins that act as transcriptional activators, 
with MYB in particular having a key role in regulating the proliferation and 
differentiation of the stem and progenitor cell niches in bone marrow, colonic crypts 
and the adult brain (Ramsay and Gonda, 2008). The three family members share 
extensive amino acid sequence homology and the structure of the MYB proteins has 
three main functional regions, including DNA-binding domains, a transactivating 
domain and a leucine-rich negative regulatory domain (NRD) (Figure 3-1) (Oh and 
Reddy, 1999). The major translational product of MYB is a 75kDa nuclear protein, 
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which has a short half-life of around 30 minutes (Bies and Wolff, 1997). However 
alternative splicing of the gene can produce a number of protein isoforms that have 
altered structures, and are discussed in more detail below.  
 
The DNA binding domain of the protein is constructed of three tandem 50 amino acid 
repeats (R1-3), and deletion analysis showed that R2 and R3 are required for the 
interaction between MYB and DNA (Howe et al., 1990; Saikumar et al., 1990), with 
MYB operating through recognition of the DNA sequence t/cAACt/gG known as the 
MYB binding site (MBS) (Ramsay and Gonda, 2008). However there are reports of MYB 
activation of gene transcription that is independent of DNA binding, such as activation 
of heat shock protein 70 (HSP70). Experiments revealed that MYB was capable of 
activating HSP70 through a heat shock element (HSE) within the promoter, but the HSE 
did not contain a MYB binding site, suggesting that alternate activation mechanisms 
such as interactions with other transcription factors or sequestration of promoter 
repressors by MYB facilitate gene activation (Foos et al., 1993; Kanei-Ishii et al., 1994). 
Additionally the DNA-binding domain of MYB was found to share strong structural 
similarity to the SANT (Swi3, Ada2, N-Cor and TFIIIB) domain, variants of which are 
found in the subunits of several regulatory chromatin-remodelling complexes and is 
responsible for the recognition of histone tails (Boyer et al., 2004). 
 
To induce target gene transcription that is DNA-binding dependent, the transactivation 
domain is required and involves the recruitment of co-activators CREB-binding protein 
(CBP) and p300 (Dai P. et al., 1996). MYB can also cooperate with other transcription 
factor families such as ETS and CEBP (CAAT enhancer binding protein) to enhance the 
transcription of target genes (Oh and Reddy, 1999). There have been a number of 
studies using various approaches, such as knockdown or over-expression of MYB as 
well as microarrays, to determine the targets of MYB, mainly using haematopoietic 
cells or cancer cell lines. More than 80 target genes have been identified and include 
other transcription regulators such as E2F4 and STAT5A, as well as genes involved in 
cell cycle progression, proliferation and survival such as c-Myc, Cyclin B1 (CCNB1), c-
Kit, and Bcl-2 (Bengtsen et al., 2015; Lang et al., 2005; Liu F. et al., 2006; Lorenzo et al., 
2011; Quintana et al., 2011; Zhao L. et al., 2011). Together these studies have 
contributed to understanding how MYB functions and the cellular processes that it 
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augments, but as is highlighted in section 1.1.4 the specificity of which target genes 
are activated is very much dependent on the cell context. 
Figure 3-1:  A schematic diagram of the protein structure of MYB and v-MYB. 
The major functional domains of c-MYB are shown in the top illustration. This includes the highly 
conserved DNA binding domain at the N-terminus, with the three, tandem amino acid repeats shown in 
blue. The transactivation domain in the middle is shown in green, with the negative regulatory domain 
in purple. The EVES motif (pink) includes sites for inter-protein interactions to modify the transcriptional 
activity of MYB. Below are the structures of the viral MYB oncogenes for comparison. v-MYBAMV is 
truncated at both the N and C terminals, and contains 11 point mutations (red stars) which contribute to 
the oncogenic transformation of the protein. Equally v-MYBE26 is truncated at both terminals but is fused 
with viral Gag and ETS proteins to form an active three-component fusion protein capable of 
transformation. Domains are not drawn to scale. (Image adapted from (Ramsay and Gonda, 2008). 
3.1.3 The proto-oncogene MYB 
The proto-oncogene MYB was first identified as the mammalian homologue of the 
transforming v-MYB oncogenes of the avian myeloblastosis virus (AMV) and E26 virus 
that induced erythroid and myeloid leukaemias, respectively, in chickens (Figure 3-1) 
(Beug et al., 1979; Leprince et al., 1983). Subsequently MYB was identified as a 
common integration site for other avian and murine retroviruses that caused 
leukaemia, due to the retroviral insertions of MYB translating into proteins with N- and 
C-terminal truncations which led to the disruption of key regulatory domains, and 
ultimately resulted in over-expression or inappropriate expression of MYB proteins 
with transforming capabilities (Ramsay and Gonda, 2008). Indeed duplication, genomic 
rearrangement and aberrant expression of MYB has been reported in various human 
malignancies, and is associated with poorly differentiated tumours, including different 
forms of leukaemia (Clappier et al., 2007; Lahortiga et al., 2007; Prinzhorn et al., 2016), 
breast cancer (Kauraniemi et al., 2000; Li Y. et al., 2016), colon cancer (Hugo et al., 
2006; Ramsay, Thompson, et al., 1992), melanoma (Hijiya et al., 1994), ACC (Bell et al., 
2016; Fehr et al., 2011; Ho et al., 2013), and oesophageal adenocarcinoma (Brabender 
et al., 2001).  
 
 
DNA binding Transactivation/Negative regulation 
 
    N C R1 R2 R3    
EVES 
c-MYB 
   N C R2 R3   ETS GAG v-MYBE26 
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In contrast to v-MYB and despite the association of MYB with several tumour types, 
the cellular counterpart MYB was found to only be capable of weak transformation of 
cells in vitro (Fu and Lipsick, 1997), in addition to being incapable of inducing 
leukaemia when over-expressed in all tissues of transgenic mice (Furuta et al., 1993). 
To this end comparisons have been made between the actions of v-MYB and the 
normal functioning of MYB proteins to try and elucidate the oncogenic switches in 
MYB activity. In addition to N- and C-terminal truncations (Grasser et al., 1991), there 
are 11 mutations that have been acquired in v-MYB of AMV. Those mutations that are 
situated in the DNA binding domain have been shown to abrogate the protein 
interactions between MYB and regulatory proteins and affect binding to target genes 
(Ivanova et al., 2007; Leverson and Ness, 1998; Tahirov et al., 2002; Wilczek et al., 
2009). Furthermore v-MYB and MYB were found to regulate largely distinct sets of 
target genes, implying that they are qualitatively different (Liu F. et al., 2006; Zhou and 
Ness, 2011). Due to some of the target genes of MYB being associated with 
proliferation and differentiation, it is thought that in general the persistent over 
expression of MYB leads to a blockade of anti-oncogenic differentiation and therefore 
maintains the cancer cells in an immature oncogenic proliferative state (George and 
Ness, 2014; Ramsay and Gonda, 2008). Indeed disrupting the function of v-MYB in 
transformed cells leads to a shift from proliferation to differentiation (Beug et al., 
1987). Of note however is the interesting observation that in luminal breast cancer, 
comprised of differentiated, mature luminal cells, MYB is highly expressed and may 
actually have a tumour suppressor role, as over-expression may be beneficial due to 
stabilisation of p53 (Thorner et al., 2010). This finding again suggests that the cell 
context is influential in the functioning of MYB. Overall the evidence so far has 
unveiled some of the potential mechanisms behind the transformation potential of 
MYB, but yet it still remains to be clarified how exactly MYB becomes oncogenic, and 
which of its target genes are responsible for cell transformation.  
3.1.4 Function of MYB 
Many studies involving MYB have focussed on its function in haematopoietic cells, due 
to the induction of leukaemia by v-MYB and after it was shown that the loss of MYB in 
homozygous null mutant mice was embryonically lethal at day 15 due to catastrophic 
defects in the development of the blood cell lineages, thus demonstrating the critical 
role of the protein in haematopoiesis (Mucenski et al., 1991). More recently the 
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conditional knockout of MYB has shown the importance of MYB as a key regulator of 
self-renewal and multi-lineage differentiation in adult haematopoietic stem cells 
(HSCs) (Lieu and Reddy, 2009). Additionally studies have supported a requirement of 
MYB to lineage commitment in T and B cell development (Allen R. D., 3rd et al., 1999; 
Greig et al., 2010). Furthermore differing thresholds of MYB expression levels are 
needed at distinct stages of differentiation (Emambokus et al., 2003; Sakamoto et al., 
2006) for normal development, with the highest levels of expression in the immature 
progenitor cells, which reduces as the cells differentiate (Oh and Reddy, 1999; Ramsay 
and Gonda, 2008; Zhou and Ness, 2011). In T-cells MYB expression can be activated by 
external signals, such as IL-2, and being a downstream effector of signalling pathways 
such as PI3K-Akt, protecting the cells from apoptosis (Lauder et al., 2001). Meanwhile 
identified target genes such as CyclinB1 show a role for MYB in G2/M cell cycle 
progression, and demonstrate a mechanism by which MYB regulates haematopoiesis 
(Nakata et al., 2007). Whilst others have found that the protein interactions of MYB 
are also critical to its function, especially the association of MYB with p300. In mice 
harbouring a form of MYB with a mutation in the transactivation domain, the 
interaction with p300 was disrupted leading to perturbed development and increases 
in the number of cycling HSCs, suggesting that this interaction is a key proliferation 
regulator (Sandberg M. L. et al., 2005).  
 
Equally though MYB has been shown to be involved in other high turnover cell 
compartments such as the intestinal crypts and neurogenic regions of the brain 
(Ramsay and Gonda, 2008). The epithelium lining of the intestinal crypts, much like the 
haematopoietic system, has a hierarchical structure of cell turnover, with the stem 
cells of the crypt base giving rise to progenitor cells which terminally differentiate to 
migrate to the crypt apex in the lumen. A number of MYB mouse mutant and knockout 
models were used to show that MYB is essential to the homeostasis of the crypts with 
MYB loss causing reduced crypt length and proliferation, alongside perturbation of 
lineage differentiation with a bias to just one cell type (Malaterre et al., 2007). More 
recently MYB was also shown to control the expression of intestinal stem cell genes 
like Lgr5 (Cheasley et al., 2011). Malaterre and colleagues also identified that the loss 
of MYB caused a reduction in proliferation of neural stem/progenitor cells and caused 
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a reduction in the expression of key target genes PAX6 and SOX2, suggesting that MYB 
was important in neurogenesis (Malaterre et al., 2008).  
3.1.4.1 The role of MYB in the skin and hair follicle 
It is thought that CYLD defective tumours are derived from the hair follicle (Massoumi, 
Podda, et al., 2006), and in studies regarding the development of mouse hair follicles it 
was found that MYB was abundantly expressed in hair follicles postnatally at P5, 
mainly within the outer root sheath under the bulge region (Vesela et al., 2014). This 
area is associated with transient-amplifying cells of the hair matrix leading the authors 
to conclude that MYB may be required in the activation of quiescent hair follicle stem 
cells leaving the niche. Although it was observed that there was no MYB expression at 
P21 (Vesela et al., 2014). Interestingly others have found that targeted deletion of MYB 
in CK14 (keratinocyte marker) positive cells caused a reduction in epidermal thickness 
and keratinocyte proliferation but not differentiation (Sampurno et al., 2015). 
Furthermore the loss of MYB resulted in perturbed collagen 1 production from 
fibroblasts due to a reduction in TGF-1 expression in the keratinocytes, 
demonstrating a role for MYB in the signalling axis between the two cell populations of 
the skin (Sampurno et al., 2015). Therefore from the above evidence it is clear that 
MYB expression is widespread and this evidence highlights the important functional 
role of MYB in the normal development of a variety of tissues including the skin. Taken 
alongside the different malignancies MYB has also been associated with, it suggests 
that the cell/tissue context is influential to the role of MYB; targeting different genes 
not only in different cell types but also cells at different maturity and even cell cycle 
stages (Zhou and Ness, 2011). 
3.1.5 Regulation of MYB 
A myriad of regulatory mechanisms are involved in the regulation of MYB at both the 
protein and mRNA level. The recognition of C-terminal domain truncations of both 
forms of v-MYB led to the suggestion that this deleted region of MYB may function as a 
negative regulator of its own actions. Particularly as it had been demonstrated that the 
loss of the C-terminal led to increases in the transcriptional, transformation and DNA 
binding activities of MYB (Gonda et al., 1989; Ramsay, Ishii, et al., 1992; Sakura et al., 
1989), supporting that this region is indeed important for modulating the activity of 
MYB. A number of structural motifs including a leucine zipper motif are found in the 
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NRD, and are thought to be involved after it was shown that swapping of one or more 
leucines to proline residues resulted in increased transactivation and transformation 
activity (Kanei-Ishii et al., 1992). In addition an isoform of MYB lacking the leucine 
zipper domain exhibits enhanced transactivational activities (Woo et al., 1998). The 
precise mechanism remains unresolved, but such proposals include the existence of an 
auto-regulatory loop, as MYB is capable of forming homodimers via the leucine zipper 
and is a target of itself (Nomura et al., 1993), or through interactions with proteins 
such as p67 and p160 (Favier and Gonda, 1994). Likewise the EVES motif is found in 
the NRD and was shown to interact with the DNA binding domain in the N-terminus 
(Dash et al., 1996). Similarly this motif was found in the transcriptional co-activator 
p100, which also interacted with MYB and could modify its transcriptional activity 
(Dash et al., 1996). Thus intra- and inter-molecular interactions are both involved in 
the regulation of MYB. 
 
Although perhaps the least understood post-translational modifications are another 
level of regulation that have the ability to alter the activity of MYB. For example in 
response to Wnt-1 signalling, MYB is targeted for proteasomal degradation through 
NEMO-like kinase (NLK) phosphorylation-dependent ubiquitination via the ubiquitin 
ligase Fbxw7- (Kanei-Ishii et al., 2004; Kanei-Ishii et al., 2008). Meanwhile 
phosphorylation can also alter the DNA binding capacity of MYB (Cures et al., 2001; 
Luscher et al., 1990). Similarly acetylation affects the transactivation capacity of MYB 
activity (Tomita et al., 2000), possibly by enhancing the affinity of MYB for CBP (Sano 
and Ishii, 2001), and finally sumoylation modifies its stability and transactivation 
capacity (Bies et al., 2002), again by interfering with the interaction of MYB with other 
co-activators such as p300 (Molvaersmyr et al., 2010).  
 
A blockade of transcription at the mRNA level, due to the presence of an attenuation 
sequence, exists in the first intron of c-MYB, which has to be overcome by RNA 
polymerase II to enable cells to express full-length transcripts (Bender et al., 1987). 
The differentiation of haematopoietic cells or the induction of differentiation through 
compounds such as histone deacetylase (HDAC) inhibitors causes the re-establishment 
of elongation arrest and leads to down-regulation of c-MYB expression levels (Ramsay 
et al., 1986; Thompson et al., 1998). Recently a mechanism was proposed for 
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overcoming the elongation blockade, involving the NFB subunits p50 and p65 
interacting with a RNA stem-loop and poly-T RNA tract that follows it, which is 
encoded for by the attenuator sequence in intron 1 of c-myb. The binding of p50 and 
p65 lending themselves to the recruitment of other co-factors such as P-TEFb (positive 
transcription elongation factor), a complex involving CDK9 (cyclin dependent kinase) 
and CyclinT1, allowing for Serine-2 phosphorylation of the CTD (carboxy-terminal 
domain) of RNA polymerase II and stimulation of c-MYB transcription elongation 
(Pereira et al., 2015). In addition NFB enhancer elements have been found to reside 
in Intron 1 of the murine MYB gene (Suhasini and Pilz, 1999), and NFB binding sites in 
the human c-MYB promoter (Lauder et al., 2001). Taken together these studies suggest 
that MYB is a target of NFB family members and that NFB may be able to regulate 
the MYB gene in a variety of ways. Whilst mutation of the elongation attenuation 
region of MYB has been found to be a common oncogenic mechanism in colorectal 
cancer, where sequence analysis of primary colorectal tumours revealed mutations in 
the poly-T tract allowing for greater gene expression (Hugo et al., 2006). Similarly this 
regulatory mechanism has been shown in breast cancer as the elongation of MYB 
transcripts has been found to be dependent upon the presence of ligand-bound ER 
(oestrogen receptor-alpha), which can relieve the transcriptional attenuation in 
intron1 (Drabsch et al., 2007). Indeed MYB was identified as a direct target of ER 
(Frasor et al., 2003) and subsequent studies have shown that the high MYB expression 
levels are a driver of proliferation in ER+ but not ER- breast cancer (Drabsch et al., 
2007). Similar to the action of NFB in the continuation of MYB transcription, 
independent of hormone, ER forms a complex with P-TEFb then upon oestrogen 
ligand binding this complex is recruited to the transcriptional pausing site (Mitra et al., 
2012).  
 
Finally miRNAs (microRNAS) have been found to post-transcriptionally regulate the 
expression of MYB. In haematopoietic cells, miR-15a was found to directly bind to the 
3’UTR (untranslated region) of MYB resulting in down regulation of MYB expression. 
Additionally miR-15a caused G1 cell cycle arrest when over expressed in the K562 
leukemic cell line which was partially rescued by the expression of a c-MYB construct 
that wasn’t subject to miR-15a regulation (Zhao H. et al., 2009). Equally MYB was 
shown to regulate miR-15a expression suggesting a negative autoregulatory feedback 
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loop (Zhao H. et al., 2009). Likewise miR-150 has been suggested to be a regulator of 
MYB protein translation in models of skeletal muscle differentiation and Burkitt 
lymphoma (Chen S. et al., 2013; Kaspar et al., 2015). 
 
It is clear that the function of MYB and regulation of MYB expression are complex and 
that each is controlled on many levels through a myriad of mechanisms involving a 
host of protein interactions. All of which, can be influenced by the cellular context. The 
apparent contradictory role of MYB in both stimulating proliferation and 
differentiation emphasises that MYB can regulate different sets of genes and alter its 
activities in response to different cellular circumstances. Further research is still 
needed though to decipher the context-specific transcription factor code, the post-
translational modifications and protein-protein interactions that regulate the activity 
of MYB (Ness, 2003). 
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Figure 3-2:  A schematic diagram of the isoforms of human c-MYB in relation to the 
MYB gene and protein structure. 
The structure of the c-MYB protein (top) is shown and the corresponding exons that encode for the 
different domains of the protein below. Exons 4-6 encoding the DNA binding domain, while exons 7-15 
encode for the C-terminal domains involved in transactivation, specificity and regulation. Six 
alternatively spliced isoforms of the gene exist in humans, all with alternate C-terminals isoforms 8A, 
13A and 14A are fused with extra amino acids (indicated in grey), whilst 9A and 10A have a truncated C-
terminus, Lastly isoform 9B has an insertion of 121 amino acids in the transactivational domain 
(indicated by grey striped box). Domains are not drawn to scale. (Diagram adapted from (O'Rourke and 
Ness, 2008). 
3.1.6 Alternative splicing of c-MYB and the protein isoforms of MYB 
The MYB gene is comprised of 15 exons but is subject to extensive alternative splicing 
through the use of 6 alternative exons, 8A, 9A, 9B, 10A, 13A, 14A (Figure 3-2). The 
complexity of MYB splicing is further increased due to exons 8 and 9 including cryptic 
splice donor sites, generating a short (8’) form of exon 8 lacking 9 nucleotides and a 
short (9S) form of exon 9 lacking 85 nucleotides (Close et al., 2004; Zhou and Ness, 
2011) The exon 8’ form can be spliced to either alternate exon 8A which are commonly 
seen together, or exon 9 (Close et al., 2004) The exon 9S form can be spliced to either 
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alternate exons 9A or 9B or exon 10 (Zhou and Ness, 2011). All of the exons that can 
be alternatively spliced are located in the region of the gene that encodes for the 
transcriptional activation and regulatory functions of MYB. Therefore incorporation of 
these exons leads to the production of many splice variants that can encode for MYB 
isoforms with differing C-terminal structures, and distinct transcriptional activities that 
could activate unique sets of target genes (Zhou and Ness, 2011).  
 
The work of O’Rourke and Ness analysed the alternately spliced transcripts of human 
MYB in primary haematopoietic and leukemic cells and cell lines. They showed that the 
transcripts containing exon 9A or 10A encode proteins that are prematurely truncated. 
However in the case of exon 10A it retains a part the negative regulatory domain of 
the c-terminus. Meanwhile exons 8A, 13A or 14A again create transcripts with a 
unique c-terminus by fusing MYB with an extra 34, 100 or 10 amino acids, respectively 
(O'Rourke and Ness, 2008). Additionally quantitative assays showed the expression 
patterns of the MYB variants to be considerably different between the cell types, and 
in particular increased MYB levels in the leukaemia patient samples. This was 
suggestive of a tightly regulated programme of alternative splicing of MYB, creating 
cell-type specific ratios of the different transcripts that are important to the regulation 
of haematopoiesis in normal cells, which when uncontrolled can promote oncogenesis 
(O'Rourke and Ness, 2008).  
 
Indeed recently it was demonstrated that in adult T-cell leukaemia (ATL) MYB 
expression was dysregulated and it was over expression of the c-MYB isoform 9A in 
particular that was a driver of the malignancy (Nakano et al., 2016). Likewise alternate 
transcripts that include exon 9B (confusingly the avian and murine forms are referred 
to as exon 9A) encode for a protein that is 89kDA, due to the insertion of 121 
additional amino acids in the middle of the transcriptional activation domain of MYB 
(O'Rourke and Ness, 2008). When over-expressed this isoform has been shown to have 
increased transactivational activities in avian and human cells (O'Rourke and Ness, 
2008; Woo et al., 1998), and was capable of transformation of avian cells (Woo et al., 
1998). In addition cell viability was increased when the isoform was over-expressed in 
murine cells (Kumar A. et al., 2003). Alongside this down-regulation of isoform 9B in 
BCR/ABL transformed cells, suppressed the proliferation and colony forming 
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capabilities of these cells as well as reducing their sensitivity to Imatinib (Manzotti et 
al., 2012). Attempts to understand the role of this isoform has led to the generation of 
a p89 c-MYB knockout mouse model but this showed no apparent phenotype, which is 
in stark contrast to the embryonic lethality at day 15 seen in p75 c-MYB knockouts, 
and suggests that the expression of the predominant p75 isoform of c-MYB can 
compensate for the loss (Baker et al., 2010; Mucenski et al., 1991). So as with the 
other isoforms, further studies are required to elucidate the differing functions of the 
transcripts and their downstream target genes to fully understand their role. 
 
 
 
 
 
 
 
Figure 3-3:  The differential activities of A-MYB, B-MYB and c-MYB. 
The Venn diagram summarises the number of genes that were activated following expression of each 
MYB protein. This highlights the specificity in the gene sets that are activated (>two fold) by each of the 
MYB proteins, with very little overlap seen between them. Of the 65,000 genes that were represented 
on the array, only 4 genes were activated in response to all 3 MYB family members. MCF7 cells were 
infected by adenoviruses expressing each of the MYB family members and assayed using the Affymetrix 
U95A-E Gene chips. Diagram was taken from (Ness, 2003) and based on results from (Rushton et al., 
2003). 
3.1.7 The other MYB family members: A-MYB and B-MYB 
The other family members A-MYB and B-MYB also encode transcription factors, which 
share a high degree of sequence homology, largely in the DNA binding domain. 
Therefore all three members of the family can bind the same DNA sequences and 
activate the same promoters in reporter gene assays (Rushton and Ness, 2001). 
However microarray assays have found each member to activate its own unique set of 
endogenous genes when over-expressed in MCF7 cells, suggesting that each member 
has its own distinct interacting partners and functions in a context-specific manner 
(Figure 3-3) (Rushton et al., 2003). As with the c-MYB isoforms it appears to be the 
variation in the C-terminus structure that determines the unique functional roles of 
these family members, as only the DNA binding domain was shown to be 
interchangeable in domain swapping experiments (Rushton and Ness, 2001). On the 
contrary a study by Bergholtz et al found that small conserved differences of the DNA-
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binding domain fine-tuned the specificity of each family member. Whilst A-MYB and c-
MYB functioned similarly, B-MYB was found to form complexes with less stability and 
had a lower tolerance for variations within the MBS (Bergholtz et al., 2001). 
Furthermore differences in specificity between A-, B- and c-MYB maybe explained by 
studies that have found sub domains within the transactivation domain between A-
MYB and c-MYB (Lei et al., 2004), and likewise B-MYB was found to have a c-terminus 
with functional subdomains different to A-MYB and c-MYB, that acted as both positive 
and negative regulators of its transcription activation (Nakagoshi et al., 1993; Oh and 
Reddy, 1998). 
 
There is some overlap in the expression of all three family members, with some cell 
types particularly within the bone marrow, capable of expressing more than one family 
member. The expression pattern of A-MYB compared to B-MYB is more restrictive as it 
is found in select tissue compartments such as the developing mammary gland and 
testis (Toscani et al., 1997), central nervous system and B-lymphocytes (Trauth et al., 
1994). Meanwhile B-MYB is more ubiquitously expressed (Oh and Reddy, 1999), with 
very early developmental arrest observed in mice when this gene is knocked out 
(Tanaka Y. et al., 1999). The expression of B-MYB plays an important role in the cell 
cycle by inducing the transcription of genes that promote entry in to the S and M 
phases of the cycle. Conversely B-MYB repression induces premature senescence 
(Martinez and Dimaio, 2011). Indeed B-MYB has been found to have an important role 
in maintaining the undifferentiated phenotype of keratinocytes and enhancing their 
proliferation (Maruyama et al., 2014). Due to the control B-MYB can exert on cell 
behaviour it is therefore not surprising that it has also been suggested to have a role in 
tumourigenesis as the over-expression of B-MYB is associated with a poorer prognosis 
in neuroblastoma (Raschella et al., 1999) and breast cancer (Thorner et al., 2009). 
Similarly A-MYB has been shown to be a potential interchangeable oncogenic driver 
with c-MYB in adenoid cystic carcinoma (Brayer et al., 2016). 
3.1.8 CYLD-defective tumours and Adenoid cystic carcinoma 
A cancer of the secretory glands, ACC is commonly found in the salivary glands of the 
head and neck and in rare incidences the breast. A slow growing tumour, it is 
aggressive and can lead to metastasis (Drier et al., 2016). However with restricted 
treatment options, especially for patients with metastatic disease, of surgery and/or 
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radiation therapy, research has been focused at the molecular level to discover targets 
for curative and non-operative treatment approaches (Adelstein et al., 2012; Stenman 
et al., 2014). MYB over-expression has been found to be a key alteration in ACC 
development, and in a sub-set of ACCs a molecular hallmark is the chromosomal 
translocation t(6;9)(q22-23;p23-24), which results in the fusion of the oncogene MYB 
with the transcription factor gene NFIB (Nuclear Factor I B) (Ho et al., 2013; Mitani et 
al., 2010; Persson et al., 2009; Stenman et al., 2014). The genomic rearrangement 
causes constitutive activation of MYB, due to the loss of miRNA binding sites in the 
3’UTR, which negatively regulate MYB expression. The fusion protein MYB-NFIB, 
however retains the DNA-binding and transactivation domains, and is therefore 
capable of activating MYB target genes and thus promote oncogenesis (Persson et al., 
2009; Stenman et al., 2010). With alternative splicing and variable breakpoints in both 
MYB and NFIB, a number of fusion transcript variants have been identified with the 
most common consisting of MYB exon 14 linked to NFIB exons 8c or 9 (Persson et al., 
2009; Persson et al., 2012). More recently analysis of MYB in ACC found the MYB-NFIB 
fusion to only disrupt the 3’UTR in a third of cases, and proposed that the high levels of 
MYB expression found in ACC were due to chromosomal ‘regulatory rearrangements’ 
that juxtapose super-enhancer regions to the MYB locus. Here the enhancers interact 
with the MYB promoter and MYB itself then binds the enhancers to establish a positive 
feedback loop and augment its own expression (Drier et al., 2016).  
 
Interestingly the MYB-NFIB fusion transcript provides a genetic link between ACC and 
cylindroma, with sporadic cases of dermal cylindromas having also been found to 
express fusion transcripts or show increased activation of MYB in the absence of such 
fusions, although at a lower frequency (Fehr et al., 2011). Meanwhile other striking 
similarities between ACC and cylindroma have been observed. Histologically the two 
tumour types share a cylindrical pattern arrangement of multiple lobules of tumour 
cells.  Alongside this others have reported areas of ACC-like differentiation arising in 
spiradenocylindroma and spiradenomas (Petersson et al., 2009). There have also been 
somatic CYLD mutations reported in ACC, although due to the very low frequency (4%) 
it is unlikely that CYLD contributes to ACC tumourigenesis (Daa et al., 2013; Stephens 
et al., 2013). Conversely there are incidences of patients with germline CYLD mutations 
who develop multiple cylindromas also developing membranous basal cell adenomas 
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(MBCA), another salivary gland tumour with morphological similarities to cylindroma 
(Jungehulsing et al., 1999). Finally the overlap between ACC and cylindroma is 
indicated further with both tumour types over-expressing TrkC (Ivanov et al., 2013; 
Rajan, Elliott, et al., 2011). It was found that TrkC expression levels were increased up 
to 100-fold compared to normal salivary tissue, and that in the presence of its cognate 
ligand NT-3 it stimulated pro-invasive signalling and behaviour, providing a link 
between TrkC and cancer progression in ACC (Ivanov et al., 2013). The conclusions 
from these studies therefore warranted further investigation of MYB in inherited CYLD- 
defective tumours. 
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3.2 Chapter specific materials and methods 
3.2.1 Nester RT-PCR 
Nested PCR is a modified approach to traditional PCR that is used to reduce the 
amplification of non-specific products by running two successive rounds of PCR 
amplification. The product from the first round is used as the template for the second 
round, with the separate rounds using different primer sets. The second set of nested 
primers is designed to only amplify a target within the intended product from the first 
round of amplification, therefore increasing the specificity of the PCR reaction. 
3.2.1.1 Sample preparation 
Total RNA was extracted from five 10m sections obtained from snap frozen 
cylindroma tumour samples using the RNeasy Mini-kit (Qiagen). Subsequently 2000ng 
of extracted RNA was converted to cDNA using Superscript First-strand synthesis 
system (Invitrogen) as explained in section 2.2.6, to give a final concentration of 
100ng/l in the final 20l reaction volume. 
3.2.1.2 RT-PCR 
RT-PCR was carried out according to the validated protocol in (Persson et al., 2009). 
Each reaction was set up on a 96 well plate according to Table 3-1, with a total 
reaction volume of 25l/well. Both rounds of PCR followed the same cycling program 
and were run under the conditions according to Table 3-2. Final PCR products were 
then run out on a 2% agarose gel at 100 volts for 1 hour to visualise the presence of an 
amplification product. For all samples each RT-PCR was repeated in triplicate. 
 
 
 
 
 
 
 
Table 3-1: Reaction mixture for nested RT-PCR. 
 
 
Reaction component Per reaction 
MyTaq™ HS Mix 12.5μl 
Primer F (20μM) 0.6μl 
Primer R (20μM) 0.6μl 
Nuclease-free water 10.3μl 
Template (100ng) or from PCR1 1 μl 
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Table 3-2: Thermocycling conditions for nested RT-PCR 
3.2.2 Fluorescence in situ hybridisation (FISH) 
FISH is a technique widely used to detect genomic rearrangements by using 
fluorophore-labeled probes that specifically hybridise to the part of a chromosome 
with a high degree of sequence complementarity, which can then be visualised with a 
fluorescent microscope to indicate the location of the target DNA. A dual colour split 
FISH probe is designed with two different coloured fluorophores to detect gene 
translocations. FISH analysis for the detection of MYB gene rearrangements, was very 
kindly carried out by the group of Prof. Goran Stenman (University of Gothenburg, 
Sweden). FFPE sections (5m) from 10 cylindroma tumours were probed using a dual 
colour MYB split FISH probe (Abnova, Taiwan), according to manufacturer’s 
instructions. Flourescence signals were imaged and analysed using the Isis FISH 
imaging system v5.5 (MetaSystems GmbH, Germany) and at least 50 nuclei were 
scored from each tumour. 
3.2.3 Gene silencing in cell culture 
3.2.3.1 RNA inteference 
RNA interference is a post-transcriptional process mediated by short interfering RNA 
(siRNA) that leads to gene silencing. siRNAs are double-stranded RNA (dsRNA) 
duplexes that are 20-25bp in length with 3’ dinucleotide overhangs, formed by the 
cleavage of long dsRNAs by the RNA endonuclease Dicer enzyme. Upon entry into the 
cell siRNA is incorporated into the RNA-induced silencing complex (RISC), whereby the 
siRNA is unwound and one of the RNA strands is selected and the partner strand 
degraded. The selected ‘guide strand’ stays within the complex regulating gene 
expression via hybridising to their complementary nucleotide sequence within the 
target mRNA, initiating mRNA fragmentation and degradation by activated 
Step/Cycles Temperature Time 
Initial denaturation 94°C 2 minutes 
31 cycles 94°C 30 seconds 
60°C 30 seconds 
72°C 45 seconds 
Final extension 72°C 8 minutes 
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endonucleases and thus preventing translation into proteins. This is a mechanism that 
has been exploited in the laboratory using synthetic siRNAs that are designed 
accordingly to ‘knock down’ the expression of a target gene of interest. 
 
The use of short-hairpin RNAs (shRNAs) works on the same principles as above. 
shRNAs are double-stranded RNA duplexes that are 19-22bp in length linked by a short 
loop. The main difference to siRNA is the requirement of an expression vector to 
deliver the artificial RNA molecule to the nucleus of the cells to allow for shRNA 
expression. Once integrated into the genome, the shRNA is then transcribed by RNA 
polymerases and processed by the RNA endonuclease Drosha, before finally being 
exported into the cytoplasm. Here further processing of the loop structure by Dicer 
occurs before being loaded into RISC and following the same downstream processing 
leading to silencing of the target gene. 
3.2.3.2 siRNA transfection of primary cylindroma cell cultures 
siRNA gene silencing experiments in primary cylindroma cells were kindly carried out 
by the group of Prof. Goran Stenman (University of Gothenburg, Sweden). Briefly 
primary cylindroma cells were cultured in assay plates, until at the desired confluency 
for transfection. Cells were then transfected with 50nM Stealth RNAi MYB siRNAs 
(HSS106819 and HSS106821) (Thermo Fisher Scientific), using Lipofectamine RNAiMAX 
transfection reagent in antibiotic-free medium (Life Technologies) according to the 
manufacturer’s instructions. A non-targeting siRNA was used as a negative control. In 
line with the manufacturer’s guarantee to yield >70% gene knockdown, efficient 
knockdown was confirmed by qPCR and Western blotting for each siRNA duplex used. 
Experiments were performed in triplicate and cells were treated with siRNA for the 
time periods indicated. 
3.2.3.3 shRNA transfection of cell lines 
Lentiviral vectors were used for the delivery of CYLD shRNAs to HEK293T and HaCaT 
cells for gene silencing experiments. See Materials and Methods section 2.6.12 for the 
generation and packaging of lentiviral vectors and cell transduction.  
3.2.4 Cell proliferation assay 
As part of the knockdown experiments, these assays were also kindly carried out by 
the group of Prof. Goran Stenman (University of Gothenburg, Sweden). Cell 
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proliferation was assayed using alamarBlue reagent (Thermo Fisher Scientific), 
according to the manufacturer’s instructions. This assay measures cell proliferation by 
using an oxidation-reduction indicator which results in a colour change from blue 
(oxidised) to red (reduced) in response to the metabolic activity of cell growth, which 
can be quantified by taking absorbance readings. In brief alamarBlue reagent was 
added directly to the cells to be assayed at a 1:10 dilution, before being left to 
incubate at 37C. Readings were taken using a VICTOR-3 multilabel reader (Perkin-
Elmer). 
3.2.5 Treatment of cells with NF-B inhibitors 
Primary cylindroma cells were plated out into 6 well plates at a density of 1.5 x105 
cells/well. Cells were left for 24 hours before being treated with DMSO, TPCA-1 or 
BMS345541 for 48 hours and subsequently trypsinised and collected for lysates. DMSO 
only controls were included at the larger dilution volume of the two drugs. 
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3.3 Results 
3.3.1 Familial CYLD-defective tumours do not express MYB-NFIB fusion transcripts 
As the fusion oncogene MYB-NFIB has previously been described in sporadic 
cylindromas (Fehr et al., 2011), a validated nested RT-PCR approach was used to detect 
the presence of fusion transcripts in inherited CYLD-defective tumours. A panel of 13 
cylindroma tumours, from five patients, were screened for the most common MYB-
NFIB fusion transcript variants (Table 3-3) (as described by (Fehr et al., 2011; Persson 
et al., 2009). As a positive control cDNA generated from a fusion-positive 
(MYBexon14–NFIBexon8c) ACC was used, as this fusion variant was one of the more 
commonly detected fusion transcripts (sample gifted from Prof. Goran Stenman, 
University of Gothenburg, Sweden). None of the tumour samples were found to 
express any of the MYB-NFIB fusion transcript variants tested for, as indicated by the 
lack of amplified fragments in Figure 3-4.  
 
In collaboration with the Prof. Stenman, 10 additional inherited CYLD defective 
tumours (FFPE samples), which included cylindroma, spiradenoma and spiradeno-
cylindroma, were also screened using nested RT-PCR as above, for the expression of 
the same MYB-NFIB fusion transcript variants. All 10 tumours were also found to be 
negative for each transcript variant. Additionally fluorescence in situ hybridisation 
(FISH) analysis with a dual-colour MYB break apart probe, was carried out by Prof. 
Stenman and colleagues, on the same 10 tumour samples to identify any 
rearrangements of the MYB locus. A fusion-positive ACC was used as a control. In 
support of the findings of the RT-PCR experiments, no rearrangements or copy number 
gains/amplifications involving the MYB locus were identified in any of the inherited 
tumour samples, as indicated by the fused red/green signals in the FISH analysis which 
represent an intact MYB allele (Figure 3-5). Together these results indicate that 
inherited tumours do not express MYB-NFIB fusion transcripts. (Prof. Stenman and 
colleagues at the University of Gothenburg, Sweden, performed the FISH analysis 
included in this results section). 
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Table 3-3: MYB-NFIB fusion primer pairs and their corresponding fusion transcript. 
Fusion primer pairs with numbers corresponding to the fusion transcript variant screened for and 
numbering for the lanes of the gel showing the nested RT-PCR result (below). 
 
Figure 3-4: MYB-NFIB fusion transcripts were not detectable in inherited cylindromas 
using nested RT-PCR. 
Representative agarose gel images from RT-PCR analysis of each of the five MYB-NFIB fusions (Table 3-3) 
screened for in a panel of inherited cylindroma tumour samples (left panel n=13). The expected PCR-
fragments from the fusion-positive (MYBexon14–NFIBexon8c) ACC control are also shown for 
comparison (right panel). Lane numbering corresponds to Table 3-3 above (Data representative of N=3 
independent experiments). 
  
Gel label Primer Pair  
(2nd round PCR) 
Fusion transcripts 
1 MYB Exon6-876 
NFIB Exon9-1952 
MYBexon8-NFIBexon9 
2 MYB Exon9-1334 
NFIB Exon9-1952 
MYBexon10-NFIBexon9 
3 MYB Exon 11-1554 
NFIB Exon9-1952 
MYBexon12-NFIBexon9 
4 MYB Exon 12-1693 
NFIB Exon9-1952 
MYBexon14-NFIBexon9 
5 MYB Exon 12-1693 
NFIB Exon8c-1067 
MYBexon14-NFIBexon8c 
Inherited 
Cylindroma 
L        1     2     3     4     5  
MYB-NFIB fusion 
primer pairs 
100 
500 
1500 
Control 
(ACC fusion positive) 
100 
500 
1500 
L      1     2     3     4     5  
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Figure 3-5: MYB-NFIB fusion transcripts were not detectable in inherited cylindromas 
using FISH. 
(A & B) FISH analysis of two inherited cylindromas, each showing two non-rearranged copies of MYB in 
each cell nucleus (arrows indicate fused red/green signals) (C) FISH analysis of an adenoid cystic 
carcinoma that is MYB-NFIB fusion-positive (control), showing rearranged copies of MYB, the split signal 
consistent with a MYB gene fusion (arrows indicate separated red and green signals; arrowhead, intact 
MYB allele). Figure taken from (Rajan et al., 2016) and produced by collaborators at the University of 
Gothenburg, Sweden. 
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3.3.2 MYB protein is overexpressed in inherited CYLD-defective tumours 
In both ACC and sporadic cylindromas small sub-sets of tumours were found to have 
MYB activation despite a lack of fusion transcripts (Fehr et al., 2011; Persson et al., 
2012). Due to the lack of fusion transcripts in the inherited CYLD-defective tumours, 
the expression of MYB protein was assessed using immunohistochemistry to further 
investigate. Tissue sections from 16 tumours including both cylindromas and 
spiradenomas, were probed with MYB antibody, visualised with DAB and quantified. 
Samples were considered MYB positive if >15% of cells demonstrated MYB expression. 
In both the cylindromas (Figure 3-6A) and the spiradenomas (Figure 3-6B) MYB 
expression was shown to have a nuclear localisation (Figure3-6A&B; Black and White 
arrows in inset), which varied in intensity throughout the tissue sections. In both 
tumour types there was a scattered pattern of MYB expression, which was not 
restricted to the basal cells of the tumour cell islands as immuno-positive cells were 
seen throughout some of the islands in the cylindroma samples. In comparison in 
control perilesional (CYLD +/-) and normal skin (CYLD +/+) MYB demonstrated a 
cytoplasmic localisation in the majority of cells (Figure 3-6C & D). Positive nuclear MYB 
expression was also observed within the hair follicles surrounding the dermal papilla 
(Figure 3-6E). Semi-quantitative analysis of the immunostaining intensity using ImageJ 
software showed that out of the 16 tumours analysed, 11 tumours (69%) were 
considered MYB-positive (Figure 3-7A). Furthermore there was a significant increase in 
MYB expression in the CYLD-defective tumours when compared to control perilesional 
epidermis (CYLD +/-) (p = 0.031) (Figure 3-7B).  
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Figure 3-6:  MYB protein expression is increased in inherited CYLD-defective tumours 
as assessed by IHC. 
(A & B) MYB protein expression in (A) cylindromas and (B) spiradenomas demonstrating nuclear 
localisation (black arrows inset (A) and white arrows inset (B)). (C & D) MYB protein expression in 
control perilesional skin from a CYLD mutation carrier (C) and age matched control unaffected skin (D) 
demonstrating cytoplasmic nuclear localisation. (E) MYB protein expression in hair follicles 
demonstrating nuclear localisation surrounding the dermal papilla (black arrows). Scale bars represent 
50m. 
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Figure 3-7: Quantification of MYB protein expression in CYLD-defective tumours. 
(A) Semi-quantitative analysis of the immunostaining intensity of MYB showed that 11 /16 (69%) 
samples analysed were MYB positive. (B) Protein expression of MYB was significantly increased in CYLD-
defective tumours compared to control perilesional skin (CYLD +/-) (* p <0.05, unpaired t-test) 
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3.3.3 A MYB gene expression signature is found in inherited CYLD-defective 
tumours 
Microarray gene expression studies, in a pool of CYLD-defective tumours (n=32) and 
perilesional skin controls (n=10), had previously been performed by Dr. Neil Rajan 
(Rajan, Elliott, et al., 2011). Using this dataset the expression of MYB and selected MYB 
target genes from the published literature were analysed by Dr. Neil Rajan, and the 
results have been included as further supporting evidence of the expression of MYB 
and of the work within this chapter to offer insight into its activity within the tumours. 
Differentially expressed MYB target genes in CYLD-defective tumours compared to 
controls were determined with a threshold for statistical significance of p < 0.05 after 
correction for multiple hypothesis testing. To visualise the expression of each of the 
genes (n=48) at an individual sample level, normalised signal values were plotted on a 
heat map, following logarithmic transformation (Figure 3-8) and as described in (Rajan 
et al., 2016). Clustering by Euclidean distance separated the majority of tumours, 
including all cylindromas and spiradenomas, from control skin with the exception of 
two trichoepitheliomas (tumours 1 and 30). 
 
In this independent dataset, MYB was shown to be overexpressed in the tumours 
(fold-change increase = x 2.04). Gene targets that were found to be overexpressed 
included BIRC3 (fold-change increase = x 3.93) and Bcl-2 (fold-change increase = x 2.34) 
(Table 3-4), which are both anti-apoptotic proteins. In contrast the expression of some 
gene targets that have previously been reported to be overexpressed in certain 
malignancies, such as CCNE1 (Cyclin E1) in colorectal cancer (Cheasley et al., 2011), 
and CD34 in ACC (Persson et al., 2009), were downregulated in CYLD-defective 
tumours; CCNE1 fold-change increase = x 0.55, CD34 fold-change increase = x 0.50 
(Table 3-4). These results again highlight the cell-specific nature of MYB activity, whilst 
also suggesting that MYB may contribute to tumourigenesis in the tumour cells by 
preventing apoptosis. 
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Figure 3-8: The expression of MYB and MYB target genes in CYLD-defective tumours 
and perilesional skin. 
A heat map plot illustrating the expression levels of MYB and known MYB target genes in 32 CYLD-
defective tumours and 10 controls (samples indicated at the bottom of the heat map). Differentially 
expressed genes were determined (p <0.05) between tumours and controls, and transcript expression 
levels at a single sample level are displayed on the heat map; red, over-expressed transcripts; blue, 
under-expressed transcripts; gene names indicated on the right-hand side of the figure; where data 
from multiple transcripts for a single gene were available are indicated with a numerical suffix (n = 8). 
Clustering by similarity is shown, determined by Euclidean distance. 
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Table 3-4: Differentially expressed MYB target genes in CYLD-defective tumours 
compared to perilesional control skin. 
The fold changes (FC) of transcripts are included for differentially expressed genes with a threshold of p 
< 0.05. Red indicates genes that are overexpressed and blue indicates genes that have reduced 
expression in CYLD-defective tumours compared to control. (For genes with more than one transcript as 
indicated on the heat map the highest value is shown). 
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3.3.4 MYB overexpression promotes the proliferation of primary CYLD-defective 
cylindroma cells 
To investigate the biological significance of MYB over-expression in inherited CYLD-
defective tumours MYB mRNA expression was silenced using two siRNAs in cultured 
primary CYLD-defective cylindroma cells. Cells were cultured from three different 
primary tumours, which had been taken from two patients whom were undergoing 
surgical excision. Analysis by qPCR of MYB mRNA expression following 48 hours of 
siRNA treatment showed successful knockdown of MYB by both siRNAs (Figure 3-9A). 
This result was confirmed by MYB protein expression also being reduced following 72 
hours of siRNA treatment (Figure 3-9B). Primary cell cultures were treated with MYB 
siRNA for 6 days, and it was shown that in each of the three primary CYLD-defective 
cell cultures the silencing of both MYB mRNA and protein levels led to a significant 
decrease in cell proliferation (p = < 0.001) (Figure 3-9C). This result suggests that MYB 
expression is important in the regulation of proliferation in CYLD-defective 
cylindromas. (Prof. Stenman and colleagues at the University of Gothenburg, Sweden, 
generated the data included in this results section). 
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Figure 3-9:  Silencing MYB expression reduces the proliferation of primary CYLD-
defective cylindroma cells. 
(A) RT-qPCR analysis of MYB mRNA expression in cultured cells from case 1, following 48 hours of MYB 
siRNA treatment. (B) Western blot analysis of MYB protein expression in cultured cells form case 1, 
following 72 hours of MYB siRNA treatment (Data representative of 3 independent experiments) (C) 
Effect of MYB knockdown on the proliferation of cultured primary cylindroma cells, following 6 days of 
MYB siRNA treatment. Cells were derived from three individual tumours. (Data are the mean and error 
bars represent SEM of n=3 experiments. **p <0.01 ***p <0.001.) Figure taken from (Rajan et al., 2016) 
and produced by collaborators at the University of Gothenburg, Sweden. 
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3.3.5 CYLD can regulate MYB expression in HEK293T and HaCaT cell lines 
In order to recapture the cellular context of the tumours and to determine if a loss of 
CYLD directly affected MYB expression, CYLD mRNA expression was silenced using two 
shRNAs, shCYL1 and shCYL2, in HEK293T and HaCaT cells alongside the relevant 
negative non-scrambled shRNA control (NSC). The haematopoietic cell line Jurkat, was 
included as a positive control for MYB. In both cell lines a conflicting result is seen in 
response to each of the shRNAs. Conversely in the HEK293T cells compared to control 
MYB levels decrease when CYLD expression is repressed using shCYL1, but increase 
when shCYL2 is used (Figure 3-10A). In HaCaTs the opposite result is seen with shCYL1 
increasing the level of MYB expression and shCYL2 decreasing it (Figure 3-10B). CYLD 
expression is reduced by each shRNA but there is no detectable difference in the 
efficiency of the transduction between the two shRNAs in either cell line. Intriguingly 
however the band for MYB in the HaCaT cells occurs above the 85kDA protein ladder 
marker, in contrast to the 75kDA MYB band seen in the HEK293T cells. This suggests 
differential splicing between the two cell types and that the prominent isoform 
expressed in keratinocytes is isoform MYB 9B (89kDA). 
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Figure 3-10: Silencing CYLD expression affects MYB protein expression in HEK293T 
and HaCaT cells. 
(A&B) Western blot showing the effect of CYLD knockdown using two shRNA constructs on MYB protein 
levels in the HEK293T cell line (A) or the HaCaT cell line (B). The Jurkat cell line was used as a positive 
control for MYB. The Western blot shown is representative of 3 independent repeats (A) and 2 
independent repeats (B). GAPDH was used as a loading control. 
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3.3.6 Overexpression of catalytically inactive or truncated CYLD affects MYB 
expression in the HEK293T cell line 
Due to the conflicting results from the shRNA silencing experiments, the up-regulation 
of MYB in CYLD-defective tumours was instead further investigated in overexpression 
studies. Lysates from HEK293T cells over-expressing either wild-type CYLD, catalytically 
inactive (p.C601S) or truncated CYLD harbouring patient specific mutations, were 
probed with an anti-MYB antibody to determine whether the loss of CYLD accounted 
for the increase in the expression of MYB. Empty vector was used as a negative control 
(Figure 3-11). For all CYLD mutants except c.2290-94del5, there was no observed 
change in MYB protein expression when compare to wild-type CYLD or empty vector. A 
slight decrease in the expression of MYB protein was seen in cells overexpressing 
c.2290-94del5 mutated CYLD, however this may be due to the reduced level of 
overexpression and is contrary to the hypothesis of mutant CYLD causing an increase 
in the expression of MYB. These results indicate that the loss of functional CYLD alone 
is not the determining factor for increased MYB expression in the tumours, and that 
other indirect mechanisms that are independent of CYLD catalytic activity have a role 
in driving the increased expression of MYB.  
 
Figure 3-11: Overexpression of wild-type, catalytically inactive or truncated CYLD in 
HEK293T cells does not affect MYB protein expression.  
Cell lysates were generated from cells overexpressing wild-type, catalytically inactive or truncated CYLD, 
run on a membrane and probed with MYB and CYLD antibodies. GAPDH was used as a loading control. 
The Western blot shown is representative of 3 independent repeats.  
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3.3.7 MYB isoform MYB 9B is upregulated in inherited CYLD-defective tumours 
RNA-seq data was utilised to look at the expression of alternatively spliced isoforms of 
MYB in a number of cylindroma tumours (n=16), with aligned and exon junction sorted 
reads visualised using the UCSC genome browser and IGV. When comparing the 
tumours to control perilesional skin (n=4; from mutated CYLD carriers) it was observed 
that expression of the MYB gene was increased (Figure 3-12), as indicated by the scale 
of the Y-axis and the difference in the height of the read-depth peaks. The RNA-seq 
data supporting what had been shown at the protein level with IHC. The mapping of 
the RNA-seq reads to exon junctions (see Figure 3-13) demonstrated that there was 
also an increase in the tumours of alternate exon inclusion in the MYB transcripts 
compared to the controls (Figure 3-12 & 13), as indicated by the number and thickness 
of the red arcs in the IGV software. In particular it was shown that there were an 
increased number of reads at the 5’ and 3’ splice junctions for exon 9B in the tumours 
(Table 3-5). In addition it was observed that whilst constitutive exon 10 predominantly 
followed exon 9 in the majority of transcripts, the alternate exon 9S was also 
occasionally used exclusively in the tumours. In fact for many of the alternate exons 
very low read numbers or no reads at all were recorded at alternate exon junctions in 
control skin samples. 
 
Following the findings at the mRNA level and the observations from the HaCaT cell line 
for MYB isoforms, tumour lysates from 4 patients were probed for MYB to determine 
the presence of isoforms at the protein level. Normal skin lysates (CYLD +/+) from 3 
patients were used as controls. In agreement with the HaCaT result, in normal skin the 
prominent isoform that was detected was MYB 9B (89kDa) with variable levels of 
expression between samples (Figure 3-14). There was also variabliity in the tumour 
lysates as MYB was not detectable in all the samples, but in those samples in which 
MYB was present (3/6) MYB expression was increased compared to controls. 
Interestingly wild-type MYB (75kDA) was present in the tumour lysates in which MYB 
9B had been seen. In addition the same samples were probed for TrkB and intriguingly 
the tumours with increased MYB protein levels also showed strong TrkB.T1 expression 
(Figure 3-14). 
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Figure 3-12: UCSC genome browser view of the MYB gene showing aligned RNA-seq 
reads from a panel of CYLD-defective tumours (red track) and perilesional skin 
controls (green track). 
The height of the peaks illustrating the number of reads which align to the exons of the MYB gene, with 
a scale given on the Y-axis (note the scales are different on each axis to reflect the difference between 
CYLD-defective tumours and perilesional skin controls). The blue dashed line rectangles highlight the 
increased inclusion of exon 9B in the tumour samples. 
 
 
Figure 3-13: IGV view of the MYB gene showing aligned exon junctions of RNA-seq 
reads in a panel of CYLD-defective tumours and perilesional skin controls.  
(A) IGV view illustrating the inclusion of alternatively spliced exons of MYB from the alignment of RNA-
seq reads by exon junctions. The red arcs represent the alignment of RNA-seq reads between the 5’ and 
3’ splice junctions of the exons and the thickness of the red arcs is reflective of the number of reads that 
aligned to that region. Blue circles are to highlight the alternate exons. 
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Table 3-5: RNA-seq exon junction read depth counts for MYB exon 9 and alternate 
exons 9S, 9A and 9B from a panel of CYLD-defective tumours and perilesional skin 
controls.  
Schematic diagram above the table displays the possible alternative splicing events. Stars included in the 
sample column of the table denote samples that have been taken from the same patient, with the 
samples assigned an equivalent number of stars to indicate matched samples (i.e samples Control (2), 1, 
9 and 13 are from the same patient) 
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Figure 3-14: Expresssion of both MYB and MYB9B isoforms is increased in CYLD-
defective tumours compared to normal skin controls.  
Lysates from tumours A Western blot showing the expression of MYB and TrkB isoforms in a panel of 
cylindroma tumours and normal skin controls. Tumours 2, 4 and 5 are from the same patient. -actin 
was used as a loading control. The Western blot shown is representative of 2 independent repeats.  
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3.3.8 Inhibition of NF-B does not perturb MYB expression in primary cylindroma 
cells in vitro 
NF-B signalling is dysregulated in CYLD-defective tumours due to the loss of CYLD 
(Brummelkamp 2003), meanwhile MYB has been found to be a target of NF-B 
signalling (Lauder, 2001, Pereira, 2015). Therefore the aim was to investigate by 
inhibition of NF-B whether this was a molecular mechanism through which MYB 
expression is driven in the tumours. HaCaT cells and two cylindroma primary cell 
cultures (CPCC), derived from two tumours from different individuals, were treated 
with the NF-B inhibitors TPCA-1 and BMS345541. Cell cultures were treated with 
1M and 5M of TPCA-1 and BMS345541 for 48 hours, with DMSO only included as a 
control. When MYB protein expression was analysed by Western blotting all cell 
culture samples showed that with increasing levels of TPCA-1 MYB expression also 
increased (Figure 3-15). This is contrary to the hypothesis that blocking NF-B would 
reduce MYB expression. As the same trend was observed in the HaCaTs and primary 
cylindroma cultures this suggests that in keratinocytes alternate mechanisms are 
responsible for the expression of MYB. 
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Figure 3-15: The effect of NF-B inhibition in CPCCs and HaCaTs on MYB protein 
expression. 
Cell cultures were treated with the NF-B inhibitors TPCA-1 and BMS345541 at the concentrations 
indicated for 48 hours and MYB protein levels were analysed by Western blot. DMSO only was included 
as a control. The Western blots shown are from one experimental repeat on each cell culture sample. 
GAPDH was used as a loading control. 
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3.4 Discussion 
MYB is a proto-oncogene that encodes for a transcription factor whose targets include 
genes associated with cell cycle progression and regulation of cell survival. As such, 
aberrant activation of MYB has been shown to be involved in many types of 
malignancies, including salivary gland cancers such as ACC (Ho et al., 2013). In ACC the 
genomic rearrangement of MYB with NFIB leads to the expression of a fusion 
transcript that is considered a molecular hallmark of this tumour type (Stenman et al., 
2014). Due to the observation of the striking histological and morphological similarities 
between salivary gland tumours and cylindromas, this led others to hypothesise that 
the MYB-NFIB fusion may also be a recurrent gene fusion in cylindroma. Indeed in a 
cohort of sporadic cylindromas 55% of the tumours were found to be MYB-NFIB fusion 
positive, whilst some tumours that were lacking the fusion transcript still showed 
increased activation of MYB (Fehr et al., 2011). These results suggesting that the 
activation of MYB is involved in the pathogenesis of sporadic tumours. However the 
status of MYB in inherited CYLD-defective tumours remained to be investigated and 
led to the hypothesis that MYB may be over-expressed or genomically rearranged in 
inherited tumours similar to their sporadic counterparts. 
3.4.1 MYB activation but no MYB-NFIB fusion in inherited CYLD-defective tumours 
The work in this chapter showed that in contrast to sporadic cylindromas, there was no 
expression of a MYB-NFIB fusion transcript in any of the 23 cylindromas taken from 
patients who have inherited germ-line mutations of CYLD. Two approaches were taken 
to identify if a fusion gene was present; firstly all tumour samples were negative for 
the amplification of a fusion product when using nested RT-PCR with primers designed 
for the most commonly found MYB-NFIB fusions (Figure 3-4). Secondly in support of 
this result FISH analysis indicated that the MYB locus was not rearranged or showed 
any gain/amplification, as the dual-colour red-green probe was shown to have not 
broken apart in the inherited tumour samples (n=10) (Figure 3-5). This also validated 
that other infrequent MYB fusions were not present, which may have been missed in 
the nested RT-PCR. Whilst no MYB-NFIB fusions were found, immunohistochemical 
analysis did show an increase in MYB expression, in the majority of inherited tumours 
when compared to perilesional skin (Figure 3-7), which is akin to a sub-set of MYB-NFIB 
fusion negative sporadic tumours (Fehr et al., 2011). Furthermore it is evident from the 
immunohisotchemical staining that the nuclear localisation of MYB in the tumours, 
  110 
compared to the cytoplasmic location in normal (CYLD wild-type) skin (Figure 3-6), is 
indicative of increased MYB activation, as MYB Is situated within the tumour cells in a 
position where it is available to carry out its function as a transcription factor. 
 
The finding of MYB activation, whether it is by gene fusion or alternate mechanisms, in 
inherited and sporadic tumours suggests a link between the MYB and CYLD pathways.  
This result is intriguing as the formation of inherited cylindromas is largely restricted to 
the inheritance of a germ-line mutation of CYLD and LOH at the CYLD locus, in the 
majority (approximately 70%) of tumours (n=23) (Biggs et al., 1996; Bignell et al., 
2000). Furthermore the discrepancy in the activation of MYB between the tumour 
types may be reflective of the timing of the acquirement of an activated MYB state, 
which could act synergistically with non-functional CYLD in promoting cylindroma 
development. Approximately 50% of sporadic tumours demonstrate LOH at the CYLD 
locus (n=14) (Biggs et al., 1996), which correlates with 55% of tumours (n=12) having 
been shown to be MYB-NFIB fusion positive in a similar sized study (Fehr et al., 2011). 
In contrast to the average age of onset at 16 years for inherited tumours (Rajan, 
Langtry, et al., 2009) sporadic tumours typically present beyond the fifth decade of life 
(Rajan et al., 2016; Sicinska et al., 2007). It could therefore be speculated that the gain 
of MYB activation achieved through fusion transcripts could be due to increased 
genomic instability that comes with ageing (Vijg and Dolle, 2002; Vijg and Suh, 2013).  
 
Alongside these findings it was also shown that the depletion of MYB expression using 
siRNA knockdown in CPCCs from three individual tumours led to a significant reduction 
in cellular proliferation (Figure 3-9) and in the expression of MYB target genes Bcl-2 
and BIRC3 (data not shown-supplementary material from (Rajan et al., 2016)). It was 
shown that in addition to Bcl-2 and BIRC3 a number of MYB target genes (n=48) were 
differentially expressed when comparing CYLD-defective tumours to perilesional skin 
controls (Table 3-4). Taken together these results reinforce the idea that MYB 
contributes to the promotion of these tumours, possibly through inhibition of 
apoptosis. Therefore it would be interesting to carry out further analysis with larger 
numbers of tumours to further explore the molecular heterogeneity of MYB activation 
and its targets between sporadic and inherited tumours types. Also to determine if 
genetic alterations of CYLD and increased MYB activation are mutually exclusive 
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molecular events to corroborate that together, changes to these two genes can 
promote tumourigenesis.  
3.4.2 Mechanisms by which MYB expression may be altered in a CYLD-defective 
context 
In light of the previous results confirming a link between MYB and CYLD, the 
association of aberrant MYB activation and the loss of functional CYLD, was explored 
further by assessing MYB expression in HEK293T cells overexpressing either wild-type 
CYLD or various CYLD mutants. An increase in MYB expression in the presence of 
mutant CYLD was not observed (Figure 3-11). This result could indicate that CYLD is not 
directly involved in the regulation of the expression of MYB. The lack of a response to 
catalytically inactive or truncated CYLD, with the exception of c.2290-94del, may also 
highlight the possible limitations of using the HEK293T cell line, cells of embryonic 
kidney origin, to model molecular mechanisms that occur in keratinocytes. HEK293T 
cells are a useful tool for over-expression studies for deducing protein function and 
mechanisms of action. However it may be that in this cellular context the protein 
partners involved in pathways that are perturbed by a loss of functional CYLD and are 
responsible for increased MYB expression in keratinocytes, may not be expressed in 
the HEK293T cells, as the cells are not dependent on them. Therefore exogenously 
over-expressing a non-functional form of CYLD has no effect. Certainly the expression 
and functions of MYB have been found to be cell-type specific, with differing protein 
interactions in differing cellular contexts regulating MYB activity (Ness, 2003; Zhou and 
Ness, 2011). Other possibilities are that off-target events as a consequence of the 
random integration of the lentiviral vector into the genome may negate an effect, 
however this is unlikely as these were polyclonal cultures and this would have had to 
occur across six separate transduction experiments.  
 
The small reduction in MYB expression seen in cells over-expressing CYLD c.2290-94del 
could suggest that tumours from patients who have inherited this genotype may not 
have increased MYB expression; indeed 30% of tumours (n=16) in the 
immunohistochemical analysis did not show an increase in MYB expression. However 
care should be taken in the interpretation of this result as experimental factors such as 
the lower transfection efficiency for this CYLD mutant indicated by the lower level of 
overall CYLD expression may also account for this observation (Figure 3-11). Ideally 
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CYLD over-expression experiments would be repeated in HaCaT cells to assess the 
relationship between CYLD and MYB in a more biologically relevant context. The 
conflicting results from the silencing of CYLD with lentiviral shRNA constructs in the 
two cell lines would appear to support this strategy (Figure 3-10), as shCYL1 caused an 
opposing effect on MYB expression in the two cell lines; in HEK293T cells it was 
decreased whilst in HaCaTs it was increased. It is acknowledged that there are 
limitations to the data from the knockdown experiments as the result is not consistent 
between the two shRNA constructs. This may be a real result as the targeting of CYLD 
by the two individual constructs is different, or there could be differences in the 
achieved levels of knockdown that were not detectable on the Western blots. 
Therefore further experimental repeats perhaps with the inclusion of a third construct 
would give a more definitive result.  
 
CYLD is a negative regulator of NF-B signalling, with the deubiquitination of several 
targets including TRAF2, TRAF6, NEMO (Kovalenko et al., 2003) and TAK1 (Reiley W. W. 
et al., 2007) preventing IB degradation and maintaining NF-B in an inactive state. 
Consequently the loss of CYLD function in the tumours causes increased NF-B 
signalling (Brummelkamp et al., 2003). As mentioned previously MYB is a recognised 
target of NF-B with the presence of NF-B binding sites in the promoter of MYB 
(Lauder et al., 2001), and an ability to overcome the transcriptional attenuation of 
MYB (Pereira et al., 2015). It was therefore hypothesised that in a subset of tumours 
MYB may be activated due to aberrant activation of NF-B caused by the loss of CYLD. 
In HaCaTs and two CPCCs treated with the NF-B inhibitors TPCA-1 and BMS345541 it 
was found that there was no down-regulation of MYB following NF-B inhibition 
(Figure 3-15). On the contrary MYB expression actually increased in response to both 
treatments particularly TPCA-1. Both TPCA-1 and BMS345541 indirectly target NF-B, 
as they are potent selective inhibitors of IKK- over IKK-. Therefore NF-B may not be 
fully inactivated, as IKK- has been shown to be capable of activating NF-B even in 
the absence of IKK-, but the way the two kinases cooperate is dependent on the cell-
type (Adli et al., 2010). In the context of keratinocytes IKK- is a key regulator of 
epidermal differentiation, although this is independent of NF-B (Descargues et al., 
2008). The result may therefore demonstrate that inhibition by TPCA-1 of particular 
IKK components changes the activation of NF-B and its downstream targets through 
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imbalances in the IKK-: IKK- ratio, leading to altered expression of MYB, that may be 
isoform specific, in an anti-differentiation response. The result could also suggest that 
alternative mechanisms are responsible for the activation of MYB within the tumours 
and that conversely inhibition of NF-B could interfere with the negative regulation of 
MYB.  
 
TPCA-1 is also an inhibitor of Stat3 (Signal transducer and activator of transcription 3) 
(Nan et al., 2014) and it has been observed that Stat3 can repress MYB expression. For 
example In M1 leukaemia cells dominant-negative forms of Stat3 were shown to 
inhibit IL-6 induced repression of MYB and subsequent terminal differentiation 
(Nakajima et al., 1996). Therefore the increase in MYB expression that was observed 
could potentially be due to Stat3 inhibition. Determination of the protein levels of 
Stat3 would be required to confirm this. Although the increased p-Stat3 expression in 
the tumours that was observed in Chapter 4, alongside increased MYB expression in 
the tumours is at odds with Stat3 having a negative regulatory role. On the other hand 
the tumours are a heterogeneous population of cells, which upon a genetic 
background of a loss of functional CYLD are committed to perturbed pathways of 
differentiation. Therefore dependent on the programming of the individual cells within 
the tumours, some cells may be driven by the activities of Stat3 whilst for others this 
may be MYB. Also of note is that these experiments were conducted in 2D cell cultures 
in vitro, which may have altered the signalling pathways within the cells. Therefore it 
may be useful in future to further explore the elusive mechanism of aberrant MYB 
expression in 3D cell cultures as discussed in Chapter 5. 
  
As it appears that NF-B may not be responsible for augmented MYB expression in 
CYLD-defective tumours, an alternative mechanism that requires further exploration is 
Wnt-1 signalling. This is a pathway of interest that is both dysregulated in the tumours 
(Rajan, Burn, et al., 2011; Tauriello et al., 2010) and is implicated in the regulation of 
MYB (Kanei-Ishii et al., 2004). The Wnt-1 signal is transduced to MYB through TAK1 
(TGF--activated kinase), HIPK2 (homeodomain-interacting protein kinase 2 and NLK, 
resulting in phosphorylation of MYB by NLK and leading to ubiquitination and 
subsequent degradation of MYB (Kanei-Ishii et al., 2004). The E3 ubiquitin ligase 
responsible for ubiquitin attachment to MYB is Fbxw7 (F-box and WD40 domain 
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protein 7). Mutations of Fbxw7 have been reported in a number of malignancies 
(Welcker and Clurman, 2008) such as colorectal (Rajagopalan et al., 2004), pancreatic 
(Calhoun et al., 2003) and endometrial cancers (Spruck et al., 2002),  due to Fbxw7 
inducing the degradation of a number of positive regulators of the cell cycle such as 
Cyclin E (Koepp et al., 2001) or of proto-oncogenes such as c-MYC (Sato M. et al., 2015) 
and c-Jun (Wei et al., 2005). In addition Notch, another aberrantly active signalling 
pathway in the tumours (Rajan et al., 2014), and NF-B regulate the activity of miR223, 
which represses Fbxw7 (Kumar V. et al., 2014). It would therefore be interesting to 
assess the expression of Fbxw7 or its mutational status, and expression of miR223 in 
the RNA-seq and microarray datasets. Validating these findings with qPCR and 
Western blotting to determine if alterations to Fbxw7 or its regulation were 
responsible for the up regulation of MYB.  
 
A final hypothesis is that up-regulation of MYB may be due to epigenetic alterations 
such as chromatin remodelling of the MYB locus. Indeed recently activation of the MYB 
locus was demonstrated by epigenetic profiling of enhancer regions in MYB-NFIB 
fusion negative but translocation positive ACCs (Drier et al., 2016). CYLD has been 
shown to negatively regulate the activity of the histone deacetylases, HDAC6 and 7 
(Pannem et al., 2014; Wickstrom et al., 2010). Whilst interestingly in leukaemic cells 
treated with the pan-HDAC inhibitor Givinostat, MYB expression was strongly 
repressed (Amaru Calzada et al., 2012). Taken together the results indicate that a loss 
of CYLD in the tumours could consequently alter the acetylation of histones associated 
with the promoter of MYB to drive its activation. A future approach could be to 
perform drug assays, treating CPCCs with HDAC inhibitors to see if the MYB result can 
be recapitulated or if cell viability is affected. Further to this the DNA-binding domain 
of MYB shares strong structural similarity to a SANT domain, a domain that is found in 
several chromatin remodelling enzymes (Boyer et al., 2004). Through the SANT domain 
MYB has been found to be involved in chromatin organisation by directing Histone H3 
acetylation and tail positioning (Mo et al., 2005), indicating that MYB also has a role in 
the epigenetic regulation of target genes. Conversely the strategy of HDAC inhibition 
may then also prevent the acetylation and activation of MYB target genes by indirectly 
down regulating MYB expression. 
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3.4.3 MYB 9B isoform expression in inherited cylindromas 
Splicing of the MYB gene is complex with 6 alternate exons and two exons that contain 
alternate splice donor sites a number of variants can be generated (Close et al., 2004; 
O'Rourke and Ness, 2008; Zhou and Ness, 2011). The functional significance of each 
variant however is not fully understood. The data in this chapter showed that at the 
mRNA level not only was the expression of MYB higher in the CYLD-defective tumours 
(Figure 3-12) as indicated by the increased depth of the reads aligned to the MYB gene, 
but in parallel there was increased expression of alternatively spliced isoforms of MYB 
which were almost exclusive to the tumours compared to perilesional skin, as 
evidenced by the increased read depth at alternatively spliced exon junctions (Figure 
3-13 and Table 3-5). In particular in the tumours exon 9B was the most frequently 
incorporated alternate exon, but others such as 8A, 9A and 10A were also used (see 
Appendix). Conflictingly at the protein level in the normal (CYLD+/+) skin samples the 
MYB 9B isoform was detected (Figure 3-14) with the presence of a band that 
corresponded to MYB 9B at 89kDA on the Western blot membranes. This was also 
seen in the HaCaTs (Figure 3-8), suggesting that in keratinocytes this is the isoform that 
is usually expressed and required for normal maintenance of the cell. Although only 
one perilesional (CYLD+/-) skin sample showed inclusion of exon 9B in the RNA-seq data 
and had very low read counts. In agreement with the previous results though is the 
finding that in the same tumour samples in which MYB 9B was found on the Western 
blot a band for wild-type MYB at 75kDA was also detected, demonstrating increased 
expression of MYB (Figure 3-14) and a possible change in the dependency of particular 
MYB isoforms in the tumours. Of all the alternate isoforms MYB 9B is the best 
characterised. It has shown enhanced transactivational activities (Kumar A. et al., 
2003) and is required for the proliferation and survival of BCR/ABL expressing 
leukaemic cells (Manzotti et al., 2012). Meanwhile aberrant expression of MYB 9A was 
also found to promote T-cell leukaemia (Nakano et al., 2016). This suggests that the 
isoforms are capable of promoting tumourigenesis but again reiterates that each MYB 
isoform may have a different role in different cellular contexts.  
 
Speculative explanations for the discord between the mRNA and protein levels could 
be non-specific binding of the antibody on the Western blots, however the same band 
was also present in a proportion (3/6) of the tumours at increased levels consistent 
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with the RNA-seq data. Alternatively it is recognised that the control samples used in 
each experimental instance were derived from different genetic backgrounds of CYLD 
using normal skin (CYLD+/+) for Western blotting and perilesional skin from CYLD 
mutated carriers (CYLD+/-) for RNA-seq. So the expression of MYB protein in the 
perilesional samples is unknown and it may be that there are perturbations within 
these cells that can alter the splicing of MYB prior to a complete loss of CYLD. Another 
consideration is that the area of the body from which the control samples were taken 
may have had an affect. The exact sites are unknown, but the perilesional skin is likely 
to have come from a hairy area of skin such as the scalp, chest or pubic region, as this 
is where the tumours are frequently found. These samples may therefore have a dense 
concentration of hair follicles compared to normal skin taken from less hairy sites, and 
the expression of MYB isoforms may again be altered in different skin compartments.  
 
Finally even though only detected in two tumours on the Western blot, strong TrkB.T1 
expression was seen in the same tumour samples that were positive for MYB. This 
implies that there could be an association between the overexpression of TrkB and 
MYB in some tumours. This is of interest as it has been found that expression of 
another Trk family member TrkC, is increased in ACC (Ivanov et al., 2013) and 
NGF/TrkA signalling may contribute to perineural invasion of ACC (Kobayashi et al., 
2015) As TrkB signalling has previously been shown to be dysregulated in CYLD-
defective tumours (Rajan, Elliott, et al., 2011), this link may be worth exploring in 
future studies. 
 
The expression of these isoforms in CYLD-defective tumours clearly requires further 
clarification. Particularly as no evidence could be found in the literature of isoforms of 
MYB having been looked at in the skin so these are novel findings. The alternate 
isoforms identified in the RNA-seq data will need to be validated by RT-PCR and qPCR. 
At the protein level Western blots need to be repeated on an increased number of 
samples from different individuals as the positive results seen were from tumours 
taken from the same patient. Cellular fractionation of the lysates may also enhance 
the detection of individual isoforms, as MYB is active in the nucleus. Obtaining positive 
controls such as the MYB isoform vector constructs used by Nakano et al. (Nakano et 
al., 2016) would be useful to validate the antibody and increase confidence in the 
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interpretation of the results. However the evidence here supports increased splicing of 
MYB in the tumours, and gaining further insight into the functions of the different 
isoforms and whether they differ in the genes they target would be useful, as it may 
point to a potential mechanism by which the Increased expression of MYB can 
promote tumour development. 
3.4.4 MYB and disease severity in females  
It has been reported that the severity of CYLD defective tumour syndromes such as BSS 
and FC is greater in women (Rajan, Langtry, et al., 2009). In a cohort of 26 patients 5 
women required complete scalp removal compared to only one man (Rajan, Langtry, 
et al., 2009). Furthermore in the same familial study one woman reported an increase 
in the number of tumours during pregnancy and when hormone replacement therapy 
started (Rajan, Langtry, et al., 2009). Interestingly it has been shown in breast cancer 
cells that the over-expression of MYB is dependent on the ER receptor as activation of 
the receptor can override the transcriptional attenuation region in the first intron of 
the MYB gene (Drabsch et al., 2007). Furthermore there were genome-wide changes in 
MYB activity in human MCF7 breast cancer cells treated with beta-estradiol and 
consequently changes in gene expression (Quintana et al., 2011). Therefore MYB is an 
interesting target to potentially explore in the context of differing disease severity 
between the genders, as increased exposure to oestrogen in the females may alter the 
activity of MYB and the expression of target genes in the inherited tumours. 
3.4.5 Targeting MYB as a therapeutic option for CYLD-defective tumours 
Small molecule inhibitors of MYB are being developed as MYB is recognised as an 
attractive therapeutic target for the treatment of leukaemia and other solid tumours 
such as ACC, that are driven by deregulation of MYB (Uttarkar et al., 2017). A strategy 
for the inhibition of MYB is to target the MYB/p300 interaction (Uttarkar et al., 2015), 
as this is an essential partner for the transcriptional activation of MYB (Dai P. et al., 
1996). A promising compound, the naphthoquinone Plumbagin has been identified, 
which binds to the p300 binding site of MYB and was found to selectively supress the 
proliferation of primary AML cells but not normal haematopoietic progenitors 
(Uttarkar et al., 2016). Another favourable compound is the multi-kinase inhibitor 
Rigosertib, which has been shown to selectively induce cell death in diffuse large B cell 
lymphoma through suppression of MYB and TRAF6 (Dai Y. H. et al., 2016). This 
  118 
mechanism of action is interesting as TRAF6 is an adaptor protein involved that is 
involved in tumour development through its role in NF-B signalling (Inoue et al., 
2007) and has been shown to be a target of CYLD (Sun S. C., 2010; Trompouki et al., 
2003). Therefore it would be interesting to carry out preclinical experiments to assess 
the effect of MYB inhibitors on the proliferation and survival of primary cylindroma 
cells.  
3.4.6 Conclusions 
In summary it has been shown that in a proportion of both sporadic and inherited 
CYLD-defective tumours there is increased activation of MYB, however in the sporadic 
tumours this is commonly caused by the expression of a MYB-NFIB fusion transcript. 
The expression of MYB changed in response to both CYLD silencing and overexpression 
experiments, and together the ex vivo and in vitro studies here strongly indicate an 
association between MYB and CYLD for the first time in inherited cylindromas. The 
molecular mechanisms behind overexpression of MYB in the cylindromas however 
remains to be determined, as the evidence from these results did not support 
dysregulated NF-B signalling as the mechanism responsible for MYB activation. In the 
tumours increased expression of alternate isoforms of MYB particularly of MYB 9B, 
were also observed which may have implications for the activity of MYB within the 
cells. Overall the overexpression of MYB is intriguing, as it demonstrates an additional 
molecular event that has the potential to contribute to tumour formation. Whilst the 
role of MYB does require further exploration, the development of inhibitory MYB 
compounds makes it an attractive therapeutic target for the treatment of CYLD-
defective tumours. 
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4 Chapter 4: Investigation of TrkB isoforms in CYLD-defective tumours 
4.1 Introduction 
4.1.1 Chapter aims 
The over-expression of TrkB and neurotrophic ligands in CYLD-defective tumours, and 
the known functions of receptor activation in the skin and hair follicle compartments 
and their potential contributory roles to tumourigenesis, the overall objective of the 
work in this chapter was to investigate the implications of TrkB upregulation upon the 
underlying pathology of CYLD-defective tumours. The main aims were: 
 Identify the expression of TrkB isoforms in CYLD-defective tumours 
 Identify signalling pathways activated by TrkB isoforms in CYLD-defective 
tumours 
 Assess if pharmacological inhibition of identified signalling cascades affects 
primary CYLD-defective tumour cell cultures 
4.1.2 Neurotrophins and Trk receptors 
The four mammalian neurotrophins (NT), nerve-growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5), are 
a family of growth factors that are critical to the development and maintenance of the 
nervous system. Neurotrophins exert their trophic effects through activation of two 
different receptor classes, the tropomyosin-related kinase (Trk) family of receptor 
tyrosine kinases, TrkA, TrkB and TrkC, and the tumour necrosis factor superfamily 
member, p75 neurotrophin receptor (p75NTR) (Patapoutian and Reichardt, 2001). 
Interestingly binding of neurotrophic ligands to the different receptor types can 
produce opposing cellular responses. Upon engagement of the neurotrophins with 
their cognate Trk receptors a number of signalling cascades can be initiated which 
promote cell proliferation, differentiation and survival. These include signalling 
pathways associated with phosphatidylinositol-3-kinase (PI3K), mitogen-activated 
protein kinase (MAPK) and phospholipase-C-gamma (PLC-γ) (Huang E. J. and Reichardt, 
2001).  Alternatively engagement of neurotrophins with p75NTR can induce cell death 
(Lu et al., 2005). 
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Neurotrophins were the first to be discovered, due to a search for survival factors to 
affirm the neurotrophic factor hypothesis: that targets of neuronal innervation secrete 
limiting amounts of survival factors, which function to ensure a suitable ratio between 
the size of the target organ and the density of innervating neurons (Levi-Montalcini, 
1987). Having initially been discovered as an oncogene, the Trk receptors then came to 
pre-eminence in the field of neurobiology after the ligand-binding domain of proto-Trk 
was recognised as the elusive receptor for the neuronal survival factor NGF (Kaplan et 
al., 1991). Since their discovery neurotrophins and their receptors have been 
remarkably insightful to our understanding of key molecular mechanisms in cell 
biology. Experiments that led to their discovery revealed the significant role of cellular 
interactions in cell survival and differentiation (Jacobson et al., 1997; Raff et al., 1993). 
Alongside this the early discovery of NGF internalisation by receptor-dependent 
processes, the requirement of cytoskeletal and energy-dependent processes for 
transport along axons in membranous vesicles, and lysosomal ligand turnover, opened 
up research into mechanisms that are now recognised to be used by many if not all 
cells in controlling ligand-receptor cycling and function (Huang E. J. and Reichardt, 
2001; Thoenen and Barde, 1980). 
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Figure 4-1: The protein structure of Trk and p75NTR receptors and their binding 
ligands. 
An illustration of the major interactions of the neurotrophins and the structural domains of the three 
Trk receptors: TrkA, TrkB and TrkC, and structurally unrelated p75NTR. All proneurotrophins can bind to 
p75NTR but not Trk receptors. Each of the mature neurotrophins can bind to their preferred Trk 
receptor or p75NTR. NT-3 is able to bind to each of the Trk receptors, as indicated by the dashed 
arrows, but it is dependent on the cellular context whether it does so. Binding of the pro or mature 
neurotrophins initiates activation of the intracellular tyrosine kinases of Trk receptors or death domain 
of p75NTR. C1/C2: cysteine repeats, LRR1-3: Leucine-rich repeats, Ig1/Ig2: Immunoglobulin domains. 
CR1-4: cysteine rich domain. Figure adapted from (Reichardt, 2006). 
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Each of the neurotrophic factors interacts with the three Trk receptors with selective 
affinity; NGF binds most specifically to TrkA, BDNF and NT-4/5 to TrkB and NT-3 to TrkC 
(Figure 4-1). However NT-3 can activate TrkA and TrkB, but with less efficiency in some 
cell types (Ip et al., 1993; Reichardt, 2006). Mouse models with null mutations in each 
of the Trk receptors (Klein et al., 1994; Klein et al., 1993; Smeyne et al., 1994), or 
global knockouts for each of the neurotrophins (Conover et al., 1995; Ernfors, Lee, & 
Jaenisch, 1994; Ernfors, Lee, Kucera, et al., 1994), were shown to have overlapping 
phenotypes when either a neurotrophin or its cognate receptor was deficient, 
supporting the in vitro work of these biochemical interactions and particularly the 
promiscuity of NT-3 (Farinas et al., 1998). The importance of these factors and their 
receptors to the developing nervous system were shown in the mice, with losses of 
specific neuronal populations a particular receptor or neurotrophin was lacking and 
highlighted that differing neuron populations have specific neurotrophin 
dependencies. The loss of TrkB was the most severe with animals not surviving more 
than a day (Klein et al., 1993), however the other models still only survived a few 
weeks. In particular sympathetic and sensory neurons of the peripheral nervous 
system are severely affected by the absence of Trk receptors or their neurotrophins. In 
keeping with the work of Levi-Montalcini et al. sympathetic neurons were almost 
completely lost in the absence of NGF or TrkA (Crowley et al., 1994; Levi-Montalcini, 
1987), alongside nociceptive neurons (Huang E. J. and Reichardt, 2001). Meanwhile 
specific sensory losses of proprioceptive neurons (awareness of limbs) were seen when 
TrkC was deficient (Ernfors, Lee, Kucera, et al., 1994). Also Huang et al. demonstrated 
that in the developing sensory neuron ganglia of mice, expression of the Trk receptors 
occurs in two waves with initial generation of TrkB and TrkC expressing neurons 
followed by TrkA expressing neurons, and limited co-expression of Trk receptors in the 
later stages suggesting that Trk expression becomes more restrictive during 
development (Huang E. J. et al., 1999). Within the central nervous system, TrkB and 
TrkC are more widely expressed but their patterns of expression are also restricted to 
specific areas of the brain (Huang E. J. and Reichardt, 2001). 
However the neurotrophins and their receptors are not exclusive to the nervous 
system. Early immunohistochemical analyses showed cell-type specific, Trk receptor 
expression in many human tissues such as the colon, kidney and spleen (Shibayama 
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and Koizumi, 1996), warranting further investigation of the function of neurotrophic 
signalling in non-neuronal tissues. In particular neurotrophins and their receptors are 
expressed during cardiovascular development (as reviewed by (Caporali and Emanueli, 
2009), with NGF shown to be an autocrine pro-survival factor to cardiomyocytes 
(Caporali et al., 2008). Moreover studies using global knockout mouse models have 
revealed deficiencies in BDNF to cause reductions in endothelial cell-cell contact with 
severe consequences to heart function such as intraventricular wall haemorrhage and 
depressed cardiac contractility (Donovan et al., 2000), and deficiencies in TrkB to cause 
a reduction in blood vessel density and an increase in the number of apoptotic 
endothelial cells in the developing heart (Wagner et al., 2005). More recently BDNF 
has even been explored as a therapeutic option for heart failure (Okada et al., 2012; 
Samal et al., 2015). Meanwhile NT-3 and TrkC deficiencies cause cardiac 
malformations, with some defects appearing at embryonic day 9.5, which is before the 
onset of cardiac innervation in mice (Donovan et al., 1996; Tessarollo et al., 1997). 
Likewise broader functions for the neurotrophins in the immune system have been 
suggested (Vega et al., 2003), with TrkA and TrkB functionally deficient mice indicating 
the importance of these receptors and ligands in the development of immune organs 
such as the thymus and the survival of thymocytes (Garcia-Suarez et al., 2002; Garcia-
Suarez et al., 2000). Alongside the organs individual expression patterns of 
neurotrophins, Trk receptors and p75NTR are observed to have immunomodulatory 
roles in the different subsets of immunocompetent cells such as lymphocytes, affecting 
a range of functions from proliferation and survival to the induction of antibody 
synthesis (Brodie et al., 1996).  
Of particular interest to the work within this thesis is the function of the neurotrophins 
and their cognate receptors in the skin (discussed in more detail in section 4.1.9). 
These proteins are differentially distributed in distinct cell populations of the skin, and 
structures within the skin like the hair follicle are both a target and source of 
neurotrophins; the same structure from which CYLD-defective tumours are potentially 
derived from (Massoumi, Podda, et al., 2006). Additionally Trk and p75NTR signalling 
have been shown to have contrasting effects on hair follicle morphogenesis and hair 
cycling (Botchkarev et al., 2006). After having been shown to have an array of 
functions in and outside of the nervous system, it is not surprising that neurotrophin-
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Trk signalling is implicated in neurodegenerative diseases such as Alzheimer’s (Allen S. 
J. et al., 2011), Parkinson’s (Meldolesi, 2017; Murer et al., 2001), and various cancers 
such as neuroblastoma (Evangelopoulos et al., 2004) prostate (Montano and Djamgoz, 
2004), lung (Ricci et al., 2001; Sinkevicius et al., 2014), breast (Tsai et al., 2017; 
Vanhecke et al., 2011) and melanoma (Pasini et al., 2015; Truzzi et al., 2008). 
4.1.3 Neurotrophin processing and signalling 
Similar to other secreted proteins, neurotrophins are processed from precursor 
molecules, proneurotrophins, which undergo proteolytic cleavage and post-
translational modifications to produce their mature forms. Proneurotrophins have 
three ultimate fates: intracellular cleavage followed by secretion; secretion followed 
by extracellular cleavage; or secretion without subsequent cleavage (Lu et al., 2005). 
Initial pre-proneurotrophin synthesis occurs in the endoplasmic reticulum, before the 
proneurotrophin translocates to the trans-Golgi network for cleavage by enzymes such 
as Furin or prohormone convertases, and sorting and processing into two secretory 
pathways: the constitutive or the regulated pathway. Within each of these pathways 
neurotrophins are packed into distinct secretory vesicles; in the constitutive pathway 
the vesicles are continuously released in a calcium-independent manner, meanwhile in 
the regulatory pathway exocytosis of the vesicles occurs in response to an extracellular 
stimulus that triggers the release of intracellular calcium stores, including ligand 
engagement of Trk receptors (Canossa et al., 2001; Lessmann and Brigadski, 2009). 
 
The key determinant of the efficiency with which neurotrophins are cleaved and 
sorted is the sequence information within the C-terminal region of the prodomain of 
the neurotrophin (Nomoto et al., 2007), as studies have found that in neurons 
swapping of the prodomains between the different neurotrophins can alter the 
pathway of secretion for the neurotrophin (Brigadski et al., 2005). In general BDNF and 
NT-3 are targeted more efficiently for regulatory secretion, meanwhile NGF and NT-4 
are primarily secreted through the constitutive pathway (Lessmann and Brigadski, 
2009). The importance of the propeptide sequence is also highlighted by the secretion 
of BDNF in neurons, a naturally occurring polymorphism can cause a Valine to 
Methionine exchange in the prodomain and consequently BDNF is no longer efficiently 
targeted to regulatory secretion vesicles and release of BDNF through this pathway is 
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hindered (Egan et al., 2003). In addition this sequence information is also required for 
co-localisation of neurotrophins with the intracellular sortilin receptor; in the case of 
BDNF it is thought that this association promotes an appropriate configuration of 
proBDNF, which in conjunction with a sequence within the mature domain that 
promotes an interaction with carboxypeptidase E, allows for the sorting of BDNF into 
regulatory secretory vesicles (Lou et al., 2005; Lu et al., 2005). Other factors that 
regulate this process include the availability and localisation of proteases, as the 
enzymes are differentially expressed between cell-types and their pH-optimum 
dictates in which cellular compartment proteolysis can occur (Lessmann and Brigadski, 
2009). Proneurotrophin cleavage may also occur extracellularly by plasmin or matrix-
metalloproteinases if there are inefficiencies intracellularly (Bruno and Cuello, 2006). 
 
In addition proneurotrophins can be secreted and left uncleaved. In this form 
proneurotrophins have been found to be biologically active signalling mediators within 
their own right, distinct from their mature counterparts (Lee R. et al., 2001). Moreover 
the different neurotrophin forms are capable of inducing opposing biological 
responses, with proneurotrophins binding with high affinity to p75NTR receptors and 
inducing pro-apoptotic signalling responses (Feng et al., 2010; Lee R. et al., 2001), 
whilst in contrast mature neurotrophins preferentially bind to Trk receptors to 
promote survival signalling. Therefore the ratio of pro- to mature neurotrophins 
represents an additional mechanism that can direct the actions of neurotrophin 
signalling and determine a cells fate. 
 
4.1.4 The protein structure of Trk receptors 
The structural organisation of the Trk receptors (Figure 4-1), particularly of the 
extracellular domain, is important in the regulation of the specificity and strength of 
neurotrophin binding to each Trk family member (Huang E. J. and Reichardt, 2003). 
Heavily glycosylated, the extracellular domain consists of three leucine-rich repeats 
flanked by two cysteine repeats. These are followed by two C2-type immunoglobulin 
(Ig) domains, which are adjacent to a single transmembrane region (Deinhardt and 
Chao, 2014). Each receptor terminates with a cytoplasmic, tyrosine kinase domain 
containing several tyrosine-containing motifs, which serve as phosphorylation-
dependent docking sites for adaptor proteins and enzymes to mediate signalling 
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cascades (Skaper, 2012) 
The membrane-proximal (second) Ig domain was found to be the major interface for 
ligand binding (Urfer et al., 1995), with further evidence suggesting that the Ig domains 
function to stabilise the receptors in their monomeric forms and prevent their 
dimerization in the absence of ligand (Arevalo et al., 2000). Although several studies 
have found each of the extracellular subdomains of the Trk receptors can contribute to 
ligand binding (Arevalo et al., 2001; Arevalo et al., 2000; MacDonald and Meakin, 
1996; Ninkina et al., 1997). The intricate details of the specificity of the neurotrophin 
and Trk receptor interaction became clearer with the determination of the crystal 
structure of this domain in each of the Trk receptors (Ultsch et al., 1999), together with 
the ligand bound forms of the domain of TrkA with NGF (Wiesmann et al., 1999) and 
TrkB with NT-4/5 (Banfield et al., 2001). Structure comparisons found two important 
interaction surfaces, a conserved patch of contacts, common throughout the Trk 
receptor family members, contributing to the affinity for neurotrophin binding. 
Alongside a second set of highly specific contacts, which stabilises the N-terminal 
structure of a neurotrophin when bound to its complementary receptor surface, 
determining the specificity of neurotrophin selection for a particular Trk receptor 
(Banfield et al., 2001).  
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Figure 4-2: The transcripts and functional domains of Trk receptor isoforms. 
The splicing pattern of each Trk receptor is shown with the colours corresponding to the schematic of functional domains, with the exception of unique alternate exons shaded 
purple and orange. Black boxes with lines represent the transmembrane region. Isoforms are drawn from information from (Ichaso et al., 1998; Luberg et al., 2015; Stoilov et al., 
2002). 
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4.1.5 Trk receptor isoforms 
The three Trk receptors are each encoded for by a single gene NTRK1 (TrkA), NTRK2 
(TrkB), or NTRK3 (TrkC). However alternative splicing of each of the genes can produce 
distinct isoforms that affect the function of the receptor (Figure 4-2), up until recently 
there were three known isoforms of TrkA in humans. TrkA-I, mainly expressed in non-
neuronal cells, lacks exon 9, a six amino acid insert in the transmembrane region that 
is included in the full-length TrkA-II isoform, expressed mainly in neuronal cells (Barker 
et al., 1993). Whilst in the thymus and undifferentiated neural progenitor cells a third 
isoform exists (Tacconelli et al., 2007; Tacconelli et al., 2004). TrkA-III splices out exons 
6, 7 and 9, and therefore lacks the first Ig domain and several glycosylation sites. 
Consequently the receptor cannot bind NGF and is autophosphorylated and 
constitutively active (Luberg et al., 2015). However Luberg et al. described numerous 
transcripts of human TrkA, due to the inclusion of multiple novel 5’ terminal exons, 
which could encode for other protein isoforms (Luberg et al., 2015). There are four 
TrkB isoforms in humans, two full-length receptors that differ due to the inclusion of 
exon 17, and two C-terminal truncated isoforms that lack the kinase domain. Although 
more recently Luberg et al. have described thirty-six novel isoforms of TrkB proteins 
with unique properties within neural cells, highlighting the need for further study of 
TrkB variants as the synthesis and regulation of the receptor is clearly a complex 
process (Luberg et al., 2010). TrkB.T1 is more broadly expressed and the transcript 
includes the unique, alternative exon 16 (Stoilov et al., 2002). Meanwhile TrkB-Shc is 
only found in the brain and spinal cord, the transcript includes the unique alternative 
exon 19, and retains the Shc binding domain in the cytoplasmic tail (Wong J. and 
Garner, 2012). TrkC also has truncated receptor isoforms with shortened cytoplasmic 
tails that are not catalytically active (Brahimi et al., 2016; Menn et al., 1998; Valenzuela 
et al., 1993), in addition to isoforms that have insertions of variable sizes in the kinase 
domain that can reduce the kinase activity of the receptor (Tsoulfas et al., 1993; 
Valenzuela et al., 1993). It is the truncated isoforms that are predominantly expressed 
in non-neuronal tissues as well as being found in the mature nervous system. The roles 
of these truncated isoforms are still largely unknown, however original postulations 
that they act solely as dominant negative receptors are being undermined, as studies 
suggest that truncated receptors may have signalling capabilities of their own (Fenner, 
2012; Renn et al., 2009; Rose et al., 2003). 
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Neurotrophins:  
NGF, BDNF, NT-3 or 
NT-4/5 
 
Figure 4-3: Neurotrophin-Trk signalling pathways. 
A simplified schematic overview depicting the three main intracellular signalling pathways by which 
neurotrophins exert their cellular responses through Trk receptors: PI3K-Akt, Ras-MAPK-Erk and PLC-. 
Once the receptor is activated by a neurotrophin, it dimerises with another Trk receptor and initiates 
phosphorylation of the kinase domain. This in turn leads to the recruitment of an array of adaptor 
proteins (not all are depicted in the figure for simplicity). Signalling through the Trk receptors promotes 
cell survival through activation of PI3K via Ras and Gab1, whilst activation of Ras and MAPK promotes 
cell differentiation, either by interacting with proteins or by influencing the transcription of genes 
involved in each of the cellular processes, such as anti-apoptotic proteins. In addition activation of PLC- 
results in the release of intracellular calcium stores and activation of PKC regulated pathways, which in 
neurons promote synaptic plasticity. Figure adapted from (Reichardt, 2006). 
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4.1.6 Signalling via Trk receptors 
The signalling pathways activated by neurotrophins through Trk receptors have been 
extensively studied and comprehensively reviewed by (Chao, 2003; Deinhardt and 
Chao, 2014; Huang E. J. and Reichardt, 2001, 2003; Kaplan and Miller, 2000; Reichardt, 
2006). As shown in Figure 4-3 these pathways include the PI3K, MAPK and PLC- 
signalling pathways, which are discussed in more detail below. Neurotrophin-Trk 
signalling has been shown to influence many aspects of neural development, function 
and maintenance after injury including: precursor cell proliferation and commitment, 
cell survival and differentiation, synaptic formation and plasticity, axon and dendrite 
growth, growth cone motility, and cell death. Initially Trk signalling was mainly 
delineated in the rat adrenal pheochromocytoma (PC12) cell line, which expresses 
TrkA and p75NTR (Barker and Shooter, 1994), and later validated in normal primary 
neurons, as well as being studied in non-neuronal tissues and cell cultures. Ligand 
binding to Trk receptors by their corresponding mature neurotrophin induces receptor 
dimerization, and activation of the kinase domain through phosphorylation of several 
of ten conserved tyrosine (Y) residues present on the cytoplasmic tail of the receptor. 
Three of these tyrosines Y670, Y674, Y675 (numbering scheme based on human TrkA) 
are within the auto-regulatory loop of the tyrosine kinase domain, and when 
phosphorylated potentiate tyrosine kinase activity (Cunningham and Greene, 1998). 
Whilst also providing a mechanism for initiation of signalling pathways via recruitment 
of adaptor proteins such as FRS2 (fibroblast growth factor receptor substrate) and Shc 
(Src homology domain containing) (Meakin et al., 1999), Grb2 (growth factor receptor-
bound protein-2), SH2B and rAPS (Arevalo and Wu, 2006; Qian et al., 1998). Outside of 
the kinase domain, the phosphorylation of the tyrosine residues Y490 and Y785 have 
been the most characterised, with these positions creating docking sites for adaptor 
proteins which trigger downstream signalling, phosphorylation of Y490 coupling the 
Trk receptors to pathways such as Ras-ERK and PI3K-Akt, and phosphorylation of Y785 
to PLC- (Patapoutian and Reichardt, 2001). Although these tyrosine sites have been 
the main focus in unravelling Trk signalling, mutations to three of the five remaining 
tyrosines inhibited NGF-dependent neurite outgrowth, suggesting that they too 
contribute to Trk-mediated signalling (Inagaki et al., 1995). Additionally others have 
indicated that the cytoplasmic tyrosine kianse c-Abl has a role in mediating a 
differentiation response via Trk receptors. Yet c-Abl interacts with the juxtamembrane 
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region of TrkA in PC12 cells regardless of the phosphorylation status of tyrosines in this 
region, thus indicating that not all Trk interactions are dependent on phosphorylation 
of tyrosines (Yano et al., 2000). 
In addition to the three main pathways discussed in more detail below neurotrophin-
Trk signalling can activate members of the Rho (Ras homolog gene family, member A) 
family of GTPases, which control cytoskeleton organisation and cell motility, including 
Cdc42 and Rac (Reichardt, 2006). Furthermore in neuronal cell populations Trk 
receptors can also be activated through neurotrophin independent mechanisms, such 
as glucocorticoids (Jeanneteau et al., 2008) and adenosine and G-protein coupled 
receptors (Lee F. S. and Chao, 2001). 
4.1.6.1 PI3K-Akt signalling pathway 
The initiation of PI3K signalling by Trk receptors has been shown to be a main 
mechanism by which Trk signalling promotes cell survival and is mediated by two 
distinct pathways (Vaillant et al., 1999). The phosphorylation of tyrosine Y490, and the 
analogous phospho-tyrosine residues in TrkB and TrkC, leads to the recruitment of the 
adaptor protein Shc, which in complex with Grb2 and the Ras exchange factor SOS (son 
of Sevenless) stimulates activation of Ras and consequently PI3K (Patapoutian and 
Reichardt, 2001; Rodriguez-Viciana et al., 1994). Alternatively phosphorylated Grb2 
also provides a docking site for Gab-1 (Grb2 associated binding protein-1), which 
allows for subsequent binding and activation of PI3K independently of Ras (Holgado-
Madruga et al., 1997). Additionally in some neuronal subpopulations it has been 
shown that phosphorylation of IRS1 (insulin receptor substrate) by Trk receptor 
activation is also involved in the recruitment and activation of PI3K (Yamada et al., 
1997). The generation of P3-phosphorylated phosphoinositide lipids by PI3K, together 
with PDKs (phosphoinositide-dependent protein kinases), recruit and activate the 
protein kinase Akt, leading to the phosphorylation of several substrates that are 
important regulators of cell survival. For instance the phosphorylation of BAD (Bcl-
2/Bcl-x-associated death promoter) and the transcription factor FKHRL1 (Forkhead) 
induces their association with 14-3-3 proteins. Thus suppressing apoptosis via 
preventing the pro-apoptotic binding of BAD to Bcl-xL (Datta et al., 1997), and 
inhibiting the transcription of apoptosis promoting genes such as Bim and FasL by 
FKHRL1 (Brunet et al., 1999; Brunet et al., 2001). Moreover the inhibition of GSK3- 
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(glycogen synthase kinase 3-) through Akt-mediated phosphorylation is another 
mechanism by which signalling through this pathway promotes cell survival, as 
elevated levels of GSK3- have been shown to promote apoptosis in cultured neurons 
(Hetman et al., 2000). Whilst similarly targets of Akt also include the S6 kinases and 
liberation of NF-B, which can both regulate the transcription and translation of 
subsets of mRNAs that contribute to cell survival (Hamanoue et al., 1999; Moritz et al., 
2010). Likewise another potential target of PI3K capable of promoting cell survival is 
the IAP (inhibitor of apoptosis) family of caspase inhibitors, with suppression of XIAP 
(X-linked inhibitor of apoptosis) levels decreasing NGF-induced survival in chick 
neurons (Wiese et al., 1999). Finally aside from cell survival mechanisms recruitment 
by P3-phosphorylated phosphoinositides of signalling molecules to the plasma 
membrane, including regulators of the cdc42, Rac, and Rho family of G proteins that 
organise the F-actin cytoskeleton, thus implicating PI3K mediated signalling in the 
promotion of axonal growth and neuronal differentiation (Yuan et al., 2003). 
4.1.6.2 MAPK signalling pathway 
The activation of Ras through the adaptor proteins Shc-Grb2 and SOS can also initiate 
Raf-MEK-Erk and p38MAPK signalling. Through the activation of Akt and Erk, Trk 
signalling can promote cell survival via a two-pronged mechanism, suppressing 
apoptotic proteins and activating anti-apoptotic proteins, with the activation of ERK 
increasing the activity or expression of Bcl-2 (Liu Y. Z. et al., 1999). Alternatively the 
activation of Ras also promotes cell differentiation, with transient or prolonged 
activation of ERK determining the outcome of neurotrophin binding (Meakin et al., 
1999). Prolonged expression of ERK signalling induces transcription factors, and at 
least in PC12 cells has its own distinct pathway that requires the recruitment of Frs2 
(fibroblast growth factor receptor substrate 2) to phospho-Y490. This adaptor protein 
provides binding sites for additional signalling proteins such as Grb2 and Crk, Src, SH-
PTP2 (Src homology protein tyrosine phosphatase-2) and the cyclin-dependent kinase 
substrate p13suc1. The association with Crk activates the Rap1 exchange factor C3G, 
triggering Rap1-Raf dependent ERK signalling (Reichardt, 2006). Alternatively Crk can 
be recruited to the Trk receptor by binding to ARMS (ankyrin repeat-rich membrane 
spanning adaptor) (Arevalo et al., 2004). Meanwhile the association of SH-PTP2 with 
Frs2 facilitates activation of the MAPK pathway, particularly in response to BDNF 
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(Easton et al., 2006). The Src family of kinases work synergistically with MAPK to 
promote differentiation (Huang E. J. and Reichardt, 2003).  
It is thought that the activation of p38MAPK is initiated through the sequential 
activation of Ras-RalGDS-Ral and Src (Ouwens et al., 2002). In turn p38MAPK activates 
MAP kinase-activated protein kinase-2 and ERK5. The activation of ERK5 may also 
occur due to Ras activation of Wnk1, MEKK2 and MEK5. The complexities of Trk 
signalling and the diversity in signalling outcomes further illustrated by the fact that 
these cascades can have overlapping as well as distinct targets such as differing 
transcription factor targets, for example ERK5 specifically activates MEF2 (myocyte 
enhancer factor-2) while ERK1/2 specifically activates Elk1 (Reichardt, 2006). In 
contrast overlapping targets of the MAPK signalling cascades include CREB (cAMP 
response element binding protein), which activates the transcription of genes that 
regulate the normal differentiation and survival of neurons (Riccio et al., 1999). 
4.1.6.3 PLC- signalling pathway 
The phosphorylation of Y785 on TrkA, and corresponding tyrosines in TrkB and TrkC, 
recruits PLC- to the receptor where it is then activated by Trk kinase. This triggers a 
cascade of events involving hydrolysis of phosphatidylinositides to generate DAG and 
IP3, and consequently leading to the release and increase of intracellular Ca2+(calcium) 
levels. This flux of calcium activates enzymes such as Ca2+-calmodulin regulated protein 
kinases and PKC (protein kinase C) isoforms (Huang E. J. and Reichardt, 2003). Targets 
include ion channels such as TRPC (transient receptor potential channel) (Li H. S. et al., 
1999) and the voltage-dependent sodium channel PN1 (Choi et al., 2001).  
4.1.6.4 Specificity in Trk signalling 
The complexities of Trk signalling are further revealed in the specificity of Trk 
signalling, highlighting that not only can the cell type influence the response 
depending on which signalling adaptors are present, but also the type of neurotrophin 
and which receptor signalling is initiated from. The work of Minichello et al. with 
mutant Y490 TrkB mice showed a loss of NT-4/5 dependent but not of BDNF-
dependent neurons, possibly due to the reduced ability of NT-4/5 to activate MAPK 
signalling, indicating that signalling by two different neurotrophins through the same 
receptor could have different consequences (Minichiello et al., 1998). Furthermore 
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Atwal et al. showed in primary sympathetic neurons that in contrast to TrkA being 
dependent on PI3K for survival, TrkB uses both PI3K and MAPK, indicating that each 
receptor may have distinct signalling properties and preferential interactions with 
certain signalling substrates (Atwal et al., 2000). 
4.1.7 Regulation of neurotrophin responsiveness by Trk 
There are many complexities to neurotrophin and Trk receptor interactions which 
make it an over simplification to suggest that endogenous expression of a specific Trk 
receptor confers responsiveness to a particular neurotrophin. As stated in section 
4.1.5, alternative splicing generates Trk receptor isoforms with differing extra- and 
intracellular domains, including isoforms that lack the catalytic intracellular domain, 
which can influence a ligands interaction with the Trk receptors and subsequent 
signalling. For example, studies have shown the inclusion of a short amino acid 
sequence into the juxtamembrane regions of each of the Trk receptors (Clary and 
Reichardt, 1994; Shelton et al., 1995; Strohmaier et al., 1996). In TrkA the inclusion of 
the exon strengthens its affinity for NT-3, in addition to NGF (Clary and Reichardt, 
1994), similarly the insertion allows for activation of TrkB by NT-3 and NT-4/5, in 
addition to BDNF (Boeshore et al., 1999; Strohmaier et al., 1996). Meanwhile amino 
acid inserts in the tyrosine kinase domain of TrkC modifies the receptors ability to 
activate particular downstream substrates (Guiton et al., 1995). Additionally the co-
expression of the pan-neurotrophin p75NTR receptor can modulate the function of the 
Trk receptors and regulate neurotrophin responsiveness in a number of ways (see 
Section 4.1.8), one of which is to refine the specificity of the Trk receptor for its 
cognate ligand (Benedetti et al., 1993). Likewise the processing and secretion of 
neurotrophins from pro-neurotrophins (see section 4.1.3) dictates the availability and 
levels of each type of neurotrophin, thus influencing the cells environment and the 
type of response (Lu et al., 2005).  
Other major determinants of the responsiveness of Trk receptors to neurotrophins are 
the kinetics of Trk receptor trafficking and localisation, which can dictate the biological 
response of a cell by bringing the activated receptors into proximity with different 
cellular compartments, especially in neurons where the axon terminals can be far from 
the cell body, and by making the receptor available to adaptor and intermediate 
signalling proteins in specific membrane compartments. Saragovi et al. who showed 
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that rapid internalisation of TrkA, induced by an NGF-mAb complex in PC12 cells (a rat 
pheochromocytoma cell line), prevented NGF-dependent phosphorylation of the 
adaptor protein FRS2 and normal differentiation. This suggested that activated 
receptors require sufficient time on the cell surface to interact with FRS2, as it may not 
be immediately accessible due to it being myristoylated and located in lipid rafts 
(Saragovi et al., 1998). Furthermore Zhang et al. showed that disruption of receptor 
internalisation, via a thermo-sensitive mutant of dynamin in PC12 cells, altered the 
biological response of the cells to NGF. Activated receptors embedded in the plasma 
membrane elicited a survival response via PI3K, but endocytosis of the neurotrophin-
receptor complex was necessary for differentiation of the cells by preferential 
activation of MAPK (Zhang Y. et al., 2000). Alongside this it was shown in neuronal cells 
that the endocytosis of TrkA receptors was specifically required for sustained ERK 
activation by NGF and that this internalisation was facilitated by PI3K (York et al., 
2000). Taken together it is evident that membrane sorting influences the ability of Trk 
receptors to activate specific signalling pathways. 
4.1.7.1 Endocytosis and transport of Trk receptors 
As demonstrated by the examples above, upon binding the neurotrophin-Trk receptor 
complex is internalised into endosomal compartments that provide a vehicle for 
retrograde transport and allowing propagation of the signal to the effector site. 
However it is thought that activated Trk receptors are regulated by the sorting of the 
complex into distinct endosome populations that can affect the outcome of 
intracellular signalling. An example of this was shown in sensory neurons where local 
application of NGF to distal axons or cell bodies activated both ERK1/2 and ERK5 
locally. But when NGF was applied to distal axons ERK5 only was activated in the cell 
body (Watson et al., 2001). Two mechanisms have been proposed for internalisation of 
the activated receptors, clathrin-mediated endocytosis and a Trk selective process of 
macropinocytosis mediated by Pincher, with these endosomes differing in their 
signalling potential (Valdez et al., 2005; Valdez et al., 2007). Both of these pathways 
converge on peripheral early endosomes, however whilst this can lead to recycling of 
the components or maturation to late endosomes and lysosomal degradation, pincher-
associated endosomes appear to be preferentially recruited for retrograde signalling as 
they are not readily degraded by lysosomes and are associated with EKR5 (Valdez et 
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al., 2005). 
4.1.7.2 Ubiquitylation of Trk receptors 
The post-translational modification of ubiquitylation is a relatively recent area that is 
being explored as a mechanism for regulating Trk receptor internalisation, recycling 
and degradation (reviewed by (Sanchez-Sanchez and Arevalo, 2017)). Other tyrosine 
kinases such as EGFR are rapidly degraded upon ligand activation due to ubiquitination 
(Yokouchi et al., 1999). Indeed TrkA has been found to be ubiquitinated by the E3 
ubiquitin ligase TRAF6, influenced by interactions with p75NTR and p62 (Geetha et al., 
2008; Jadhav et al., 2008). This promotes lysine (K) 63-linked polyubiquitination and 
consequently internalisation of the receptor and downstream signalling events 
(Geetha et al., 2005). However others have suggested p75NTR to negatively regulate 
ubiquitination of Trks to delay internalisation and degradation (Makkerh et al., 2005). 
Likewise Nedd4-2, a ligase that specifically ubiquitylates TrkA due to a PPXY motif not 
present in the other Trks, has been shown to regulate TrkA degradation by modulating 
receptor trafficking and sorting of the receptor to the degradative pathway (Arevalo 
and Wu, 2006; Yu T. et al., 2014; Yu et al., 2011). Others have found that the ubiquitin 
ligase Cbl also induces lysosomal degradation of TrkA (Takahashi Y. et al., 2011), and 
that SOCS2 (suppressor of cytokine signalling 2) may mediate the ubiquitination of 
TrkA to regulate its signalling (Uren and Turnley, 2014). 
 To date little is known about the ubiquitination of TrkB and TrkC. Although TRAF6/p62 
and Cbl have been implicated in the ubiquitination of TrkB (Jadhav et al., 2008; Pandya 
et al., 2014). Mutations of specific lysine residues on TrkB (Lys811) impaired 
ubiquitination and the ability of p62 to interact with the receptor, disrupting 
downstream signalling through the PI3K pathway (Jadhav et al., 2008). Meanwhile 
ligases for TrkC remain at the prediction stages based on bioinformatic information, so 
further characterisation is needed for both of theses receptors. Interesting 
observations have been made though about the TrkB receptors dependency on 
ubiquitination in inducing different responses to the different ligands BDNF and NT-4. 
Activation by BDNF induces ubiquitination efficiently and causes downregulation of the 
receptor, while NT-4 causes slower ubiquitination and internalisation of the receptor 
leading to the receptor being kept active and sustaining downstream signalling, 
suggestive of a further possible mechanism for regulating the specificity of Trk 
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signalling (Proenca et al., 2016). 
 The reversal of ubiquitination by deubiquitinase enzymes is required for TrkA recycling 
and degradation (Geetha and Wooten, 2008). Furthermore CYLD, which as mentioned 
previously in the introduction is a deubiquitinase responsible for the removal of K63-
linked polyubiquitin chains, has been suggested as an enzyme that mediates the 
deubiquitination of Trks after Geetha et al. showed polyubiquitination of TrkA to be 
increased when CYLD is depleted and that p62 facilitates this interaction. Although no 
direct interaction was found between TrkA and CYLD (Geetha et al., 2005). Taken 
together these studies highlight ubiquitination as an important regulatory modification 
and suggest possible mechanisms by which CYLD could be involved in Trk homeostasis. 
Through extensive research efforts the complexity of Trk receptor mediated signalling 
has become evident. Distinct biological processing pathways, the availability of 
different neurotrophins in the local environment, cellular co-expression of Trk receptor 
splice variants and other associated receptors, trafficking and cellular localisation of 
the Trk receptors, and the recruitment and availability of adaptor and intermediate 
signalling molecules, are all factors that have to integrate to evoke a signalling 
response, which can be specific to a Trk receptor or cell type.  
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Figure 4-4: Neurotrophin-p75NTR signalling pathways. 
A simplified schematic overview depicting the main intracellular signalling pathways by which 
neurotrophins exert their cellular responses through p75NTR: JNK and NF-B. The p75NTR receptor can be 
activated by either pro- or mature neurotrophins, however for proneurotrophin signalling activation 
requires the Sortilin receptor. The activation of signalling pathways by p75NTR can initiate opposing 
cellular outcomes, with proneurotrophins usually activating an apoptotic response through the JNK 
pathway. Alternatively independently of neurotrophnis p75NTR can also activate NF-B signalling to 
promote cell survival. The p75NTR receptor can also mediate Trk receptor specificity and facilitate Trk 
signalling. Figure adapted from (Reichardt, 2006). 
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4.1.8 The p75NTR receptor 
As mentioned previously, alongside Trk receptors neurotrophins also interact with the 
structurally unrelated p75NTR. Initially thought of as just an accessory binding partner 
to modulate Trk receptor signalling (Chao and Hempstead, 1995), it subsequently 
became apparent that p75NTR had a key role in sculpting the nervous system too. As 
both a Trk co-receptor and as an autonomous signalling unit, the receptor can mediate 
an array of cellular responses (Figure 4-4), from cell proliferation and survival, to 
myelination and ligand-dependent cell death (as reviewed by (Kraemer et al., 2014; 
Lee F. S. et al., 2001; Roux and Barker, 2002)). 
 
In humans the receptor is encoded for by the NGFR gene, which contains six exons and 
spans 23kb of the chromosome region 17q12 -17q22, producing a 3.8kb mRNA with a 
single consensus polyadenylation signal included in the long (2000 nucleotides) 
3’untranslated region (Huebner et al., 1986; Johnson et al., 1986). A Type 1 
transmembrane protein, which is 427 (amino acid) in length (inclusive of it’s 28  
signal peptide), p75NTR has an extra cellular domain comprised of four repeated 
cysteine-rich motifs, with a single transmembrane domain which connects to a 
cytoplasmic region that includes a ‘death’ domain (Johnson et al., 1986; Liepinsh et al., 
1997). A splice variant of the full-length form of p75NTR that lacks exon III has been 
reported (von Schack et al., 2001). Exon III is the coding region for the cysteine-rich 
domains 2, 3 and 4, which are required for neurotrophin binding. Therefore the 
receptor cannot bind neurotrophic factors but retention of the transmembrane and 
cytoplasmic domains means that it is still capable of interacting with Trk receptors (von 
Schack et al., 2001). However the existence of s- p75NTR remains controversial and its 
function is unknown (Kraemer et al., 2014). 
 
The p75NTR receptor is capable of binding to each of the mature neurotrophins with 
similar affinity, however this is approximately 1000 fold lower than the receptors 
preferred pro-neurotrophin ligands (Reichardt, 2006). Crystallographic studies of the 
three-dimensional structure of NT-3, pro- and mature NGF each in complex with 
p75NTR indicate that all four cysteine rich motifs are involved in binding neurotrophin 
dimers (Gong et al., 2008; He and Garcia, 2004), and suggest that the binding 
stoichiometries of p75NTR with the different pro and mature neurotrophins may 
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mediate distinct signalling activities due to conformational changes of p75, as pro-NGF 
dimers bind in a 2:2 complex whilst mature NGF- binds in a 2:1 complex with the 
receptor, through sets of contact residues that are conserved across the neurotrophin 
family (Feng et al., 2010). Furthermore a disulphide link, which connects p75NTR 
monomers, in the transmembrane domain acts as a pivot point so that upon 
neurotrophin binding the intracellular domains can separate to facilitate the binding of 
signalling molecules (Vilar et al., 2009).  
 
The receptor is widely expressed during early development of the nervous system with 
a more restrictive expression pattern in adult cell populations, however p75NTR is re-
expressed in response to neuronal injury (Ibanez and Simi, 2012). Many studies have 
highlighted the role of p75NTR in promoting programmed cell death in response to 
proneurotrophin binding in a number of different neuronal and non-neuronal cell 
types both in vitro and in vivo; such as oligodendrocytes (Casaccia-Bonnefil et al., 
1996), retinal neurons (Frade et al., 1996), vascular smooth muscle cells (Wang S. et 
al., 2000) and keratinocytes (Botchkarev et al., 2006) The phenoptypes of p75NTR -/- 
mice (Lee K. F. et al., 1992; von Schack et al., 2001) showed an increase in the number 
of some neuronal populations (summarised by (Underwood and Coulson, 2008). This 
demonstrated that p75NTR is a key regulator of normal developmental neural 
apoptosis; providing a mechanism that promotes the elimination of neurons that 
aren’t receiving sufficient neurotrophic support to refine target innervation (Kraemer 
et al., 2014; Lee F. S. et al., 2001; Nykjaer et al., 2005). 
 
In order for pro-neurotrophins to elicit an apoptotic response p75NTR is required to 
form a receptor complex with Sortilin, a Vps10p-domain containing receptor protein. 
The co-expression of these two receptors creates a high affinity receptor complex for 
pro-neurotrophins (Nykjaer et al., 2004; Teng et al., 2005), with pro-NGF interacting 
with Sortilin via its pro-domain and p75NTR by its mature domain (Nykjaer et al., 2004). 
Furthermore the presence of Sortilin regulates the rate of p75NTR cleavage (Skeldal et 
al., 2012). The cleavage of the intracellular domain (ICD) of p75NTR has been shown to 
potentiate cell death or survival in a cell-type specific manner in differing neuron types 
(Vicario et al., 2015). The ectodomain is firstly liberated in an -secretase 
TACE/ADAM17 (tumour necrosis factor- converting enzyme/ a disintegrin and 
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metallopeptidase domain)-dependent, followed by -secretase mediated release of 
the ICD into the cytoplasm where it acts as a signalling entity (Kanning et al., 2003; 
Weskamp et al., 2004), and can interact with a number of cytoplasmic adaptor 
proteins such as TRAF6 (Khursigara et al., 1999), NRIF (neurotrophin receptor 
interacting factor) (Kenchappa et al., 2006), NRAGE (neurotrophin receptor p75 
interacting MAGE (melanoma associated antigen) homologue) (Salehi et al., 2000), 
RhoGDI (Rho GDP-dissociation inhibitor) (Yamashita and Tohyama, 2003) and NADE 
(p75NTR -associated cell death executor) (Mukai et al., 2000). These interactions then 
mediate mobilisation of the ICD to the nucleus, which depending on the cellular 
context can promote apoptosis or survival. 
 
Neurotrophin binding to p75NTR results in the activation of different intracellular 
signalling pathways (Figure 4-4). Without an intracellular catalytic domain downstream 
signalling occurs through the interaction with cytoplasmic adaptor proteins, such as 
those mentioned previously, and frequently this induces an apoptotic response. A 
major pathway that is activated is the JNK (c-Jun N terminal kinase)-p53 signalling 
cascade leading to the up-regulation in transcription of genes for a number of pro-
apoptotic proteins including Bax, Bim and Bad, accumulating in the release of 
cytochrome c and caspase-dependent apoptosis involving the mitochondria (Becker et 
al., 2004; Bhakar et al., 2003; Linggi et al., 2005). TRAF6 has been shown to be an 
important adaptor protein in mediating p75NTR cell death (Khursigara et al., 1999), with 
sympathetic neurons in TRAF6 -/- mice failing to activate JNK in response to BDNF and 
thus do not undergo apoptosis (Yeiser et al., 2004). Furthermore BDNF induced JNK 
activation was significantly attenuated in sympathetic neurons from NRIF -/- mice 
(Linggi et al., 2005). Meanwhile the over expression of NRIF together with TRAF6 
enhanced JNK activation (Gentry et al., 2004), alongside TRAF6 mediated 
ubiquitination of NRIF having been shown to be required for its nuclear entry (Geetha 
et al., 2005). Altogether the evidence suggesting that the interaction of NRIF and 
TRAF6 is essential for p75NTR mediated apoptosis. In addition p75NTR can stimulate 
ceramide production in certain circumstances to stimulate JNK activation (Brann et al., 
2002). 
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Conversely p75NTR is also capable of promoting cell survival, with indications of this 
role coming from the observation of a loss of sensory innvervation of the limbs of 
p75NTR -/- mice (Lee K. F. et al., 1992). The survival response is mediated by p75NTR in 
response to neurotrophins either via interacting with Trk receptors or activating NF-B 
signalling independently of Trks, through the formation of TRAF6-IRAK-aPKC-p62 
complexes (Hamanoue et al., 1999; Khursigara et al., 1999; Wooten et al., 2001). The 
presence of the adaptor protein RIP2 (receptor-interacting protein 2) in Schwann cells 
was found to interact with the p75NTR ICD, and mediate NGF-dependent activation of 
NF-B through TRAF6 and suppression of JNK activation; presenting a potential 
molecular switch to determine an apoptotic or survival outcome through TRAF6 
signalling (Khursigara et al., 2001). 
Alternatively through cooperation with the Trk receptor family p75NTR can also regulate 
cell survival. A key mediator of regulating responsiveness to neurotrophins as 
mentioned previously in section 4.1.7, the influence of p75NTR on neurotrophin 
mediated cell survival is three fold. Firstly p75NTR expression can facilitate NGF binding 
to TrkA, co-expression of the two receptors creates a high-affinity receptor complex 
(Hempstead et al., 1991) enhancing the nanomolar affinity of NGF for TrkA 100-fold 
(Esposito et al., 2001). Secondly p75NTR expression refines the ligand specificity of Trk 
receptors to inhibit the activation of Trk receptors by non-preferred ligands, increasing 
the selectivity of TrkA for NGF over NT-3 (Benedetti et al., 1993) and TrkB for BDNF 
over NT-3 and NT4/5 (Bibel et al., 1999). Thirdly p75NTR expression can modulate the 
signalling pathways activated by Trks. Potential mechanisms include influencing the 
ubiquitylation and internalisation of Trk receptors, although reports are conflicting in 
how this positively affects Trk signalling (see section 4.1.7.2). In addition p75NTR was 
required for Akt activation and promotion of cell survival, as silencing of p75NTR in PC12 
cells reduced neurotrophin-induced activation of Akt (Ceni et al., 2010). In a reciprocal 
manner Trk activation was found to induce p75NTR cleavage, which was also required 
for activation of Akt (Ceni et al., 2010; Kommaddi et al., 2011). Furthermore to 
potentiate a survival response Trk activation also suppresses pro-apoptotic Jun kinase 
signalling mediated by p75NTR, but does not affect the induction of survival promoting 
NF-B signalling in the same way (Yoon et al., 1998). Yet in conjunction with Sortilin, 
ProNGF binding to p75NTR upregulated PTEN (phosphatase and tensin homolog) 
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resulting in suppression of Akt signalling and apoptosis of basal forebrain neurons, 
even if TrkB was activated by BDNF suggesting that Akt activity is regulated by 
neurotrophin processing and co-receptor expression. Therefore Trk and p75NTR exist 
together in a paradoxical relationship, each capable of suppressing and enhancing the 
others actions. 
 Additional roles of the engagement of neurotrophins with p75NTR include regulation of 
RhoA signalling (Yamashita et al., 1999), which can affect neurite outgrowth, and 
activation of acidic sphingomyelinase resulting in the generation of ceramide 
(Dobrowsky et al., 1994), which can alter TrkA activity through phosphorylation of the 
receptor (MacPhee and Barker, 1999).  
4.1.9 Neurotrophins and Trk receptors in the skin 
The important role that neurotrophins and their receptors were found to play in the 
nervous system, regulating cell proliferation, apoptosis and differentiation have been 
replicated in non-neuronal tissues (Sariola, 2001). The ectodermal origin of both the 
nervous system and skin epithelium has prompted investigations into the possible role 
of neurotrophins in skin development and homeostasis, with differential expression 
patterns of the neurotrophins and their receptors found in distinct non-neuronal cell 
populations of the skin (Botchkarev et al., 2006; Bothwell, 1997). Unsurprisingly 
neurotrophins have been found to influence innervation of the skin (Davis B. M. et al., 
1997; Harper and Davies, 1990), but have also been shown to have roles in hair follicle 
cycling and act as growth factors governing skin homeostasis (Botchkarev et al., 2004). 
Further evidenced by neurotrophin expression in mice occurring early on in embryonic 
development at E9.5 and coinciding with the expression of the epidermal keratin 
markers K5 and K14 (Botchkarev et al., 2006) 
4.1.9.1 Keratinocytes 
In human keratinocytes all four neurotrophin receptors, TrkA, TrkB and TrkC and 
p75NTR
 
are expressed (Marconi et al., 2003), alongside synthesis and secretion of their 
cognate ligands, NGF (Di Marco et al., 1991), BDNF, NT-4/5 and NT-3 (Botchkarev et 
al., 1999; Marconi et al., 2003) (botchkarev, 1999, Marconi, 2003) respectively, 
although at low levels. Keratinocytes produce and secrete biologically active NGF at 
the highest levels compared to the other neurotrophic factors, with keratinocyte stem 
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cells expressing and secreting the most whilst in transit amplifying cells levels almost 
disappear (Marconi et al., 2003). NGF is capable of inducing proliferation of human 
keratinocytes, supported by the establishment of an autocrine NGF loop, as NGF is 
released in increasing amounts by proliferating cells, whereas secretion ends in more 
differentiated keratinocytes (Di Marco et al., 1991; Di Marco et al., 1993; Pincelli et al., 
1994). Furthermore inhibition of TrkA phosphorylation with the natural alkaloid K252a, 
in the absence of exogenous NGF, led to a reduction in keratinocyte proliferation 
(Pincelli et al., 1994). 
Alongside this NT-3 also promotes keratinocyte proliferation, as shown by the 
inhibition of proliferation with increasing levels of anti-NT-3 neutralising antibody, in 
the absence of exogenous NT-3. Whilst NT-4/5 and BDNF appeared to have no effect 
on keratinocyte proliferation (Marconi et al., 2003). Furthermore NT-3 and NGF up-
regulate each other’s secretion, although NGF does this to a greater extent (Marconi et 
al., 2003). Expression of the cognate Trk A and TrkC receptors for NGF and NT-3 
respectively, have been shown in keratinocytes and therefore mediate the 
proliferation response by the neurotrophins, particularly as overexpression of TrkA in 
keratinocytes was shown to increase their proliferative capacity compared to controls. 
However keratinocytes were found to express only the truncated TrkB isoform 
(TrkB.T1) (Marconi et al., 2003), but as the function of this isoform isn’t fully 
understood, the notion of NT4/5 or BDNF still being able to exert a response can’t be 
totally disregarded.  
In human keratinocytes neurotrophins have also been shown to influence the 
susceptibility of keratinocytes to apoptosis. In vitro NGF and TrkA expression is 
downregulated by ultraviolet-B (UVB) irradiation, whereas NGF over-expressing 
keratinocytes are protected from UVB-induced apoptosis via expression of anti-
apoptotic Bcl-2 family members (Marconi et al., 2003; Marconi et al., 1999). Also UVB 
augments secretion of NT-3 and NT-4/5, suggesting that they may have a role in 
promoting apoptosis in certain circumstances, as they could interact with p75NTR. 
Indeed p75NTR is almost exclusively expressed in transit-amplifying keratinocytes and 
treatment with either BDNF or NT-4/5 of normal keratinocyte cultures significantly 
induced apoptosis, with BDNF shown to induce proapoptotic JNK phosphorylation and 
reduce the DNA-binding activity of NF-B (Truzzi et al., 2011).  
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4.1.9.2 Fibroblasts 
Fibroblasts are the main cellular component of the dermis, the layer of the skin that 
underlies the epidermis, and are important for wound healing and the production of 
ECM proteins such as collagens (Sorrell and Caplan, 2004). Similar to keratinocytes, 
fibroblasts express all neurotrophins and their corresponding receptors (Palazzo et al., 
2012). Neurotrophins were shown to have a number of effects on fibroblasts, 
supporting their survival through both Trk and p75NTR receptors, stimulating their 
migration, promoting their differentiation into myofibroblasts, and finally NGF and 
BDNF stimulated their contraction in a 3D collagen gel. The more differentiated 
myofibroblasts releasing higher amounts of neurotrophins, mostly NGF and NT-3, and 
expressing TrkB and p75NTR at higher levels (Palazzo et al., 2012). These results 
together showing that a neutrophin network extends across the layers of the skin and 
at the level of the dermis is responsible for regulation of it biomechanical functions. 
4.1.9.3 Melanocytes 
Another cell population of the skin, melanocytes reside in the basal layer and hair 
follicles to produce pigmentation in the skin and hairs. Neurotrophins have been found 
to be important for melanocyte migration and viability (Pincelli and Yaar, 1997) and 
also for melanogenesis (Marconi et al., 2006). Melanocytes express all neurotrophins 
at low levels and appear to release only NT-3 and NT-4/5 under physiological culture 
conditions, yet treatment with the differentiation inducer TPA increases expression of 
TrkA, TrkB and p75ntr but not TrkC, suggesting that melanocytes are stimulated by 
neurotrophins in a paracrine manner (Marconi et al., 2006; Yaar et al., 1994). In 
addition NGF expression is thought to be a protective mechanism for melanocytes to 
sun-exposure, as in response to UV irradiation NGF secretion increases and enhances 
cell survival through promoting Bcl-2 expression to prevent apoptosis (Stefanato et al., 
2003). In response to UVB irradiation NT-3 levels were also increased, suggesting that 
this factor too may support survival of the cells (Marconi et al., 2006). 
4.1.10 Neurotrophins and Trk receptors in the hair follicle 
The hair follicle is considered a mini organ within the skin (see Introduction chapter) 
and neurotrophins have been found to be involved in the control of both hair follicle 
development and cycling (Botchkarev et al., 2006). Indeed in transgenic mouse models 
overexpressing NGF, BDNF or NT-3, NGF and NT-3 were shown to increase hair follicle 
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morphogenesis, whilst the same effect was not seen in BDNF mice (Botchkarev et al., 
1998; Botchkareva et al., 2000). In contrast accelerated hair morphogenesis was seen 
in p75NTR knockout mice, and results indicated an inhibitory role for p75NTR in hair 
follicle development mediated by an effect of p75NTR upon FGF7 (fibroblast growth 
factor) signalling (Botchkareva et al., 1999). Furthermore there were restrictive 
expression patterns of the Trk receptors and their ligands to certain areas of the hair 
follicle during development, which during the final stages showed TrkA and NGF 
expression to be restricted to the ORS, TrkB and BDNF to the ORS and also the dermal 
papilla, and finally TrkC appearing in these regions also, but NT-3 only appearing at the 
late stages of development (Botchkarev et al., 1998; Botchkareva et al., 2000). 
Meanwhile there are fluctuations in neurotrophin levels throughout the hair cycle. 
NGF levels increase during the hair growth stage of anagen, whilst BDNF and NT-4/5 
increase prior to the onset of the hair regression phase of catagen, during which NT-3 
levels are also upregulated. Further evidenced in BDNF over-expressing mice, who 
displayed shortened hair lengths when compared to wild-type animals (Botchkarev et 
al., 2004). In cultured late anagen, human scalp hair follicles, BDNF-TrkB signalling was 
found to inhibit hair shaft elongation and induce catagen through upregulation of 
TGF2 (Peters et al., 2005), with BDNF secreted from both the dermal papilla and TrkB 
expressing keratinocytes in the inner and outer root sheaths. Together this data 
suggests mesenchymal-epithelial cross-talk occurs to promote catagen, with BDNF 
functioning as a terminal differentiation promoter in this skin compartment (Peters et 
al., 2005), with further support from p75NTR expression (Peters et al., 2006).  
4.1.11 Neurotrophins and Trk receptors in CYLD-defective tumours 
As the hair follicle is a primary source and target of functional neurotrophin signalling 
in the skin and this is the same compartment from which CYLD-defective tumours are 
thought to originate, it is intriguing that Rajan et al. using a gene expression 
microarray, found that Trk receptors and neurotrophin expression was altered in CYLD-
defective tumours. TrkB and TrkC in particular were overexpressed as well as each of 
the neurotrophin ligands NT-3, NT-4/5, BDNF and NGF, whilst in contrast TrkA 
expression was down regulated (Rajan, Elliott, et al., 2011). In vitro experiments on 
primary tumour cells showed that silencing of TrkB and TrkC reduced cell viability and 
3D primary cell cultures were sensitive to pan-Trk inhibitor treatment, together 
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indicating that the tumours were dependent on Trk signalling for their survival (Rajan, 
Elliott, et al., 2011). 
 
Indeed CYLD was previously found to be involved in the deubiquitination of TrkA, 
which could consequently disrupt Trk homeostasis and internalisation (Geetha et al., 
2005), and with others having shown ubiquitination of TrkB by the same E3 ligases, 
TRAF6 and p62, as TrkA (Jadhav et al., 2008), it is not inconceivable that CYLD may also 
be capable of deubiquitination of the TrkB receptor, in which case a loss of CYLD may 
disrupt Trk regulatory mechanisms and alter receptor homeostasis which may lead to 
tumourigenesis.  
 
Furthermore previous work identified TrkB.T1 as the predominantly expressed TrkB 
isoform in cultured, normal human keratinocytes (Marconi et al., 2003). Therefore an 
aim of this chapter was to determine if this was the case in CYLD-defective tumours, as 
it is only in the nervous system that this isoform has been more extensively explored. 
Evidence suggests that far from being solely a dominant negative inhibitor of TrkB.FL 
via sequestration of neurotrophic ligands and inhibition of Trk autophosphorylation 
(Eide et al., 1996), it is an independent receptor, which even without a catalytic 
domain can induce intracellular signalling cascades (Fenner, 2012). For example in 
astrocytes TrkB.T1 has been shown to mediate calcium signalling, through BDNF 
stimulation of TrkB.T1 inducing activation of G-protein dependent PLC activation 
leading to calcium release and entry (Rose et al., 2003). In glial cells TrkB.T1 was shown 
to be capable of mediating ligand dependent RhoGDI1 (Rho GDP dissociation inhibitor) 
signalling leading to inhibition of Rho GTPases and cytoskeletal rearrangement (Ohira 
et al., 2005). In addition it can also affect cellular metabolism (Baxter et al., 1997) and 
regulate TrkB.FL surface expression (Haapasalo et al., 2002) and neuronal 
differentiation (Fenner, 2012; Yacoubian and Lo, 2000). Therefore as the truncated 
isoform has not been characterised in keratinocytes and TrkB expression is 
upregulated in CYLD-defective tumours, this warranted further investigation.  
4.1.12 Neurotrophins and the TrkB receptor in cancer 
The control of cell fate that Trk signalling can have, alongside the range of signalling 
networks that are responsive to Trk activation, are now recognised mechanisms that 
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can contribute to the pathogenesis of a variety of cancers. Indeed whilst neurotrophin-
Trk signalling came to pre-eminence in the field of neurobiology, NTRK was initially 
identified as a proto-oncogene (Martin-Zanca et al., 1986). The 5’ region of TPM3 (non-
muscle tropomyosin) fused with a tyrosine kinase domain characteristic of a cell 
surface receptor, that was capable of transforming NIH3T3 cells (Martin-Zanca et al., 
1986; Martin-Zanca et al., 1989).  Mutations and genetic rearrangements of the Trk 
receptors, which create oncogenic fusion genes, can occur in multiple types of 
malignancies such as colon, lung and thyroid, although these tend to be sporadic 
incidences (Amatu et al., 2016; Geiger et al., 2011). In recent years pan-Trk inhibitors 
have been developed, prompted by the significance of the receptors role in 
carcinogenesis. Although in early phase clinical trials the inhibitors are showing 
promising anti-tumour effects (Lange and Lo, 2016). 
 
The expression of TrkB is often associated with poor prognosis and increased 
metastatic potential in numerous cancers, including neuroblastoma (Nakagawara et 
al., 1994), head and neck carcinoma (Kupferman et al., 2010), lung (Sinkevicius et al., 
2014), breast (Vanhecke et al., 2011), colon (Tanaka K. et al., 2014) and pancreatic 
(Sclabas et al., 2005). Furthermore in neuroblastoma expression of TrkA and TrkC is 
predictor of a good prognosis highlighting that the receptors can be differentially 
regulated in tumour cells and the activated transciptomes have different functional 
effects (Thiele et al., 2009). Some of the tumour promoting functions that the BDNF-
TrkB signalling axis has been found to be responsible for include increased resistance 
of neuroblastoma cells to cytotoxic drugs (Scala et al., 1996) and survival under limited 
growth factor conditions (Kim C. J. et al., 1999), in addition to induction of 
angigogenesis via increased VEGF (vascular endothelial growth factor) through TrkB 
induction of HIF-1 (Nakamura et al., 2006). Similarly TrkB signalling was found to 
mediate the acquirement of metastatic ability in breast cancer, via c-Src dependent 
PI3K-Akt and IL6-JAK2-Stat3 activation. Signalling via these pathways led to 
upregulation of target genes such as Twist 1 and 2, which contributed to cancer stem 
cell renewal and epithelial-mesenchymal transition (EMT), traits of cells with 
metastatic potential (Kim M. S. et al., 2015). Furthermore Yin et al. showed that a 
subpopulation of TrkB positive cancer stem cells in triple negative breast cancer 
(TNBC) were responsible for tumour recurrence. Differentiated TNBC cells upregulate 
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BDNF secretion during paclitaxel chemotherapy treatment, which acts in a paracrine 
manner to promote cell self renewal of the TrkB positive cancer stem cell 
subpopulation through induction of KL4 expression (Yin et al., 2015). However the role 
that alternate TrkB isoforms may have has not been extensively studied in cancer cells. 
Yet a recent study showed that in breast tumours, autocrine BDNF and NT4/5 
stimulation had an anti-apoptotic effect that was mediated by TrkB.T1 in cooperation 
with p75NTR, contributing to tumour cell survival. Alongside this there was limited 
expression of TrkB.FL (Vanhecke et al., 2011). Altogether these studies exemplifying 
the many ways in which TrkB expression has a pathological role in a multitude of cell 
contexts. 
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4.2 Chapter specific material and methods 
4.2.1 Polymerase chain reaction (PCR) for TrkB (NTRK2) isoforms  
The cDNA from tumour samples and the SHSY-5Y cell-line treated with retinoic acid 
were used for PCR for detection of NTRK2 isoforms. Primers were designed around 
exons 15-18 for the full-length isoform (TRKB.FL) and 15-16 for the truncated isoform 
(TRKB.T1), and were based on sequences obtained from Ensembl (www.ensembl.org) 
(Table 4-1). Each of the NTRK2 transcripts was amplified using MyTaq HS Mix 
polymerase (Bioline) in a total reaction volume of 25μl (reaction mix shown in Table 4-
2). Primers and reactions were run in a thermal cycler following the conditions in Table 
4-3. All reactions were repeated at least three times. 
 
Table 4-1:Primers used for amplification of NTRK2 isoforms 
 
Table 4-2: Reaction mixture composition for NTRK2 isoforms  
 
Table 4-3: Thermocycler PCR program for NTRK2 isoforms 
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4.2.2 Pathscan antibody array 
To give an overview of receptor tyrosine kinases that could be active in cell models of 
cylindroma, a PathScan RTK Signalling Antibody Array (7982, Cell Signaling 
Technologies, USA) was carried out according to the manufacturer’s protocol. The kit 
incorporates glass slides with panels that have been spotted with antibodies, which 
allows for the simultaneous detection of 28 receptor tyrosine kinases and 11 signalling 
nodes when phosphorylated at specified residues (Table of Antibody layout in 
Appendix). The principle of the assay is the binding of added sample lysate to primary 
antibody on the slide, and detection via amplifying the binding signal with horseradish 
peroxidase, which is then detected via chemiluminescence and the signal captured 
onto film.  
4.2.2.1 Preparing cell lysates 
1X Cell Lysis Buffer- 1ml of 10X Cell Lysis Buffer diluted in 9mls dH2O with PMSF (1mM 
final concentration) 
Cells were grown until confluent in 25cm2 flasks, media was removed and the cells 
were initially washed with 1ml of ice cold PBS (Invitrogen), before adding 600l of ice 
cold 1X cell lysis buffer and incubating the flask on ice for 5 minutes. Cells were 
dislodged with a cell scraper and the lysed cells were transferred to a 1.5ml eppendorf 
tube on ice. The samples were centrifuged at 14000rpm for 10 minutes at 4C to 
remove cell debris. The concentration of each sample was determined using the Qubit 
Protein Assay (see Section 2.4.3), and the samples diluted to 0.5mg/ml in Array Diluent 
Buffer. 
4.2.2.2 Preparing tissue lysates 
Frozen tissue from CYLD defective tumours and normal skin was cut using a cryostat 
and the curls collected into Precellys 2ml bead tubes to which 100l of cell lysis 
buffer was added. To lyse the tissue the samples underwent a 30 second shake cycle 
program at 6000 rpm in a Precellys Evolution machine. The samples were then 
centrifuged at 14000rpm and the supernatant transferred to a 1.5ml eppendorf. The 
concentration of each sample was determined using the Qubit Protein Assay (see 
Section 2.4.3), and the samples diluted to 0.5mg/ml in Array Diluent Buffer. 
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4.2.2.3 Antibody array 
1X Array Wash Buffer- 1ml of 20X Array Wash Buffer diluted in 19mls dH2O 
1X Detection Antibody Cocktail- 150l of 10X Detection Antibody Cocktail diluted in 
1350l Array Diluent Buffer 
1X HRP-linked Streptavidin- 150l of 10X HRP-linked Streptavidin diluted in 1350l 
Array Diluent Buffer 
The antibody array slide was fitted with an 8-well gasket and 150l of Array Blocking 
Buffer was added to each well and left to incubate on a rocker at room temperature 
for 15 minutes. All further incubation and wash steps were also carried out at room 
temperature with agitation on a rocker.  After removal of the Blocking Buffer, 150l of 
the diluted cell lysates were added to each well and incubated for 2 hours. 
Subsequently each well was washed for 5 minutes in Array Wash Buffer and repeated 
three more times.  The wells then had 150l of Detection Antibody Cocktail added and 
left to incubate for 1 hour before the same washing procedure as before. Finally 150l 
HRP-linked Streptavidin was added to each well and left to incubate for 30 minutes 
before the usual washing steps followed by a brief wash of the slide after removal of 
the well gasket. To visualize antibody binding via a chemiluminescent readout, 
LumiGlo and peroxide reagents were diluted and the slide submerged in the solution. 
The slide was transferred into a plastic protector and exposed to photographic film to 
develop an image. 
4.2.2.4 Analysis of array 
Array images were analysed using ImageJ software (v 1.48) and duplicate spot 
intensities for each antibody were quantified. Following correction for background, the 
pixel intensity for each antibody was plotted using GraphPad Prism software v6.0. 
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4.3 Results 
4.3.1 Trk related genes distinguish the majority of CYLD-defective tumours from 
controls 
Prior to this study a dataset was derived from microarray gene expression studies 
carried out by Dr. Neil Rajan, monitoring the gene expression of 24,526 transcripts in a 
pool of 32 CYLD defective tumours, including cylindromas, spiradenomas and 
trichoepitheliomas, and a pool of 10 perilesional skin controls (Rajan et al, Oncogene, 
2011). Using this independent dataset the expression of NTRK2 (TrkB) transcripts and 
associated receptors and cognate ligands were analysed. Differentially expressed 
genes in CYLD-defective tumours compared to controls were determined with a 
threshold for statistical significance of p < 0.05 after correction for multiple hypothesis 
testing. To visualise the expression of each of the genes (n=16) at an individual sample 
level, normalised signal values were plotted on a heat map, following logarithmic 
transformation (Figure 4-5). Clustering by Euclidean distance separated the majority of 
tumours from control skin with the exception of a trichoepithelioma (tumours 1) and 
two control samples (Control 3 and 7). Indeed in tumour samples the expression levels 
of NTRK2 (Figure 4-5) transcripts were increased in the tumour samples as indicated by 
the red colour of the heat map. The same was also seen for certain transcripts of TrkB 
neurotrophic ligands BDNF and NT-4/5.  
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Figure 4-5: The expression of Trk related genes in CYLD-defective tumours and 
perilesional skin. 
A heat map plot illustrating the expression levels of NTRK2 and associated receptors and ligands in 32 
CYLD-defective tumours and 10 controls (samples indicated at the bottom of the heat map). 
Differentially expressed genes were determined (p <0.05) between tumours and controls, and transcript 
expression levels at a single sample level are displayed on the heat map; red, over-expressed transcripts; 
blue, under-expressed transcripts; gene names indicated on the right-hand side of the figure; where 
data from multiple transcripts for a single gene were available are indicated with a numerical suffix (n = 
7). Clustering by similarity is shown, determined by Euclidean distance. BDNF = brain derived 
neurotrophic factor, NGF = nerve growth factor, NT-3 & 45 = neurotrophins 3 and 4/5, NGFR = p75NTR 
receptor, NGFRAP1 = p75NTR associated protein 1 (Bex3), NGFRAP1L1 = p75NTR associated protein 1 like 
(Bex5), NTRK1, 2 & 3 = Trk receptors A, B and C, SORCS1, 2 & 3 = sortilin related Vps10 domain 
containing receptor 1,2 and 3, SORL- sortilin-related receptor, TNFRSF1B = tumour necrosis factor 
receptor superfamily member 1B. 
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4.3.2 TrkB.T1 is the predominantly expressed TrkB isoform in CYLD-defective 
tumours 
Having previously found that TrkB is over-expressed in CYLD-defective tumours (Rajan, 
Elliott, et al., 2011), and that TrkB.T1 is the predominant isoform expressed in 
keratinocytes (Marconi, 2003), alongside the differential expression of the different 
NTRK2 transcripts shown in the previous data-set (Section 4.3.1), the splicing of NTRK2 
was investigated further to identify which of the full-length (FL) and truncated (T1) 
isoforms of TrkB were present in CYLD-defective tumours. RNA-seq analysis of a pool 
of 16 CYLD-defective tumours and 4 perilesional skin controls (from mutated CYLD 
carriers) was performed and the sorted reads visualized using the UCSC genome 
browser. Expression of the truncated NTRK2 (TrkB.T1) isoform was increased in 
tumours compared to the controls (Figure 4-6), as indicated by the scale of the Y-axis 
and the difference in height of the read-depth peaks.  
To validate the RNA-seq data, RT-PCR was carried out on cDNA generated from a panel 
of male and female cylindroma tumours. The neuroblastoma cell line SH-SY5Y (treated 
with 1M retinoic acid - section 4.2.1) was used as a positive control, as this cell line 
has been shown to express both TrkB isoforms when treated (Kaplan et al., 1993). For 
the isoform NTRK2.FL, two products were detected in all samples that were of the 
expected sizes of 300bp and 252bp. A single product was detected in all samples for 
the isoform NTRK2.T1, which was of the expected size of 158bp (Figure 4-7). The two 
full-length products are due to splicing of exon 17, which is 48bp in length and 
corresponds with the size of the two PCR products seen.  
Following this the levels of expression of each of the NTRK2 isoforms in cylindromas 
were semi-quantitatively measured using qPCR. Two control groups were also 
included; normal control skin from patients with no CYLD mutation, and perilesional 
skin from a CYLD-defective patient taken from hair-bearing (HB) (scalp) and non-hair 
bearing (non-HB) sites. All tumours showed an increase in NTRK2.FL and NTRK2.T1 
expression when compared to normal skin (Figure 4-8).  
The increase at transcript level translated to an increase in TrkB.T1 protein (90kDA) in 
CYLD-defective tumours compared to normal skin controls (Figure 4-9). The TrkB.FL 
protein (140kDA) was not detected in any of the samples, suggestive of TrkB.FL not 
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being translated into protein in either sample type despite the increases seen at the 
mRNA level in the tumours. The membranes were also probed for CYLD (108kDA), 
which showed a lack of full-length protein in the tumour samples.  
 
Figure 4-6: NTRK2 transcripts in CYLD-defective tumours. 
UCSC genome browser view of the NTRK2 gene showing aligned RNA-seq reads from a panel of CYLD-
defective tumours (red track) and perilesional skin controls (green track). The height of the peaks 
illustrating the number of reads which align to the exons of the NTRK2 gene, with a scale given on the Y-
axis (note the scales are different on each axis to reflect the difference between CYLD-defective tumours 
and perilesional skin controls). The black dashed line rectangles highlight the increased inclusion of the 
alternate exon 16 in the samples, indicative of the TrkB.T1 isoform. 
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Figure 4-7: TrkB.FL and TrkB.T1 mRNA is expressed in CYLD-defective tumours. 
PCR products were generated from cylindroma cDNA for each of the TrkB isoforms, with primer pairs 
designed around exons 15-18 for TrkB.FL and exons 15-16 for TrkB.T1, as exon 16 is exclusive to the 
TrkB.T1 isoform. cDNA from SH-SY5Y cells treated with 1M retinoic acid was used as a positive control. 
A representative agarose gel image is shown (n=6). 
 
Figure 4-8: TrkB.FL and TrkB.T1 mRNA is over-expressed in CYLD-defective tumours 
compared to normal skin. 
Primers were designed around exon regions exclusive to each of the TrkB isoforms (TrkB.FL: exons 23-
24; TrkB.T1: exon 16) and their expression quantified by qPCR analysis in normal skin, perilesional CYLD-
defective skin and CYLD-defective tumours, using the SYBR green method. mRNA expression for each 
isoform was normalised and expressed relative to the housekeeping gene GAPDH. Data are the mean 
and error bars represent the SEM of n=3 experiments. 
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Figure 4-9: TrkB.T1 protein is increased in CYLD-defective tumours compared to 
normal skin. 
Tissue lysates collected from CYLD-defective tumours and normal skin were subjected to 
immunoblotting with antibodies raised against TrkB and CYLD to determine the levels of protein 
expression, with -actin used as a loading control. Western blot shown is representative of n=2 
experimental repeats.  
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4.3.3 Exogenous overexpression of TrkB.T1 in the keratinocyte cell line, HaCaT, 
does not induce a proliferative advantage 
Having shown that TrkB.T1 is the predominantly expressed isoform in CYLD-defective 
tumours, particularly in cylindromas, the isoform was explored further in vitro to 
characterise the role of TrkB.T1 in keratinocytes. The human keratinocyte cell line, 
HaCaT was transfected with the lentiviral vector pLEX-TrkB.T1 and empty pLEX-MCS 
expression vector as a control (Figure 4-10A). Unfortunately repeated attempts to 
transfect HaCaT cells with pLEX-TrkB.FL were unsuccessful, so comparative 
experiments between the isoforms in a more biologically relevant keratinocyte cell 
model were not possible in this project. 
 
To see if TrkB.T1 conferred a growth advantage to the cells, a cell viability assay was 
performed 72 hours after plating into 96 well plates. The assay detected ATP levels to 
determine metabolically active or ‘live’ cells via a luminescent read out. Cell viability 
was increased in HaCaTs over expressing TrkB.T1 compared to empty vector control 
but did not reach a level of significance (Figure 4-10B). The TrkB.T1 ligand BDNF 
(100ng/ml) was added to the culture media for 72 hours before assaying as above, to 
assess if activation of the receptor by the ligand would influence cell survival or 
growth. The addition of BDNF consistently reduced cell viability in HEK293T cells over 
expressing TrkB.FL, nearly reaching significance (paired t-test; p = 0.06) (Figure 4-11A). 
However in both cell lines no such reduction was seen in cells over expressing TrkB.T1 
(Figure 4-11A & B). 
Colony forming assays were also carried out, in HaCaTs only, to see if TrkB.T1 over 
expression induced proliferation of the cells. Cells were seeded into a 6 well plate and 
left to grow for 8 days before being fixed and stained. Plates were scanned and 
particles analysed using ImageJ software. Cell over expressing TrkB.T1 did not show a 
significant difference in colony size or number compared to empty vector controls 
(Figure 4-12) This was further supported when the number of cells/colony, with a 
threshold of >10 cells/colony, were counted by eye on a microscope within a defined 
region of the same size in T75cm2 cell culture flasks. This result showed that there was 
no difference in the average colony size between control and TrkB.T1 over expressing 
cells, with a similar total number of colonies counted for each sample within the 
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designated area which met the threshold; Empty vector: 103 TrkB.T1: 108. Taken 
together these results suggest that TrkB.T1 may confer a survival advantage but does 
not necessarily promote cell proliferation in keratinocytes. 
 
 
Figure 4-10: Over-expression of TrkB.T1 in HaCaT cells does not significantly increase 
cell viability. 
 A) HaCaT cells were transfected with pLEX TrkB.T1 vector to over-express TrkB.T1, or pLEX MCS vector 
(empty vector control), and successfully transfected cells selected for with puromycin. Protein lysates 
were collected and Western blotting carried out to ensure successful transfection. B) HaCaT cells 
transfected with either empty vector or pLEX TrkB.T1 vector were seeded in a 96 well plate at a density 
of 10000 cells/well and left for 72hours before being analysed. Non-transfected HaCaTs were used as a 
control. Data are the mean and error bars represent the SEM of n= 3 independent experiments. 
(Statistical analysis unpaired t-test). 
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Figure 4-11: Exogenous BDNF stimulation does not increase cell viability in TrkB.T1 
over-expressing cells. 
A) HEK293T cells transfected with either empty vector, pLEX TrkB.FL or pLEX TrkB.T1 vector were seeded 
in a 96 well plate at a density of 10000 cells/well, treated with 100ng/ml BDNF and left for 72 hours 
before being analysed. B) HaCaT cells transfected with either empty vector or pLEX TrkB.T1 were treated 
the same as the cells in (A). In both figures data are the mean and error bars represent the SEM of n= 3 
independent experiments. 
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Figure 4-12: TrkB.T1 does not increase colony formation in TrkB.T1 over-expressing 
HaCaT cells. 
A) Cells were plated at a density of 2000 cells/well in triplicate into 6 well plates and left to grow for 8 
days before being fixed in 4% PFA and stained with Sulphorhodamine B. Plates were scanned and 
images were analysed using ImageJ software. The size of the colonies and the area of the plate that the 
colonies covered were measured. The experiment was repeated 4 times. Data are the mean and error 
bars represent the SEM of n=4. B) Colonies within a defined area of a75cm2 flask were counted on a 
microscope with a threshold of >10 cells/colony and each colony size value plotted. The experiment was 
repeated on 3 flasks for each sample. Data are the mean and error bars represent SEM of colony size. 
  
B) 
A) 
  164 
4.3.4 Identification of potential targets of TrkB isoform signalling using an antibody 
array 
TrkB is a member of one of a variety of receptor tyrosine kinase families that are able 
to transduce signals through a variety of signalling pathways. To give an overview of 
the effect of TrkB overexpression on the phosphorylation of other tyrosine kinases and 
downstream signalling nodes and to identify which pathways could be activated, the 
Pathscan RTK signalling antibody array was used (Section 4.2.2). The resulting film 
image was analysed using ImageJ to quantify signal intensity. The array was performed 
on a number of cell types, firstly HEK293T cells transfected with pLEX-TrkB.FL. pLEX-
TrkB.T1 or empty vector as a control (Figure 4-13A). In cells overexpressing TrkB.T1 
there were increases in the phosphorylation of p-Akt (Ser473) and p-Src (pan Tyrosine) 
compared to cells overexpressing TrkB.FL or empty vector (Figure 4-13 B, C & D). These 
are known downstream targets of neurotrophin-TrkB signalling that are involved in 
promoting cell survival and differentiation. The TrkB signal on the array acted as an 
internal control in these cells, however it was noted that there was only an intense 
signal from the TrkB.FL over-expressing cells and not TrkB.T1. It is assumed this is 
because TrkB.T1 does not contain the tyrosine kinase domain where phosphorylation 
occurs and therefore the antibody cannot recognise the phosphorylated residues and 
bind to create a signal. Secondly the array was performed using HEK293T cells 
transfected with pLEX-CYLD or a CYLD gene that harboured one of four different 
patient mutations, which encoded for truncated or catalytically inactive CYLD protein. 
This showed that over-expression of CYLD caused a reduction in Stat3 (Tyr705) 
phosphorylation (Figure 4-14). Lastly CYLD-defective tumour lysates were used on the 
array alongside normal skin controls. In the previously identified targets from the over-
expression cell lines, p-Akt (Ser473), p-Src (pan Tyrosine) and p-Stat3 (Tyr705), 
phosphorylation of these targets was increased but there was variation in 
phosphorylation levels across the tumour samples, representing the heterogeneity of 
the samples. However one of the tumour samples (Tumour-5) consistently had lower 
readings compared to the other samples suggesting a loading or technical error (Figure 
4-15). 
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Figure 4-13: Identification of targetable kinases and their downstream targets in 
HEK293T cells over-expressing TrkB isoforms using an antibody array. 
A) HEK293T cells were transfected either with empty, pLEX TrkB.FL or pLEX TrkB.T1 expression vectors 
and selected for with puromycin. Protein lysates were collected and Western blotting carried out to 
ensure successful transfection. -Actin was used as a loading control B) Protein lysates were prepared 
and quantified with 0.5mg/ml of each sample was used for the array. Pathscan Array panel captured 
onto film to show the expression of the proteins. Antibody dots are paired; purple box = TrkB, orange 
box = p-Akt (Ser473), turquoise box = Src. C&D) Protein expression was quantified using densitometry 
(see next two pages). The experiment was only carried out once with each sample and the duplicate 
readings for each antibody were plotted. Data are the mean and error bars represent the SEM of n=2. 
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Figure 4-14: Identification of targetable kinases and their downstream targets in 
HEK293T cells over-expressing mutant CYLD using an antibody array. 
A) HEK293T cells were transfected with empty vector or vectors with the specified CYLD mutations that 
are reflective of the mutations found in patients and selected for with puromycin. Protein lysates were 
collected and Western blotting carried out to ensure successful transfection. GAPDH was used as a 
loading control. B) Protein lysates were prepared and quantified with 0.5mg/ml of each sample was 
used for the array. Pathscan Array panel captured onto film to show the expression of the proteins. 
Antibody dots are paired; pink box = p-Stat3 (Tyr705). C) Protein expression was quantified using 
densitometry. The experiment was only carried out once with each sample and the duplicate readings 
for each antibody were plotted. Data are the mean and error bars represent the SEM of n=2.  
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Figure 4-15: Identification of targetable kinases and their downstream targets in 
CYLD-defective tumours using an antibody array. 
A) Protein lysates were collected from CYLD-defective tumours and normal skin samples as control. The 
amount of protein was quantified and 0.5mg/ml of each sample used in the array. The Pathscan Array 
panel was captured onto film to show the expression of the proteins. Antibody dots are paired; purple 
box = TrkB, orange box = p-Akt (Ser473), turquoise box = Src and pink box = p-Stat3 (Tyr705). B,C) 
Protein expression was quantified using densitometry. The experiment was only carried out once with 
each sample and the duplicate readings for each antibody were plotted. Data are the mean and error 
bars represent the SEM of n=2. 
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4.3.5 Validation of identified targets Akt, Src and Stat3 in TrkB.T1 over-expressing 
HaCaTs 
From the findings of the Pathscan RTK signalling antibody array, the identified 
targets Akt, Src and Stat3 were validated in BDNF (100ng/ml) stimulated TrkB.T1 over-
expressing HaCaTs and compared to empty vector as a control. A time course indicated 
that phosphorylation of Akt (Ser 473) did not occur until after four hours of exposure 
to BDNF (Figure 4-16A) in TrkB.T1 over-expressing cells, indicating a delayed response 
in Akt phosphorylation. Whist no difference in Akt phosphorylation was observed 
between control and TrkB.T1 over-expressing cells, with both showing the same level 
of p-Akt (Ser473) expression, which did not change upon BDNF stimulation (Figure 4-
16B). However the cells were only stimulated with BDNF for 15 minutes due to 
experimental constraints of using the lysates to look at different targets, therefore it 
may be that sustained stimulation of TrkB.T1 is required to initiate Akt signalling.  
 The experiment was repeated in 2D cylindroma primary cell cultures, comparing cells 
from three separate cylindromas. The result replicated what had been shown in the 
over-expressing cell line, with p-Akt (Ser 473) remaining unchanged in cells exposed to 
BDNF, and that Akt was already phosphorylated in untreated cells (Figure 4-16C). 
Similarly the levels of Src phosphorylation did not change when TrkB.T1 over-
expressing cells were stimulated with BDNF or over a prolonged period as indicated 
(Figure 4-17A & B). With no apparent changes these targets were not explored further. 
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Figure 4-16: Phosphorylation of Akt (Ser473) remains unchanged following BDNF 
stimulation in HaCaTs over-expressing TrkB.T1 and 2D primary cylindroma cells. 
A) HaCaT cells over-expressing TrkB.T1 were treated with BDNF (100ng/ml) for the time points stated. 
Lysates were collected for Western blot and membranes were probed with p-Akt (Ser 473), and Akt 
antibodies. Western blot shown is representative of n=1 experimental repeat B) HaCaT cells over-
expressing TrkB.T1 and empty vector as a control were treated with BDNF (100ng/ml) for 15 minutes 
and lysates were probed with the same antibodies as (A). Western blot shown is representative of n = 3 
experimental repeats. C) Primary cylindroma cells were treated with BDNF and membranes probed 
under the same experimental conditions. Western blot shown is representative of n=1 experimental 
repeat. 
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Figure 4-17: Phosphorylation of Src remains unchanged following BDNF stimulation 
in HaCaTs over-expressing TrkB.T1. 
A) HaCaT cells over-expressing TrkB.T1 were treated with BDNF (100ng/ml) for the time points stated. 
Lysates were collected for Western blot and membranes were probed with p-Src (Tyr 416), p-Src (Tyr 
527), p-Src (Ser 17), and Src antibodies. GAPDH was used as a loading control. Western blot shown is 
representative of n=3 experimental repeat B) HaCaT cells over-expressing TrkB.T1 and empty vector as a 
control were treated with BDNF (100ng/ml) for 15 minutes and lysates were probed with the same 
antibodies as (A). Western blot shown is representative of n = 1 experimental repeat.  
  
p-Src  
(Tyr416) 
p-Src  
(Tyr527) 
p-Src  
(Ser17) 
Src  
GAPDH 
     0       15      60      90 Minutes 
+BDNF (100ng/mL)  
HaCaTs TrkB.T1 
 
 
 
 
 
p-Src (Tyr416) 
(60kDA) 
p-Src (Tyr527) 
(60kDA) 
p-Src (Ser17) 
(60kDA) 
Src 
(60kDA) 
  
         -             +            -            + 
pLEX 
MCS 
pLEX 
TrkB.T1 BDNF 
 (100ng/ml) 
HaCaTs 
 
 
 
 
A) 
B) 
  176 
4.3.6 Exogenous over-expression of TrkB.T1 leads to an increase in p-Stat3 (Tyr705) 
expression in vitro 
From the Pathscan RTK signalling antibody array it was interesting that in the 
presence of CYLD p-Stat3 (Tyr705) expression was reduced, and conversely in cells 
over-expressing mutant CYLD expression was increased. The increase in p-Stat3, 
particularly at the Tyrosine 705 residue, was a trend also observed in HEK293T cells 
over-expressing the two TrkB isoforms and in CYLD-defective tumour lysates. 
Furthermore Stat3 has been shown to be a downstream target of neurotrophin 
signalling (Ng et al., 2006), and phosphorylation of Stat3 at Tyr 705 leads to homo-
dimerisation and activation of Stat3 molecules, consequently p-Stat3 relocates to the 
nucleus and can initiate gene transcription. Therefore Stat3 was explored in HaCaTs 
over-expressing TrkB.T1. A time course of BDNF (100ng/ml) treatment of TrkB.T1 
HaCaTs, to see the effect on Stat3 phosphorylation levels at the stated time points, 
showed that p-Stat3 (Tyr705) peaked at 15 minutes after which the levels dropped off, 
meanwhile p-Stat3 (Ser727) was increased between 5 and 15 minutes and this level 
was sustained for the following time points (Figure 4-18A). Compared to the empty 
vector control, cells over-expressing TrkB.T1 had a higher basal level of phosphorylated 
Stat3 at Tyr705, with exposure to BDNF (100ng/ml) causing a significant increase (p = 
0.0169) in Stat3 phosphorylation that was not duplicated in BDNF treated empty 
vector control HaCaTs (Figure 4-18B & C). This increase was also observed in the 
primary cylindroma cells (Figure 4-19). The phosphorylation of Stat3 at Ser727 
remained unchanged upon BDNF treatment in both empty vector and TrkB.T1 cells 
(Figure 4-18B). The expression levels are conflicting for untreated TrkB.T1 cells and the 
zero time point, however all cells were exposed to BDNF in the time course, with BDNF 
removed straight away at the zero time point. Meanwhile cells were not treated with 
BDNF in the comparative study therefore it may be that BDNF has an immediate 
biological effect on phosphorylation of Stat3 at this site.  
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Figure 4-18: Phosphorylation of Stat3 (Tyr705) is increased following BDNF 
stimulation in HaCaTs over-expressing TrkB.T1. 
A) HaCaT cells over-expressing TrkB.T1 were treated with BDNF (100ng/ml) for the time points stated. 
Lysates were collected for Western blot and membranes were probed with p-Stat3 (Tyr705), p-Stat3 
(Ser727) and Stat3 antibodies. GAPDH was used as a loading control. Western blot shown is 
representative on n=3 experimental repeats. B) HaCaT cells over-expressing TrkB.T1 and empty vector 
as a control were treated with BDNF (100ng/ml) for 15 minutes. Lysates were collected for Western blot 
and membranes were probed with p-STAT3 (Tyr705), p-STAT3 (Ser727) and STAT3 antibodies. Western 
blot shown is representative on n=3 experimental repeats. C) Densitometry analysis of Western blots in 
(B). The samples were normalised to Stat3 and expressed relative to untreated empty vector control. 
Data are the mean and error bars represent the SEM of n=3 (* p < 0.05, paired t-test). 
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Figure 4-19: p-Stat3 (Tyr705) is increased following BDNF stimulation in 2D primary 
cylindroma cells. 
Primary cylindroma cells were treated with BDNF (100ng/ml) for 15 minutes. Lysates were collected for 
Western blot and membranes were probed with p-STAT3 (Tyr705) and STAT3 antibodies. Western blot 
shown is representative of n=1 experimental repeat. 
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4.3.7 Stat3 expression is increased in CYLD-defective tumours 
Having found that p-Stat3 expression is increased upon BDNF stimulation of TrkB.T1 
over-expressing cells, p-Stat3 expression was assessed in CYLD-defective tumours, as 
they also over-express TrkB.T1, by using immunohistochemistry. Tissue sections from 
17 tumours including both cylindromas and spiradenomas, were probed with p-Stat3 
(Tyr705) and total Stat3 antibodies, visualised with DAB and quantified (p-Stat3 
samples only). Samples were considered p-Stat3 (Tyr705) positive if >15% of cells 
demonstrated p-Stat3 expression. In both cylindromas and spiradenomas p-Stat3 
(Tyr705) expression was shown to have a nuclear localisation, which varied in intensity 
throughout the tissue sections, with some areas of the tumour showing no 
immunoreactivity. In control perilesional skin (CYLD +/-), some cells of the basal layer 
of the epidermis demonstrated nuclear p-Stat3 (Tyr705) and Stat3 expression (Figure 
4-20 A & B).  In both tumour types there was a scattered pattern of p-Stat3 (Tyr705) 
expression, however in the cylindroma cells expression was more restricted to the 
basal cells of the tumour cell islands (Figure 4-20C and black arrow in inset), in contrast 
to the immuno-positive cells that were seen throughout the spiradenoma (Figure 4-
20E). In comparison Stat3 expression had cytoplasmic and nuclear localisation in both 
tumour types (Figure 4-20D & F), and did not show the same restrictive expression 
pattern as was seen in the cylindroma for the phosphorylated form. Semi-quantitative 
analysis of the immunostaining intensity using ImageJ software showed that out of the 
17 tumours analysed, 11 tumours (65%) were considered p-Stat3 (Tyr705)-positive 
(Figure 4-21A). Furthermore there was a significant increase in p-Stat3 (Tyr705) 
expression in the CYLD-defective tumours when compared to adjacent normal 
epidermis (CYLD +/-) (p = 0.0017) (Figure 4-21B). Within the different structures of the 
skin, the eccrine glands showed a scattered pattern of p-Stat3 expression and the inner 
layers of the hair follicle were positive for p-Stat3 (Figure 4-20G-J).  
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Figure 4-20: Stat3 expression is increased in CYLD-defective tumours as assessed by 
immunohistochemistry. 
Sections of CYLD-defective tumours underwent antigen retrieval and were probed with p-stat3 (Tyr 705) 
and Stat3 antibodies. A & B) p-Stat3 (Tyr 705) and Stat3 expression in control perilesional skin from a 
CYLD mutation carrier, (C & D) cylindroma (E & F) spiradenoma and (G, H, I & J) structures of the skin 
such as the eccrine gland and hair follicles. In cylindroma p-stat3 expression was demonstrated to have 
nuclear localisation in the peripheral cells of the cylindroma tumour islands (black arrow, inset (C)). 
Scale bar represents 100m. 
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Figure 4-21: Quantification of p-Stat3 (Tyr705) protein expression in CYLD-defective 
tumours. 
A) Semi-quantitative analysis of the immunostaining intensity of p-Stat3 (Tyr705) was carried out using 
ImageJ. A ratio of positive DAB staining was determined and the data represent the mean of the ratios 
taken from across 5 images per sample B) The protein expression of p-Stat3 (Tyr705) was compared 
between CYLD-defective tumours and control perilesional skin. Data are the mean and error bars 
represent the SEM of n= 3 control and n = 17 tumours (**p < 0.01,unpaired t-test). 
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Furthermore the increased expression was replicated in tumour lysates from 
cylindromas when run on a Western blot and probed with p-Stat3 (Tyr705) and 
compared to normal skin samples. This showed a variation in the levels of p-Stat3 
protein expression but in 3 out of the 4 tumour samples it was increased. It was also 
observed that for 2 out of the 4 tumour samples this corresponded with increased 
TrkB.T1 protein expression (Figure 4-22). 
 
 
 
 
 
Figure 4-22: Stat3 protein expression is increased in CYLD-defective tumours. 
Lysates from tumours and normal skin controls were collected and Western blot membranes were 
probed with p-Stat3 (Tyr705), Stat3 and TrkB antibodies. -Actin was used as a loading control. Western 
blot shown is representative of n= 2 experiments. 
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4.3.8 BDNF expression is upregulated at the mRNA level in CYLD-defective tumours 
As an activating ligand of TrkB and with TrkB expression upregulated in the tumours, 
experiments were performed to try and determine if the tumour cells themselves were 
a source of BDNF, which may be driving TrkB.T1 activation and downstream signalling. 
The heat map in Figure 4-5 showed that there was increased expression of some 
transcripts of BDNF in the CYLD-defective tumours from that data set. In support of 
this, qPCR analysis of BDNF expression in a panel of cylindroma tumours showed that 
at the mRNA level BDNF expression was significantly increased (p = 0.0015) in all the 
tumours compared to perilesional control skin, although there was variation in the 
level of BDNF over-expression between tumour samples (Figure 4-23 A & B). To see if 
increased BDNF mRNA expression translated into protein and whether this was then 
secreted in an autocrine manner by the tumour cells, attempts were made to 
determine protein levels by utilising both Western blotting and ELISA (enzyme-linked 
immunosorbent assay) methods. BDNF was detected in the majority of the tumour 
lysates on Western blot membranes, with levels also detected in the normal skin 
(Figure 4-24). Unfortunately the ELISA experiments were unsuccessful with no 
detectable concentrations of BDNF protein detected in either tumour lysates, cultured 
primary cylindroma cell lysates, or in media harvested from the same cell cultures. This 
may be indicative of problems with the experimental procedure such as interference 
of inhibitory enzymes in the lysis buffer preventing the reactions in the ELISA and the 
media samples not being concentrated. Alternatively biological reasons such as the 
tumour cells secreting very low concentrations of the protein may account for the 
negative results and requires further investigation. 
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Figure 4-23: BDNF mRNA expression is increased in CYLD-defective tumours. 
A) The expression of BDNF was determined by qPCR using Taqman probes, with the levels of expression 
normalised and expressed relative to the housekeeping gene PUM1. Data are the mean and error bars 
represent the SEM of n=3 experiments B) Data are the mean and error bars represent the SEM of n=3 
perilesional skin control and n=7 tumour samples (** p < 0.01, unpaired t-test). 
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Figure 4-24: BDNF protein expression is increased in a panel of CYLD-defective 
tumours. 
Lysates from tumours and normal skin controls were collected and Western blot membranes were 
probed with BDNF antibody. GAPDH was used as a loading control. Western blot shown is 
representative of n= 3 experimentsal repeats. 
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4.3.9 Stat3 relocates to the nucleus upon BDNF stimulation in primary cylindroma 
cell cultures 
From the results of the over-expression studies in HaCaTs and the expression of BDNF 
in tumour cells, this led to looking at the effect of BDNF stimulation on tumour cells in 
vitro. Primary cylindroma cells were plated onto transwell cell culture slides and left 
for 5 days before adding either BDNF (100ng/ml) or IL-6 (25ng/ml) to the culture 
medium for 30 minutes. Cells were fixed following stimulation and the expression of 
Stat3 and CK17 assessed using immunofluorescence. Cells were treated with IL-6 as a 
positive control, as this is a known activator of Stat3 signalling (Zhong et al., 1994), and 
CK17 was used as a marker for keratinocytes. In cylindroma primary cell cultures 
addition of BDNF induced translocation of Stat3 to the nucleus (Figure 4-25), matching 
the response seen from IL-6 stimulation of the cells (see Appendix). This relocation of 
Stat3 suggests it is activated and able to promote the transcription of target genes in 
response to BDNF. Further to this the expression of TrkB and Stat3 in cylindroma tissue 
sections was also assessed using IF and IHC. There was an overlap in TrkB and Stat3 
expression observed, particularly in cells at the periphery of the tumour islands (Figure 
4-26 & 27).  
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Figure 4-25: Stat3 nuclear localisation is seen in response to BDNF stimulation.  
Primary cylindroma cells were treated with BDNF (100ng/ml) for 30 minutes, before being fixed and undergoing immunofluorescence using CK17 and Stat3 antibodies. 
Representative images are shown with experiments set up in duplicate and repeated on primary cells derived from three separate tumours. Scale bars represent 50m. 
 
DAPI STAT3 / CK17/ 
+ BDNF 
DAPI STAT3 / CK17/ 
Untreated DAPI / CK17/ STAT3 
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Figure 4-26: Stat3 and TrkB are expressed together in vivo. 
Cylindroma tissue sections underwent antigen retrieval and indirect double stain immunofluorescence 
using antibodies against TrkB and Stat3. DAPI was used as a nuclear stain. Scale bars represent 50m. 
 
 
Figure 4-27: Stat3 and TrkB are expressed together in vivo. 
Cylindroma tissue sections underwent antigen retrieval and immunohistochemical staining using DAB 
and antibodies against TrkB and p- Stat3. Scale bars represent 50m. 
 
  
DAPI STAT3 TRKB 
p-Stat3 (Tyr705) TRKB 
DAPI STAT3 / TrkB/ DAPI STAT3 / TrkB/ 
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4.3.10 Stat3 target gene expression is altered in CYLD-defective tumours. 
As stated in Section 3.3.1, microarray gene expression studies in a pool of CYLD-
defective tumours (n=32) and perilesional skin controls (n=10) had previously been 
performed by Dr. Neil Rajan (Rajan, Elliott, et al., 2011). Using this dataset the 
expression of selected Stat3 target genes from the published literature were analysed. 
Differentially expressed Stat3 target genes in CYLD-defective tumours compared to 
controls were determined with a threshold for statistical significance of p < 0.05 after 
correction for multiple hypothesis testing. To visualise the expression of each of the 
genes (n=18) at an individual sample level, normalised signal values were plotted on a 
heat map, following logarithmic transformation. Clustering by Euclidean distance 
separated the majority of tumours, including all cylindromas and spiradenomas, from 
control skin with the exception of two trichoepitheliomas (tumours 1 and 30) (Figure 
4-28). In this independent dataset, gene targets that were found to be upregulated in 
CYLD-defective tumours included the anti-apoptotic protein Bcl-2 (fold-change 
increase = x 2.34), and well-documented oncogenes such as Myc (fold-change increase 
= x 1.36), and Jun (fold-change increase = x 1.33) (Table 4-4). In addition at the protein 
level other targets including Bcl-xL and CyclinD1 were also increased in the 
cylindromas (Figure 4-29), suggesting possible mechanisms in which increased Stat3 
activity may promote tumourigenesis.  
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Figure 4-28: The expression of Stat3 target genes in CYLD-defective tumours and 
perilesional skin. 
A heat map plot illustrating the expression levels of known Stat3 target genes in 32 CYLD-defective 
tumours and 10 controls (samples indicated at the bottom of the heat map). Differentially expressed 
genes were determined (p <0.05) between tumours and controls, and transcript expression levels at a 
single sample level are displayed on the heat map; red, over-expressed transcripts; blue, under-
expressed transcripts; gene names indicated on the right-hand side of the figure; where data from 
multiple transcripts for a single gene were available are indicated with a numerical suffix (n = 2). 
Clustering by similarity is shown, determined by Euclidean distance. 
Table 4-4: Differentially expressed Stat3 target genes in CYLD-defective tumours 
compared to perilesional control skin. 
The fold changes (FC) of transcripts are included for differentially expressed genes with a threshold of p 
< 0.05. Red indicates genes that are overexpressed and blue indicates genes that have reduced 
expression in CYLD-defective tumours compared to control.  
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Figure 4-29: Stat3 target genes in tumour lysates 
Lysates from tumours and normal skin controls were collected and Western blot membranes were 
probed with Bcl-xL and CyclinD1 antibody. -Actin was used as a loading control. Western blot shown is 
representative of n= 2 experimentsal repeats. 
 
4.3.11 Three dimensional (3D) primary cylindroma cell cultures are sensitive to Stat3 
inhibition 
Having identified that Stat3 is overexpressed and phosphorylation is increased in CYLD-
defective tumours, this warranted determining if the tumours were dependent on the 
expression and activity of Stat3 for their survival. Primary cylindroma cell cultures, and 
HaCaTs were grown on 3D scaffolds in the presence of Stat3 inhibitors. The four 
different Stat3 inhibitors that were used were Cryptotanshinone, Niclosamide, 
NSC74859 and Stattic (Figure 4-30). The primary cylindroma cells were more 
susceptible to Stat3 inhibition compared to HaCats, with the exception of 
Cryptotanshinone. The CPCC demonstrated sensitivity to Stat3 inihbition at 
micromolar concentrations in the presence of NSC74859 and nanomolar cocentrations 
of Stattic, which was not seen in the HaCaTs (Figure 4-31). 
  
Bcl-xL (30kDa) 
CyclinD1 (36kDa) 
β-Actin 
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Stat3 Inhibitor 
(Tocris Bioscience) 
Mechanism of Action Reference 
Stattic 
Target the SH2 domain of Stat3 to 
inhibit Stat3 activation, 
dimerisation and nuclear 
translocation. (Although 
Niclosamide may act 
independently of the SH2 domain). 
(Schust et al., 2006) 
NSC 74859 (Siddiquee et al., 2007) 
Niclosamide (Ren et al., 2010) 
Cryptotanshinone (Shin et al., 2009) 
Figure 4-30: Chemical structures of Stat3 inhibitors and their mechanism of action. 
  
Stattic NSC74859 
Cryptotanshinone Niclosamide 
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Figure 4-31: Primary cylindroma cells are sensitive to Stat3 inhibition. 
Primary cylindroma cells and HaCaTS were cultured on 3D culture scaffolds for 4 weeks before being 
plated out in triplicate in 96 well plates and grown in the presence of NSC74859, Stattic, Niclosamide 
and Cryptotanshinone for 2 weeks. Cells were derived from two individual tumours from two patients. 
Cell viability was then assessed using a luminescent assay. Data are displayed as the mean of triplicate 
readings and error bars represent the SEM. 
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4.4 Discussion 
TrkB is a receptor tyrosine kinase that once activated by its cognate neurotrophic 
ligands BDNF or NT-4/5, is capable of inducing a myriad of signalling responses 
including promotion of cell proliferation and survival (as reviewed by (Reichardt, 
2006)). In this chapter it was shown that a BDNF-TrkB.T1-Stat3 signalling axis is active 
and targetable in cylindromas. Trk receptor homeostasis had previously been shown to 
be dysregulated in CYLD-defective tumours, with increased expression of both TrkB 
and TrkC (Rajan, Elliott, et al., 2011). Further to this primary cylindroma cells grown on 
3D cell culture scaffolds were sensitive to pan-Trk inhibition, suggesting a dependency 
on the Trk signalling pathway for survival. Yet normal keratinocytes were previously 
shown to express the TrkB.T1 isoform of the receptor (Marconi et al., 2003). This 
isoform lacks a kinase domain and its function is not completely understood nor has it 
been thoroughly investigated in keratinocytes. Therefore this warranted further 
investigation of the TrkB receptor in CYLD-defective tumour cells. 
4.4.1 CYLD-defective tumours express the truncated TrkB.T1 isoform  
Within this study TrkB isoform expression was characterised in CYLD-defective 
tumours, as it was shown that the expression of TrkB was increased both at a 
transcriptomic and protein level (Figure 4-8 & 4-9), alongside altered expression of 
other associated receptors and ligands as indicated by the microarray data set (Figure 
4-5). The TrkB receptor is known to have three major protein isoforms that are 
expressed in humans, which differ in their inclusion of the tyrosine kinase domain 
(Stoilov et al., 2002). When the isoforms of TrkB were looked at in more detail in the 
CYLD-defective tumours, the RNA-seq data showed that for TrkB (NTRK2) an increased 
number of reads aligned to the alternate exon, exon 16 (Figure 4-6). Using RT-PCR it 
was found that cylindroma tumours expressed both full-length and truncated 
transcripts. Further corroboration at the transcript level using qPCR found that 
expression levels of both isoform transcripts were increased in the cylindromas. Whilst 
at the protein level only the truncated TrkB.T1 isoform could be detected (Figure 4-9). 
This result is in keeping with previous in vitro studies of keratinocytes, in which TrkB.T1 
transcripts were the predominantly expressed isoform in epidermal keratinocytes 
((Marconi et al., 2003)). Yet in contrast to the report in which no full-length expression 
was found with RT-PCR, low levels of expression were seen in the normal skin samples 
used for qPCR in this study. This could possibly be due to the samples used by Marconi 
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et al. being from cultured keratinocytes compared to the tissue lysates used here.  
To determine a role for TrkB.T1 in the cells, HaCaT and HEK293T cells were transduced 
with overexpression vectors for the TrkB isoforms. HaCaT cells overexpressing TrkB.T1 
showed an increase in cell viability compared to controls, although this didn’t reach a 
level of significance. Also in colony forming assays no significant difference was seen in 
the number and size of colonies between control and TrkB.T1 overexpressing cells 
(Figure 4-12), suggesting TrkB.T1 expression does not confer a proliferative advantage. 
Furthermore when compared to the overexpression of TrkB.FL in HEK293 cells, TrkB.T1 
overexpressing cells showed sustained cell viability when exposed to BDNF, in contrast 
to a reduction in cell viability in TrkB.FL expressing cells (Figure 4-11). Taken together 
the results suggest that expression of TrkB.T1 may be protective to the cells and could 
indicate a survival role, which is also favourable for tumour cells. Unfortunately the 
TrkB.FL vector could not be characterised in the keratinocytes due to repeated 
unsuccessful transduction of the cell line, therefore no direct comparisons could be 
made between the isoforms in the keratinocytes in this study. In contrast a study by 
Rossler et al. in which HaCaT cells expressed the full length TrkB receptor, BDNF 
induced proliferation of the cells was dependent on Erk activation (Rossler and Thiel, 
2004). Yet no difference in Erk phosphorylation was found in TrkB.T1 overexpressing 
cells (data not shown) but with the change in Stat3 phosphorylation (discussed in more 
detail in section 4.4.2) it may represent the different functional roles of the TrkB 
isoforms in this cell context. In further support of a cell survival role, within normal hair 
follicles BDNF-TrkB signalling is thought to prevent hair follicle keratinocyte 
proliferation via upregulation of TGF-2 causing initiation of the regression stage of 
hair follicle cycling (Peters et al., 2005). Together this suggests that increased 
expression of the TrkB.T1 receptor isoform in tumours of hair follicle origin such as 
cylindroma, could cause perturbed differentiation and promote a benign tumour that 
is recognised to be slow growing.  
The isoforms of TrkB are due to alternative splicing, in TrkB.T1 the inclusion of exon 16, 
which contains a stop codon, leads to the translation of a protein without a tyrosine 
kinase domain (Stoilov et al., 2002) (Figure 4-2). It was previously thought that without 
a tyrosine kinase domain the TrkB.T1 isoform functioned only as a dominant negative 
receptor, capable of binding ligands and forming receptor dimers with full-length 
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receptors but unable to instigate intracellular signalling. However more recent studies 
have started to support that TrkB.T1 may be a signalling entity, although many of 
these studies are limited to a neural cell context. As mentioned previously, Rose et al 
showed that in astrocytes TrkB.T1 was responsible for mediating calcium signalling, 
through BDNF stimulation of TrkB.T1 inducing activation of G-protein dependent PLC 
activation leading to calcium release and entry (Rose et al., 2003). In glial cells TrkB.T1 
was shown to be capable of mediating ligand dependent RhoGDI1 (Rho GDP 
dissociation inhibitor) signalling leading to inhibition of Rho GTPases and cytoskeletal 
rearrangement (Ohira et al., 2005). In addition, a protein called TTIP (truncated TrkB 
interacting protein) was found by immunoprecipitation experiments in 15N 
neuroblastoma cells, showing specific binding to TrkB.T1. However to date very little is 
known about this protein but this demonstrates potential cytoplasmic adaptors 
capable of transducing signals (Kryl and Barker, 2000). In support of these findings, in 
this study TrkB.T1 was characterised in a keratinocyte cell line and was found to 
increase phosphorylation of Stat3 in response to BDNF activation. 
A possible consequence of TrkB.T1 expression in regards to translational relevance is 
that therapeutic interventions targeting Trk receptor signalling may not be completely 
effective in these tumours. Many receptor tyrosine kinase antagonists, including Trk 
inhibitors, inhibit phosphorylation of the receptor to inactivate downstream signalling. 
This may have implications for treatment, as inhibitory Trk kinase compounds such as 
K252a, to which primary cylindroma cells were susceptible (Rajan, Elliott, et al., 2011), 
tend to inhibit the phosphorylation of the receptor to inactivate signalling. Whilst 
these treatments may kill off some of the tumour cells as shown in vitro, in those cells 
that may be dependent on TrkB.T1 signalling it may leave residual tumour cells capable 
of future tumour growth. As reported in this chapter the predominant isoform 
expressed in these tumours lacks a catalytic domain and was shown to be capable of 
inducing Stat3 signalling, therefore it could be assumed that this treatment option may 
not be successful as a stand-alone therapy, as signalling could still occur and the 
receptor could still be activated by BDNF. Therefore either a synergistic therapeutic 
approach, targeting other downstream targets alongside Trks or those that target the 
binding pocket for the neurotrophic ligands with the receptor may be more beneficial.  
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4.4.2 Stat3 as a downstream target of TrkB signalling 
A novel finding of this chapter was that TrkB.T1 overexpression in keratinocytes could 
induce Stat3 Tyr705 phosphorylation in the presence of BDNF. A receptor tyrosine 
kinase array was first utilised, to give an overview of expression and phosphorylation 
of downstream signalling nodes that may be influenced by overexpression of the TrkB 
isoforms, having found that expression of TrkB.T1 was capable of promoting cell 
survival and emerging evidence suggesting it was involved in cellular signalling. For 
comparison two HEK293 models were used; depicting TrkB isoform overexpression or 
expression of mutated forms of CYLD causing truncation and catalytic inactivation of 
CYLD, matching the mutations found in patients. Also CYLD-defective tumour lysates 
were also applied to compare in vitro to in vivo. In cells overexpressing the different 
TrkB isoforms, Akt and Src were the most influenced by TrkB.T1 overexpression, yet p-
Stat3 (Tyr705) was also increased compared to control. Stat3 was deemed a target of 
interest after it was shown that overexpression of CYLD caused a decrease in p-stat3 
levels and levels were increased in the CYLD-defective tumours. When TrkB.T1 was 
further investigated in vitro, it was demonstrated in both HaCaTs and primary 
cylindroma cells, that TrkB.T1 could induce activation of Stat3 as stimulation by the 
cognate ligand, BDNF, led to increased phosphorylation of Stat3 Tyr705 (Figure 4-18 & 
4-19), in addition to an alteration in the location of Stat3 from the cytoplasm to the 
nucleus indicative of Stat3 activation (Figure 4-25), which can only be mediated by the 
TrkB.T1 receptor as the tumour cells were found to only express this isoform at the 
protein level.  
Stat3 is a transcription factor that was initially discovered to regulate gene 
transcription in response to cytokine signals (Darnell et al., 1994), and subsequently 
downstream of growth factor tyrosine kinases such as epidermal growth factor (Shao 
et al., 2003). The canonical Stat 3 activation pathway involving activation of a receptor 
by its corresponding ligand and inducing phosphorylation of tyrosine residues on JAKs 
(Janus kinases). Subsequently the JAKs serve as docking sites that are capable of 
phosphorylating Stat3 at the Tyr 705 residue, which leads to activation and 
dimerization of Stat3 followed by translocation of the homodimers to the nucleus and 
binding to promoters of various target genes to initiate their transcription (Darnell, 
1997). Many target genes of Stat3 are involved in promoting cellular proliferation and 
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resistance to apoptosis, therefore constitutive activation of Stat3 has also been 
recognised in many solid and haematological malignancies (as reviewed by (Yu H. et 
al., 2014). Furthermore constitutive Stat3 expression has been reported to alter the 
behavior of keratinocyte stem/progenitor cells within the hair follicle (Rao et al., 2015) 
and when a constitutively active form of Stat3 was expressed in keratinocytes of 
transgenic mice, it led to an increased susceptibility to skin tumourigenesis by both 
chemical and UV carcinogenesis (Chan et al., 2008; Kim D. J. et al., 2009). 
Indeed Stat3 has previously been recognised as a downstream target of Trk signalling, 
although this is mainly delineated in neural cells in which full-length receptor isoforms 
are expressed. The originality of this study is that the particular isoforms of TrkB have 
been investigated and have shown for the first time that TrkB.T1 overexpression can 
mediate phosphorylation of Stat3 at the Tyr705 residue. The work of Ng et al. was the 
first report to demonstrate the ability of Trk receptors to influence Stat3 
phosphorylation, but in contrast to the work in this chapter it was NGF stimulation of 
TrkA in PC12 cells that resulted in phosphorylation of residue Ser727 on Stat3 (Ng et 
al., 2006). Also within the same study in cultured hippocampal neurons silencing of 
Stat3 expression abrogated BDNF induced neurite extension (Ng et al., 2006). 
Furthermore it was shown that BDNF could induce neural stem cell survival and 
differentiation through activation of Stat3, in addition to Akt and Erk, although the 
phosphorylation site was not specified. The presence of BDNF also enhanced neural 
stem cell proliferation in the presence of EGF (epidermal growth factor) (Islam et al., 
2009). In keeping with the work included in this thesis, it was acknowledged in the 
study by Islam et al that phosphorylation of Akt, Erk and Stat3 in response to BDNF 
may be mediated by TrkB.T1, as the neural stem cells were shown to predominantly 
express this isoform (Islam et al., 2009).  
Trk-Stat3 signalling has also been explored in cancer, for example in non-small-cell lung 
cancer BDNF-TrkB signalling triggers Stat3 activation due to phosphorylation of Tyr705, 
which can then stimulate BDNF synthesis in an autocrine feedback loop, contributing 
to cell proliferation through TrkB-Stat3 dependent Akt activation (Chen B. et al., 2016). 
In contrast in in vitro transformation of NIH3T3 cells expressing constitutively active 
Trk oncogenes, with intact kinase domains, reduced Stat3 levels are associated with 
morphological transformation but transcriptional Stat3 activity is required for cell 
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growth (Miranda et al., 2010). 
Traditionally phosphorylation of Stat3 at the Tyrosine 705 residue is a prerequisite for 
activation and homodimerisation of Stat3 molecules (Kaptein et al., 1996). Meanwhile 
the role of Ser727 phosphorylation of Stat3 is more ambiguous. It has been suggested 
that Ser727 phosphorylation is required for maximal transcriptional activity of Stat3 
(Wen et al., 1995), in contrast others have demonstrated an inhibitory effect on 
Tyr705 phosphorylation of Stat3 (Wakahara et al., 2012). Furthermore Ser727 
phosphorylation of Stat3 has also been reported to mediate transcriptional activation 
of Stat3 independently of Tyr705 phosphorylation. This was shown in PC12 cells where 
NGF stimulation induced CyclinD1 expression and increased association of Stat3 with 
the transcriptional regulator p300, demonstrating the importance of Ser727 Stat3 
activation, as phosphorylation at the Tyr705 site was not observed in the neuronal 
cells (Ng et al., 2006). In this thesis it was shown that in the HaCaT cells overexpression 
of TrkB.T1 did not alter phosphorylation of Stat3 at the serine residue (Figure 4-18) 
and was therefore not extensively looked at, but yet the presence of phosphorylation 
at this site may indicate that Stat3 could also have Tyr705 independent functions in the 
tumours.  
Stat3 (Tyr705) phosphorylation was significantly increased by BDNF stimulation in 
TrkB.T1 overexpressing HaCaTs, which was reproduced in 2D primary cylindroma 
cultures treated with BDNF (Figure 4-18 & 4-19), even when expression of TrkB is 
lower in 2D primary cell cultures (see chapter 5). In addition immunohistochemical 
analysis showed a significant increase in p-Stat3 (Tyr705) in the tumours compared to 
perilesional controls (Figure 4-20 & 40-21). There was an irregular pattern of 
expression of p-Stat3 that was found in the tumour sections, which may be due to a 
possible transient nature of Stat3 phosphorylation as levels started to reduce after 15 
minutes of stimulation with exogenous BDNF in TrkB.T1 overexpressing HaCaTs. 
Although this is within an artificial system and it is not to say that in vivo BDNF 
expression and therefore activation is not sustained. Positive p-stat3 (Tyr705) 
expression also corresponded with TrkB expression in some cells (Figure 4-26 & 27). All 
these results support that in the keratinocyte cell context in response to BDNF 
stimulus Stat3 Tyr705 phosphorylation is triggered, although the precise kinase 
mechanism needs to be further investigated. In different cell contexts, the availability 
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of kinases, the cellular stimuli and the levels of receptor expression could affect Stat3 
phosphorylation (Miranda et al., 2010). Indeed in other overexpression studies, such 
as PC12 cells overexpressing TrkA and stimulated with NGF, showed Tyr705 
phosphorylation when this isn’t usually seen in PC12 cells, with the authors 
hypothesising that overexpression my lead to perturbation of an intrinsic 
dephosphorylation mechanism (Miranda et al., 2010; Ng et al., 2006). In this scenario it 
is possible that in the tumour cells as a consequence of TrkB.T1 expression levels 
increasing, alterations to the phosphorylation equilibrium of Stat3 leading to aberrant 
activation of Stat3 and driving expression of target genes that promote tumour growth 
or survival.  
To improve our understanding of TrkB.T1 and Stat3 in this cell context, future 
experiments would assess if a direct interaction or molecular mechanism has not been 
established in the CYLD-defective cells for TrkB.T1 and Stat3 activation. Therefore in 
future experiments, preferably in 3D cultures particularly as primary cylindroma cell 
spheroid cultures have been generated (see Chapter 5), it would be useful to treat 
these with a neutralizing TrkB antibody or use TrkB shRNA, followed by BDNF 
stimulation and assess if the levels of p-Stat3 Tyr 705 were affected. Although as the 
primary cells are sensitive to Trk inhibition this may lead to cell death so may not be a 
viable option. In addition to repeating the BDNF stimulation of primary cells in 3D 
cultures, to see if phosphorylation occurs as this is more reflective of the in vivo, 
tumour environment. Without a kinase domain, immunoprecipitation assays may also 
be utilised to identify novel interacting partners of TrkB.T1, to elucidate how TrkB.T1 is 
capable of initiating phosphorylation of Stat3. Alternatively calcium signalling could be 
another area for further research as TrkB.T1 was found to be capable of evoking 
calcium signalling (Rose et al., 2003) and the TRPM7 calcium channel can regulate 
Stat3 phosphorylation in breast cancer cells (Davis F. M. et al., 2014). 
4.4.3 Stat3 inhibition in CYLD-defective tumours 
To determine if primary cylindroma cultures were dependent on Stat3 for their 
survival, 3D scaffold cultures were treated with small molecule Stat3 inhibitors 
(mechanisms of action described in Figure 4-30). The cylindroma cells were shown to 
be susceptible to Stat3 inhibition in comparison to the HaCaTs, demonstrating a 
dependency of the tumour cells on this pathway. NSC74859 and Stattic in particular 
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caused a reduction in cell viability at micromolar concentrations (Figure 4-31), 
demonstrating that this could be a potential treatment strategy. As would be expected 
there was variability in the response between the different tumour cultures reflective 
of the inherent heterogeneity of the tumours, but also the error bars may be reflective 
of irregular cell growth across the scaffold (as will be discussed in chapter 5).  
Inhibition of Stat3 has been an area of intense investigation in cancer therapy research 
in recent years as it is a target that is constitutively active in a variety of malignancies 
and Stat3 activation has been recognised as a mechanism of resistance to primary 
tyrosine kinase inhibitor treatment such as those targeting BCR-Abl and EGFR (Bewry 
et al., 2008; Ishiguro et al., 2013). Conversely disruption of the Stat3 feedback 
mechanism restored sensitivity to inhibitors of the oncogenic pathway to which the 
tumours were addicted (Lee H. J. et al., 2014). However moving from in vitro to clinical 
trials with small molecule inhibitors of Stat3 compounds has proven challenging, with 
concerns of unpredictable pharmacokinetic profiles and potential toxicity (Wong A. L. 
et al., 2015; Wong A. L. A. et al., 2017). An advantage of the skin is the accessibility of 
lesions for topical treatment options, which can reduce some of the systemic side 
effects and drug toxicity. A topical ointment containing the Stat3 inhibitory compound 
STA-21 has been used in a trial for psoriatic lesions, which demonstrates a possibility of 
topical Stat3 compounds that could potentially be repurposed and trialled in patients 
with CYLD cutaneous syndrome (Miyoshi et al., 2011). 
Stat3 is also a convergence point for other signalling pathways, such as NF-B. The two 
transcription factors have been shown to cooperate in a number of ways including 
modifying their transcriptionl activity through direct interactions between NF-B 
family member RelA and Stat3 (Lee H. et al., 2009). In addition both factors can 
collaboratively bind at target gene promoters to induce their expression (Hagihara et 
al., 2005). Therefore as NF-B is a pathway that is well documented to be dysregulated 
due to a loss of CYLD (Brummelkamp et al., 2003), targeting of Stat3 is attractive as this 
could demonstrate an opportunity in cylindroma cells to use a multi-pronged approach 
and be a wider reaching intervention, treating cells even if they aren’t dependent on 
Trk signalling. Indeed it is acknowledged that Stat3 is a convergence point for different 
signalling pathways and the changes in expression of Stat3 target genes demonstrated 
in the heat map (Figure 4-28), might not all be mediated by TrkB.T1 activation of Stat3. 
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Therefore further research is required to investigate other moderators of Stat3 in 
these tumours as further understanding of the mechanisms could inform of synergistic 
treatment strategies to gain maximum therapeutic benefit. 
4.4.4 The source of BDNF and establishment of an autocrine loop 
In this study it was found that the expression of BDNF was shown to be increased in 
the tumour cells compared to perilesional controls at the transcriptomic level, which 
was replicated at the protein level (Figure 4-23 & 24). This leads one to propose that 
the cells are capable of producing and secreting BDNF, and may function in an 
autocrine manner, as has been demonstrated in lung tumour cells where an autocrine 
loop of BDNF-TrkB-Stat3 signalling is established to induce BDNF expression and drive 
Stat3 activity (Chen B. et al., 2016). In this study the ELISA method employed to try and 
quantitate the amount of BDNF secreted was unsuccessful. Technical reasons for this 
could have been inhibitory enzymes such as phosphatases may have stopped the 
reaction working or the samples were too dilute. For the media samples in particular it 
would be useful to concentrate the media in future to increase the chances of 
detection. Alternatively BDNF may also be produced in a paracrine manner from 
surrounding stromal fibroblasts or even possible infiltrating immune cells. The 
prevalent expression of p-Stat3 in the outer palisading cells of the tumour islands 
could be an indicator of a paracrine source as these are the cells in contact with the 
stroma and infiltrating immune cells. Immunohistochemical analysis of BDNF 
expression in tumour sections would also be useful to look at. 
4.4.5 Conclusions 
Overall the increased expression of the truncated Trk receptor isoform, TrkB.T1, has 
been identified to have potential intracellular signalling capabilities. In keratinocytes in 
response to its cognate ligand BDNF, there was increased phosphorylation of Stat3 at 
the Tyr705 residue leading to activation and relocation to the nucleus. This indicates 
that increased TrkB.T1 expression has the potential to drive the transcription of target 
genes, which may be capable of supporting tumour formation in CYLD-defective cells. 
Indeed in primary cultures the sensitivity of cells to inhibition of Stat3 supports that 
targeting of Stat3 may be a potential therapeutic strategy for CYLD cutanteous 
syndrome.  
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5 Chapter 5: Development of three dimensional (3D) primary 
cylindroma spheroid cultures  
5.1 Introduction 
5.1.1 Chapter aims 
Taking in to account that cells cultured in 3D are more representative of their in vivo 
counterparts, and the drawbacks of an established scaffold culture method for CPCC: 
the laborious nature, long time scales and difficulty in monitoring cell growth, the 
overall objective of the work in this chapter was to establish a reproducible and more 
amenable 3D cylindroma primary cell culture model that could be utilised in a variety 
of downstream applications. The main aims were: 
 
 To develop a protocol for the generation of cylindroma primary cell spheroid 
cultures 
 To perform functional analyses on cylindroma primary cell spheroids to validate 
transcriptomic and experimental data using immunofluorescence staining 
 To evaluate the efficacy of compounds against potential therapeutic targets 
5.1.2 An overview of cell culture 
Since its conception and development over the past century, cell culture is now a 
routine technique that allows for the maintenance of cells outside of the body from a 
variety of animal and human tissues, using growth medium supplemented with 
nutrients to support their growth and survival (Antoni et al., 2015). It is a method that 
has contributed vastly and is invaluable to all fields of contemporary biology; not only 
advancing our understanding of basic cell biology, but also to allowing the modelling of 
disease systems, following through to compound screening as part of the drug 
discovery process, and leading to translational outputs from the knowledge gained. 
However the routine culturing of cells as two dimensional (2D) monolayers isn’t 
without disadvantages, a key limitation being the lack of the three dimensional (3D) 
microenvironment in which cells reside in vivo; surrounded by other cells and an 
extracellular matrix (ECM) (Edmondson et al., 2014). To this end a significant 
advancement in the technique has been the development of 3D cell culture methods, 
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which take into account the spatial organisation and interactions of the cells to provide 
more physiologically relevant knowledge of cell behaviour, and aid in bridging the gap 
between in vitro and in vivo (Haycock, 2011).  
5.1.2.1 Keratinocyte cell culture 
Serial cultivation of primary human epidermal keratinocytes was first established in 
1975 by Rheinwald and Green (Rheinwald and Green, 1975). The formation of 
keratinocyte colonies was initiated in the presence of an irradiated NIH3T3 embryonic 
mouse fibroblast feeder layer, which supported keratinocyte growth through secretion 
of soluble growth factors into the culture medium and propagation of extracellular 
matrix deposition. More modern, commercially available animal derivative-free, 
defined culture mediums have been developed (Rasmussen et al., 2013). Most of 
these being variations of the serum free, low calcium supplemented MCDB153 
medium, which supports the clonal expansion of keratinocytes independently of 
fibroblast feeder layers (Boyce and Ham, 1983; Tsao et al., 1982). Keratinocytes in 
culture have the ability to form three distinguishable clonal types: holoclones, 
paraclones and meroclones, classified by the frequency with which they give rise to 
terminal progeny (Barrandon and Green, 1987). Holoclones are composed of 
proliferative cells with the greatest growth potential, whilst paraclones have a limited 
replicative lifespan. Meroclones are considered a transitional stage containing a 
mixture of cells with different growth potentials. 
 
The original culture method still remains widely used to date, however it has also 
inspired in vitro advances, taking keratinocyte cultures from 2D to 3D with the 
generation of living skin equivalents (LSE). These 3D multi-layered organtoypic models 
are formed when keratinocytes are seeded onto a collagen lattice containing dermal 
fibroblasts, which are then grown at the liquid-air interface. This allows for epidermal 
stratification of the cells that recapitulates a number of features of the human 
epidermis including the morphology and spatiotemporal expression of both 
proliferative/terminal differentiation markers and re-epithelialisation markers 
(Mertsching et al., 2008; O'Leary et al., 2002). Whilst as skin equivalents, like with all in 
vitro models, they cannot completely simulate the complexity of human skin, these 
models do offer a tool with which to study cutaneous biology experimentally that is 
more physiologically relevant than 2D cell monolayers.  
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Figure 5-1: A diagram of different 3D cell culture models. 
In typical 2D cell culture, cells adhere to plastic culture vessels and grow in monolayers. 3D cell cultures 
can be achieved with a variety of methods. Cells can be seeded into specialised culture vessels treated 
with a non-adherent coating to promote cell aggregation leading to the formation of spheroid cultures 
in suspension. Spheroids may also be generated by coating culture plastic-ware with protein mixtures 
such as Matrigel or ECM proteins such as collagen hydrogels, to mimic the cellular microenvironment 
and encourage cell-ECM interactions to support the growth of spheroids either within the mixture or on 
top. Alternatively support may be provided in the form of a synthetic or natural material 3D membrane 
such as a porous scaffold, on to which cells can be seeded to encourage cellular interaction and growth 
in 3D. (Image adapted from (Edmondson et al., 2014). 
5.1.3 Methods for 3D cell cultures 
A number of methods have been developed for 3D cell cultures which fall into two 
main categories: (i) scaffold/matrix-based and (ii) non-scaffold based, as shown in 
Figure 5-1 and reviewed by (Breslin and O'Driscoll, 2013). The generation of 3D cell 
aggregates, also known as spheroids, in suspension can be achieved using either of the 
hanging drop method, forced floating method, or agitation-based approaches such as 
rotational culture systems or spinner flask bioreactors. In each case the main principle 
of the method design is to promote cell-cell interactions, leading the cells to adhere to 
each other rather than the surface of the culture vessel. This is achieved either by 
rotary movement or by coating the surface of the culture vessels with substances such 
as agarose or poly-2-hydroxyethyl methacrylate (poly-HEMA), and having round or 
conical shaped well bottoms. The benefits, particularly when using the forced floating 
and hanging drop methods, are that these are generally low cost procedures and allow 
for the production of a large number of spheroids in reproducible conditions, which is 
particularly useful for drug cytotoxicity assays (Breslin and O'Driscoll, 2013). 
 
Alternatively cells that are difficult to aggregate can be cultured on artificial substrates 
to generate 3D spheroid cultures. One method is to culture cells on or within a matrix 
that contains components of the ECM, such as agar or Matrigel (BD Biosciences), 
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which is an extract of Engelbreth-Holm-Swarm (EHS) mouse sarcoma proteins. These 
substances encourage cell-ECM interactions in 3D to promote cell aggregation and 
organisation of the cells, which can then grow into structures that mimic those found 
in vivo (Kleinman and Martin, 2005; Zegers et al., 2003), such as the LSE organotypic 
model mentioned above. Another method is to use scaffolds made from either 
synthetic materials such as polystyrene, like the ones used in this thesis from 
Alvetex, or biodegradable materials such as collagen or alginate as hydrogels. The 
scaffold inserts are porous to allow for the exchange of oxygen and nutrients, with 
cells seeded onto the scaffolds left to grow in the interstitial space within the 
structure, maintaining their 3D morphology. Finally other more complex 3D culturing 
systems use microfluidics and coated microcarrier beads (Kim J. B., 2005). 
5.1.4 Comparison of 2D vs 3D cell cultures 
The requirement for 3D cultures has been recognised for a number of decades, with 
the conception of one of the first 3D cultures in agar in the 1970’s (Hamburger and 
Salmon, 1977) The disparity between 2D and 3D cultures was highlighted by Bissell and 
colleagues, who discovered that human breast epithelial cells in monolayer cultures 
displayed characteristics of tumour cells in vivo, but when grown in 3D culture 
reverted back to their usual growth behaviour (Petersen et al., 1992). To this end the 
limitations of 2D cultures have been reviewed by many (Breslin and O'Driscoll, 2013; 
Edmondson et al., 2014; Kim J. B., 2005; Kimlin et al., 2013; Ravi et al., 2015; Rimann 
and Graf-Hausner, 2012) (summarised in Table 5-1 below), and it is evident that it is 
not just the genome, but the interpretation of cues from the extracellular environment 
of a cell that dictates its phenotype; cues that need to be taken into account when 
examining cellular biology (Tibbitt and Anseth, 2009). 
 
The superiority of 3D to 2D cell cultures is evident in many aspects of cell biology, 
which has made their use particularly attractive for exploring tumour biology. Firstly 
the growth of cells as a monolayer on a flat rigid surface flattens and stretches the 
cells, compared to 3D where the morphology is more representative of that seen in 
vivo (Edmondson et al., 2014). The morphological alteration can influence many 
processes such as cell proliferation, differentiation, apoptosis and gene expression 
(Birgersdotter et al., 2005; Chen C. S. et al., 1997), which have been highlighted in a 
number of comparison experiments. For example a number of cell lines have shown a 
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reduced proliferation rate in 3D cultures, including those from endometrial 
(Chitcholtan et al., 2012) and colorectal cancers (Luca et al., 2013), as well as non-
cancerous kidney HEK293 (Kim E. and Jeon, 2013)  and mammary epithelial MCF10A 
cell lines (Wang X. et al., 2010). Meanwhile JIMT1 breast cancer cells have shown an 
increased and decreased rate, dependent on the 3D model used (Hongisto et al., 
2013). Furthermore MCF-7 cells when grown on a chitosan-based scaffold, provided a 
model that simulated both tumour-like metabolic activity, as the cells produced more 
lactate compared to cells grown on plastic, and drug efficacy with increased Tamoxifen 
resistance in the scaffold cultures (Dhiman et al., 2005).  
 
These changes in behaviour are governed by altered gene and protein expression, with 
gene expression patterns of 3D cultures being comparable to those observed in solid 
tumours in vivo (Costa et al., 2016). Indeed it is approximated that 30% of genes are 
differentially expressed in cell lines compared to their corresponding tissues (Sandberg 
R. and Ernberg, 2005; Virtanen et al., 2002). For instance in melanoma NA8 cells, genes 
that have been shown to have a role in melanoma progression and metastasis, such as 
IL-8 and CXCL1, were over-expressed when cultured as spheroids as opposed to 
monolayers (Ghosh et al., 2005). Likewise in colorectal cancer cell lines that were 
cultured in a laminin-rich-ECM and compared to 2D cultures, alongside differential 
gene expression, which included genes involved in the MAPK pathway, there was also 
a reduction in the protein expression of epidermal growth factor receptor (EGFR), a 
therapeutic target for advanced colorectal cancer, and whose reduction may be 
associated with acquisition of therapy resistance during cancer progression (Luca et 
al., 2013). These studies again demonstrate the importance of the cell and ECM 
interactions when modelling these cell types for molecular studies. Furthermore 
modifications to the ECM structure can be instrumental in tumour progression and 
migration (van Dijk et al., 2013), but genes for cell adhesion and cell-ECM signalling 
proteins are commonly repressed in cell lines. However it was shown that the 
expression of these gene types was restored when immortalised cell lines were 
transplanted back into mice (Birgersdotter et al., 2005; Creighton et al., 2003).  
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Figure 5-2: The structure of spheroid cell cultures.  
Spheroids are organised into three layers with the outer layer (represented by the blue circles) 
containing proliferating cells, whilst an inner layer (represented by the green circles) contains quiescent 
live cells. In spheroids reaching certain sizes (>500m diameter) the core of the spheroid will contain 
necrotic or hypoxic cells (represented by the red circles), which mimic the biology of the tumour, as this 
is reflective of the cell microenvironments found in tumours. Nutrient and oxygen gradients 
(represented by the green triangle) and the reciprocal waste gas and products gradient (represented by 
the red triangle) are established between the different cell layers. For drug assays these gradients can 
mirror the pharmacokinetics of drug delivery within in vivo tumours. Image adapted from (Edmondson 
et al., 2014). 
The structural formation of spheroid cultures is another aspect of 3D cell culture in 
which these cell models are more representative of the in vivo environment. Spheroid 
cultures are comprised of a heterogeneous population of proliferative, quiescent and 
hypoxic cells organised by the differential distribution of oxygen, nutrients and carbon 
dioxide along diffusion gradients (as shown in Figure 5-2). These closely resemble the 
multiple phenotypes found in solid tumours (Kim J. B., 2005). This is in stark contrast to 
the cellular homogeneity of 2D cultures, where all the aforementioned requirements 
of the cell are equally accessible and waste products are removed during routine 
culturing. Additionally it has been found that 3D cultures are more resistant to 
anticancer therapeutics (Breslin and O'Driscoll, 2013), the differences in drug 
sensitivity and response between the two culture environments attributed to a 
number of factors, which again mimic the behaviour of tumours in response to therapy 
in vivo. Firstly hypoxic regions within the core of a spheroid, generated from the build 
up of waste products, create a low pH environment. This can reduce drug uptake by 
the cells (Swietach et al., 2012) and also alter the gene expression profile of the cell 
(Wilson W. R. and Hay, 2011). This occurs in tumour cells where low pH induces the 
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expression of members of the hypoxia inducible factor-1 family (HIF-1), which in turn 
enhances the survival of malignant cells (Eales et al., 2016). The size of the spheroid 
also affects the pharmacokinetics of the drug and the rate at which it can diffuse into 
the spheroid, meaning cells receive variable concentrations of the drug much like the 
drug gradients that can be created in tumours in vivo (Thurber and Wittrup, 2008). 
Moreover cellular interactions, alterations to signal transduction and gene expression 
in 3D cultures can all influence the spatial organisation and localisation of cell surface 
receptors, alongside the availability of proteins involved in the pharmacodynamics of a 
drug, including the targets to which a drug maybe designed for, thus leading to 
differences in the effectiveness of the treatment (Edmondson et al., 2014). Equally 
some drugs are effective at specific cell stages, such as 5-fluorouracil and Paclitaxel 
which target proliferating cells, so have poorer therapeutic efficacy in the quiescent 
interior cells of spheroids and tumours alike (Edmondson et al., 2014; Mitchison, 
2012). Overall these features contribute to producing a model that resembles the in 
vivo tumour and the acquirement of drug resistance, thus making spheroid cultures a 
useful drug-screening tool. 
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Cell characteristic 2D 3D 
Morphology Cells grow in a monolayer, 
adhering to a plastic or glass 
surface 
Cells grow in their natural 
shape forming a 
spheroid/aggregate structure 
Cell cycle stage All cells tend to be at a 
similar proliferative stage as 
necrotic cells detach and are 
removed during medium 
changes 
Cells are at different cell cycle 
stages with outer proliferating 
cells, inner quiescent but 
viable cells, and a core of 
necrotic or hypoxic cells 
(dependent on the spheroid 
size) 
Cellular barriers Cells have limited interaction 
with each other as 
monolayers 
Cell interaction is increased 
and promotion of deposition 
of ECM proteins and cellular 
adhesion 
Gene/protein 
expression 
Cells have altered gene and 
protein expression levels to 
those seen in vivo due to a 
lack of cellular interaction in 
monolayers 
Cells have gene and protein 
expression profiles that are 
comparable to those found in 
the tissue of origin 
Drug exposure All cells are exposed equally 
to drug treatments in the 
media and the distribution 
of the drug within all the 
cells is therefore equal 
Drugs may not be able to 
penetrate into all cells of the 
spheroids, particularly those 
within the core 
Drug sensitivity Cells are often more 
sensitive, and drugs appear 
very effective 
Cells are more resistant to 
drug treatments, and 
therefore better predictors of 
the in vivo response 
 
Table 5-1: A summary of the cellular characteristics that differ between 2D and 3D 
cell cultures (adapted from (Edmondson et al., 2014) 
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Figure 5-3: A Western blotting image of CPCC grown in 2D and 3D. 
Membranes were probed with TrkB antibody to show the difference in expression of TrkB between cells 
grown in 2D cell culture and cells that had been seeded onto a 3D scaffold and left to grow for 4 weeks. 
As a control lysates from fresh tumours were also included for comparison. Image taken from (Rajan, 
Elliott, et al., 2011). 
 
5.1.5 3D spheroid cell cultures to model CYLD defective tumours 
Cylindroma primary cell cultures (CPCC) have previously been described (Bruckner-
Tuderman et al., 1991; Weber L. et al., 1984), with a methodology of enzymatic 
digestion of the tissue with trypsin and collagenase and culture of the cells in serum-
free keratinocyte medium. This protocol was further developed and optimised by Dr. 
Rajan (Rajan, Elliott, et al., 2011) and again in this thesis, to successfully produce 
primary cultures (Material and Methods section 2.6). The cylindroma cells displayed 
two morphologies: typical small keratinocytes and occasional larger flat cells with an 
increased nuclear size, whilst the colonies formed were predominantly holoclones and 
meroclones. These primary cell cultures derived from CYLD defective tumours are 
important in vitro models, as at present CYLD deficient mouse models do not 
spontaneously develop tumours (Massoumi, Chmielarska, et al., 2006), impeding 
functional analyses in relevant models in vivo. Therefore primary cell cultures provide 
a tool for functional studies of perturbed gene expression profiles and signalling 
pathways identified by transcriptomic analyses, in a CYLD defective context. The lack of 
an in vivo model reinforcing the need to make the in vitro primary cell culture models 
as representative of the tumours as possible. 
 
Indeed with the establishment of primary cultures from CYLD defective tumours, Rajan 
et al. have previously investigated culturing the cells in 3D by seeding the primary cells 
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onto polystyrene scaffolds (Rajan, Elliott, et al., 2011). As highlighted above cells in a 
3D cell culture environment differ in their gene and protein expression profiles from 
2D cultured cells (Edmondson et al., 2014). To recapitulate the point, the work by 
Rajan et al. found that cylindroma primary cells cultured on scaffolds in 3D showed an 
increase in expression of both TrkB and TrkC, compared to matched cells grown in 2D 
culture (Figure 5-3). This was influential to the identification of Trk receptors as 
potential therapeutic targets in subsequent downstream in vitro assays (Rajan, Elliott, 
et al., 2011). The generation of these 3D scaffold cultures however takes 28 days, and 
as is the nature of long-term cultures this is therefore a costly and labour-intensive 
process. Though having demonstrated that 3D primary cell cultures provide a more 
biologically relevant cylindroma culture model, this warranted development of the 
methodology to generate an alternative 3D cell culture system such as spheroids, 
which has not previously been attempted in this cell model.  
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5.2 Chapter specific materials and methods 
The protocol for generating spheroids was adapted from an established protocol for 
3D culture of murine keratinocyte stem cells provided by Dr. Julia Reichelt (Wallace 
and Reichelt, 2013). 
 
Solutions for 3D cell culture: 
102mM CaCl2: 102l of a 1M CaCl2 stock solution was diluted per 1ml of distilled H2O 
 
1.2mM CaCl2 in KSFM: 1.2l of a 1M CaCl2 stock solution was diluted per 1ml of KSFM 
cell culture medium 
 
1.2% alginate: 0.6g of alginate salt (Sigma-Aldrich) was added to 100mls of distilled 
H2O, and left to dissolve on a heated magnetic stirrer ensuring that half of the solution 
was evaporated off to reach the desired concentration. 
5.2.1 Obtaining primary cells 
Primary cylindroma cells, derived from fresh tumour samples taken from patients 
undergoing surgery and processed into a single cell suspension, were defrosted and 
plated out initially into cell culture flasks coated with collagen I. Cells were left to grow 
until 70-90% confluent before being trypsinised for seeding for 3D cell cultures 
(according to Materials and Methods section 2.6). 
5.2.2 Cell seeding for spheroid formation 
For the generation of spheroids in large numbers AggreWell400 Ex plates (STEMCELL 
technologies) were used. These are 6 well plates with each well containing an insert 
composed of 4,700 microwells, with a repellent surface that prevents the adhesion of 
cells. Plates were first prepared by washing each well with 2ml of AggreWellRinsing 
solution (a surfactant solution to lower the surface tension of the plate to aid the 
removal of bubbles), and centrifuged at 300 x g for 10 minutes to remove bubbles. 
Wells were then rinsed with 1ml of KSFM (keratinocyte-serum free medium) before 
adding 2ml of KSFM containing 1.2mM calcium chloride (CaCl2). Trypsinised cells were 
counted and the required number of cells added to a volume of KSFM w/ CaCl2, to give 
a total volume of 3mls that was then added to each 6 well (final volume in the well 
5mls). Between 2.26 x 105 and 6.78 x 105 cells were seeded per well equating to 50-
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150 cells per microwell The cell suspension in each 6 well was gently resuspended to 
ensure even distribution of the cells between the microwells, before a final 
centrifugation at 200 x g for 3 minutes. Cells were left for at least 24 hours at 37C/5% 
CO2 to allow for spheroid formation, and left in culture for 5-7 days, with 3ml media 
exchanges every 48 hours. 
5.2.3 Cell seeding for spheroid formation for assays in a 96 well format 
For the generation of spheroids per well for proliferation and drug assays primary cells 
and HaCaTs were seeded into the inner 60 wells of ultra-low attachment surface 96 
well microplates (Corning). Trypsinised cells were counted, and the volume of cells 
calculated to obtain the required number of cells per well. The cell suspension was 
then centrifuged and the cell pellet resuspended in the same volume of KSFM w/ 
CaCl2. The cells were seeded at a density of 2.5 x 104 cells per well. All wells were then 
topped up to a final volume of 280l with KSFM w/ CaCl2 before plates were 
centrifuged at 100xg for 3 minutes. Cells were left for 24 hours at 37C/5% CO2 to 
allow for spheroid formation, before a 1:1 media change (140l removed and 140l 
fresh media). Cells were then left for another 72 hours before being treated. 
5.2.3.1 Drug Assay of CPCC spheroids  
Once spheroids had formed and had been in culture for 72 hours, they were then 
treated with the following inhibitors, diluted in DMSO, with a final concentration of 
DMSO at 0.1%; NSC74859, Stattic (both TOCRIS) or K252a (Sigma Aldrich). Each drug 
was prepared as a 10X stock solution at a range of concentrations in KSFM media 
containing 1.2mM CaCl2. Then 28l of drug added per well to the spheroid culture 
plate in triplicate for each concentration of each compound (Figure 6-4). Spheroids 
were treated for a further 72 hours before being assayed using CellTiter-Glo 
(Materials and Methods section 2.6.10). 
5.2.3.2 Proliferation Assay of CPCC spheroids  
Cells were also seeded at a range of densities from 1.25 x103 to 8 x104 in triplicate, 
with a final well volume of 280l.  The spheroids were then maintained for four days 
before being assayed using CellTiter-Glo (Materials and Methods section 2.6.9). 
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5.2.4 Harvesting of CPCC spheroids 
For use in downstream applications, medium was carefully removed until 1ml 
remained. Spheroids were then fixed in 5mls of 4% PFA for 20 minutes, before being 
replaced (again leaving 1ml) with 5mls of PBS and left for an hour. PBS was then 
removed and the remaining 1ml was pipetted over the bottom of the well to dislodge 
the spheroids. The spheroids were then transferred into a FACS plastic tube and left to 
sit for 5 minutes to settle down to the bottom. PBS was removed until 500l remained, 
before the spheroids were resuspended and transferred to a 1.5ml eppendorf and 
centrifuged at 5000rpm for 1 minute. The spheroids could then be stored at 4C until 
needed. 
5.2.5 Cryosectioning of CPCC spheroids 
For immunofluorescence analysis, spheroids were frozen down in OCT for 
cryosectioning. Harvested spheroids had as much of the storage PBS removed without 
disturbing the spheroids, leaving 20-30l. To this 40l of 1.2% alginate was added and 
the spheroids resuspended. The spheroid-alginate solution was then dripped from a 
pipette into a petri dish containing 102mM CaCl2 solution and left for 10 minutes to 
solidify and form a ball. The spheroid-alginate drops were then removed with tweezers 
and placed on to blue roll before being placed into OCT on parafilm, which had been 
stained with 10l of 1% Neutral Red solution to help distinguish the spheroid-alginate 
drops. The OCT containing the spheroid-alginate drops was left to set on dry ice before 
being transferred into a pot to store at -80C. The OCT drop was then mounted onto a 
corkboard and the spheroids sectioned at a thickness of 7m and mounted onto slides.  
5.2.6 IF on CPCC spheroids 
Sections underwent immunoflourescence as described in section 2.5.4. Additional 
antibodies that had not been used in any of the previous experiments and were used 
for spheroid characterisation are included below. 
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Table 5-2: Primary and antibodies used for immunofluorescent staining of spheroid 
cultures 
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5.3 Results 
5.3.1 Spheroid culture of cylindroma primary cells is a novel in vitro model 
As mentioned in the methods a protocol had been developed by the Reichelt Lab to 
generate spheroid cultures from murine keratinocyte stem cells. This was adapted and 
optimised for the generation of cylindroma primary cell culture spheroids. The 
protocol included growing the cells in a physiological calcium concentration of 1.2mM, 
which is higher than the low calcium (0.05mM) conditions the cells are usually grown 
in in 2D cultures. Primary cylindroma cells that were 70-90% confluent were 
trypsinised in the usual manner and counted, before being seeded at the correct 
density in to the appropriate plate and centrifuged to encourage aggregate formation. 
Figure 5-4 depicts the process of culturing and seeding the primary cylindroma cells, 
through to the successful generation of spheroids in both the Aggrewell and 96 well 
plate formats (A-D). The following images show the processing of the spheroids into 
OCT blocks so that functional analyses could be carried out such as H & E staining and 
immunofluorescence (E-F). To gain insight into the number of cells that made up the 
spheroids and the proportions from the numbers plated, the nuclei of 50 
spheroids,which had been stained with DAPI, were counted with an average of 24.6 
(13.78 SD) cells per spheroid. Overall this protocol was a much quicker process 
compared to the 4 week culturing of the cells on scaffolds, with successful generation 
of spheroid cultures in 24 to 48 hours.  
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Figure 5-4: The generation and processing of CPCC spheroids. 
A) Brightfield image of primary cylindroma cells in 2D. B) Primary cells were trypsinised 
and seeded into Aggrewell plates. C) Cells that had been in Aggrewell plates for 48 
hours and had formed spheroids. D) Spheroids that had formed in 96 well plates and 
had been treated with an inhibitor. E) Spheroids that had been fixed were suspended 
in alginate, which solidified in calcium chloride. Theses alginate balls were then 
mounted in OCT with neutral red included for visualisation. F) H&E staining of spheroid 
sections. 
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5.3.2 CPCC spheroids have a protein signature that recapitulates human cylindroma 
tumours 
The primary cells once they had formed CPCC spheroids were characterised, to 
determine a) if as a model of cylindroma they replicated the expression pattern of 
proteins that have previously been shown in CYLD-defective tumours, such as 
cytokeratins (CKs), TrkB, MYB and Stat3, and b) to gain insight into the 3D structure 
and behaviour of the spheroids, looking at the expression of cytoskeletal proteins such 
as -actin and -catenin alongside the proliferation marker Ki-67. Spheroid sections 
underwent antigen retrieval followed by indirect immunofluorescence staining with 
antibodies raised against the range of proteins mentioned above, that are expressed in 
vivo. No primary antibody controls were included for each antibody, examples of 
which are shown in Figure 5-5. The spheroid sections used for this analysis were 
generated from cells from one cylindroma tumour from one patient. A proportion of 
cells within the spheroids were shown to be proliferating, as a number of the cells 
were positive for Ki-67 expression (Figure 5-6A). The spheroids were found to express 
both CK14 and CK17, markers of keratinocytes and keratinocytes of the hair follicle 
respectively (Figure 5-6B & C). There was also cytoplasmic staining of the cytoskeletal 
protein -actin, with a thicker border surrounding the spheroid and mainly cytoplasmic 
staining of the cell adhesion protein -catenin observed in the spheroids (Figure 5-6D 
& E).  
 
Figure 5-5: Representative images of no primary antibody controls for 
immunofluorescence staining of CPCC spheroid sections.  
DAPI was used as a nuclear counterstain. All images 20x magnification. Scale bar represents 50m. 
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Figure 5-6: Characterisation of CPCC spheroids using immunofluorescence. 
CPCC spheroid sections were probed with a panel of antibodies. A) The proliferation marker Ki-67, B & 
C) the keratinocyte marker CK14 and hair follicle keratinocyte marker CK17, D) the cytoskeletal protein 
-Actin and E) the cell adhesion protein -Catenin. DAPI was used as a nuclear counterstain.. DAPI 
images on the left, protein probed for middle images and merged images on the right. All images 20x 
magnification. Scale bar represents 50m. 
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Further to this Stat3 was previously found to be over-expressed in CYLD-defective 
tumours (Chapter 4), and p-Stat3 (Tyr705) levels were increased in TrkB.T1 over-
expressing HaCaT cells following stimulation with BDNF. Therefore the expression of 
TrkB, p-Stat3 (Tyr705) and Stat3 proteins was looked at in the spheroids, to 
corroborate these 3D cultures as models that replicate cylindroma tumours. Many of 
the spheroid cells were positive for TrkB, with some cells showing stronger cytoplasmic 
staining of TrkB (Figure 5-7A). The spheroids were also shown to express Stat3, with 
some cells displaying nuclear expression indicated by the pink-purple colour tone of 
the nuclei indicating active Stat3 (Figure 5-7B).  
 
Figure 5-7: Expression of TrkB and Stat3 in CPCC spheroids.  
CPCC spheroid sections were probed with antibodies for proteins that had previously been shown to be 
over-expressed in cylindromas A) TrkB and B) Stat3. DAPI was used as a nuclear counterstain. The 
images shown are representative of at least 3 different CPCC spheroids. DAPI images on the left, protein 
probed for middle images and merged images on the right. All images 20x magnification. Scale bar 
represents 50m. 
 
Some of the spheroid sections were also analysed using confocal microscopy. The 
enhanced detail again showed that TrkB wasn’t expressed in all the cells. In those cells 
that were positive for TrkB, alongside membranous staining there was also a 
punctate/pigmented pattern of staining in the cytoplasm (Figure 5-8). This could 
suggest localisation of the TrkB receptor to certain organelle structures such as the 
mitochondria. Alternatively it could also represent the vesicular endocytosis and 
DAPI/TRKB A 
DAPI/STAT3 B 
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transport of the receptor within the cell. Overall the results here show that the 
enhanced cell-cell contact that is promoted in CPCC spheroids leads to the 
maintenance of a protein expression profile that is similar to that seen in vivo. 
 
Figure 5-8: TrkB expression in CPCC spheroids visualised by confocal microscopy. 
Spheroid sections were probed with a TrkB antibody. Confocal microscopy images are shown, with one 
image from a series of 19. White box indicates zoomed in section to show the punctate pattern of TrkB 
staining. DAPI was used as a nuclear counterstain. DAPI image on the left, TrkB centre image and 
merged image on the right. All images 20x magnification. Scale bar represents 50m. 
 
  
 
 
 
DAPI/TRKB 
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5.3.3 Stat3 signal transduction is modulated by BDNF and IL-6 in CPCC spheroids  
To investigate the effect of BDNF on TrkB and Stat3, as was shown in the 2D cultures in 
Chapter 4, spheroid cultures were treated with 100ng/mL BDNF or 25ng/mL IL-6 for 30 
minutes prior to being fixed, harvested and sectioned. Untreated spheroids were 
included as a negative control, whilst IL-6 was included as a positive control for Stat3 
activation. Indirect immunofluorescence double staining was attempted on sections of 
the treated spheroids to see if TrkB and Stat3 were active within the same cells in 
response to BDNF. As expected it was shown that TrkB and Stat3 were both expressed 
in all spheroids regardless of treatment (Figure 5-9A&B). There was however no 
noticeable difference in the localisation of Stat3 between spheroids exposed to BDNF 
and untreated spheroids, with nuclear expression seen in both conditions, suggesting 
that Stat3 is active regardless of whether exogenous BDNF is present or not in contrast 
to the result in 2D. Meanwhile in IL-6 treated spheroids Stat3 expression was 
exclusively nuclear, showing that the positive control had worked (see Appendix). It 
was noted that the spheroids used for these experiments appeared a lot smaller than 
the previous samples. Thus with the quality of the images it could not be deduced 
whether cells in which Stat3 was deemed to be active were also the same cells that 
displayed strong TrkB expression.  
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Figure 5-9: The effect of BDNF 
treatment on TrkB and Stat3 
expression in CPCC spheroids. 
CPCC spheroids were initially 
treated with BDNF or IL-6 
ligands for 30 minutes. 
Spheroids were then 
processed and sectioned. 
Sections of treated spheroids 
were double stained with 
TrkB and Stat3 antibodies. 
DAPI was used as a nuclear 
counterstain. Far left images 
TrkB, inner left Stat3, inner 
right DAPI and far right 
merged images. All images 
40x magnification. Scale bar 
represents 20m. (Data 
representative of n = 1 
experiment).
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5.3.4 CPCC spheroids are sensitive to Stat3 and Trk inhibition 
As spheroid cultures are regarded as more biologically relevant models for testing 
compounds for drug development, the CPCC spheroids were assessed as models for 
drug assays, and whether as a model they were comparable to the 3D scaffold cultures 
(as seen in Chapter 4) in their response. The density at which to seed the cells into 
assay plates was initially determined by a viability assay which showed a linear trend 
with an increase in the number of cells correlating with an increase in the 
luminescence read out (Figure 5-10). 25,000 cells/well were therefore plated due to 
the level of luminescence and the number of available cells.  
 
CPCC spheroids were established in 96 well ULA plates and treated for 72 hours with 
the Stat3 inhibitors NSC74859 and Stattic at the specified concentrations, with DMSO 
as a drug free control. These inhibitors were selected due to the scaffold cultures in 
Chapter 4 being more susceptible to these treatments compared to HaCaTs, out of the 
four compounds initially tested. The pan Trk inhibitor K252a was used as a positive 
control, as cylindroma cells grown on scaffolds had previously been shown to be 
sensitive to this treatment (surviving fraction (SF50) 366nM) (Rajan, Elliott, et al., 2011). 
Indeed the CPCC spheroids demonstrated increased sensitivity to the K252a inhibitor 
compared to the keratinocyte cell line HaCaT, at nanomolar concentrations (Figure 5-
11). The CPCC spheroids were more sensitive than the HaCaTs in response to both 
NSC74859 and Stattic compounds, but with variability in the response between the 
individual cylindroma samples (Figure 5-12 & 13). It was also shown that the CPCC 
spheroids were more sensitive to Stattic than NSC74859, with a significant reduction in 
cell viability seen at nanomolar concentrations with Stattic compared to the high 
micromolar concentrations with NSC74859. This is in accordance with the scaffold data 
from Chapter 4. 
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Figure 5-10: Cell viability assay to determine the number of cells to plate for CPCC 
spheroids. 
Cells were plated into 96 well ULA plates at the specified numbers in triplicate and left 
for 72 hours for spheroid formation and cell viability assessed. Data are the mean of 
triplicate readings and error bars represent the SEM. 
 
 
Figure 5-11: Trk inhibition of CPCC spheroids with K252a  
Primary cylindroma and HaCaT cells were plated into 96 well ULA plates and left for 72 
hours to allow for spheroid formation. Cells were then treated with K252a at a range 
of concentrations for 72 hours before cell viability was assessed using a luminescent 
assay. Data are the mean of triplicate readings and error bars represent the SEM. 
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Figure 5-12: CPCC spheroids are susceptible to Stat3 inhibition by Stattic. 
Primary cylindroma and HaCaT cells were plated into 96 well ULA plates and left for 72 
hours to allow for spheroid formation. Cells were then treated with Stattic at a range 
of concentrations for 72 hours before cell viability was assessed using a luminescent 
assay. Each graph represents cells derived from an individual tumour from the same 
patient. Data shown are normalised and error bars represent the SEM of triplicate 
readings. 
  
A) B) 
C) 
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Figure 5-13: CPCC spheroids are susceptible to Stat3 inhibition by NSC74859.  
Primary cylindroma and HaCaT cells were plated into 96 well ULA plates and left for 72 
hours to allow for spheroid formation. Cells were then treated with NSC74859 at a 
range of concentrations for 72 hours before cell viability was assessed using a 
luminescent assay. Each graph represents cells derived from an individual tumour from 
the same patient. Data shown are normalised and error bars represent the SEM of 
triplicate readings. 
 
  
A) B) 
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5.4 Discussion 
Although 2D cell culture has proven to be a valuable method for cell-based studies, as 
a technique it is cost-effective, reproducible, easy to handle, and enables the growth 
of a myriad of cell types, the limitations have increasingly become recognised. A key 
inadequacy being that it does not take into account the natural 3D environment of the 
cells; the forced monolayer morphology of cells grown on a flat surface in 2D cultures 
is at odds with the in vivo environment, in which almost all cells are surrounded by 
other cells and extracellular matrix (Antoni et al., 2015; Breslin and O'Driscoll, 2013; 
Edmondson et al., 2014; Rimann and Graf-Hausner, 2012). As a result, 2D cell culture 
experiments sometimes provide misleading and non-predictive data for in vivo 
responses (Hongisto et al., 2013). This can waste valuable time and resources when 
looking for promising treatment options, as compounds are permitted to enter clinical 
trials which subsequently show little efficacy or unacceptable toxicity, or potential 
candidate targets and compounds are over-looked, making the 2D cell cultures 
inefficient models for drug development (Fang and Eglen, 2017). To this end advances 
have been made over the last decade in the generation of 3D spheroid cultures as a 
tool for biological discovery and drug-screening platforms, particularly in the field of 
cancer research (Kim J. B., 2005; Kimlin et al., 2013). These 3D culture systems are 
born out of the natural tendency of some cell types to aggregate, allowing for cell-cell 
and cell-matrix interactions, which can both influence the cells behaviour due to 
alterations in cell signalling and gene expression (Birgersdotter et al., 2005; Luca et al., 
2013). As such 3D cultured cells are considered to be more representative of their in 
vivo counterparts, making the 3D cultures more suitable model systems. 
5.4.1 The development of novel CPCC 3D cultures-from scaffold to spheroid 
The work included in this chapter showed the successful establishment of 3D spheroid 
cultures from cylindroma primary cell cultures for the first time (Figure 5-4). The CPCC 
spheroids were comparable, both in their expression of proteins and in their responses 
to the different drug treatments, to the scaffold cultures (Chapter4). This illustrated 
the viability of the CPCC spheroids as an alternative 3D culture model that can 
overcome some of the limitations of the scaffold cultures. The protocol was more 
amenable for primary cell cultures and downstream assays, not least because of the 
reduction in time from 4 weeks to 24-48 hours to establish the 3D cultures. This would 
allow for an increased throughput of cell samples from a larger cohort of tumours for 
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future study, with the additional benefits of reducing the infection risk and the 
acquirement of additional genomic mutations that come with long-term cultures. This 
leads to the primary cells maintaining a similar genomic profile to the tumour in vivo. 
The protocol also increased the robustness and reproducibility of the 3D cultures as 
there was assurance that the same number of cells could be seeded per well to 
produce spheroids that had a degree of homogeneity in their size. This is in contrast to 
the scaffolds where attempts are made to seed the same number of cells onto each 
scaffold, however there is no way of knowing how many cells have adhered to the 
scaffold. Furthermore due to using primary cylindroma cells from different patients 
there is variability in cell growth between the different CPCC samples, which can’t be 
easily monitored under a microscope throughout the culture period due to the opaque 
nature of the scaffolds. This means that 2mm punches from different areas of the 
scaffold taken periodically for viability assays are required to monitor cell growth, 
which reduces the amount of working sample; an important consideration when cells 
are limited in supply due to their rarity. Overall this leads to an inefficient use of time 
and reagents and increases costs, which the spheroid cultures can overcome. 
5.4.2 CPCC spheroids maintain stem cell like characteristics when grown in high 
calcium conditions 
Within the skin, it is hypothesised that the loss of functional CYLD within the 
keratinocyte stem cell (KSC) niche of the hair follicle perturbs the normal proliferation 
and differentiation of the stem cells or their progeny to give rise to adnexal tumours 
such as cylindroma (Rajan and Ashworth, 2015; Verhoeft et al., 2016). The ability of 
cells derived from primary cylindromas to form spheroids demonstrates that these 
cells maintain stem cell like characteristics when cultured in this 3D format, as the 
capacity to form cell aggregates in suspension is a hallmark of stem cells (Vollmers et 
al., 2012), which is exemplified by the aggregate formation of mesenchymal stem cells 
(Cesarz and Tamama, 2016; Frith et al., 2010). This is further evidenced by the fact 
primary murine keratinocyte cultures and cell cultures not enriched for KSCs are 
unable to form spheroids (Vollmers et al., 2012).  
 
In skin biology a widely accepted view is that calcium gradients control the 
differentiation of keratinocytes, with the calcium concentration increasing as 
immature keratinocytes in the basal cell layer of the epidermis proliferate, then 
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terminally differentiate and migrate through the spinal and granular layers to the 
outermost layer of the skin to replace fully differentiated keratinocytes (as reviewed 
by (Bikle et al., 2012). Although a conflicting report found that the calcium 
concentration within the epidermal basal layer, of which the hair follicle is an 
extension of and is where epidermal stem cells reside, is as high as that found in the 
granular layer (Leinonen et al., 2009). Indeed the aggregation and growth of CPCC 
spheroid cultures was achieved in the presence of a high calcium concentration in the 
medium. Whilst keratinocytes are usually propagated in a low calcium environment in 
2D cell cultures to prevent differentiation of the cells, it does not induce the 
differentiation of keratinocyte stem cells in 3D culture (Vollmers et al., 2012). Instead 
extracellular calcium is required for the formation of cell-cell contacts, allowing the 
formation of calcium-dependent cell junctions and inducing changes to overall 
cytoskeletal organisation (Watt et al., 1984; Zamansky et al., 1991). This was in 
accordance with the positive expression of the cytoskeletal protein -actin and cell-
adhesion protein -catenin in the spheroids (Figure 5-6). In addition -catenin is also a 
signal transducer in the Wnt signalling pathway (Valenta et al., 2012), and as a 
pathway that has been shown to be dysregulated in CYLD-defective tumours (Rajan, 
Burn, et al., 2011), the positive expression further supports that the model is 
representative of the tumours. However the predominantly cytoplasmic staining 
suggests the function of -catenin is to promote cell-adhesion in these 3D cell cultures. 
The cytoplasmic location corresponds with interactions with the cell adhesion 
glycoprotein E-cadherin complexes, located at the cell membrane, as opposed to a 
nuclear location in a downstream response to active Wnt signalling (Gottardi and 
Gumbiner, 2004). Furthermore in previous studies nuclear -catenin was found in a 
minority of cylindroma cells, and at the periphery of tumour islands (Rajan, Burn, et al., 
2011). This suggests that the tumour stroma may be necessary for activated Wnt/-
catenin signalling within the cells, and as this is lacking in cell culture it may be that this 
pathway is not active. 
 
The positive Ki-67 expression that was shown in a proportion of the cells within the 
spheroids (Figure 5-6) indicates that these cells can maintain a proliferative phenotype 
in 3D spheroid culture. Indeed cylindromas have been shown to have increased 
expression of 21 integrins (Tunggal et al., 2002), which are part of a family of cell 
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surface receptors that mediate cell adhesion. Interestingly up-regulated expression of 
these integrins is associated with keratinocytes with the highest proliferative potential, 
the keratinocyte stem cells (Jones and Watt, 1993; Levy et al., 2000). This evidence is 
concurrent with the argument that enhanced cell adhesion promoted by the high 
calcium environment maintains stem cell like properties of the primary cells, with 
proliferation an indicative marker of stem cells or undifferentiated progenitors. 
Altogether these findings strongly suggest that cylindroma primary cells cultured in a 
higher calcium 3D environment behave like their in vivo counterparts, and makes this 
culture system a representative in vitro model in which to explore cylindroma biology. 
 
Calcium signalling could be a potential area of interest to take forward into future 
studies of CYLD-defective tumours with these models. Despite the well-established 
role of calcium in the differentiation of keratinocytes (Bikle et al., 2012), a direct role 
for calcium in hair follicle cycling is unclear. As normal keratinocyte differentiation is 
clearly perturbed in CYLD-defective tumours it is not unreasonable to hypothesise that 
calcium homeostasis may also be altered. The TRP (transient receptor potential) 
channel family are cation channels that are permeable to calcium and can modulate 
intracellular calcium signalling through their activation (Gees et al., 2010). The TRP 
family of receptors are recognised to have a contributory role to many physiological 
processes within the skin ranging from sensation to skin homeostasis (Caterina and 
Pang, 2016). The TRPA1 (transient receptor potential ankyrin 1) family member has 
been shown to be a target of CYLD, with deubiquitination of TRPA1 increasing the 
cellular pool of the receptor (Stokes et al., 2006). This is interesting as the structurally 
similar family member TRPV1 (transient receptor potential vanilloid 1) is expressed 
within the hair follicle and is involved in negatively regulating human hair growth by 
inhibiting proliferation and down-regulating known hair growth promoters (Bodo et 
al., 2005). Of note was the finding that in outer root sheath keratinocytes the cellular 
actions of TRPV1 were shown to be calcium dependent, but activation of TRPV1, at 
least by capsaicin, did not affect their terminal differentiation. This indicates that 
calcium has alternate biological functions in these cells that are independent of the 
promotion of differentiation (Bodo et al., 2005). Furthermore in breast cancer cells 
activation of TRPV1 also caused inhibition of cell growth (Weber L. V. et al., 2016). It is 
therefore speculated that as a member of the same TRP family it too could be a target 
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of CYLD, whose expression levels are possibly altered due to ubiquitination of the 
receptor, and subsequent changes in calcium signalling within the cell may promote 
cell growth. Alternatively in response to BDNF, TrkB.T1 elicits the release of calcium 
from intracellular stores in glia cells (Rose et al., 2003). As TrkB.T1 is over-expressed in 
CYLD-defective tumours, this could represent another mechanism that leads to 
alterations in calcium signalling within the tumour cells and promote tumour 
formation. 
5.4.3 The CPCC spheroids protein expression profile reflects that of the in vivo 
tumour 
Spheroid cultures were characterised using indirect immunofluorescence. The 
spheroids were found to express keratinocyte markers, such as CK14 and CK17 (Figure 
5-6), which are expressed in 2D and 3D scaffold CPCC cultures, but more importantly 
by the tumours in vivo (Meybehm and Fischer, 1997; Rajan, Elliott, et al., 2011). CK14 
is normally expressed in the proliferative basal layer of keratinocytes of stratified 
epithelia, which along with its partner CK5 decreases in expression as the cells 
differentiate (Alam et al., 2011; Coulombe et al., 1989). It is also expressed in the hair 
follicle (Coulombe et al., 1989). Likewise CK17 is recognised as a marker for 
keratinocytes within the outer root sheath of the hair follicle, as it is a regulator for 
hair follicle cycling (Tong and Coulombe, 2006; Troyanovsky et al., 1989). Recently 
CK17 expression was identified as a marker of another cutaneous lesion of the hair 
follicle, keratoacanthoma (Leblebici et al., 2017). Expression of both CK14 and CK17 
reflects that the CPCC spheroids model tumour biology by maintaining the expression 
of these keratinocyte markers, and is in keeping with the current consensus that the 
hair follicle is the site of origin for cylindromas (Massoumi, Podda, et al., 2006; 
Sellheyer, 2015). Additionally their expression also indicates that the majority of the 
CPCC cells that form the spheroids are keratinocytes. As these are primary samples, a 
heterogeneous population of cell types can be found, indeed in 2D CPCC occasional 
fibroblasts are seen. Specific markers of fibroblasts would have to be applied to 
determine if these cell types were incorporated in the spheroids, but having a mixture 
of cells would again recapitulate the in vivo environment more so as the cells would be 
surrounded by those with which they live within the tumour. This is akin to alternative 
3D skin models such as LSEs, where keratinocytes are grown atop of a support/lattice 
populated with fibroblasts (O'Leary et al., 2002). The expression of TrkB further 
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supported CPCC spheroids as a tumour model. Whilst the majority of the cells had 
membranous staining of TrkB, aligning with its expression as a receptor protein, there 
was variation in the cytoplasmic expression, possibly indicating the cells in which TrkB 
signalling is active (Figure 5-7 & 8). The punctate pattern of staining was also of 
interest, suggesting the localisation of TrkB to certain cellular structures such as the 
mitochondria, the membranes of which TrkB has previously been shown to localise 
(Wiedemann et al., 2006), or even endocytic vesicles for the recycling of the receptors 
(Chen Z. Y. et al., 2005; Huang S. H. et al., 2009) This could be determined with the use 
of a mitochondrial marker to see if the signal for both TrkB and mitochondria co-
localised within the cells. 
 
Finally due to the finding of Stat3 activation downstream of TrkB.T1 signalling in 
Chapter 4, TrkB/Stat3 immunofluorescence double staining was carried out on 
spheroids that had been treated with the TrkB ligand BDNF. Unfortunately the imaging 
of the spheroids was not clear enough, possibly due to the spheroids being too small, 
to conclusively state if activated TrkB signalling occurred in the same cells as active 
Stat3. However it was shown that there was no visible difference in the localisation of 
Stat3 between the treated and untreated spheroids (Figure 5-9). Within some 
untreated cells, Stat3 was shown to localise in the nucleus, indicating that it was active 
even in the absence of exogenous BDNF. This was in direct contrast to the 2D CPCC 
cultures where there was a clear alteration in the localisation of Stat3 with the 
addition of BDNF from the cytoplasm to the nucleus. Whilst on one hand this could 
demonstrate that Stat3 activity is not dependent on the activation of TrkB signalling. It 
may also illustrate that as a 3D spheroid culture, the cells may instead be producing 
their own supply of BDNF stimulated by either an unknown mechanism, Stat3 itself or 
even an increase in Trk expression, as it was previously shown that Trk expression is 
increased in 3D CPCCs compared to 2D CPCCs (Rajan, Elliott, et al., 2011). This could 
therefore be activating Trk and driving Stat3 activation in an autocrine feedback loop, 
much like the one that was demonstrated by Chen et al. in lung cancer cells (Chen B. et 
al., 2016). Again this highlights the suitability of 3D cultures as in vitro models, as the 
cells display signalling behaviours that are reminiscent of the in vivo tumours, even 
though a source of BDNF is still to be determined. In the future it would be interesting 
to carry out ELISA assays on the spheroids and the growth medium, to see if the 
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spheroid cultures produced BDNF, or other secreted ligands, to create signalling 
feedback loops. The previous attempts in 2D culture were not successful, which could 
be due to the lower levels of expression in the 2D CPCCs as discussed in Chapter 4. In 
addition this experiment was only carried out once due to difficulties with obtaining 
spheroid sections on slides again due to the small size. The spheroids therefore could 
be cultured for longer or a larger numbers of cells plated in future to allow for larger 
spheroids to form, and also to improve the clarity of the immunofluorescence staining.  
5.4.4 CPCC spheroids are targetable with Stat3 inhibitors 
In Chapter 4 Stat3 had previously been identified as a downstream target of interest of 
TrkB.T1 signalling, that was over-expressed in cylindromas and thus led to an in vitro 
treatment assay to determine if the cells would respond to Stat3 inhibition. These 
experiments were repeated on the CPCC spheroids to evaluate the sensitivity of this 
3D culture method in comparison to the CPCC scaffolds. Cells grown in 3D are more 
resistant to treatment (Edmondson 2014) and HepG2 liver cells grown on these 
scaffolds had been shown to be less susceptible to lower concentrations of 
methotrexate compared to 2D cultures (Bokhari et al., 2007). CPCC spheroids were 
sensitive to Stat3 inhibition, showing a reduction in cell viability, indicating that the 
loss of catalytically active CYLD increases the dependency of the cylindroma cells on 
Stat3 for their survival (Figure 5-12 & 13). There was a slight variation in response from 
the different CPCC cultures, which could be due to the heterogeneity of the cells 
within the samples. Also these results replicated the response seen in the scaffold 
cultures (Chapter4), with responses seen at micromolar and nanomolar concentrations 
for NSC74859 and Stattic respectively. This finding demonstrates that as a 3D cell 
culture model CPCC spheroids are comparable to CPCC scaffolds, and aspects of the 
cell biology are maintained between the two 3D methods. However in addition to the 
constraints of scaffold cultures mentioned above, the use of the scaffolds in drug 
assays exposes further limitations of the method. The potential for inconsistency in cell 
growth across the scaffold could give a bias to the results, as there is uncertainty of 
whether the result from a 2mm punch is reflective of the effect of the drug or that 
there were fewer cells in the first place. Setting up in triplicate does aim to minimise 
this but it can lead to large standard error. On the other hand the CPCC spheroids 
allows for control over the number of cells plated and assumption that the same 
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number of cells are being treated in each well meaning that experiments are easier to 
replicate. 
 
The CPCC spheroids do have their own weaknesses with regards to reproducibility 
however. The potential morphological heterogeneity of the spheroids formed with 
regards to size and shape, are two areas of variability that could introduce a bias to 
drug assay results; the extent to which this heterogeneity contributes to data 
variability within spheroid cultures was recently explored by Zanoni et al. (Zanoni et 
al., 2016). Larger spheroids (>500m diameter) are structured into zones of cells at 
different proliferative stages (Figure 5-2) alongside developing chemical gradients. 
Having spheroids of different sizes may affect how effectively the drug can penetrate 
all of the cells causing discrepancy in the cells level of exposure, and the way in which 
the cells respond due to varying proportions of cells at different cell cycle stages. 
Whilst this may be a feature that is more reflective of the in vivo environment, a lack of 
vasculature in this model system means that some of the pharmacological 
complexities cannot be mimicked and in an experimental set-up control is needed over 
such variables. Equally irregular, non-spherical shaped spheroids were found to have 
alterations to the dimensions of the inner core and thickness of the exterior cell layer, 
alongside more frequent budding of secondary spheroids. Together this led to a 
significant increase in viability compared to spherical spheroids of the same volume, 
which again could impact the response of the cells to treatment (Zanoni et al., 2016). 
To reduce data variability they suggested pre-selection criteria for spheroids that are 
homogenous in shape and size prior to treatment, using open source software for 
monitoring and selection (Piccinini, 2015; Piccinini et al., 2015).  
 
Indeed the parameters of size and shape were not specifically investigated or 
accounted for in the therapeutic screening of the CPCC spheroids included in this 
thesis. However in the monitoring of the generation of spheroid cultures it was 
observed that multiple spheroids formed in each of the 96 wells, but no 
measurements were taken as to the number or size of the CPCC spheroids formed in 
each well. The lack of formation of a single spheroid may be due to the fact that these 
are heterogeneous populations of primary cells, that may not all have the capability to 
aggregate and form a spheroid. In light of the limitations mentioned above though it 
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would indicate that the protocol needs optimising for future experiments to increase 
the robustness of the methodology. Possible ways in which to address these issues 
include more precision in the monitoring of the spheroids, using available resources 
such as AnaSP (Piccinini, 2015), or consider the generation of the spheroids in another 
vessel, from which homogenously sized spherical spheroids can be pre-selected and 
transferred to the 96 well ULA plate to ensure one spheroid per well. Whilst also taking 
into consideration the handling time for this protocol and not substantially adding to 
the workload. 
 
The reagents used for the cytotoxicity assays of the spheroids are a final consideration, 
to ensure they can reliably penetrate the cells. In this instance the CellTiter-Glo 
viability assay (Promega) was used, which showed an increasing linear trend when 
tested on increasing cell numbers (Figure 5-10) indicating that it can still penetrate the 
spheroids and give a reliable readout. Also the spheroid cultures were only left for 4 
days prior to treatment and although not assessed experimentally, it is assumed that 
they would not have grown to 500m in diameter in this time, so would still be small 
enough for the reagent to penetrate the spheroids. However it may be beneficial in 
the future to adopt the CellTiter-Glo 3D viability assay. This works on the same 
principle as the 2D assay in detecting ATP levels as a marker of metabolically active 
cells, but has increased lytic capacity to allow for permeation through larger spheroids 
and shows superiority as spheroids reach 350m in diameter, as shown in a technical 
resource from Promega (Valley et al., 2014). 
5.4.5 Conclusions 
Primary cell cultures can be utilised to explore disease biology and to assess the 
efficacy of targeting identified dysregualted pathways with therapeutic agents. 
However when grown in 2D they do not best represent the in vivo sitatuion they are 
trying to model. In this chapter it has been demonstrated in this chapter that 3D 
spheroid cultures derived from primary cylindroma cells can be achieved, and that the 
increased cell-cell contact of the spheroids promotes an expression profile that models 
the in vivo tumour. Whilst having established 3D cultures on scaffolds previously, the 
spheroids represent a more amenable approach, which can be taken forward into 
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downstream applications. Yet they do hold their own limitations in size and 
reproducibility, which will require further optimisation.  
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6 Chapter 6: Concluding remarks and future directions 
 
CYLD cutaneous syndrome is a rare inherited condition in which painful and disfiguring 
tumours, namely cylindroma, spiradenoma and trichoepithelioma occur (Rajan, 
Langtry, et al., 2009), yet at present there are no curative treatments. The only option 
for patients at present is repetitive surgery throughout a patient’s lifetime to control 
tumour burden (Rajan, Trainer, et al., 2009).  
 
The MYB-NFIB fusion gene was one such target of interest that had previously been 
found in sporadic cylindromas (Fehr et al., 2011) and considered an oncogenic 
hallmark in salivary gland tumours (Persson et al., 2009). Genetic drivers of 
cylindromas beyond CYLD are poorly characterised, and hence an aim of this thesis 
was to see if this fusion transcript was also expressed in inherited cylindromas. Using 
RT-PCR and FISH analysis it was found that the inherited cylindromas were negative for 
the fusion transcript but instead were found to overexpress MYB, as shown by 
immunohistochemical analysis, which is also seen in the sporadic tumours in the 
absence of the fusion gene (Fehr et al., 2011). A significant difference in expression 
was observed between the tumours and perilesional controls. Furthermore 
knockdown of MYB in primary cylindroma cells caused a reduction in cell viability, 
demonstrating that the cells were dependent on the expression of MYB for their 
survival. MYB is a transcription factor that has roles in regulating the proliferation and 
differentiation of stem cell niches (Lieu and Reddy, 2009; Malaterre et al., 2007). As 
tumours of hair follicle origin it is interesting that within the mouse hair follicle, 
specific MYB expression was found in a population of cells just below the bulge region 
in which the stem cell niche is found, suggesting that MYB may be involved in 
regulating the activation of quiescent stem cells and commitment to differentiation of 
the cells (Vesela et al., 2014). Therefore perturbed expression of MYB in human hair 
follicle stem cells expressing catalytically defunct CYLD could have a role in promoting 
hair follicle tumour formation.  
 
To investigate the promotion of MYB overexpression in cylindromas both 
overexpression of mutated forms of CYLD and silencing of CYLD were utilised. This 
showed that truncating mutations of CYLD did not have any obvious effect on MYB 
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expression when compared to controls, suggesting that mechanisms independent of 
CYLD account for the increased expression in tumours. This was in contrast to the 
knockdown studies in which an increase in MYB expression was observed in the HaCaT, 
keratinocyte cell line. But as this was not a consistent result between the two shRNAs 
it requires further investigation with additional shRNAs to ensure the result is not 
accountable to off target effects. Alternatively MYB expression is regulated by a 
transcriptional attenuator sequence in the first intron, which can be overcome by 
NFB (Pereira et al., 2015), alongside the presence of NFB binding sites in the c-MYB 
promoter (Lauder et al., 2001). As the role of CYLD remained inconclusive it was 
hypothesised that dysregulated NFB signalling in the tumour cells, due to a lack of 
functional CYLD (Brummelkamp et al., 2003), may be causing increased MYB 
expression instead. To investigate, primary cylindroma cells were treated with NFB 
inhibitors, however this caused a surprising increase in MYB expression as opposed to 
the expected decrease, suggesting that the NFB pathway may act in a suppressive 
manner and alternate mechanisms are responsible for driving MYB expression in the 
tumours. Yet the same trend was seen in the HaCaT cells, which may also imply that 
inhibition may alter the ratio of certain MYB isoforms. This requires further 
clarification in future studies, with inhibition of NFB in a larger cohort of primary 
samples.  
 
Indeed a novel finding of this work was that in HaCaTs and primary cylindroma cells an 
89kDA alternate isoform was observed at the protein level, which corresponds to MYB 
9B (O'Rourke and Ness, 2008). Analysis of exon junctions from the RNA-seq data 
showed that the frequency of transcripts including these alternate exons was 
increased in the tumours, with MYB 9B the most predominant alternate form after c-
MYB (75kDA), corresponding with the protein expression levels shown by Western 
blot. At present knowledge about the function of alternate isoforms of MYB is limited, 
especially in a keratinocyte cell context, although studies have demonstrated that the 
different splice variants can activate unique sets of target genes (Zhou and Ness, 
2011). Therefore an alteration in the splicing of MYB and the ratio of alternate isoform 
expression may demonstrate an additional molecular event that has the potential to 
contribute to tumour formation. These isoforms will need further characterisation, in 
the CYLD-defective tumours using overexpression studies similar to the ones used in 
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this study for TrkB. The implications of MYB overexpression makes MYB an attractive 
therapeutic target to follow up and characterise further in CYLD-defective tumours in 
future work. In addition with the development of inhibitory MYB compounds (Dai Y. H. 
et al., 2016; Uttarkar et al., 2016) a natural progression based on the findings of this 
thesis is to perform preclinical experiments on 3D primary cell cultures and explore the 
translational potential of MYB as a treatment in the clinic.  
 
Another target of interest that was explored in this thesis was the receptor tyrosine 
kinase TrkB, having previously found that TrkB was differentially expressed on a 
microarray comparing CYLD-defective tumours to perilesional control skin (Rajan, 
Elliott, et al., 2011). Using RT-PCR and qPCR it was shown that in cylindromas the 
truncated TrkB.T1 isoform was the predominantly expressed isoform in the tumours, 
which was confirmed at the protein level by Western blot. This was in keeping with 
previous in vitro work in keratinocytes (Marconi et al., 2003), however in cylindromas, 
this isoform was increased in tumours compared to normal skin. In addition expression 
of the TrkB receptors cognate ligand, BDNF was also increased in the tumours, 
suggesting that a stimulatory autocrine, signalling loop may exist in cylindromas.  
 
To investigate the role of the TrkB.T1 isoform in the tumours overexpression of 
TrkB.T1 was achieved in the biologically relevant HaCaT cell line and HEK293T cells. 
TrkB.T1 was shown not to promote proliferation but possibly cell survival, by using cell 
viability and colony forming assays. As has been found with MYB, alternate isoforms 
can have their own distinct functions, and with TrkB.T1 not having a kinase domain it is 
only recently that its signalling capabilities have started to be realised (Ohira et al., 
2005; Rose et al., 2003). A key novel finding of this work was that when cells 
overexpressing TrkB.T1 were exposed to BDNF this caused an increase in 
phosphorylation of Stat3 at the Tyrosine 705 residue that was replicated in primary 
cylindroma cell cultures. The phosphorylation of Stat3 at Tyr705 causing activation of 
Stat3, where it can then enter the nucleus and induce expression of target genes such 
as those involved in cell proliferation and cell cycling (Yu H. et al., 2014), which are 
beneficial to aberrant growth of the tumour cells. The altered localisation of Stat3 was 
shown using immunofluorescence, in primary cylindroma cell cultures exposed to 
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BDNF treatment and coincided with altered expression of Stat3 target genes observed 
in the tumour microarray data. 
 
Having identified Stat3 as a potential downstream target of TrkB, it was determined 
whether this was a mechanism by which the overexpression of TrkB.T1 could promote 
cell survival. Treatment of primary cylindroma cells grown on 3D scaffolds with Stat3 
inhibitors in particular NSC74859 and Stattic caused a reduction in cell viability at 
micromolar and nanomolar levels respectively, demonstrating a dependency of the 
cells on Stat3 and validating Stat3 as a potential therapeutic target. To improve our 
understanding further future experiments would include identifying a direct link 
between TrkB.T1 and Stat3 in the cylindroma cells which could be achieved using 
knockdown studies to see if silencing of TrkB leads to a reduction in Stat3 
phosphorylation in response to BDNF stimulation. In addition immunoprecipitation 
studies could be utilised to identify other potential interacting partners of TrkB.T1, 
which may have a pathogenic role in this highly disfiguring disease and may also be 
targetable. 
 
For exploring targets in CYLD cutaneous syndrome, the need for robust experimental 
tools is reinforced by the lack of in vivo mouse models that can replicate the human 
phenotype, meaning that translation of experimental findings into the clinic is reliant 
on primary cell cultures at present. Although with access to patient tumour samples 
and a cutaneous tumour type, development of patient-derived xenograft (PDX) models 
could be considered for future studies. Either CYLD-defective tumour cell suspension 
or parts of the tumour tissue could be engrafted onto immunodeficient mice, creating 
models that could bridge the gap between the culture dish and clinical applications, 
providing a useful tool for validating in vitro findings and evaluating preclinical 
investigations (Lai et al., 2017). 
 
As further insights into tumour biology are gained in the era of transcriptomics and 
sequencing, leading to identification of potential targets such as MYB and Stat3 for 
therapeutic intervention, in vitro models are invaluable tools for validation of 
experimental findings. 3D cell culture is considered a more representative model and is 
increasingly evolving as a technique for drug screening platforms for disease 
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treatments, especially in cancer research (Kimlin et al., 2013). Therefore in this thesis 
for the first time cylindroma spheroid cultures were generated, as previous scaffold 
methods were time consuming and difficult to monitor. Using immunofluorescence 
the 3D spheroid cultures recapitulated the expression profile of the tumours, and 
would be a valuable tool to develop further and take forward for future screening of 
candidate compounds as more knowledge is gathered at the molecular level. Indeed 
Stat3 inhibition reduced cell viability of cylindroma spheroids. 
 
In conclusion both MYB and Stat3 have been identified as potential therapeutic targets 
for CYLD cutaneous syndrome, and warrant further preclinical investigation. 
Concurrently the establishment of primary cylindroma spheroid cultures, that are 
more biologically representative of the in vivo tumours, allows for enhanced 
translational relevance of such investigations and will aid with bringing potential non-
surgical treatment strategies for this highly disfiguring disease into the clinic. 
  
  246 
7 Appendices 
 
Appendix A 
 
Table 7-1: CYLD-defective tumour samples used for RNA-seq. 
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Appendix B 
 
 
Table 7-2: RNA-seq exon junction read depth counts for MYB exon 8 and alternate 
exons 8’ and 8A from a panel of CYLD-defective tumours and perilesional skin 
controls. 
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Appendix B (continued) 
 
Table 7-3: RNA-seq exon junction read depth counts for MYB exon 10 and alternate 
exons 10A from a panel of CYLD-defective tumours and perilesional skin controls. 
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Appendix C 
Table 7-4: Receptor Tyrosine Kinase Antibody array layout. 
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Appendix D 
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Appendix D (continued) 
Figure 7-1: Densitometric quantification of the receptor tyrosine kinase antibody array (additional graphs). 
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Appendix E 
 
Figure 7-2: The effect of IL-6 (control) treatment on TrkB and Stat3 expression in 2D 
primary cylindroma cells. 
 
DAPI CK17 
STAT3 DAPI STAT3 / CK17/ 
CPCC + IL-6 (control) 
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Appendix F 
Table 7-5: Sequencing primers for cloning vectors. 
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Appendix G 
 
Publications: 
 
 Rajan N, Andersson MK, Sinclair N, Fehr A, Hodgson K, Lord CJ, Kazakov DV, 
Vanecek T, Ashworth A, & Stenman G. Overexpression of MYB drives 
proliferation of CYLD-defective cylindroma cells. Journal of Pathology. 2016 
Jun; 239(2): 197-205. 
 Rajan N, Sinclair N, Nakai H, Shimomura Y, Natarajan S. A tale of two sisters: 
identical IL36RN mutations and discordant phenotypes. British Journal of 
Dermatology. 2016 Feb; 174(2): 417-420. 
 Rajan N, Elliott RJ, Smith A, Sinclair N, Swift S, Lord CJ, Ashworth A. The 
cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch 
signalling. Oncotarget. 2014 Dec; 5(23): 12126-12140.  
 
 
  
  255 
8 References 
 
Adelstein, D. J., Koyfman, S. A., El-Naggar, A. K., & Hanna, E. Y. (2012). Biology and 
management of salivary gland cancers. Semin Radiat Oncol, 22(3), 245-253. 
doi:10.1016/j.semradonc.2012.03.009 
Adli, M., Merkhofer, E., Cogswell, P., & Baldwin, A. S. (2010). IKKalpha and IKKbeta 
each function to regulate NF-kappaB activation in the TNF-induced/canonical 
pathway. PLoS One, 5(2), e9428. doi:10.1371/journal.pone.0009428 
Ahmed, N., Zeng, M., Sinha, I., Polin, L., Wei, W. Z., Rathinam, C., Flavell, R., Massoumi, 
R., & Venuprasad, K. (2011). The E3 ligase Itch and deubiquitinase Cyld act 
together to regulate Tak1 and inflammation. Nat Immunol, 12(12), 1176-1183. 
doi:10.1038/ni.2157 
Alam, H., Sehgal, L., Kundu, S. T., Dalal, S. N., & Vaidya, M. M. (2011). Novel function of 
keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells. 
Mol Biol Cell, 22(21), 4068-4078. doi:10.1091/mbc.E10-08-0703 
Albores-Saavedra, J., Heard, S. C., McLaren, B., Kamino, H., & Witkiewicz, A. K. (2005). 
Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma 
of the skin and adenoid cystic carcinoma of the breast. Am J Clin Pathol, 123(6), 
866-873. doi:10.1309/crwu-a3k0-mpqh-qc4w 
Allen, R. D., 3rd, Bender, T. P., & Siu, G. (1999). c-Myb is essential for early T cell 
development. Genes Dev, 13(9), 1073-1078. doi:10.1101/gad.13.9.1073  
Allen, S. J., Watson, J. J., & Dawbarn, D. (2011). The neurotrophins and their role in 
Alzheimer's disease. Curr Neuropharmacol, 9(4), 559-573. 
doi:10.2174/157015911798376190 
Almeida, S., Maillard, C., Itin, P., Hohl, D., & Huber, M. (2008). Five new CYLD 
mutations in skin appendage tumors and evidence that aspartic acid 681 in 
CYLD is essential for deubiquitinase activity. J Invest Dermatol, 128(3), 587-593. 
doi:10.1038/sj.jid.5701045 
Alsaad, K. O., Obaidat, N. A., & Ghazarian, D. (2007). Skin adnexal neoplasms--part 1: 
an approach to tumours of the pilosebaceous unit. J Clin Pathol, 60(2), 129-144. 
doi:10.1136/jcp.2006.040337 
Amaru Calzada, A., Todoerti, K., Donadoni, L., Pellicioli, A., Tuana, G., Gatta, R., Neri, A., 
Finazzi, G., Mantovani, R., Rambaldi, A., Introna, M., Lombardi, L., & Golay, J. 
(2012). The HDAC inhibitor Givinostat modulates the hematopoietic 
transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative 
neoplasm cells. Exp Hematol, 40(8), 634-645.e610. 
doi:10.1016/j.exphem.2012.04.007 
Amatu, A., Sartore-Bianchi, A., & Siena, S. (2016). NTRK gene fusions as novel targets of 
cancer therapy across multiple tumour types. ESMO Open, 1(2), e000023. 
doi:10.1136/esmoopen-2015-000023 
An, J., Mo, D., Liu, H., Veena, M. S., Srivatsan, E. S., Massoumi, R., & Rettig, M. B. 
(2008). Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-
induced NF-kappaB activation. Cancer Cell, 14(5), 394-407. 
doi:10.1016/j.ccr.2008.10.007 
Ancell, H. (1842). History of a remarkable case of tumours, developed on the head and 
face; accompanied with a similar disease in the abdomen. Med Chir Trans, 25, 
227-306.211.  
  256 
Antoni, D., Burckel, H., Josset, E., & Noel, G. (2015). Three-dimensional cell culture: a 
breakthrough in vivo. Int J Mol Sci, 16(3), 5517-5527. 
doi:10.3390/ijms16035517 
Arevalo, J. C., Conde, B., Hempstead, B. I., Chao, M. V., Martin-Zanca, D., & Perez, P. 
(2001). A novel mutation within the extracellular domain of TrkA causes 
constitutive receptor activation. Oncogene, 20(10), 1229-1234. 
doi:10.1038/sj.onc.1204215 
Arevalo, J. C., Conde, B., Hempstead, B. L., Chao, M. V., Martin-Zanca, D., & Perez, P. 
(2000). TrkA immunoglobulin-like ligand binding domains inhibit spontaneous 
activation of the receptor. Mol Cell Biol, 20(16), 5908-5916. doi 
10.1128/mcb.20.16.5908-5916.2000  
Arevalo, J. C., & Wu, S. H. (2006). Neurotrophin signaling: many exciting surprises! Cell 
Mol Life Sci, 63(13), 1523-1537. doi:10.1007/s00018-006-6010-1 
Arevalo, J. C., Yano, H., Teng, K. K., & Chao, M. V. (2004). A unique pathway for 
sustained neurotrophin signaling through an ankyrin-rich membrane-spanning 
protein. EMBO J, 23(12), 2358-2368. doi:10.1038/sj.emboj.7600253 
Arwert, E. N., Hoste, E., & Watt, F. M. (2012). Epithelial stem cells, wound healing and 
cancer. Nat Rev Cancer, 12(3), 170-180. doi:10.1038/nrc3217 
Atwal, J. K., Massie, B., Miller, F. D., & Kaplan, D. R. (2000). The TrkB-Shc site signals 
neuronal survival and local axon growth via MEK and P13-kinase. Neuron, 27(2), 
265-277.doi:10.1016/s0896-6273(00)00035-0  
Baker, S. J., Kumar, A., & Reddy, E. P. (2010). p89c-Myb is not required for fetal or 
adult hematopoiesis. Genesis, 48(5), 309-316. doi:10.1002/dvg.20619 
Banfield, M. J., Naylor, R. L., Robertson, A. G., Allen, S. J., Dawbarn, D., & Brady, R. L. 
(2001). Specificity in Trk receptor:neurotrophin interactions: the crystal 
structure of TrkB-d5 in complex with neurotrophin-4/5. Structure, 9(12), 1191-
1199. doi:10.1016/S0969-2126(01)00681-5 
Bansal, C., Batra, M., Lal, N., & Srivastava, A. N. (2012). Solitary cylindroma with 
malignant transformation. Indian J Dermatol, 57(2), 141-143. 
doi:10.4103/0019-5154.94289 
Barker, P. A., Lomen-Hoerth, C., Gensch, E. M., Meakin, S. O., Glass, D. J., & Shooter, E. 
M. (1993). Tissue-specific alternative splicing generates two isoforms of the 
trkA receptor. J Biol Chem, 268(20), 15150-15157.  
Barker, P. A., & Shooter, E. M. (1994). Disruption of NGF binding to the low affinity 
neurotrophin receptor p75LNTR reduces NGF binding to TrkA on PC12 cells. 
Neuron, 13(1), 203-215.  
Barrandon, Y., & Green, H. (1987). Three clonal types of keratinocyte with different 
capacities for multiplication. Proc Natl Acad Sci U S A, 84(8), 2302-2306.  
Baxter, G. T., Radeke, M. J., Kuo, R. C., Makrides, V., Hinkle, B., Hoang, R., Medina-
Selby, A., Coit, D., Valenzuela, P., & Feinstein, S. C. (1997). Signal transduction 
mediated by the truncated trkB receptor isoforms, trkB.T1 and trkB.T2. J 
Neurosci, 17(8), 2683-2690.  
Becker, E. B., Howell, J., Kodama, Y., Barker, P. A., & Bonni, A. (2004). Characterization 
of the c-Jun N-terminal kinase-BimEL signaling pathway in neuronal apoptosis. J 
Neurosci, 24(40), 8762-8770. doi:10.1523/jneurosci.2953-04.2004 
Bell, D., Bell, A. H., Bondaruk, J., Hanna, E. Y., & Weber, R. S. (2016). In-depth 
characterization of the salivary adenoid cystic carcinoma transcriptome with 
emphasis on dominant cell type. Cancer, 122(10), 1513-1522. 
doi:10.1002/cncr.29959 
  257 
Bender, T. P., Thompson, C. B., & Kuehl, W. M. (1987). Differential expression of c-myb 
mRNA in murine B lymphomas by a block to transcription elongation. Science, 
237(4821), 1473-1476.  
Benedetti, M., Levi, A., & Chao, M. V. (1993). Differential expression of nerve growth 
factor receptors leads to altered binding affinity and neurotrophin 
responsiveness. Proc Natl Acad Sci U S A, 90(16), 7859-7863.  
Bengtsen, M., Klepper, K., Gundersen, S., Cuervo, I., Drablos, F., Hovig, E., Sandve, G. 
K., Gabrielsen, O. S., & Eskeland, R. (2015). c-Myb Binding Sites in 
Haematopoietic Chromatin Landscapes. PLoS One, 10(7), e0133280. 
doi:10.1371/journal.pone.0133280 
Bergholtz, S., Andersen, T. O., Andersson, K. B., Borrebaek, J., Luscher, B., & 
Gabrielsen, O. S. (2001). The highly conserved DNA-binding domains of A-, B- 
and c-Myb differ with respect to DNA-binding, phosphorylation and redox 
properties. Nucleic Acids Res, 29(17), 3546-3556.  
Beug, H., Blundell, P. A., & Graf, T. (1987). Reversibility of differentiation and 
proliferative capacity in avian myelomonocytic cells transformed by tsE26 
leukemia virus. Genes Dev, 1(3), 277-286.  
Beug, H., von Kirchbach, A., Doderlein, G., Conscience, J. F., & Graf, T. (1979). Chicken 
hematopoietic cells transformed by seven strains of defective avian leukemia 
viruses display three distinct phenotypes of differentiation. Cell, 18(2), 375-390.  
Bewry, N. N., Nair, R. R., Emmons, M. F., Boulware, D., Pinilla-Ibarz, J., & Hazlehurst, L. 
A. (2008). Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone 
marrow microenvironment model of drug resistance. Mol Cancer Ther, 7(10), 
3169-3175. doi:10.1158/1535-7163.mct-08-0314 
Bhakar, A. L., Howell, J. L., Paul, C. E., Salehi, A. H., Becker, E. B., Said, F., Bonni, A., & 
Barker, P. A. (2003). Apoptosis induced by p75NTR overexpression requires Jun 
kinase-dependent phosphorylation of Bad. J Neurosci, 23(36), 11373-11381.  
Bibel, M., Hoppe, E., & Barde, Y. A. (1999). Biochemical and functional interactions 
between the neurotrophin receptors trk and p75NTR. EMBO J, 18(3), 616-622. 
doi:10.1093/emboj/18.3.616 
Bies, J., Markus, J., & Wolff, L. (2002). Covalent attachment of the SUMO-1 protein to 
the negative regulatory domain of the c-Myb transcription factor modifies its 
stability and transactivation capacity. J Biol Chem, 277(11), 8999-9009. 
doi:10.1074/jbc.M110453200 
Bies, J., & Wolff, L. (1997). Oncogenic activation of c-Myb by carboxyl-terminal 
truncation leads to decreased proteolysis by the ubiquitin-26S proteasome 
pathway. Oncogene, 14(2), 203-212. doi:10.1038/sj.onc.1200828 
Biggs, P. J., Chapman, P., Lakhani, S. R., Burn, J., & Stratton, M. R. (1996). The 
cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour 
suppressor gene involved in the development of cylindromas. Oncogene, 12(6), 
1375-1377.  
Bignell, G. R., Warren, W., Seal, S., Takahashi, M., Rapley, E., Barfoot, R., Green, H., 
Brown, C., Biggs, P. J., Lakhani, S. R., Jones, C., Hansen, J., Blair, E., Hofmann, B., 
Siebert, R., Turner, G., Evans, D. G., Schrander-Stumpel, C., Beemer, F. A., van 
Den Ouweland, A., Halley, D., Delpech, B., Cleveland, M. G., Leigh, I., Leisti, J., & 
Rasmussen, S. (2000). Identification of the familial cylindromatosis tumour-
suppressor gene. Nat Genet, 25(2), 160-165. doi:10.1038/76006 
  258 
Bikle, D. D., Xie, Z., & Tu, C. L. (2012). Calcium regulation of keratinocyte 
differentiation. Expert Rev Endocrinol Metab, 7(4), 461-472. 
doi:10.1586/eem.12.34 
Birgersdotter, A., Sandberg, R., & Ernberg, I. (2005). Gene expression perturbation in 
vitro--a growing case for three-dimensional (3D) culture systems. Semin Cancer 
Biol, 15(5), 405-412. doi:10.1016/j.semcancer.2005.06.009 
Blake, P. W., & Toro, J. R. (2009). Update of cylindromatosis gene (CYLD) mutations in 
Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in 
cell signaling. Hum Mutat, 30(7), 1025-1036. doi:10.1002/humu.21024 
Blanpain, C., & Fuchs, E. (2006). Epidermal stem cells of the skin. Annu Rev Cell Dev 
Biol, 22, 339-373. doi:10.1146/annurev.cellbio.22.010305.104357 
Bodo, E., Biro, T., Telek, A., Czifra, G., Griger, Z., Toth, B. I., Mescalchin, A., Ito, T., 
Bettermann, A., Kovacs, L., & Paus, R. (2005). A hot new twist to hair biology: 
involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair 
growth control. Am J Pathol, 166(4), 985-998. doi:10.1016/s0002-
9440(10)62320-6 
Boeshore, K. L., Luckey, C. N., Zigmond, R. E., & Large, T. H. (1999). TrkB isoforms with 
distinct neurotrophin specificities are expressed in predominantly 
nonoverlapping populations of avian dorsal root ganglion neurons. Journal of 
Neuroscience, 19(12), 4739-4747.  
Bokhari, M., Carnachan, R. J., Cameron, N. R., & Przyborski, S. A. (2007). Culture of 
HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell 
structure and function during toxicological challenge. J Anat, 211(4), 567-576. 
doi:10.1111/j.1469-7580.2007.00778.x 
Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V. B., 
Sharpe, H. J., McKee, T., Letourneau, A., Ribaux, P. G., Popadin, K., Basset-
Seguin, N., Ben Chaabene, R., Santoni, F. A., Andrianova, M. A., Guipponi, M., 
Garieri, M., Verdan, C., Grosdemange, K., Sumara, O., Eilers, M., Aifantis, I., 
Michielin, O., de Sauvage, F. J., Antonarakis, S. E., & Nikolaev, S. I. (2016). 
Genomic analysis identifies new drivers and progression pathways in skin basal 
cell carcinoma. Nat Genet, 48(4), 398-406. doi:10.1038/ng.3525 
Borik, L., Heller, P., Shrivastava, M., & Kazlouskaya, V. (2015). Malignant cylindroma in 
a patient with Brooke-Spiegler syndrome. Dermatol Pract Concept, 5(2), 61-65. 
doi:10.5826/dpc.0502a09 
Botchkarev, V. A., Botchkarev, N. V., Albers, K. M., van der Veen, C., Lewin, G. R., & 
Paus, R. (1998). Neurotrophin-3 involvement in the regulation of hair follicle 
morphogenesis. J Invest Dermatol, 111(2), 279-285. doi:10.1046/j.1523-
1747.1998.00277.x 
Botchkarev, V. A., Botchkareva, N. V., Peters, E. M., & Paus, R. (2004). Epithelial growth 
control by neurotrophins: leads and lessons from the hair follicle. Prog Brain 
Res, 146, 493-513. doi:10.1016/s0079-6123(03)46031-7 
Botchkarev, V. A., Metz, M., Botchkareva, N. V., Welker, P., Lommatzsch, M., Renz, H., 
& Paus, R. (1999). Brain-derived neurotrophic factor, neurotrophin-3, and 
neurotrophin-4 act as "epitheliotrophins" in murine skin. Lab Invest, 79(5), 557-
572.  
Botchkarev, V. A., Yaar, M., Peters, E. M. J., Raychaudhuri, S. P., Botchkareva, N. V., 
Marconi, A., Raychaudhuri, S. K., Paus, R., & Pincelli, C. (2006). Neurotrophins in 
skin biology and pathology. Journal of Investigative Dermatology, 126(8), 1719-
1727.  
  259 
Botchkareva, N. V., Botchkarev, V. A., Albers, K. M., Metz, M., & Paus, R. (2000). 
Distinct roles for nerve growth factor and brain-derived neurotrophic factor in 
controlling the rate of hair follicle morphogenesis. J Invest Dermatol, 114(2), 
314-320. doi:10.1046/j.1523-1747.2000.00864.x 
Botchkareva, N. V., Botchkarev, V. A., Chen, L. H., Lindner, G., & Paus, R. (1999). A role 
for p75 neurotrophin receptor in the control of hair follicle morphogenesis. Dev 
Biol, 216(1), 135-153. doi:10.1006/dbio.1999.9464 
Bothwell, M. (1997). Neurotrophin function in skin. J Investig Dermatol Symp Proc, 
2(1), 27-30.  
Boukamp, P., Petrussevska, R. T., Breitkreutz, D., Hornung, J., Markham, A., & Fusenig, 
N. E. (1988). Normal keratinization in a spontaneously immortalized aneuploid 
human keratinocyte cell line. J Cell Biol, 106(3), 761-771.  
Boyce, S. T., & Ham, R. G. (1983). Calcium-regulated differentiation of normal human 
epidermal keratinocytes in chemically defined clonal culture and serum-free 
serial culture. J Invest Dermatol, 81(1 Suppl), 33s-40s.  
Boyer, L. A., Latek, R. R., & Peterson, C. L. (2004). The SANT domain: a unique histone-
tail-binding module? Nat Rev Mol Cell Biol, 5(2), 158-163. doi:10.1038/nrm1314 
Brabender, J., Lord, R. V., Danenberg, K. D., Metzger, R., Schneider, P. M., Park, J. M., 
Salonga, D., Groshen, S., Tsao-Wei, D. D., DeMeester, T. R., Holscher, A. H., & 
Danenberg, P. V. (2001). Increased c-myb mRNA expression in Barrett's 
esophagus and Barrett's-associated adenocarcinoma. J Surg Res, 99(2), 301-
306. doi:10.1006/jsre.2001.6186 
Brahimi, F., Maira, M., Barcelona, P. F., Galan, A., Aboulkassim, T., Teske, K., Rogers, M. 
L., Bertram, L., Wang, J., Yousefi, M., Rush, R., Fabian, M., Cashman, N., & 
Saragovi, H. U. (2016). The Paradoxical Signals of Two TrkC Receptor Isoforms 
Supports a Rationale for Novel Therapeutic Strategies in ALS. PLoS One, 11(10), 
e0162307. doi:10.1371/journal.pone.0162307 
Brann, A. B., Tcherpakov, M., Williams, I. M., Futerman, A. H., & Fainzilber, M. (2002). 
Nerve growth factor-induced p75-mediated death of cultured hippocampal 
neurons is age-dependent and transduced through ceramide generated by 
neutral sphingomyelinase. J Biol Chem, 277(12), 9812-9818. 
doi:10.1074/jbc.M109862200 
Brayer, K. J., Frerich, C. A., Kang, H., & Ness, S. A. (2016). Recurrent Fusions in MYB and 
MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in 
Salivary Gland Adenoid Cystic Carcinoma. Cancer Discov, 6(2), 176-187. 
doi:10.1158/2159-8290.cd-15-0859 
Breslin, S., & O'Driscoll, L. (2013). Three-dimensional cell culture: the missing link in 
drug discovery. Drug Discov Today, 18(5-6), 240-249. 
doi:10.1016/j.drudis.2012.10.003 
Brigadski, T., Hartmann, M., & Lessmann, V. (2005). Differential vesicular targeting and 
time course of synaptic secretion of the mammalian neurotrophins. J Neurosci, 
25(33), 7601-7614. doi:10.1523/jneurosci.1776-05.2005 
Brodie, C., Oshiba, A., Renz, H., Bradley, K., & Gelfand, E. W. (1996). Nerve growth-
factor and anti-CD40 provide opposite signals for the production of IgE in 
interleukin-4-treated lymphocytes. Eur J Immunol, 26(1), 171-178. 
doi:10.1002/eji.1830260127 
Bruckner-Tuderman, L., Pfaltz, M., & Schnyder, U. W. (1991). Cylindroma 
overexpresses collagen VII, the major anchoring fibril protein. J Invest 
Dermatol, 96(5), 729-734.  
  260 
Brummelkamp, T. R., Nijman, S. M., Dirac, A. M., & Bernards, R. (2003). Loss of the 
cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. 
Nature, 424(6950), 797-801. doi:10.1038/nature01811 
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., 
Arden, K. C., Blenis, J., & Greenberg, M. E. (1999). Akt promotes cell survival by 
phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96(6), 857-
868.  
Brunet, A., Datta, S. R., & Greenberg, M. E. (2001). Transcription-dependent and -
independent control of neuronal survival by the PI3K-Akt signaling pathway. 
Curr Opin Neurobiol, 11(3), 297-305.  
Bruno, M. A., & Cuello, A. C. (2006). Activity-dependent release of precursor nerve 
growth factor, conversion to mature nerve growth factor, and its degradation 
by a protease cascade. Proc Natl Acad Sci U S A, 103(17), 6735-6740. 
doi:10.1073/pnas.0510645103 
Bubici, C., & Papa, S. (2014). JNK signalling in cancer: in need of new, smarter 
therapeutic targets. Br J Pharmacol, 171(1), 24-37. doi:10.1111/bph.12432 
Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., Hempen, P. 
M., Hilgers, W., Yeo, C. J., Hruban, R. H., & Kern, S. E. (2003). BRAF and FBXW7 
(CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: 
potential therapeutic targets. Am J Pathol, 163(4), 1255-1260. 
doi:10.1016/s0002-9440(10)63485-2 
Canossa, M., Gartner, A., Campana, G., Inagaki, N., & Thoenen, H. (2001). Regulated 
secretion of neurotrophins by metabotropic glutamate group I (mGluRI) and 
Trk receptor activation is mediated via phospholipase C signalling pathways. 
EMBO J, 20(7), 1640-1650. doi:10.1093/emboj/20.7.1640 
Caporali, A., & Emanueli, C. (2009). Cardiovascular actions of neurotrophins. Physiol 
Rev, 89(1), 279-308. doi:10.1152/physrev.00007.2008 
Caporali, A., Sala-Newby, G. B., Meloni, M., Graiani, G., Pani, E., Cristofaro, B., Newby, 
A. C., Madeddu, P., & Emanueli, C. (2008). Identification of the prosurvival 
activity of nerve growth factor on cardiac myocytes. Cell Death Differ, 15(2), 
299-311. doi:10.1038/sj.cdd.4402263 
Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T., & Chao, M. V. (1996). Death of 
oligodendrocytes mediated by the interaction of nerve growth factor with its 
receptor p75. Nature, 383(6602), 716-719. doi:10.1038/383716a0 
Castresana, J. S. (2015). Cancer as a Ciliopathy: The Primary Cilium as a New 
Therapeutic Target. Carcinogenesis and Mutagenesis, 6. doi:10.4172/2517-
2518.1000e119 
Caterina, M. J., & Pang, Z. (2016). TRP Channels in Skin Biology and Pathophysiology. 
Pharmaceuticals (Basel), 9(4). doi:10.3390/ph9040077 
Ceni, C., Kommaddi, R. P., Thomas, R., Vereker, E., Liu, X., McPherson, P. S., Ritter, B., 
& Barker, P. A. (2010). The p75NTR intracellular domain generated by 
neurotrophin-induced receptor cleavage potentiates Trk signaling. J Cell Sci, 
123(Pt 13), 2299-2307. doi:10.1242/jcs.062612 
Cesarz, Z., & Tamama, K. (2016). Spheroid Culture of Mesenchymal Stem Cells. Stem 
Cells Int, 2016, 9176357. doi:10.1155/2016/9176357 
Chan, K. S., Sano, S., Kataoka, K., Abel, E., Carbajal, S., Beltran, L., Clifford, J., Peavey, 
M., Shen, J., & Digiovanni, J. (2008). Forced expression of a constitutively active 
form of Stat3 in mouse epidermis enhances malignant progression of skin 
  261 
tumors induced by two-stage carcinogenesis. Oncogene, 27(8), 1087-1094. 
doi:10.1038/sj.onc.1210726 
Chao, M. V. (2003). Neurotrophins and their receptors: a convergence point for many 
signalling pathways. Nat Rev Neurosci, 4(4), 299-309. doi:10.1038/nrn1078 
Chao, M. V., & Hempstead, B. L. (1995). p75 and Trk: a two-receptor system. Trends 
Neurosci, 18(7), 321-326.  
Cheasley, D., Pereira, L., Lightowler, S., Vincan, E., Malaterre, J., & Ramsay, R. G. 
(2011). Myb controls intestinal stem cell genes and self-renewal. Stem Cells, 
29(12), 2042-2050. doi:10.1002/stem.761 
Chen, B., Liang, Y., He, Z., An, Y., Zhao, W., & Wu, J. (2016). Autocrine activity of BDNF 
induced by the STAT3 signaling pathway causes prolonged TrkB activation and 
promotes human non-small-cell lung cancer proliferation. Sci Rep, 6, 30404. 
doi:10.1038/srep30404 
Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., & Ingber, D. E. (1997). 
Geometric control of cell life and death. Science, 276(5317), 1425-1428.  
Chen, S., Wang, Z., Dai, X., Pan, J., Ge, J., Han, X., Wu, Z., Zhou, X., & Zhao, T. (2013). 
Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma 
differentiation by modulating c-Myb in vitro. Cancer Sci, 104(7), 826-834. 
doi:10.1111/cas.12156 
Chen, Z. Y., Ieraci, A., Tanowitz, M., & Lee, F. S. (2005). A novel endocytic recycling 
signal distinguishes biological responses of Trk neurotrophin receptors. Mol 
Biol Cell, 16(12), 5761-5772. doi:10.1091/mbc.E05-07-0651 
Chitcholtan, K., Sykes, P. H., & Evans, J. J. (2012). The resistance of intracellular 
mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial 
cancer. J Transl Med, 10, 38. doi:10.1186/1479-5876-10-38 
Choi, D. Y., Toledo-Aral, J. J., Segal, R., & Halegoua, S. (2001). Sustained signaling by 
phospholipase C-gamma mediates nerve growth factor-triggered gene 
expression. Mol Cell Biol, 21(8), 2695-2705. doi:10.1128/mcb.21.8.2695-
2705.2001 
Clague, M. J., & Urbe, S. (2010). Ubiquitin: same molecule, different degradation 
pathways. Cell, 143(5), 682-685. doi:10.1016/j.cell.2010.11.012 
Clappier, E., Cuccuini, W., Kalota, A., Crinquette, A., Cayuela, J. M., Dik, W. A., 
Langerak, A. W., Montpellier, B., Nadel, B., Walrafen, P., Delattre, O., Aurias, A., 
Leblanc, T., Dombret, H., Gewirtz, A. M., Baruchel, A., Sigaux, F., & Soulier, J. 
(2007). The C-MYB locus is involved in chromosomal translocation and genomic 
duplications in human T-cell acute leukemia (T-ALL), the translocation defining 
a new T-ALL subtype in very young children. Blood, 110(4), 1251-1261. 
doi:10.1182/blood-2006-12-064683 
Clary, D. O., & Reichardt, L. F. (1994). An alternatively spliced form of the nerve growth 
factor receptor TrkA confers an enhanced response to neurotrophin 3. Proc 
Natl Acad Sci U S A, 91(23), 11133-11137.  
Clement, C. A., Ajbro, K. D., Koefoed, K., Vestergaard, M. L., Veland, I. R., Henriques de 
Jesus, M. P., Pedersen, L. B., Benmerah, A., Andersen, C. Y., Larsen, L. A., & 
Christensen, S. T. (2013). TGF-beta signaling is associated with endocytosis at 
the pocket region of the primary cilium. Cell Rep, 3(6), 1806-1814. 
doi:10.1016/j.celrep.2013.05.020 
Close, J., Game, L., Clark, B., Bergounioux, J., Gerovassili, A., & Thein, S. L. (2004). 
Genome annotation of a 1.5 Mb region of human chromosome 6q23 
  262 
encompassing a quantitative trait locus for fetal hemoglobin expression in 
adults. BMC Genomics, 5(1), 33. doi:10.1186/1471-2164-5-33 
Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K., & Baldwin, A. S., Jr. (2000). 
Selective activation of NF-kappa B subunits in human breast cancer: potential 
roles for NF-kappa B2/p52 and for Bcl-3. Oncogene, 19(9), 1123-1131. 
doi:10.1038/sj.onc.1203412 
Conover, J. C., Erickson, J. T., Katz, D. M., Bianchi, L. M., Poueymirou, W. T., McClain, J., 
Pan, L., Helgren, M., Ip, N. Y., Boland, P., & et al. (1995). Neuronal deficits, not 
involving motor neurons, in mice lacking BDNF and/or NT4. Nature, 375(6528), 
235-238. doi:10.1038/375235a0 
Costa, E. C., Moreira, A. F., de Melo-Diogo, D., Gaspar, V. M., Carvalho, M. P., & 
Correia, I. J. (2016). 3D tumor spheroids: an overview on the tools and 
techniques used for their analysis. Biotechnol Adv, 34(8), 1427-1441. 
doi:10.1016/j.biotechadv.2016.11.002 
Cotton, D. W., & Braye, S. G. (1984). Dermal cylindromas originate from the eccrine 
sweat gland. Br J Dermatol, 111(1), 53-61.  
Coulombe, P. A., Kopan, R., & Fuchs, E. (1989). Expression of keratin K14 in the 
epidermis and hair follicle: insights into complex programs of differentiation. J 
Cell Biol, 109(5), 2295-2312.  
Crain, R. C., & Helwig, E. B. (1961). Dermal cylindroma (dermal eccrine cylindroma). Am 
J Clin Pathol, 35, 504-515.  
Creighton, C., Kuick, R., Misek, D. E., Rickman, D. S., Brichory, F. M., Rouillard, J. M., 
Omenn, G. S., & Hanash, S. (2003). Profiling of pathway-specific changes in 
gene expression following growth of human cancer cell lines transplanted into 
mice. Genome Biol, 4(7), R46. doi:10.1186/gb-2003-4-7-r46 
Crowley, C., Spencer, S. D., Nishimura, M. C., Chen, K. S., Pitts-Meek, S., Armanini, M. 
P., Ling, L. H., McMahon, S. B., Shelton, D. L., Levinson, A. D., & et al. (1994). 
Mice lacking nerve growth factor display perinatal loss of sensory and 
sympathetic neurons yet develop basal forebrain cholinergic neurons. Cell, 
76(6), 1001-1011.  
Cunningham, M. E., & Greene, L. A. (1998). A function-structure model for NGF-
activated TRK. EMBO J, 17(24), 7282-7293. doi:10.1093/emboj/17.24.7282 
Cures, A., House, C., Kanei-Ishii, C., Kemp, B., & Ramsay, R. G. (2001). Constitutive c-
Myb amino-terminal phosphorylation and DNA binding activity uncoupled 
during entry and passage through the cell cycle. Oncogene, 20(14), 1784-1792. 
doi:10.1038/sj.onc.1204345 
Daa, T., Nakamura, I., Yada, N., Arakane, S., Nishida, H., Kashima, K., Suzuki, M., & 
Yokoyama, S. (2013). PLAG1 and CYLD do not play a role in the tumorigenesis of 
adenoid cystic carcinoma. Mol Med Rep, 7(4), 1086-1090. 
doi:10.3892/mmr.2013.1311 
Dai, P., Akimaru, H., Tanaka, Y., Hou, D. X., Yasukawa, T., Kanei-Ishii, C., Takahashi, T., 
& Ishii, S. (1996). CBP as a transcriptional coactivator of c-Myb. Genes Dev, 
10(5), 528-540.  
Dai, Y. H., Hung, L. Y., Chen, R. Y., Lai, C. H., & Chang, K. C. (2016). ON 01910.Na inhibits 
growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of 
sumoylated C-MYB/TRAF6 complex. Transl Res, 175, 129-143.e113. 
doi:10.1016/j.trsl.2016.04.001 
Darnell, J. E., Jr. (1997). STATs and gene regulation. Science, 277(5332), 1630-1635.  
  263 
Darnell, J. E., Jr., Kerr, I. M., & Stark, G. R. (1994). Jak-STAT pathways and 
transcriptional activation in response to IFNs and other extracellular signaling 
proteins. Science, 264(5164), 1415-1421.  
Dash, A. B., Orrico, F. C., & Ness, S. A. (1996). The EVES motif mediates both 
intermolecular and intramolecular regulation of c-Myb. Genes Dev, 10(15), 
1858-1869.  
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. 
(1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic 
death machinery. Cell, 91(2), 231-241.  
Davis, B. M., Fundin, B. T., Albers, K. M., Goodness, T. P., Cronk, K. M., & Rice, F. L. 
(1997). Overexpression of nerve growth factor in skin causes preferential 
increases among innervation to specific sensory targets. J Comp Neurol, 387(4), 
489-506.  
Davis, F. M., Azimi, I., Faville, R. A., Peters, A. A., Jalink, K., Putney, J. W., Jr., Goodhill, 
G. J., Thompson, E. W., Roberts-Thomson, S. J., & Monteith, G. R. (2014). 
Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is 
calcium signal dependent. Oncogene, 33(18), 2307-2316. 
doi:10.1038/onc.2013.187 
Davis, R. J. (2000). Signal transduction by the JNK group of MAP kinases. Cell, 103(2), 
239-252.  
Deinhardt, K., & Chao, M. V. (2014). Trk receptors. Handb Exp Pharmacol, 220, 103-
119. doi:10.1007/978-3-642-45106-5_5 
Descargues, P., Sil, A. K., & Karin, M. (2008). IKKalpha, a critical regulator of epidermal 
differentiation and a suppressor of skin cancer. EMBO J, 27(20), 2639-2647. 
doi:10.1038/emboj.2008.196 
Dhiman, H. K., Ray, A. R., & Panda, A. K. (2005). Three-dimensional chitosan scaffold-
based MCF-7 cell culture for the determination of the cytotoxicity of tamoxifen. 
Biomaterials, 26(9), 979-986. doi:10.1016/j.biomaterials.2004.04.012 
Di Marco, E., Marchisio, P. C., Bondanza, S., Franzi, A. T., Cancedda, R., & De Luca, M. 
(1991). Growth-regulated synthesis and secretion of biologically active nerve 
growth factor by human keratinocytes. Journal of Biological Chemistry, 266(32), 
21718-21722.  
Di Marco, E., Mathort, M., Bondanza, S., Cutuli, N., Marchisio, P. C., Cancedda, R., & De 
Luca, M. (1993). Nerve growth factor binds to normal human keratinocytes 
through high and low affinity receptors and stimulates their growth by a novel 
autocrine loop. Journal of Biological Chemistry, 268(30), 22838-22846.  
Dobrowsky, R. T., Werner, M. H., Castellino, A. M., Chao, M. V., & Hannun, Y. A. (1994). 
Activation of the sphingomyelin cycle through the low-affinity neurotrophin 
receptor. Science, 265(5178), 1596-1599.  
Donovan, M. J., Hahn, R., Tessarollo, L., & Hempstead, B. L. (1996). Identification of an 
essential nonneuronal function of neurotrophin 3 in mammalian cardiac 
development. Nat Genet, 14(2), 210-213. doi:10.1038/ng1096-210 
Donovan, M. J., Lin, M. I., Wiegn, P., Ringstedt, T., Kraemer, R., Hahn, R., Wang, S., 
Ibanez, C. F., Rafii, S., & Hempstead, B. L. (2000). Brain derived neurotrophic 
factor is an endothelial cell survival factor required for intramyocardial vessel 
stabilization. Development, 127(21), 4531-4540.  
Drabsch, Y., Hugo, H., Zhang, R., Dowhan, D. H., Miao, Y. R., Gewirtz, A. M., Barry, S. C., 
Ramsay, R. G., & Gonda, T. J. (2007). Mechanism of and requirement for 
estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer 
  264 
cells. Proc Natl Acad Sci U S A, 104(34), 13762-13767. 
doi:10.1073/pnas.0700104104 
Drier, Y., Cotton, M. J., Williamson, K. E., Gillespie, S. M., Ryan, R. J., Kluk, M. J., Carey, 
C. D., Rodig, S. J., Sholl, L. M., Afrogheh, A. H., Faquin, W. C., Queimado, L., Qi, 
J., Wick, M. J., El-Naggar, A. K., Bradner, J. E., Moskaluk, C. A., Aster, J. C., 
Knoechel, B., & Bernstein, B. E. (2016). An oncogenic MYB feedback loop drives 
alternate cell fates in adenoid cystic carcinoma. Nat Genet, 48(3), 265-272. 
doi:10.1038/ng.3502 
Dubois, A., Hodgson, K., & Rajan, N. (2017). Understanding Inherited Cylindromas: 
Clinical Implications of Gene Discovery. Dermatol Clin, 35(1), 61-71. 
doi:10.1016/j.det.2016.08.002 
DuBridge, R. B., Tang, P., Hsia, H. C., Leong, P. M., Miller, J. H., & Calos, M. P. (1987). 
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle 
system. Mol Cell Biol, 7(1), 379-387.  
Durani, B. K., Kurzen, H., Jaeckel, A., Kuner, N., Naeher, H., & Hartschuh, W. (2001). 
Malignant transformation of multiple dermal cylindromas. Br J Dermatol, 
145(4), 653-656.  
Dwane, L., Gallagher, W. M., Ni Chonghaile, T., & O'Connor, D. P. (2017). The Emerging 
Role of Non-traditional Ubiquitination in Oncogenic Pathways. J Biol Chem, 
292(9), 3543-3551. doi:10.1074/jbc.R116.755694 
Eales, K. L., Hollinshead, K. E., & Tennant, D. A. (2016). Hypoxia and metabolic 
adaptation of cancer cells. Oncogenesis, 5, e190. doi:10.1038/oncsis.2015.50 
Easton, J. B., Royer, A. R., & Middlemas, D. S. (2006). The protein tyrosine 
phosphatase, Shp2, is required for the complete activation of the RAS/MAPK 
pathway by brain-derived neurotrophic factor. J Neurochem, 97(3), 834-845. 
doi:10.1111/j.1471-4159.2006.03789.x 
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014). Three-dimensional cell 
culture systems and their applications in drug discovery and cell-based 
biosensors. Assay Drug Dev Technol, 12(4), 207-218. doi:10.1089/adt.2014.573 
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., 
Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B., & Weinberger, D. R. (2003). 
The BDNF val66met polymorphism affects activity-dependent secretion of 
BDNF and human memory and hippocampal function. Cell, 112(2), 257-269.  
Eguether, T., Ermolaeva, M. A., Zhao, Y., Bonnet, M. C., Jain, A., Pasparakis, M., 
Courtois, G., & Tassin, A. M. (2014). The deubiquitinating enzyme CYLD controls 
apical docking of basal bodies in ciliated epithelial cells. Nat Commun, 5, 4585. 
doi:10.1038/ncomms5585 
Eide, F. F., Vining, E. R., Eide, B. L., Zang, K., Wang, X. Y., & Reichardt, L. F. (1996). 
Naturally occurring truncated trkB receptors have dominant inhibitory effects 
on brain-derived neurotrophic factor signaling. J Neurosci, 16(10), 3123-3129.  
Emambokus, N., Vegiopoulos, A., Harman, B., Jenkinson, E., Anderson, G., & Frampton, 
J. (2003). Progression through key stages of haemopoiesis is dependent on 
distinct threshold levels of c-Myb. EMBO J, 22(17), 4478-4488. 
doi:10.1093/emboj/cdg434 
Ernfors, P., Lee, K. F., & Jaenisch, R. (1994). Mice lacking brain-derived neurotrophic 
factor develop with sensory deficits. Nature, 368(6467), 147-150. 
doi:10.1038/368147a0 
  265 
Ernfors, P., Lee, K. F., Kucera, J., & Jaenisch, R. (1994). Lack of neurotrophin-3 leads to 
deficiencies in the peripheral nervous system and loss of limb proprioceptive 
afferents. Cell, 77(4), 503-512.  
Espinosa, L., Cathelin, S., D'Altri, T., Trimarchi, T., Statnikov, A., Guiu, J., Rodilla, V., 
Ingles-Esteve, J., Nomdedeu, J., Bellosillo, B., Besses, C., Abdel-Wahab, O., 
Kucine, N., Sun, S. C., Song, G., Mullighan, C. C., Levine, R. L., Rajewsky, K., 
Aifantis, I., & Bigas, A. (2010). The Notch/Hes1 pathway sustains NF-kappaB 
activation through CYLD repression in T cell leukemia. Cancer Cell, 18(3), 268-
281. doi:10.1016/j.ccr.2010.08.006 
Esposito, D., Patel, P., Stephens, R. M., Perez, P., Chao, M. V., Kaplan, D. R., & 
Hempstead, B. L. (2001). The cytoplasmic and transmembrane domains of the 
p75 and Trk A receptors regulate high affinity binding to nerve growth factor. J 
Biol Chem, 276(35), 32687-32695. doi:10.1074/jbc.M011674200 
Evangelopoulos, M. E., Weis, J., & Kruttgen, A. (2004). Neurotrophin effects on 
neuroblastoma cells: correlation with trk and p75NTR expression and influence 
of Trk receptor bodies. J Neurooncol, 66(1-2), 101-110.  
Evans, C. D. (1954). Turban tumour. Br J Dermatol, 66(12), 434-443.  
Ezratty, E. J., Stokes, N., Chai, S., Shah, A. S., Williams, S. E., & Fuchs, E. (2011). A role 
for the primary cilium in Notch signaling and epidermal differentiation during 
skin development. Cell, 145(7), 1129-1141. doi:10.1016/j.cell.2011.05.030 
Fang, Y., & Eglen, R. M. (2017). Three-Dimensional Cell Cultures in Drug Discovery and 
Development. SLAS Discov, 22(5), 456-472. doi:10.1177/1087057117696795 
Farinas, I., Wilkinson, G. A., Backus, C., Reichardt, L. F., & Patapoutian, A. (1998). 
Characterization of neurotrophin and Trk receptor functions in developing 
sensory ganglia: direct NT-3 activation of TrkB neurons in vivo. Neuron, 21(2), 
325-334.  
Favier, D., & Gonda, T. J. (1994). Detection of proteins that bind to the leucine zipper 
motif of c-Myb. Oncogene, 9(1), 305-311.  
Fehr, A., Kovacs, A., Loning, T., Frierson, H., Jr., van den Oord, J., & Stenman, G. (2011). 
The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic 
carcinoma and dermal cylindroma. J Pathol, 224(3), 322-327. 
doi:10.1002/path.2909 
Feng, D., Kim, T., Ozkan, E., Light, M., Torkin, R., Teng, K. K., Hempstead, B. L., & Garcia, 
K. C. (2010). Molecular and structural insight into proNGF engagement of 
p75NTR and sortilin. J Mol Biol, 396(4), 967-984. doi:10.1016/j.jmb.2009.12.030 
Fenner, B. M. (2012). Truncated TrkB: beyond a dominant negative receptor. Cytokine 
Growth Factor Rev, 23(1-2), 15-24. doi:10.1016/j.cytogfr.2012.01.002 
Fisher, G. H., & Geronemus, R. G. (2006). Treatment of multiple familial 
trichoepitheliomas with a combination of aspirin and a neutralizing antibody to 
tumor necrosis factor alpha: A case report and hypothesis of mechanism. Arch 
Dermatol, 142(6), 782-783. doi:10.1001/archderm.142.6.782 
Foos, G., Natour, S., & Klempnauer, K. H. (1993). TATA-box dependent trans-activation 
of the human HSP70 promoter by Myb proteins. Oncogene, 8(7), 1775-1782.  
Frade, J. M., Rodriguez-Tebar, A., & Barde, Y. A. (1996). Induction of cell death by 
endogenous nerve growth factor through its p75 receptor. Nature, 383(6596), 
166-168. doi:10.1038/383166a0 
Frasor, J., Danes, J. M., Komm, B., Chang, K. C., Lyttle, C. R., & Katzenellenbogen, B. S. 
(2003). Profiling of estrogen up- and down-regulated gene expression in human 
breast cancer cells: insights into gene networks and pathways underlying 
  266 
estrogenic control of proliferation and cell phenotype. Endocrinology, 144(10), 
4562-4574. doi:10.1210/en.2003-0567 
Friedman, C. S., O'Donnell, M. A., Legarda-Addison, D., Ng, A., Cardenas, W. B., Yount, 
J. S., Moran, T. M., Basler, C. F., Komuro, A., Horvath, C. M., Xavier, R., & Ting, 
A. T. (2008). The tumour suppressor CYLD is a negative regulator of RIG-I-
mediated antiviral response. EMBO Rep, 9(9), 930-936. 
doi:10.1038/embor.2008.136 
Frith, J. E., Thomson, B., & Genever, P. G. (2010). Dynamic three-dimensional culture 
methods enhance mesenchymal stem cell properties and increase therapeutic 
potential. Tissue Eng Part C Methods, 16(4), 735-749. 
doi:10.1089/ten.TEC.2009.0432 
Fu, S. L., & Lipsick, J. S. (1997). Constitutive expression of full-length c-Myb transforms 
avian cells characteristic of both the monocytic and granulocytic lineages. Cell 
Growth Differ, 8(1), 35-45.  
Fuchs, E., & Raghavan, S. (2002). Getting under the skin of epidermal morphogenesis. 
Nat Rev Genet, 3(3), 199-209. doi:10.1038/nrg758 
Fujii, A., Matsuyama, K., Mizutani, Y., Kanoh, H., Nakano, H., & Seishima, M. (2017). 
Multiple familial trichoepithelioma with a novel mutation of the CYLD gene. J 
Dermatol. doi:10.1111/1346-8138.13901 
Furuta, Y., Aizawa, S., Suda, Y., Ikawa, Y., Nakasgoshi, H., Nishina, Y., & Ishii, S. (1993). 
Degeneration of skeletal and cardiac muscles in c-myb transgenic mice. 
Transgenic Res, 2(4), 199-207.  
Fusco, N., Colombo, P. E., Martelotto, L. G., De Filippo, M. R., Piscuoglio, S., Ng, C. K., 
Lim, R. S., Jacot, W., Vincent-Salomon, A., Reis-Filho, J. S., & Weigelt, B. (2016). 
Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? 
The role of massively parallel sequencing. Histopathology, 68(2), 262-271. 
doi:10.1111/his.12735 
Gao, J., Huo, L., Sun, X., Liu, M., Li, D., Dong, J. T., & Zhou, J. (2008). The tumor 
suppressor CYLD regulates microtubule dynamics and plays a role in cell 
migration. J Biol Chem, 283(14), 8802-8809. doi:10.1074/jbc.M708470200 
Gao, J., Sun, L., Huo, L., Liu, M., Li, D., & Zhou, J. (2010). CYLD regulates angiogenesis by 
mediating vascular endothelial cell migration. Blood, 115(20), 4130-4137. 
doi:10.1182/blood-2009-10-248526 
Garcia-Suarez, O., Blanco-Gelaz, M. A., Lopez, M. L., Germana, A., Cabo, R., Diaz-Esnal, 
B., Silos-Santiago, I., Ciriaco, E., & Vega, J. A. (2002). Massive lymphocyte 
apoptosis in the thymus of functionally deficient TrkB mice. J Neuroimmunol, 
129(1-2), 25-34.  
Garcia-Suarez, O., Germana, A., Hannestad, J., Ciriaco, E., Laura, R., Naves, J., Esteban, 
I., Silos-Santiago, I., & Vega, J. A. (2000). TrkA is necessary for the normal 
development of the murine thymus. J Neuroimmunol, 108(1-2), 11-21.  
Gees, M., Colsoul, B., & Nilius, B. (2010). The role of transient receptor potential cation 
channels in Ca2+ signaling. Cold Spring Harb Perspect Biol, 2(10), a003962. 
doi:10.1101/cshperspect.a003962 
Geetha, T., Kenchappa, R. S., Wooten, M. W., & Carter, B. D. (2005). TRAF6-mediated 
ubiquitination regulates nuclear translocation of NRIF, the p75 receptor 
interactor. EMBO J, 24(22), 3859-3868. doi:10.1038/sj.emboj.7600845 
Geetha, T., Seibenhener, M. L., Chen, L., Madura, K., & Wooten, M. W. (2008). p62 
serves as a shuttling factor for TrkA interaction with the proteasome. Biochem 
Biophys Res Commun, 374(1), 33-37. doi:10.1016/j.bbrc.2008.06.082 
  267 
Geetha, T., & Wooten, M. W. (2008). TrkA receptor endolysosomal degradation is both 
ubiquitin and proteasome dependent. Traffic, 9(7), 1146-1156. 
doi:10.1111/j.1600-0854.2008.00751.x 
Geiger, T. R., Song, J. Y., Rosado, A., & Peeper, D. S. (2011). Functional characterization 
of human cancer-derived TRKB mutations. PLoS One, 6(2), e16871. 
doi:10.1371/journal.pone.0016871 
Gentry, J. J., Rutkoski, N. J., Burke, T. L., & Carter, B. D. (2004). A functional interaction 
between the p75 neurotrophin receptor interacting factors, TRAF6 and NRIF. J 
Biol Chem, 279(16), 16646-16656. doi:10.1074/jbc.M309209200 
George, O. L., & Ness, S. A. (2014). Situational awareness: regulation of the myb 
transcription factor in differentiation, the cell cycle and oncogenesis. Cancers 
(Basel), 6(4), 2049-2071. doi:10.3390/cancers6042049 
Gerdes, J. M., Liu, Y., Zaghloul, N. A., Leitch, C. C., Lawson, S. S., Kato, M., Beachy, P. A., 
Beales, P. L., DeMartino, G. N., Fisher, S., Badano, J. L., & Katsanis, N. (2007). 
Disruption of the basal body compromises proteasomal function and perturbs 
intracellular Wnt response. Nat Genet, 39(11), 1350-1360. 
doi:10.1038/ng.2007.12 
Gerretsen, A. L., Beemer, F. A., Deenstra, W., Hennekam, F. A., & van Vloten, W. A. 
(1995). Familial cutaneous cylindromas: investigations in five generations of a 
family. J Am Acad Dermatol, 33(2 Pt 1), 199-206.  
Gerretsen, A. L., van der Putte, S. C., Deenstra, W., & van Vloten, W. A. (1993). 
Cutaneous cylindroma with malignant transformation. Cancer, 72(5), 1618-
1623.  
Ghosh, S., Spagnoli, G. C., Martin, I., Ploegert, S., Demougin, P., Heberer, M., & 
Reschner, A. (2005). Three-dimensional culture of melanoma cells profoundly 
affects gene expression profile: a high density oligonucleotide array study. J Cell 
Physiol, 204(2), 522-531. doi:10.1002/jcp.20320 
Gilberto, S., & Peter, M. (2017). Dynamic ubiquitin signaling in cell cycle regulation. J 
Cell Biol, 216(8), 2259-2271. doi:10.1083/jcb.201703170 
Goetz, S. C., & Anderson, K. V. (2010). The primary cilium: a signalling centre during 
vertebrate development. Nat Rev Genet, 11(5), 331-344. doi:10.1038/nrg2774 
Gonda, T. J., Buckmaster, C., & Ramsay, R. G. (1989). Activation of c-myb by carboxy-
terminal truncation: relationship to transformation of murine haemopoietic 
cells in vitro. EMBO J, 8(6), 1777-1783.  
Gong, Y., Cao, P., Yu, H. J., & Jiang, T. (2008). Crystal structure of the neurotrophin-3 
and p75NTR symmetrical complex. Nature, 454(7205), 789-793. 
doi:10.1038/nature07089 
Gottardi, C. J., & Gumbiner, B. M. (2004). Distinct molecular forms of beta-catenin are 
targeted to adhesive or transcriptional complexes. J Cell Biol, 167(2), 339-349. 
doi:10.1083/jcb.200402153 
Graham, F. L., Smiley, J., Russell, W. C., & Nairn, R. (1977). Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5. J Gen Virol, 36(1), 
59-74. doi:10.1099/0022-1317-36-1-59 
Grasser, F. A., Graf, T., & Lipsick, J. S. (1991). Protein truncation is required for the 
activation of the c-myb proto-oncogene. Mol Cell Biol, 11(8), 3987-3996.  
Greig, K. T., de Graaf, C. A., Murphy, J. M., Carpinelli, M. R., Pang, S. H., Frampton, J., 
Kile, B. T., Hilton, D. J., & Nutt, S. L. (2010). Critical roles for c-Myb in lymphoid 
priming and early B-cell development. Blood, 115(14), 2796-2805. 
doi:10.1182/blood-2009-08-239210 
  268 
Grossmann, P., Vanecek, T., Steiner, P., Kacerovska, D., Spagnolo, D. V., Cribier, B., 
Rose, C., Vazmitel, M., Carlson, J. A., Emberger, M., Martinek, P., Pearce, R. L., 
Pearn, J., Michal, M., & Kazakov, D. V. (2013). Novel and recurrent germline and 
somatic mutations in a cohort of 67 patients from 48 families with Brooke-
Spiegler syndrome including the phenotypic variant of multiple familial 
trichoepitheliomas and correlation with the histopathologic findings in 379 
biopsy specimens. Am J Dermatopathol, 35(1), 34-44. 
doi:10.1097/DAD.0b013e31824e7658 
Guiton, M., Gunn-Moore, F. J., Glass, D. J., Geis, D. R., Yancopoulos, G. D., & Tavare, J. 
M. (1995). Naturally occurring tyrosine kinase inserts block high affinity binding 
of phospholipase C gamma and Shc to TrkC and neurotrophin-3 signaling. J Biol 
Chem, 270(35), 20384-20390.  
Haapasalo, A., Sipola, I., Larsson, K., Akerman, K. E., Stoilov, P., Stamm, S., Wong, G., & 
Castren, E. (2002). Regulation of TRKB surface expression by brain-derived 
neurotrophic factor and truncated TRKB isoforms. J Biol Chem, 277(45), 43160-
43167. doi:10.1074/jbc.M205202200 
Hadweh, P., Chaitoglou, I., Gravato-Nobre, MJ., Ligoxygakis, P., Mosialos, G., 
Hatzivassiliou, E. (2018). Functional analysis of the C.elegans cyld-1 gene 
reveals extensive similarity with its human homolog. PLoS One, 13(2), 
e0191864. doi: 10.1371/journal.pone.0191864 
Hagihara, K., Nishikawa, T., Sugamata, Y., Song, J., Isobe, T., Taga, T., & Yoshizaki, K. 
(2005). Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum 
amyloid A gene expression. Genes Cells, 10(11), 1051-1063. doi:10.1111/j.1365-
2443.2005.00900.x 
Haglund, K., & Dikic, I. (2005). Ubiquitylation and cell signaling. EMBO J, 24(19), 3353-
3359. doi:10.1038/sj.emboj.7600808 
Hamanoue, M., Middleton, G., Wyatt, S., Jaffray, E., Hay, R. T., & Davies, A. M. (1999). 
p75-mediated NF-kappaB activation enhances the survival response of 
developing sensory neurons to nerve growth factor. Mol Cell Neurosci, 14(1), 
28-40. doi:10.1006/mcne.1999.0770 
Hamburger, A. W., & Salmon, S. E. (1977). Primary bioassay of human tumor stem 
cells. Science, 197(4302), 461-463.  
Harper, S., & Davies, A. M. (1990). NGF mRNA expression in developing cutaneous 
epithelium related to innervation density. Development, 110(2), 515-519.  
Haycock, J. W. (2011). 3D cell culture: a review of current approaches and techniques. 
Methods Mol Biol, 695, 1-15. doi:10.1007/978-1-60761-984-0_1 
He, X. L., & Garcia, K. C. (2004). Structure of nerve growth factor complexed with the 
shared neurotrophin receptor p75. Science, 304(5672), 870-875. 
doi:10.1126/science.1095190 
Headington, J. T., Batsakis, J. G., Beals, T. F., Campbell, T. E., Simmons, J. L., & Stone, 
W. D. (1977). Membranous basal cell adenoma of parotid gland, dermal 
cylindromas, and trichoepitheliomas. Comparative histochemistry and 
ultrastructure. Cancer, 39(6), 2460-2469.  
Hempstead, B. L., Martin-Zanca, D., Kaplan, D. R., Parada, L. F., & Chao, M. V. (1991). 
High-affinity NGF binding requires coexpression of the trk proto-oncogene and 
the low-affinity NGF receptor. Nature, 350(6320), 678-683. 
doi:10.1038/350678a0 
  269 
Hetman, M., Cavanaugh, J. E., Kimelman, D., & Xia, Z. (2000). Role of glycogen synthase 
kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci, 
20(7), 2567-2574.  
Hijiya, N., Zhang, J., Ratajczak, M. Z., Kant, J. A., DeRiel, K., Herlyn, M., Zon, G., & 
Gewirtz, A. M. (1994). Biologic and therapeutic significance of MYB expression 
in human melanoma. Proc Natl Acad Sci U S A, 91(10), 4499-4503.  
Ho, A. S., Kannan, K., Roy, D. M., Morris, L. G., Ganly, I., Katabi, N., Ramaswami, D., 
Walsh, L. A., Eng, S., Huse, J. T., Zhang, J., Dolgalev, I., Huberman, K., Heguy, A., 
Viale, A., Drobnjak, M., Leversha, M. A., Rice, C. E., Singh, B., Iyer, N. G., 
Leemans, C. R., Bloemena, E., Ferris, R. L., Seethala, R. R., Gross, B. E., Liang, Y., 
Sinha, R., Peng, L., Raphael, B. J., Turcan, S., Gong, Y., Schultz, N., Kim, S., 
Chiosea, S., Shah, J. P., Sander, C., Lee, W., & Chan, T. A. (2013). The mutational 
landscape of adenoid cystic carcinoma. Nat Genet, 45(7), 791-798. 
doi:10.1038/ng.2643 
Hoesel, B., & Schmid, J. A. (2013). The complexity of NF-kappaB signaling in 
inflammation and cancer. Mol Cancer, 12, 86. doi:10.1186/1476-4598-12-86 
Holgado-Madruga, M., Moscatello, D. K., Emlet, D. R., Dieterich, R., & Wong, A. J. 
(1997). Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase 
activation and the promotion of cell survival by nerve growth factor. Proc Natl 
Acad Sci U S A, 94(23), 12419-12424.  
Hongisto, V., Jernstrom, S., Fey, V., Mpindi, J. P., Kleivi Sahlberg, K., Kallioniemi, O., & 
Perala, M. (2013). High-throughput 3D screening reveals differences in drug 
sensitivities between culture models of JIMT1 breast cancer cells. PLoS One, 
8(10), e77232. doi:10.1371/journal.pone.0077232 
Hovelmeyer, N., Wunderlich, F. T., Massoumi, R., Jakobsen, C. G., Song, J., Worns, M. 
A., Merkwirth, C., Kovalenko, A., Aumailley, M., Strand, D., Bruning, J. C., Galle, 
P. R., Wallach, D., Fassler, R., & Waisman, A. (2007). Regulation of B cell 
homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med, 
204(11), 2615-2627. doi:10.1084/jem.20070318 
Howe, K. M., Reakes, C. F., & Watson, R. J. (1990). Characterization of the sequence-
specific interaction of mouse c-myb protein with DNA. EMBO J, 9(1), 161-169.  
Huang, E. J., & Reichardt, L. F. (2001). Neurotrophins: roles in neuronal development 
and function. Annu Rev Neurosci, 24, 677-736. 
doi:10.1146/annurev.neuro.24.1.677 
Huang, E. J., & Reichardt, L. F. (2003). Trk receptors: roles in neuronal signal 
transduction. Annu Rev Biochem, 72, 609-642. 
doi:10.1146/annurev.biochem.72.121801.161629 
Huang, E. J., Wilkinson, G. A., Farinas, I., Backus, C., Zang, K., Wong, S. L., & Reichardt, 
L. F. (1999). Expression of Trk receptors in the developing mouse trigeminal 
ganglion: in vivo evidence for NT-3 activation of TrkA and TrkB in addition to 
TrkC. Development, 126(10), 2191-2203.  
Huang, S. H., Zhao, L., Sun, Z. P., Li, X. Z., Geng, Z., Zhang, K. D., Chao, M. V., & Chen, Z. 
Y. (2009). Essential role of Hrs in endocytic recycling of full-length TrkB receptor 
but not its isoform TrkB.T1. J Biol Chem, 284(22), 15126-15136. 
doi:10.1074/jbc.M809763200 
Huebner, K., Isobe, M., Chao, M., Bothwell, M., Ross, A. H., Finan, J., Hoxie, J. A., 
Sehgal, A., Buck, C. R., Lanahan, A., & et al. (1986). The nerve growth factor 
receptor gene is at human chromosome region 17q12-17q22, distal to the 
  270 
chromosome 17 breakpoint in acute leukemias. Proc Natl Acad Sci U S A, 83(5), 
1403-1407.  
Hugo, H., Cures, A., Suraweera, N., Drabsch, Y., Purcell, D., Mantamadiotis, T., Phillips, 
W., Dobrovic, A., Zupi, G., Gonda, T. J., Iacopetta, B., & Ramsay, R. G. (2006). 
Mutations in the MYB intron I regulatory sequence increase transcription in 
colon cancers. Genes Chromosomes Cancer, 45(12), 1143-1154. 
doi:10.1002/gcc.20378 
Hutti, J. E., Shen, R. R., Abbott, D. W., Zhou, A. Y., Sprott, K. M., Asara, J. M., Hahn, W. 
C., & Cantley, L. C. (2009). Phosphorylation of the tumor suppressor CYLD by 
the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell, 
34(4), 461-472. doi:10.1016/j.molcel.2009.04.031 
Ibanez, C. F., & Simi, A. (2012). p75 neurotrophin receptor signaling in nervous system 
injury and degeneration: paradox and opportunity. Trends Neurosci, 35(7), 431-
440. doi:10.1016/j.tins.2012.03.007 
Ichaso, N., Rodriguez, R. E., Martin-Zanca, D., & Gonzalez-Sarmiento, R. (1998). 
Genomic characterization of the human trkC gene. Oncogene, 17(14), 1871-
1875. doi:10.1038/sj.onc.1202100 
Ikeda, F., & Dikic, I. (2008). Atypical ubiquitin chains: new molecular signals. 'Protein 
Modifications: Beyond the Usual Suspects' review series. EMBO Rep, 9(6), 536-
542. doi:10.1038/embor.2008.93 
Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010). STAT3 
activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the 
epigenetic switch linking inflammation to cancer. Mol Cell, 39(4), 493-506. 
doi:10.1016/j.molcel.2010.07.023 
Inagaki, N., Thoenen, H., & Lindholm, D. (1995). TrkA tyrosine residues involved in 
NGF-induced neurite outgrowth of PC12 cells. Eur J Neurosci, 7(6), 1125-1133.  
Inoue, J., Gohda, J., Akiyama, T., & Semba, K. (2007). NF-kappaB activation in 
development and progression of cancer. Cancer Sci, 98(3), 268-274. 
doi:10.1111/j.1349-7006.2007.00389.x 
Ip, N. Y., Stitt, T. N., Tapley, P., Klein, R., Glass, D. J., Fandl, J., Greene, L. A., Barbacid, 
M., & Yancopoulos, G. D. (1993). Similarities and differences in the way 
neurotrophins interact with the Trk receptors in neuronal and nonneuronal 
cells. Neuron, 10(2), 137-149.  
Ishiguro, Y., Ishiguro, H., & Miyamoto, H. (2013). Epidermal growth factor receptor 
tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces 
subsequent development of interstitial pneumonia. Oncotarget, 4(4), 550-559. 
doi:10.18632/oncotarget.939 
Islam, O., Loo, T. X., & Heese, K. (2009). Brain-derived neurotrophic factor (BDNF) has 
proliferative effects on neural stem cells through the truncated TRK-B receptor, 
MAP kinase, AKT, and STAT-3 signaling pathways. Curr Neurovasc Res, 6(1), 42-
53.  
Ivanov, S. V., Panaccione, A., Brown, B., Guo, Y., Moskaluk, C. A., Wick, M. J., Brown, J. 
L., Ivanova, A. V., Issaeva, N., El-Naggar, A. K., & Yarbrough, W. G. (2013). TrkC 
signaling is activated in adenoid cystic carcinoma and requires NT-3 to 
stimulate invasive behavior. Oncogene, 32(32), 3698-3710. 
doi:10.1038/onc.2012.377 
Ivanova, O., Braas, D., & Klempnauer, K. H. (2007). Oncogenic point mutations in the 
Myb DNA-binding domain alter the DNA-binding properties of Myb at a 
  271 
physiological target gene. Nucleic Acids Res, 35(21), 7237-7247. 
doi:10.1093/nar/gkm675 
Jacobson, M. D., Weil, M., & Raff, M. C. (1997). Programmed cell death in animal 
development. Cell, 88(3), 347-354.  
Jadhav, T., Geetha, T., Jiang, J., & Wooten, M. W. (2008). Identification of a consensus 
site for TRAF6/p62 polyubiquitination. Biochem Biophys Res Commun, 371(3), 
521-524. doi:10.1016/j.bbrc.2008.04.138 
Jeanneteau, F., Garabedian, M. J., & Chao, M. V. (2008). Activation of Trk neurotrophin 
receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad 
Sci U S A, 105(12), 4862-4867. doi:10.1073/pnas.0709102105 
Jin, W., Chang, M., Paul, E. M., Babu, G., Lee, A. J., Reiley, W., Wright, A., Zhang, M., 
You, J., & Sun, S. C. (2008). Deubiquitinating enzyme CYLD negatively regulates 
RANK signaling and osteoclastogenesis in mice. J Clin Invest, 118(5), 1858-1866. 
doi:10.1172/jci34257 
Jin, Y. J., Wang, S., Cho, J., Selim, M. A., Wright, T., Mosialos, G., & Zhang, J. Y. (2016). 
Epidermal CYLD inactivation sensitizes mice to the development of sebaceous 
and basaloid skin tumors. JCI Insight, 1(11). doi:10.1172/jci.insight.86548 
Johnson, D., Lanahan, A., Buck, C. R., Sehgal, A., Morgan, C., Mercer, E., Bothwell, M., 
& Chao, M. (1986). Expression and structure of the human NGF receptor. Cell, 
47(4), 545-554.  
Jones, P. H., & Watt, F. M. (1993). Separation of human epidermal stem cells from 
transit amplifying cells on the basis of differences in integrin function and 
expression. Cell, 73(4), 713-724.  
Jono, H., Lim, J. H., Chen, L. F., Xu, H., Trompouki, E., Pan, Z. K., Mosialos, G., & Li, J. D. 
(2004). NF-kappaB is essential for induction of CYLD, the negative regulator of 
NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J 
Biol Chem, 279(35), 36171-36174. doi:10.1074/jbc.M406638200 
Jungehulsing, M., Wagner, M., & Damm, M. (1999). Turban tumour with involvement 
of the parotid gland. J Laryngol Otol, 113(8), 779-783.  
Kallam, A. R., Satyanarayana, M. A., Aryasomayajula, S., & Krishna, B. A. (2016). Basal 
Cell Carcinoma Developing from Trichoepithelioma: Review of Three Cases. J 
Clin Diagn Res, 10(3), Pd17-19. doi:10.7860/jcdr/2016/15432.7464 
Kanei-Ishii, C., MacMillan, E. M., Nomura, T., Sarai, A., Ramsay, R. G., Aimoto, S., Ishii, 
S., & Gonda, T. J. (1992). Transactivation and transformation by Myb are 
negatively regulated by a leucine-zipper structure. Proc Natl Acad Sci U S A, 
89(7), 3088-3092.  
Kanei-Ishii, C., Ninomiya-Tsuji, J., Tanikawa, J., Nomura, T., Ishitani, T., Kishida, S., 
Kokura, K., Kurahashi, T., Ichikawa-Iwata, E., Kim, Y., Matsumoto, K., & Ishii, S. 
(2004). Wnt-1 signal induces phosphorylation and degradation of c-Myb 
protein via TAK1, HIPK2, and NLK. Genes Dev, 18(7), 816-829. 
doi:10.1101/gad.1170604 
Kanei-Ishii, C., Nomura, T., Takagi, T., Watanabe, N., Nakayama, K. I., & Ishii, S. (2008). 
Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase 
(NLK)-induced degradation. J Biol Chem, 283(45), 30540-30548. 
doi:10.1074/jbc.M804340200 
Kanei-Ishii, C., Yasukawa, T., Morimoto, R. I., & Ishii, S. (1994). c-Myb-induced trans-
activation mediated by heat shock elements without sequence-specific DNA 
binding of c-Myb. J Biol Chem, 269(22), 15768-15775.  
  272 
Kanning, K. C., Hudson, M., Amieux, P. S., Wiley, J. C., Bothwell, M., & Schecterson, L. 
C. (2003). Proteolytic processing of the p75 neurotrophin receptor and two 
homologs generates C-terminal fragments with signaling capability. J Neurosci, 
23(13), 5425-5436.  
Kaplan, D. R., Martin-Zanca, D., & Parada, L. F. (1991). Tyrosine phosphorylation and 
tyrosine kinase activity of the trk proto-oncogene product induced by NGF. 
Nature, 350(6314), 158-160. doi:10.1038/350158a0 
Kaplan, D. R., Matsumoto, K., Lucarelli, E., & Thiele, C. J. (1993). Induction of TrkB by 
retinoic acid mediates biologic responsiveness to BDNF and differentiation of 
human neuroblastoma cells. Eukaryotic Signal Transduction Group. Neuron, 
11(2), 321-331.  
Kaplan, D. R., & Miller, F. D. (2000). Neurotrophin signal transduction in the nervous 
system. Curr Opin Neurobiol, 10(3), 381-391.  
Kaptein, A., Paillard, V., & Saunders, M. (1996). Dominant negative stat3 mutant 
inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem, 
271(11), 5961-5964.  
Karin, M. (2009). NF-kappaB as a critical link between inflammation and cancer. Cold 
Spring Harb Perspect Biol, 1(5), a000141. doi:10.1101/cshperspect.a000141 
Karin, M., Cao, Y., Greten, F. R., & Li, Z. W. (2002). NF-kappaB in cancer: from innocent 
bystander to major culprit. Nat Rev Cancer, 2(4), 301-310. doi:10.1038/nrc780 
Kariya, Y., Moriya, T., Suzuki, T., Chiba, M., Ishida, K., Takeyama, J., Endoh, M., 
Watanabe, M., & Sasano, H. (2005). Sex steroid hormone receptors in human 
skin appendage and its neoplasms. Endocr J, 52(3), 317-325.  
Kaspar, P., Zikova, M., Bartunek, P., Sterba, J., Strnad, H., Kren, L., & Sedlacek, R. 
(2015). The Expression of c-Myb Correlates with the Levels of 
Rhabdomyosarcoma-specific Marker Myogenin. Sci Rep, 5, 15090. 
doi:10.1038/srep15090 
Kauraniemi, P., Hedenfalk, I., Persson, K., Duggan, D. J., Tanner, M., Johannsson, O., 
Olsson, H., Trent, J. M., Isola, J., & Borg, A. (2000). MYB oncogene amplification 
in hereditary BRCA1 breast cancer. Cancer Res, 60(19), 5323-5328.  
Kazakov, D. V., Thoma-Uszynski, S., Vanecek, T., Kacerovska, D., Grossmann, P., & 
Michal, M. (2009). A case of Brooke-Spiegler syndrome with a novel germline 
deep intronic mutation in the CYLD gene leading to intronic exonization, 
diverse somatic mutations, and unusual histology. Am J Dermatopathol, 31(7), 
664-673. doi:10.1097/DAD.0b013e3181a05dad 
Kazakov, D. V., Zelger, B., Rutten, A., Vazmitel, M., Spagnolo, D. V., Kacerovska, D., 
Vanecek, T., Grossmann, P., Sima, R., Grayson, W., Calonje, E., Koren, J., 
Mukensnabl, P., Danis, D., & Michal, M. (2009). Morphologic diversity of 
malignant neoplasms arising in preexisting spiradenoma, cylindroma, and 
spiradenocylindroma based on the study of 24 cases, sporadic or occurring in 
the setting of Brooke-Spiegler syndrome. Am J Surg Pathol, 33(5), 705-719. 
doi:10.1097/PAS.0b013e3181966762 
Kenchappa, R. S., Zampieri, N., Chao, M. V., Barker, P. A., Teng, H. K., Hempstead, B. L., 
& Carter, B. D. (2006). Ligand-dependent cleavage of the P75 neurotrophin 
receptor is necessary for NRIF nuclear translocation and apoptosis in 
sympathetic neurons. Neuron, 50(2), 219-232. 
doi:10.1016/j.neuron.2006.03.011 
Khursigara, G., Bertin, J., Yano, H., Moffett, H., DiStefano, P. S., & Chao, M. V. (2001). A 
prosurvival function for the p75 receptor death domain mediated via the 
  273 
caspase recruitment domain receptor-interacting protein 2. J Neurosci, 21(16), 
5854-5863.  
Khursigara, G., Orlinick, J. R., & Chao, M. V. (1999). Association of the p75 
neurotrophin receptor with TRAF6. J Biol Chem, 274(5), 2597-2600.  
Kim, C. J., Matsuo, T., Lee, K. H., & Thiele, C. J. (1999). Up-regulation of insulin-like 
growth factor-II expression is a feature of TrkA but not TrkB activation in SH-
SY5Y neuroblastoma cells. Am J Pathol, 155(5), 1661-1670. doi:10.1016/s0002-
9440(10)65481-8 
Kim, D. J., Angel, J. M., Sano, S., & DiGiovanni, J. (2009). Constitutive activation and 
targeted disruption of signal transducer and activator of transcription 3 (Stat3) 
in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. 
Oncogene, 28(7), 950-960. doi:10.1038/onc.2008.453 
Kim, E., & Jeon, W. B. (2013). Gene expression analysis of 3D spheroid culture of 
human embryonic kidney cells. Toxicol. Environ. Health Sci., 5(2), 97-106. 
doi:10.1007/s13530-013-0160-y 
Kim, J. B. (2005). Three-dimensional tissue culture models in cancer biology. Semin 
Cancer Biol, 15(5), 365-377. doi:10.1016/j.semcancer.2005.05.002 
Kim, M. S., Lee, W. S., Jeong, J., Kim, S. J., & Jin, W. (2015). Induction of metastatic 
potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in 
breast cancer. Oncotarget, 6(37), 40158-40171. doi:10.18632/oncotarget.5522 
Kim, Y., & He, Y. Y. (2014). Ultraviolet radiation-induced non-melanoma skin cancer: 
Regulation of DNA damage repair and inflammation. Genes Dis, 1(2), 188-198. 
doi:10.1016/j.gendis.2014.08.005 
Kimlin, L. C., Casagrande, G., & Virador, V. M. (2013). In vitro three-dimensional (3D) 
models in cancer research: an update. Mol Carcinog, 52(3), 167-182. 
doi:10.1002/mc.21844 
Klein, R., Silos-Santiago, I., Smeyne, R. J., Lira, S. A., Brambilla, R., Bryant, S., Zhang, L., 
Snider, W. D., & Barbacid, M. (1994). Disruption of the neurotrophin-3 receptor 
gene trkC eliminates la muscle afferents and results in abnormal movements. 
Nature, 368(6468), 249-251. doi:10.1038/368249a0 
Klein, R., Smeyne, R. J., Wurst, W., Long, L. K., Auerbach, B. A., Joyner, A. L., & 
Barbacid, M. (1993). Targeted disruption of the trkB neurotrophin receptor 
gene results in nervous system lesions and neonatal death. Cell, 75(1), 113-122.  
Kleinman, H. K., & Martin, G. R. (2005). Matrigel: basement membrane matrix with 
biological activity. Semin Cancer Biol, 15(5), 378-386. 
doi:10.1016/j.semcancer.2005.05.004 
Knudson, A. G., Jr. (1971). Mutation and cancer: statistical study of retinoblastoma. 
Proc Natl Acad Sci U S A, 68(4), 820-823.  
Kobayashi, K., Ando, M., Saito, Y., Kondo, K., Omura, G., Shinozaki-Ushiku, A., 
Fukayama, M., Asakage, T., & Yamasoba, T. (2015). Nerve Growth Factor 
Signals as Possible Pathogenic Biomarkers for Perineural Invasion in Adenoid 
Cystic Carcinoma. Otolaryngol Head Neck Surg, 153(2), 218-224. 
doi:10.1177/0194599815584762 
Koepp, D. M., Schaefer, L. K., Ye, X., Keyomarsi, K., Chu, C., Harper, J. W., & Elledge, S. 
J. (2001). Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 
ubiquitin ligase. Science, 294(5540), 173-177. doi:10.1126/science.1065203 
Komander, D., Lord, C. J., Scheel, H., Swift, S., Hofmann, K., Ashworth, A., & Barford, D. 
(2008). The structure of the CYLD USP domain explains its specificity for Lys63-
  274 
linked polyubiquitin and reveals a B box module. Mol Cell, 29(4), 451-464. 
doi:10.1016/j.molcel.2007.12.018 
Komander, D., & Rape, M. (2012). The ubiquitin code. Annu Rev Biochem, 81, 203-229. 
doi:10.1146/annurev-biochem-060310-170328 
Komander, D., Reyes-Turcu, F., Licchesi, J. D., Odenwaelder, P., Wilkinson, K. D., & 
Barford, D. (2009). Molecular discrimination of structurally equivalent Lys 63-
linked and linear polyubiquitin chains. EMBO Rep, 10(5), 466-473. 
doi:10.1038/embor.2009.55 
Kommaddi, R. P., Thomas, R., Ceni, C., Daigneault, K., & Barker, P. A. (2011). Trk-
dependent ADAM17 activation facilitates neurotrophin survival signaling. Faseb 
j, 25(6), 2061-2070. doi:10.1096/fj.10-173740 
Kostler, E., Schonlebe, J., Mentzel, T., Haroske, G., & Wollina, U. (2005). Psoriasis and 
Brooke-Spiegler syndrome with multiple malignancies. J Eur Acad Dermatol 
Venereol, 19(3), 380-381. doi:10.1111/j.1468-3083.2005.01037.x 
Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israel, A., Wallach, D., & Courtois, G. 
(2003). The tumour suppressor CYLD negatively regulates NF-kappaB signalling 
by deubiquitination. Nature, 424(6950), 801-805. doi:10.1038/nature01802 
Kraemer, B. R., Yoon, S. O., & Carter, B. D. (2014). The biological functions and 
signaling mechanisms of the p75 neurotrophin receptor. Handb Exp Pharmacol, 
220, 121-164. doi:10.1007/978-3-642-45106-5_6 
Kryl, D., & Barker, P. A. (2000). TTIP is a novel protein that interacts with the truncated 
T1 TrkB neurotrophin receptor. Biochem Biophys Res Commun, 279(3), 925-
930. doi:10.1006/bbrc.2000.4058 
Kuklani, R. M., Glavin, F. L., & Bhattacharyya, I. (2009). Malignant cylindroma of the 
scalp arising in a setting of multiple cylindromatosis: a case report. Head Neck 
Pathol, 3(4), 315-319. doi:10.1007/s12105-009-0138-x 
Kumar, A., Baker, S. J., Lee, C. M., & Reddy, E. P. (2003). Molecular mechanisms 
associated with the regulation of apoptosis by the two alternatively spliced 
products of c-Myb. Mol Cell Biol, 23(18), 6631-6645.  
Kumar, V., Palermo, R., Talora, C., Campese, A. F., Checquolo, S., Bellavia, D., Tottone, 
L., Testa, G., Miele, E., Indraccolo, S., Amadori, A., Ferretti, E., Gulino, A., Vacca, 
A., & Screpanti, I. (2014). Notch and NF-kB signaling pathways regulate miR-
223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia, 28(12), 
2324-2335. doi:10.1038/leu.2014.133 
Kupferman, M. E., Jiffar, T., El-Naggar, A., Yilmaz, T., Zhou, G., Xie, T., Feng, L., Wang, J., 
Holsinger, F. C., Yu, D., & Myers, J. N. (2010). TrkB induces EMT and has a key 
role in invasion of head and neck squamous cell carcinoma. Oncogene, 29(14), 
2047-2059. doi:10.1038/onc.2009.486 
Kuphal, S., Shaw-Hallgren, G., Eberl, M., Karrer, S., Aberger, F., Bosserhoff, A. K., & 
Massoumi, R. (2011). GLI1-dependent transcriptional repression of CYLD in 
basal cell carcinoma. Oncogene, 30(44), 4523-4530. doi:10.1038/onc.2011.163 
Lahortiga, I., De Keersmaecker, K., Van Vlierberghe, P., Graux, C., Cauwelier, B., 
Lambert, F., Mentens, N., Beverloo, H. B., Pieters, R., Speleman, F., Odero, M. 
D., Bauters, M., Froyen, G., Marynen, P., Vandenberghe, P., Wlodarska, I., 
Meijerink, J. P., & Cools, J. (2007). Duplication of the MYB oncogene in T cell 
acute lymphoblastic leukemia. Nat Genet, 39(5), 593-595. doi:10.1038/ng2025 
Lai, Y., Wei, X., Lin, S., Qin, L., Cheng, L., Li, P. (2017). Current status and perspectives 
of patient-derived xenograft models in cancer research. J Hematol Oncol, 10(1), 
106. doi: 10.1186/s13045-017-0470-7 
  275 
Lang, G., White, J. R., Argent-Katwala, M. J., Allinson, C. G., & Weston, K. (2005). Myb 
proteins regulate the expression of diverse target genes. Oncogene, 24(8), 
1375-1384. doi:10.1038/sj.onc.1208301 
Lange, A. M., & Lo, H. W. (2018). Inhibiting TRK proteins in clinical cancer therapy. 
Cancers (Basel), 10(4), 105. doi: 10.3390/cancers10040105 
Lauder, A., Castellanos, A., & Weston, K. (2001). c-Myb transcription is activated by 
protein kinase B (PKB) following interleukin 2 stimulation of Tcells and is 
required for PKB-mediated protection from apoptosis. Mol Cell Biol, 21(17), 
5797-5805.  
Le Bras, S., Loyer, N., & Le Borgne, R. (2011). The multiple facets of ubiquitination in 
the regulation of notch signaling pathway. Traffic, 12(2), 149-161. 
doi:10.1111/j.1600-0854.2010.01126.x 
Leblebici, C., Pasaoglu, E., Kelten, C., Darakci, S., & Dursun, N. (2017). Cytokeratin 17 
and Ki-67: Immunohistochemical markers for the differential diagnosis of 
keratoacanthoma and squamous cell carcinoma. Oncol Lett, 13(4), 2539-2548. 
doi:10.3892/ol.2017.5793 
Lee, B. C., Miyata, M., Lim, J. H., & Li, J. D. (2016). Deubiquitinase CYLD acts as a 
negative regulator for bacterium NTHi-induced inflammation by suppressing 
K63-linked ubiquitination of MyD88. Proc Natl Acad Sci U S A, 113(2), E165-171. 
doi:10.1073/pnas.1518615113 
Lee, D. A., Grossman, M. E., Schneiderman, P., & Celebi, J. T. (2005). Genetics of skin 
appendage neoplasms and related syndromes. J Med Genet, 42(11), 811-819. 
doi:10.1136/jmg.2004.025577 
Lee, F. S., & Chao, M. V. (2001). Activation of Trk neurotrophin receptors in the 
absence of neurotrophins. Proc Natl Acad Sci U S A, 98(6), 3555-3560. 
doi:10.1073/pnas.061020198 
Lee, F. S., Kim, A. H., Khursigara, G., & Chao, M. V. (2001). The uniqueness of being a 
neurotrophin receptor. Curr Opin Neurobiol, 11(3), 281-286.  
Lee, H., Herrmann, A., Deng, J. H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., 
Pardoll, D. M., & Yu, H. (2009). Persistently activated Stat3 maintains 
constitutive NF-kappaB activity in tumors. Cancer Cell, 15(4), 283-293. 
doi:10.1016/j.ccr.2009.02.015 
Lee, H. J., Zhuang, G., Cao, Y., Du, P., Kim, H. J., & Settleman, J. (2014). Drug resistance 
via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell, 
26(2), 207-221. doi:10.1016/j.ccr.2014.05.019 
Lee, K. F., Li, E., Huber, L. J., Landis, S. C., Sharpe, A. H., Chao, M. V., & Jaenisch, R. 
(1992). Targeted mutation of the gene encoding the low affinity NGF receptor 
p75 leads to deficits in the peripheral sensory nervous system. Cell, 69(5), 737-
749.  
Lee, K. H., Kim, J. E., Cho, B. K., Kim, Y. C., & Park, C. J. (2008). Malignant 
transformation of multiple familial trichoepithelioma: case report and literature 
review. Acta Derm Venereol, 88(1), 43-46. doi:10.2340/00015555-0322 
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival 
by secreted proneurotrophins. Science, 294(5548), 1945-1948. 
doi:10.1126/science.1065057 
Lei, W., Rushton, J. J., Davis, L. M., Liu, F., & Ness, S. A. (2004). Positive and negative 
determinants of target gene specificity in myb transcription factors. J Biol 
Chem, 279(28), 29519-29527. doi:10.1074/jbc.M403133200 
  276 
Leinonen, P. T., Hagg, P. M., Peltonen, S., Jouhilahti, E. M., Melkko, J., Korkiamaki, T., 
Oikarinen, A., & Peltonen, J. (2009). Reevaluation of the normal epidermal 
calcium gradient, and analysis of calcium levels and ATP receptors in Hailey-
Hailey and Darier epidermis. J Invest Dermatol, 129(6), 1379-1387. 
doi:10.1038/jid.2008.381 
Lenardo, M., & Siebenlist, U. (1994). Bcl-3-mediated nuclear regulation of the NF-
kappa B trans-activating factor. Immunol Today, 15(4), 145-147.  
Leprince, D., Gegonne, A., Coll, J., de Taisne, C., Schneeberger, A., Lagrou, C., & 
Stehelin, D. (1983). A putative second cell-derived oncogene of the avian 
leukaemia retrovirus E26. Nature, 306(5941), 395-397.  
Lessmann, V., & Brigadski, T. (2009). Mechanisms, locations, and kinetics of synaptic 
BDNF secretion: an update. Neurosci Res, 65(1), 11-22. 
doi:10.1016/j.neures.2009.06.004 
Leverson, J. D., & Ness, S. A. (1998). Point mutations in v-Myb disrupt a cyclophilin-
catalyzed negative regulatory mechanism. Mol Cell, 1(2), 203-211.  
Levi-Montalcini, R. (1987). The nerve growth factor 35 years later. Science, 237(4819), 
1154-1162.  
Levy, L., Broad, S., Diekmann, D., Evans, R. D., & Watt, F. M. (2000). beta1 integrins 
regulate keratinocyte adhesion and differentiation by distinct mechanisms. Mol 
Biol Cell, 11(2), 453-466.  
Li, D., Gao, J., Yang, Y., Sun, L., Suo, S., Luo, Y., Shui, W., Zhou, J., & Liu, M. (2014). CYLD 
coordinates with EB1 to regulate microtubule dynamics and cell migration. Cell 
Cycle, 13(6), 974-983. doi:10.4161/cc.27838 
Li, H. S., Xu, X. Z., & Montell, C. (1999). Activation of a TRPC3-dependent cation current 
through the neurotrophin BDNF. Neuron, 24(1), 261-273.  
Li, Y., Jin, K., van Pelt, G. W., van Dam, H., Yu, X., Mesker, W. E., Ten Dijke, P., Zhou, F., 
& Zhang, L. (2016). c-Myb Enhances Breast Cancer Invasion and Metastasis 
through the Wnt/beta-Catenin/Axin2 Pathway. Cancer Res, 76(11), 3364-3375. 
doi:10.1158/0008-5472.can-15-2302 
Liepinsh, E., Ilag, L. L., Otting, G., & Ibanez, C. F. (1997). NMR structure of the death 
domain of the p75 neurotrophin receptor. EMBO J, 16(16), 4999-5005. 
doi:10.1093/emboj/16.16.4999 
Lieu, Y. K., & Reddy, E. P. (2009). Conditional c-myb knockout in adult hematopoietic 
stem cells leads to loss of self-renewal due to impaired proliferation and 
accelerated differentiation. Proc Natl Acad Sci U S A, 106(51), 21689-21694. 
doi:10.1073/pnas.0907623106 
Lim, J. H., Ha, U. H., Woo, C. H., Xu, H., & Li, J. D. (2008). CYLD is a crucial negative 
regulator of innate immune response in Escherichia coli pneumonia. Cell 
Microbiol, 10(11), 2247-2256. doi:10.1111/j.1462-5822.2008.01204.x 
Lim, X., & Nusse, R. (2013). Wnt signaling in skin development, homeostasis, and 
disease. Cold Spring Harb Perspect Biol, 5(2). doi:10.1101/cshperspect.a008029 
Linggi, M. S., Burke, T. L., Williams, B. B., Harrington, A., Kraemer, R., Hempstead, B. L., 
Yoon, S. O., & Carter, B. D. (2005). Neurotrophin receptor interacting factor 
(NRIF) is an essential mediator of apoptotic signaling by the p75 neurotrophin 
receptor. J Biol Chem, 280(14), 13801-13808. doi:10.1074/jbc.M410435200 
Liu, F., Lei, W., O'Rourke, J. P., & Ness, S. A. (2006). Oncogenic mutations cause 
dramatic, qualitative changes in the transcriptional activity of c-Myb. 
Oncogene, 25(5), 795-805. doi:10.1038/sj.onc.1209105 
  277 
Liu, H. H., Xie, M., Schneider, M. D., & Chen, Z. J. (2006). Essential role of TAK1 in 
thymocyte development and activation. Proc Natl Acad Sci U S A, 103(31), 
11677-11682. doi:10.1073/pnas.0603089103 
Liu, N., Zhang, J., & Ji, C. (2013). The emerging roles of Notch signaling in leukemia and 
stem cells. Biomark Res, 1(1), 23. doi:10.1186/2050-7771-1-23 
Liu, Y. Z., Boxer, L. M., & Latchman, D. S. (1999). Activation of the Bcl-2 promoter by 
nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids 
Res, 27(10), 2086-2090.  
Lorenzo, P. I., Brendeford, E. M., Gilfillan, S., Gavrilov, A. A., Leedsak, M., Razin, S. V., 
Eskeland, R., Saether, T., & Gabrielsen, O. S. (2011). Identification of c-Myb 
Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator. 
Genes Cancer, 2(8), 805-817. doi:10.1177/1947601911428224 
Lou, H., Kim, S. K., Zaitsev, E., Snell, C. R., Lu, B., & Loh, Y. P. (2005). Sorting and 
activity-dependent secretion of BDNF require interaction of a specific motif 
with the sorting receptor carboxypeptidase e. Neuron, 45(2), 245-255. 
doi:10.1016/j.neuron.2004.12.037 
Lu, B., Pang, P. T., & Woo, N. H. (2005). The yin and yang of neurotrophin action. Nat 
Rev Neurosci, 6(8), 603-614. doi:10.1038/nrn1726 
Luberg, K., Park, R., Aleksejeva, E., & Timmusk, T. (2015). Novel transcripts reveal a 
complex structure of the human TRKA gene and imply the presence of multiple 
protein isoforms. BMC Neurosci, 16, 78. doi:10.1186/s12868-015-0215-x 
Luberg, K., Wong, J., Weickert, C. S., & Timmusk, T. (2010). Human TrkB gene: novel 
alternative transcripts, protein isoforms and expression pattern in the 
prefrontal cerebral cortex during postnatal development. J Neurochem, 113(4), 
952-964. doi:10.1111/j.1471-4159.2010.06662.x 
Luca, A. C., Mersch, S., Deenen, R., Schmidt, S., Messner, I., Schafer, K. L., Baldus, S. E., 
Huckenbeck, W., Piekorz, R. P., Knoefel, W. T., Krieg, A., & Stoecklein, N. H. 
(2013). Impact of the 3D microenvironment on phenotype, gene expression, 
and EGFR inhibition of colorectal cancer cell lines. PLoS One, 8(3), e59689. 
doi:10.1371/journal.pone.0059689 
Luscher, B., Christenson, E., Litchfield, D. W., Krebs, E. G., & Eisenman, R. N. (1990). 
Myb DNA binding inhibited by phosphorylation at a site deleted during 
oncogenic activation. Nature, 344(6266), 517-522. doi:10.1038/344517a0 
MacDonald, J. I., & Meakin, S. O. (1996). Deletions in the extracellular domain of rat 
trkA lead to an altered differentiative phenotype in neurotrophin responsive 
cells. Mol Cell Neurosci, 7(5), 371-390. doi:10.1006/mcne.1996.0027 
MacPhee, I., & Barker, P. A. (1999). Extended ceramide exposure activates the trkA 
receptor by increasing receptor homodimer formation. J Neurochem, 72(4), 
1423-1430.  
Mahmoud, A., Hill, D. H., O'Sullivan, M. J., & Bennett, M. W. (2009). Cylindroma of the 
breast: a case report and review of the literature. Diagn Pathol, 4, 30. 
doi:10.1186/1746-1596-4-30 
Makkerh, J. P., Ceni, C., Auld, D. S., Vaillancourt, F., Dorval, G., & Barker, P. A. (2005). 
p75 neurotrophin receptor reduces ligand-induced Trk receptor ubiquitination 
and delays Trk receptor internalization and degradation. EMBO Rep, 6(10), 936-
941. doi:10.1038/sj.embor.7400503 
Malaterre, J., Carpinelli, M., Ernst, M., Alexander, W., Cooke, M., Sutton, S., Dworkin, 
S., Heath, J. K., Frampton, J., McArthur, G., Clevers, H., Hilton, D., 
Mantamadiotis, T., & Ramsay, R. G. (2007). c-Myb is required for progenitor cell 
  278 
homeostasis in colonic crypts. Proc Natl Acad Sci U S A, 104(10), 3829-3834. 
doi:10.1073/pnas.0610055104 
Malaterre, J., Mantamadiotis, T., Dworkin, S., Lightowler, S., Yang, Q., Ransome, M. I., 
Turnley, A. M., Nichols, N. R., Emambokus, N. R., Frampton, J., & Ramsay, R. G. 
(2008). c-Myb is required for neural progenitor cell proliferation and 
maintenance of the neural stem cell niche in adult brain. Stem Cells, 26(1), 173-
181. doi:10.1634/stemcells.2007-0293 
Manzotti, G., Mariani, S. A., Corradini, F., Bussolari, R., Cesi, V., Vergalli, J., Ferrari-
Amorotti, G., Fragliasso, V., Soliera, A. R., Cattelani, S., Raschella, G., Holyoake, 
T. L., & Calabretta, B. (2012). Expression of p89(c-Mybex9b), an alternatively 
spliced form of c-Myb, is required for proliferation and survival of 
p210BCR/ABL-expressing cells. Blood Cancer J, 2(5), e71. 
doi:10.1038/bcj.2012.16 
Marconi, A., Panza, M. C., Bonnet-Duquennoy, M., Lazou, K., Kurfurst, R., Truzzi, F., 
Lotti, R., De Santis, G., Dumas, M., Bonte, F., & Pincelli, C. (2006). Expression 
and function of neurotrophins and their receptors in human melanocytes. Int J 
Cosmet Sci, 28(4), 255-261. doi:10.1111/j.1467-2494.2006.00321.x 
Marconi, A., Terracina, M., Fila, C., Franchi, J., Bonté, F., Romagnoli, G., Maurelli, R., 
Failla, C. M., Dumas, M., & Pincelli, C. (2003). Expression and function of 
neurotrophins and their receptors in cultured human keratinocytes. Journal of 
Investigative Dermatology, 121(6), 1515-1521.  
Marconi, A., Vaschieri, C., Zanoli, S., Giannetti, A., & Pincelli, C. (1999). Nerve growth 
factor protects human keratinocytes from ultraviolet-B-induced apoptosis. 
Journal of Investigative Dermatology, 113(6), 920-927.  
Martin-Zanca, D., Hughes, S. H., & Barbacid, M. (1986). A human oncogene formed by 
the fusion of truncated tropomyosin and protein tyrosine kinase sequences. 
Nature, 319(6056), 743-748. doi:10.1038/319743a0 
Martin-Zanca, D., Oskam, R., Mitra, G., Copeland, T., & Barbacid, M. (1989). Molecular 
and biochemical characterization of the human trk proto-oncogene. Mol Cell 
Biol, 9(1), 24-33.  
Martinez, I., & Dimaio, D. (2011). B-Myb, cancer, senescence, and microRNAs. Cancer 
Res, 71(16), 5370-5373. doi:10.1158/0008-5472.can-11-1044 
Martins, C., & Bartolo, E. (2000). Brooke-Spiegler syndrome: treatment of cylindromas 
with CO2 laser. Dermatol Surg, 26(9), 877-880; discussion 881.  
Maruyama, H., Ishitsuka, Y., Fujisawa, Y., Furuta, J., Sekido, M., & Kawachi, Y. (2014). B-
Myb enhances proliferation and suppresses differentiation of keratinocytes in 
three-dimensional cell culture. Arch Dermatol Res, 306(4), 375-384. 
doi:10.1007/s00403-014-1450-1 
Massoumi, R., Chmielarska, K., Hennecke, K., Pfeifer, A., & Fassler, R. (2006). Cyld 
inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB 
signaling. Cell, 125(4), 665-677. doi:10.1016/j.cell.2006.03.041 
Massoumi, R., Kuphal, S., Hellerbrand, C., Haas, B., Wild, P., Spruss, T., Pfeifer, A., 
Fassler, R., & Bosserhoff, A. K. (2009). Down-regulation of CYLD expression by 
Snail promotes tumor progression in malignant melanoma. J Exp Med, 206(1), 
221-232. doi:10.1084/jem.20082044 
Massoumi, R., & Paus, R. (2007). Cylindromatosis and the CYLD gene: new lessons on 
the molecular principles of epithelial growth control. Bioessays, 29(12), 1203-
1214. doi:10.1002/bies.20677 
  279 
Massoumi, R., Podda, M., Fassler, R., & Paus, R. (2006). Cylindroma as tumor of hair 
follicle origin. J Invest Dermatol, 126(5), 1182-1184. doi:10.1038/sj.jid.5700218 
Meakin, S. O., MacDonald, J. I., Gryz, E. A., Kubu, C. J., & Verdi, J. M. (1999). The 
signaling adapter FRS-2 competes with Shc for binding to the nerve growth 
factor receptor TrkA. A model for discriminating proliferation and 
differentiation. J Biol Chem, 274(14), 9861-9870.  
Meldolesi, J. (2017). Neurotrophin receptors in the pathogenesis, diagnosis and 
therapy of neurodegenerative diseases. Pharmacol Res, 121, 129-137. 
doi:10.1016/j.phrs.2017.04.024 
Melly, L., Lawton, G., & Rajan, N. (2012). Basal cell carcinoma arising in association 
with trichoepithelioma in a case of Brooke-Spiegler syndrome with a novel 
genetic mutation in CYLD. J Cutan Pathol, 39(10), 977-978. doi:10.1111/j.1600-
0560.2012.01952.x 
Menn, B., Timsit, S., Calothy, G., & Lamballe, F. (1998). Differential expression of TrkC 
catalytic and noncatalytic isoforms suggests that they act independently or in 
association. J Comp Neurol, 401(1), 47-64.  
Mertsching, H., Weimer, M., Kersen, S., & Brunner, H. (2008). Human skin equivalent 
as an alternative to animal testing. GMS Krankenhhyg Interdiszip, 3(1), Doc11.  
Meybehm, M., & Fischer, H. P. (1997). Spiradenoma and dermal cylindroma: 
comparative immunohistochemical analysis and histogenetic considerations. 
Am J Dermatopathol, 19(2), 154-161.  
Michal, M. (1996). Spiradenoma associated with apocrine adenoma component. 
Pathol Res Pract, 192(11), 1135-1139; discussion 1140-1131. 
doi:10.1016/s0344-0338(96)80032-x 
Michal, M., Lamovec, J., Mukensnabl, P., & Pizinger, K. (1999). Spiradenocylindromas 
of the skin: tumors with morphological features of spiradenoma and 
cylindroma in the same lesion: report of 12 cases. Pathol Int, 49(5), 419-425.  
Michaud, E. J., & Yoder, B. K. (2006). The primary cilium in cell signaling and cancer. 
Cancer Res, 66(13), 6463-6467. doi:10.1158/0008-5472.can-06-0462 
Miliani de Marval, P., Lutfeali, S., Jin, J. Y., Leshin, B., Selim, M. A., & Zhang, J. Y. (2011). 
CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at 
multiple levels. Cancer Prev Res (Phila), 4(6), 851-859. doi:10.1158/1940-
6207.capr-10-0360 
Minichiello, L., Casagranda, F., Tatche, R. S., Stucky, C. L., Postigo, A., Lewin, G. R., 
Davies, A. M., & Klein, R. (1998). Point mutation in trkB causes loss of NT4-
dependent neurons without major effects on diverse BDNF responses. Neuron, 
21(2), 335-345.  
Miranda, C., Fumagalli, T., Anania, M. C., Vizioli, M. G., Pagliardini, S., Pierotti, M. A., & 
Greco, A. (2010). Role of STAT3 in in vitro transformation triggered by TRK 
oncogenes. PLoS One, 5(3), e9446. doi:10.1371/journal.pone.0009446 
Mitani, Y., Li, J., Rao, P. H., Zhao, Y. J., Bell, D., Lippman, S. M., Weber, R. S., Caulin, C., 
& El-Naggar, A. K. (2010). Comprehensive analysis of the MYB-NFIB gene fusion 
in salivary adenoid cystic carcinoma: Incidence, variability, and 
clinicopathologic significance. Clin Cancer Res, 16(19), 4722-4731. 
doi:10.1158/1078-0432.ccr-10-0463 
Mitchison, T. J. (2012). The proliferation rate paradox in antimitotic chemotherapy. 
Mol Biol Cell, 23(1), 1-6. doi:10.1091/mbc.E10-04-0335 
  280 
Mitra, P., Pereira, L. A., Drabsch, Y., Ramsay, R. G., & Gonda, T. J. (2012). Estrogen 
receptor-alpha recruits P-TEFb to overcome transcriptional pausing in intron 1 
of the MYB gene. Nucleic Acids Res, 40(13), 5988-6000. doi:10.1093/nar/gks286 
Miyoshi, K., Takaishi, M., Nakajima, K., Ikeda, M., Kanda, T., Tarutani, M., Iiyama, T., 
Asao, N., DiGiovanni, J., & Sano, S. (2011). Stat3 as a therapeutic target for the 
treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J 
Invest Dermatol, 131(1), 108-117. doi:10.1038/jid.2010.255 
Mo, X., Kowenz-Leutz, E., Laumonnier, Y., Xu, H., & Leutz, A. (2005). Histone H3 tail 
positioning and acetylation by the c-Myb but not the v-Myb DNA-binding SANT 
domain. Genes Dev, 19(20), 2447-2457. doi:10.1101/gad.355405 
Molvaersmyr, A. K., Saether, T., Gilfillan, S., Lorenzo, P. I., Kvaloy, H., Matre, V., & 
Gabrielsen, O. S. (2010). A SUMO-regulated activation function controls 
synergy of c-Myb through a repressor-activator switch leading to differential 
p300 recruitment. Nucleic Acids Res, 38(15), 4970-4984. 
doi:10.1093/nar/gkq245 
Montano, X., & Djamgoz, M. B. (2004). Epidermal growth factor, neurotrophins and 
the metastatic cascade in prostate cancer. FEBS Lett, 571(1-3), 1-8. 
doi:10.1016/j.febslet.2004.06.088 
Moritz, A., Li, Y., Guo, A., Villen, J., Wang, Y., MacNeill, J., Kornhauser, J., Sprott, K., 
Zhou, J., Possemato, A., Ren, J. M., Hornbeck, P., Cantley, L. C., Gygi, S. P., Rush, 
J., & Comb, M. J. (2010). Akt-RSK-S6 kinase signaling networks activated by 
oncogenic receptor tyrosine kinases. Sci Signal, 3(136), ra64. 
doi:10.1126/scisignal.2000998 
Moriwaki, K., Tsuruta, D., Sugawara, H., Kobayashi, H., Massoumi, R., & Ishii, M. (2007). 
A role of CYLD in hair cycling mouse. Journal of Investigative Dermatology, 127, 
S107.  
Moser, J. J., Fritzler, M. J., & Rattner, J. B. (2009). Primary ciliogenesis defects are 
associated with human astrocytoma/glioblastoma cells. BMC Cancer, 9, 448. 
doi:10.1186/1471-2407-9-448 
Mucenski, M. L., McLain, K., Kier, A. B., Swerdlow, S. H., Schreiner, C. M., Miller, T. A., 
Pietryga, D. W., Scott, W. J., Jr., & Potter, S. S. (1991). A functional c-myb gene 
is required for normal murine fetal hepatic hematopoiesis. Cell, 65(4), 677-689.  
Mukai, J., Hachiya, T., Shoji-Hoshino, S., Kimura, M. T., Nadano, D., Suvanto, P., 
Hanaoka, T., Li, Y., Irie, S., Greene, L. A., & Sato, T. A. (2000). NADE, a p75NTR-
associated cell death executor, is involved in signal transduction mediated by 
the common neurotrophin receptor p75NTR. J Biol Chem, 275(23), 17566-
17570. doi:10.1074/jbc.C000140200 
Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor 
in the control human brain, and in Alzheimer's disease and Parkinson's disease. 
Prog Neurobiol, 63(1), 71-124.  
Nagy, N., Farkas, K., Kemeny, L., & Szell, M. (2015). Phenotype-genotype correlations 
for clinical variants caused by CYLD mutations. Eur J Med Genet, 58(5), 271-278. 
doi:10.1016/j.ejmg.2015.02.010 
Nagy, N., Rajan, N., Farkas, K., Kinyo, A., Kemeny, L., & Szell, M. (2013). A mutational 
hotspot in CYLD causing cylindromas: a comparison of phenotypes arising in 
different genetic backgrounds. Acta Derm Venereol, 93(6), 743-745. 
doi:10.2340/00015555-1590 
  281 
Nakagawara, A., Azar, C. G., Scavarda, N. J., & Brodeur, G. M. (1994). Expression and 
function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol, 14(1), 
759-767.  
Nakagoshi, H., Takemoto, Y., & Ishii, S. (1993). Functional domains of the human B-
myb gene product. J Biol Chem, 268(19), 14161-14167.  
Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., Kitaoka, T., 
Fukada, T., Hibi, M., & Hirano, T. (1996). A central role for Stat3 in IL-6-induced 
regulation of growth and differentiation in M1 leukemia cells. EMBO J, 15(14), 
3651-3658.  
Nakamura, K., Martin, K. C., Jackson, J. K., Beppu, K., Woo, C. W., & Thiele, C. J. (2006). 
Brain-derived neurotrophic factor activation of TrkB induces vascular 
endothelial growth factor expression via hypoxia-inducible factor-1alpha in 
neuroblastoma cells. Cancer Res, 66(8), 4249-4255. doi:10.1158/0008-
5472.can-05-2789 
Nakano, K., Uchimaru, K., Utsunomiya, A., Yamaguchi, K., & Watanabe, T. (2016). 
Dysregulation of c-Myb Pathway by Aberrant Expression of Proto-oncogene 
MYB Provides the Basis for Malignancy in Adult T-cell Leukemia/lymphoma 
Cells. Clin Cancer Res, 22(23), 5915-5928. doi:10.1158/1078-0432.ccr-15-1739 
Nakata, Y., Shetzline, S., Sakashita, C., Kalota, A., Rallapalli, R., Rudnick, S. I., Zhang, Y., 
Emerson, S. G., & Gewirtz, A. M. (2007). c-Myb contributes to G2/M cell cycle 
transition in human hematopoietic cells by direct regulation of cyclin B1 
expression. Mol Cell Biol, 27(6), 2048-2058. doi:10.1128/mcb.01100-06 
Nan, J., Du, Y., Chen, X., Bai, Q., Wang, Y., Zhang, X., Zhu, N., Zhang, J., Hou, J., Wang, 
Q., & Yang, J. (2014). TPCA-1 is a direct dual inhibitor of STAT3 and NF-kappaB 
and regresses mutant EGFR-associated human non-small cell lung cancers. Mol 
Cancer Ther, 13(3), 617-629. doi:10.1158/1535-7163.mct-13-0464 
Narayanan, D. L., Saladi, R. N., & Fox, J. L. (2010). Ultraviolet radiation and skin cancer. 
Int J Dermatol, 49(9), 978-986. doi:10.1111/j.1365-4632.2010.04474.x 
Nasti, S., Pastorino, L., Bruno, W., Gargiulo, S., Battistuzzi, L., Zavattaro, E., Leigheb, G., 
De Francesco, V., Tulli, A., Mari, F., Scarra, G. B., & Ghiorzo, P. (2009). Five novel 
germline function-impairing mutations of CYLD in Italian patients with multiple 
cylindromas. Clin Genet, 76(5), 481-485. doi:10.1111/j.1399-0004.2009.01259.x 
Navarrete-Dechent, C., Bajaj, S., Marghoob, A. A., Gonzalez, S., & Munoz, D. (2016). 
Multiple familial trichoepithelioma: confirmation via dermoscopy. Dermatol 
Pract Concept, 6(3), 51-54. doi:10.5826/dpc.0603a10 
Ness, S. A. (2003). Myb protein specificity: evidence of a context-specific transcription 
factor code. Blood Cells Mol Dis, 31(2), 192-200.  
Ng, Y. P., Cheung, Z. H., & Ip, N. Y. (2006). STAT3 as a downstream mediator of Trk 
signaling and functions. J Biol Chem, 281(23), 15636-15644. 
doi:10.1074/jbc.M601863200 
Nikolaou, K., Tsagaratou, A., Eftychi, C., Kollias, G., Mosialos, G., & Talianidis, I. (2012). 
Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, 
inflammation, fibrosis, and cancer. Cancer Cell, 21(6), 738-750. 
doi:10.1016/j.ccr.2012.04.026 
Nilsson, M., Unden, A. B., Krause, D., Malmqwist, U., Raza, K., Zaphiropoulos, P. G., & 
Toftgard, R. (2000). Induction of basal cell carcinomas and trichoepitheliomas 
in mice overexpressing GLI-1. Proc Natl Acad Sci U S A, 97(7), 3438-3443. 
doi:10.1073/pnas.050467397 
  282 
Ninkina, N., Grashchuck, M., Buchman, V. L., & Davies, A. M. (1997). TrkB variants with 
deletions in the leucine-rich motifs of the extracellular domain. J Biol Chem, 
272(20), 13019-13025.  
Nomoto, H., Takaiwa, M., Mouri, A., & Furukawa, S. (2007). Pro-region of 
neurotrophins determines the processing efficiency. Biochem Biophys Res 
Commun, 356(4), 919-924. doi:10.1016/j.bbrc.2007.03.059 
Nomura, T., Sakai, N., Sarai, A., Sudo, T., Kanei-Ishii, C., Ramsay, R. G., Favier, D., 
Gonda, T. J., & Ishii, S. (1993). Negative autoregulation of c-Myb activity by 
homodimer formation through the leucine zipper. J Biol Chem, 268(29), 21914-
21923.  
Nowell, C., & Radtke, F. (2013). Cutaneous Notch signaling in health and disease. Cold 
Spring Harb Perspect Med, 3(12), a017772. doi:10.1101/cshperspect.a017772 
Nykjaer, A., Lee, R., Teng, K. K., Jansen, P., Madsen, P., Nielsen, M. S., Jacobsen, C., 
Kliemannel, M., Schwarz, E., Willnow, T. E., Hempstead, B. L., & Petersen, C. M. 
(2004). Sortilin is essential for proNGF-induced neuronal cell death. Nature, 
427(6977), 843-848. doi:10.1038/nature02319 
Nykjaer, A., Willnow, T. E., & Petersen, C. M. (2005). p75NTR--live or let die. Curr Opin 
Neurobiol, 15(1), 49-57. doi:10.1016/j.conb.2005.01.004 
O'Leary, R., Arrowsmith, M., & Wood, E. J. (2002). Characterization of the living skin 
equivalent as a model of cutaneous re-epithelialization. Cell Biochem Funct, 
20(2), 129-141. doi:10.1002/cbf.965 
O'Rourke, J. P., & Ness, S. A. (2008). Alternative RNA splicing produces multiple forms 
of c-Myb with unique transcriptional activities. Mol Cell Biol, 28(6), 2091-2101. 
doi:10.1128/mcb.01870-07 
Obaidat, N. A., Alsaad, K. O., & Ghazarian, D. (2007). Skin adnexal neoplasms--part 2: 
an approach to tumours of cutaneous sweat glands. J Clin Pathol, 60(2), 145-
159. doi:10.1136/jcp.2006.041608 
Oh, I. H., & Reddy, E. P. (1998). The C-terminal domain of B-Myb acts as a positive 
regulator of transcription and modulates its biological functions. Mol Cell Biol, 
18(1), 499-511.  
Oh, I. H., & Reddy, E. P. (1999). The myb gene family in cell growth, differentiation and 
apoptosis. Oncogene, 18(19), 3017-3033. doi:10.1038/sj.onc.1202839 
Ohira, K., Kumanogoh, H., Sahara, Y., Homma, K. J., Hirai, H., Nakamura, S., & Hayashi, 
M. (2005). A Truncated Tropo-Myosine-Related Kinase B Receptor, T1, 
Regulates Glial Cell Morphology via Rho GDP Dissociation Inhibitor 1. The 
Journal of Neuroscience, 25(6), 1343-1353. doi:10.1523/jneurosci.4436-04.2005 
Ohyama, M. (2007). Hair follicle bulge: a fascinating reservoir of epithelial stem cells. J 
Dermatol Sci, 46(2), 81-89. doi:10.1016/j.jdermsci.2006.12.002 
Okada, S., Yokoyama, M., Toko, H., Tateno, K., Moriya, J., Shimizu, I., Nojima, A., Ito, T., 
Yoshida, Y., Kobayashi, Y., Katagiri, H., Minamino, T., & Komuro, I. (2012). Brain-
derived neurotrophic factor protects against cardiac dysfunction after 
myocardial infarction via a central nervous system-mediated pathway. 
Arterioscler Thromb Vasc Biol, 32(8), 1902-1909. 
doi:10.1161/atvbaha.112.248930 
Oosterkamp, H. M., Neering, H., Nijman, S. M., Dirac, A. M., Mooi, W. J., Bernards, R., 
& Brummelkamp, T. R. (2006). An evaluation of the efficacy of topical 
application of salicylic acid for the treatment of familial cylindromatosis. Br J 
Dermatol, 155(1), 182-185. doi:10.1111/j.1365-2133.2006.07224.x 
  283 
Oranje, A. P., Halley, D., den Hollander, J. C., Teepe, R. G., van de Graaf, R., van den 
Ouweland, A., & Wagner, A. (2008). Multiple familial trichoepithelioma and 
familial cylindroma: one cause! J Eur Acad Dermatol Venereol, 22(11), 1395-
1396. doi:10.1111/j.1468-3083.2008.02648.x 
Ouwens, D. M., de Ruiter, N. D., van der Zon, G. C., Carter, A. P., Schouten, J., van der 
Burgt, C., Kooistra, K., Bos, J. L., Maassen, J. A., & van Dam, H. (2002). Growth 
factors can activate ATF2 via a two-step mechanism: phosphorylation of Thr71 
through the Ras-MEK-ERK pathway and of Thr69 through RalGDS-Src-p38. 
EMBO J, 21(14), 3782-3793. doi:10.1093/emboj/cdf361 
Palazzo, E., Marconi, A., Truzzi, F., Dallaglio, K., Petrachi, T., Humbert, P., Schnebert, S., 
Perrier, E., Dumas, M., & Pincelli, C. (2012). Role of neurotrophins on dermal 
fibroblast survival and differentiation. J Cell Physiol, 227(3), 1017-1025. 
doi:10.1002/jcp.22811 
Pandya, C., Kutiyanawalla, A., Turecki, G., & Pillai, A. (2014). Glucocorticoid regulates 
TrkB protein levels via c-Cbl dependent ubiquitination: a decrease in c-Cbl 
mRNA in the prefrontal cortex of suicide subjects. Psychoneuroendocrinology, 
45, 108-118. doi:10.1016/j.psyneuen.2014.03.020 
Pannem, R. R., Dorn, C., Hellerbrand, C., & Massoumi, R. (2014). Cylindromatosis gene 
CYLD regulates hepatocyte growth factor expression in hepatic stellate cells 
through interaction with histone deacetylase 7. Hepatology, 60(3), 1066-1081. 
doi:10.1002/hep.27209 
Parren, L. J., Ferdinandus, P., van der Hulst, R., Frank, J., & Tuinder, S. (2014). A novel 
therapeutic strategy for turban tumor: scalp excision and combined 
reconstruction with artificial dermis and split skin graft. Int J Dermatol, 53(2), 
246-249. doi:10.1111/ijd.12199 
Pasini, L., Re, A., Tebaldi, T., Ricci, G., Boi, S., Adami, V., Barbareschi, M., & Quattrone, 
A. (2015). TrkA is amplified in malignant melanoma patients and induces an 
anti-proliferative response in cell lines. BMC Cancer, 15, 777. 
doi:10.1186/s12885-015-1791-y 
Patapoutian, A., & Reichardt, L. F. (2001). Trk receptors: mediators of neurotrophin 
action. Curr Opin Neurobiol, 11(3), 272-280.  
Penneys, N. S., & Kaiser, M. (1993). Cylindroma expresses immunohistochemical 
markers linking it to eccrine coil. J Cutan Pathol, 20(1), 40-43.  
Pereira, L. A., Hugo, H. J., Malaterre, J., Huiling, X., Sonza, S., Cures, A., Purcell, D. F., 
Ramsland, P. A., Gerondakis, S., Gonda, T. J., & Ramsay, R. G. (2015). MYB 
elongation is regulated by the nucleic acid binding of NFkappaB p50 to the 
intronic stem-loop region. PLoS One, 10(4), e0122919. 
doi:10.1371/journal.pone.0122919 
Persson, M., Andren, Y., Mark, J., Horlings, H. M., Persson, F., & Stenman, G. (2009). 
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of 
the breast and head and neck. Proc Natl Acad Sci U S A, 106(44), 18740-18744. 
doi:10.1073/pnas.0909114106 
Persson, M., Andren, Y., Moskaluk, C. A., Frierson, H. F., Jr., Cooke, S. L., Futreal, P. A., 
Kling, T., Nelander, S., Nordkvist, A., Persson, F., & Stenman, G. (2012). 
Clinically significant copy number alterations and complex rearrangements of 
MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes 
Cancer, 51(8), 805-817. doi:10.1002/gcc.21965 
Peters, E. M., Hansen, M. G., Overall, R. W., Nakamura, M., Pertile, P., Klapp, B. F., 
Arck, P. C., & Paus, R. (2005). Control of human hair growth by neurotrophins: 
  284 
brain-derived neurotrophic factor inhibits hair shaft elongation, induces 
catagen, and stimulates follicular transforming growth factor beta2 expression. 
J Invest Dermatol, 124(4), 675-685. doi:10.1111/j.0022-202X.2005.23648.x 
Peters, E. M., Stieglitz, M. G., Liezman, C., Overall, R. W., Nakamura, M., Hagen, E., 
Klapp, B. F., Arck, P., & Paus, R. (2006). p75 Neurotrophin Receptor-Mediated 
Signaling Promotes Human Hair Follicle Regression (Catagen). Am J Pathol, 
168(1), 221-234. doi:10.2353/ajpath.2006.050163 
Petersen, O. W., Ronnov-Jessen, L., Howlett, A. R., & Bissell, M. J. (1992). Interaction 
with basement membrane serves to rapidly distinguish growth and 
differentiation pattern of normal and malignant human breast epithelial cells. 
Proc Natl Acad Sci U S A, 89(19), 9064-9068.  
Petersson, F., Kutzner, H., Spagnolo, D. V., Bisceglia, M., Kacerovska, D., Vazmitel, M., 
Michal, M., & Kazakov, D. V. (2009). Adenoid cystic carcinoma-like pattern in 
spiradenoma and spiradenocylindroma: a rare feature in sporadic neoplasms 
and those associated with Brooke-Spiegler syndrome. Am J Dermatopathol, 
31(7), 642-648. doi:10.1097/DAD.0b013e3181a1573e 
Piccinini, F. (2015). AnaSP: a software suite for automatic image analysis of 
multicellular spheroids. Comput Methods Programs Biomed, 119(1), 43-52. 
doi:10.1016/j.cmpb.2015.02.006 
Piccinini, F., Tesei, A., Arienti, C., & Bevilacqua, A. (2015). Cancer multicellular 
spheroids: volume assessment from a single 2D projection. Comput Methods 
Programs Biomed, 118(2), 95-106. doi:10.1016/j.cmpb.2014.12.003 
Pickart, C. M., & Eddins, M. J. (2004). Ubiquitin: structures, functions, mechanisms. 
Biochim Biophys Acta, 1695(1-3), 55-72. doi:10.1016/j.bbamcr.2004.09.019 
Pincelli, C., Sevignani, C., Manfredini, R., Grande, A., Fantini, F., Bracci-Laudiero, L., 
Aloe, L., Ferrari, S., Cossarizza, A., & Giannetti, A. (1994). Expression and 
function of nerve growth factor and nerve growth factor receptor on cultured 
keratinocytes. Journal of Investigative Dermatology, 103(1), 13-18.  
Pincelli, C., & Yaar, M. (1997). Nerve growth factor: its significance in cutaneous 
biology. J Investig Dermatol Symp Proc, 2(1), 31-36.  
Powell, B. C., Passmore, E. A., Nesci, A., & Dunn, S. M. (1998). The Notch signalling 
pathway in hair growth. Mech Dev, 78(1-2), 189-192.  
Prinzhorn, W., Stehle, M., Kleiner, H., Ruppenthal, S., Muller, M. C., Hofmann, W. K., 
Fabarius, A., & Seifarth, W. (2016). c-MYB is a transcriptional regulator of 
ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia. Biomark Res, 4, 
5. doi:10.1186/s40364-016-0059-2 
Proenca, C. C., Song, M., & Lee, F. S. (2016). Differential effects of BDNF and 
neurotrophin 4 (NT4) on endocytic sorting of TrkB receptors. J Neurochem, 
138(3), 397-406. doi:10.1111/jnc.13676 
Qian, X., Riccio, A., Zhang, Y., & Ginty, D. D. (1998). Identification and characterization 
of novel substrates of Trk receptors in developing neurons. Neuron, 21(5), 
1017-1029.  
Quintana, A. M., Liu, F., O'Rourke, J. P., & Ness, S. A. (2011). Identification and 
regulation of c-Myb target genes in MCF-7 cells. BMC Cancer, 11, 30. 
doi:10.1186/1471-2407-11-30 
Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., & Jacobson, M. D. (1993). 
Programmed cell death and the control of cell survival: lessons from the 
nervous system. Science, 262(5134), 695-700.  
  285 
Rajagopalan, H., Jallepalli, P. V., Rago, C., Velculescu, V. E., Kinzler, K. W., Vogelstein, 
B., & Lengauer, C. (2004). Inactivation of hCDC4 can cause chromosomal 
instability. Nature, 428(6978), 77-81. doi:10.1038/nature02313 
Rajan, N., Andersson, M. K., Sinclair, N., Fehr, A., Hodgson, K., Lord, C. J., Kazakov, D. 
V., Vanecek, T., Ashworth, A., & Stenman, G. (2016). Overexpression of MYB 
drives proliferation of CYLD-defective cylindroma cells. J Pathol, 239(2), 197-
205. doi:10.1002/path.4717 
Rajan, N., & Ashworth, A. (2015). Inherited cylindromas: lessons from a rare tumour. 
Lancet Oncol, 16(9), e460-469. doi:10.1016/s1470-2045(15)00245-4 
Rajan, N., Burn, J., Langtry, J., Sieber-Blum, M., Lord, C. J., & Ashworth, A. (2011). 
Transition from cylindroma to spiradenoma in CYLD-defective tumours is 
associated with reduced DKK2 expression. J Pathol, 224(3), 309-321. 
doi:10.1002/path.2896 
Rajan, N., Elliott, R., Clewes, O., Mackay, A., Reis-Filho, J. S., Burn, J., Langtry, J., Sieber-
Blum, M., Lord, C. J., & Ashworth, A. (2011). Dysregulated TRK signalling is a 
therapeutic target in CYLD defective tumours. Oncogene, 30(41), 4243-4260. 
doi:10.1038/onc.2011.133 
Rajan, N., Elliott, R. J., Smith, A., Sinclair, N., Swift, S., Lord, C. J., & Ashworth, A. (2014). 
The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch 
signalling. Oncotarget, 5(23), 12126-12140. doi:10.18632/oncotarget.2573 
Rajan, N., Langtry, J. A., Ashworth, A., Roberts, C., Chapman, P., Burn, J., & Trainer, A. 
H. (2009). Tumor mapping in 2 large multigenerational families with CYLD 
mutations: implications for disease management and tumor induction. Arch 
Dermatol, 145(11), 1277-1284. doi:10.1001/archdermatol.2009.262 
Rajan, N., Trainer, A. H., Burn, J., & Langtry, J. A. (2009). Familial cylindromatosis and 
brooke-spiegler syndrome: a review of current therapeutic approaches and the 
surgical challenges posed by two affected families. Dermatol Surg, 35(5), 845-
852. doi:10.1111/j.1524-4725.2009.01142.x 
Ramsay, R. G., & Gonda, T. J. (2008). MYB function in normal and cancer cells. Nat Rev 
Cancer, 8(7), 523-534. doi:10.1038/nrc2439 
Ramsay, R. G., Ikeda, K., Rifkind, R. A., & Marks, P. A. (1986). Changes in gene 
expression associated with induced differentiation of erythroleukemia: 
protooncogenes, globin genes, and cell division. Proc Natl Acad Sci U S A, 
83(18), 6849-6853.  
Ramsay, R. G., Ishii, S., & Gonda, T. J. (1992). Interaction of the Myb protein with 
specific DNA binding sites. J Biol Chem, 267(8), 5656-5662.  
Ramsay, R. G., Thompson, M. A., Hayman, J. A., Reid, G., Gonda, T. J., & Whitehead, R. 
H. (1992). Myb expression is higher in malignant human colonic carcinoma and 
premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ, 
3(10), 723-730.  
Rao, D., Macias, E., Carbajal, S., Kiguchi, K., & DiGiovanni, J. (2015). Constitutive Stat3 
activation alters behavior of hair follicle stem and progenitor cell populations. 
Mol Carcinog, 54(2), 121-133. doi:10.1002/mc.22080 
Raschella, G., Cesi, V., Amendola, R., Negroni, A., Tanno, B., Altavista, P., Tonini, G. P., 
De Bernardi, B., & Calabretta, B. (1999). Expression of B-myb in neuroblastoma 
tumors is a poor prognostic factor independent from MYCN amplification. 
Cancer Res, 59(14), 3365-3368.  
  286 
Rasmussen, C., Thomas-Virnig, C., & Allen-Hoffmann, B. L. (2013). Classical human 
epidermal keratinocyte cell culture. Methods Mol Biol, 945, 161-175. 
doi:10.1007/978-1-62703-125-7_11 
Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E., & Solomon, F. D. (2015). 3D cell 
culture systems: advantages and applications. J Cell Physiol, 230(1), 16-26. 
doi:10.1002/jcp.24683 
Reddy, S., Andl, T., Bagasra, A., Lu, M. M., Epstein, D. J., Morrisey, E. E., & Millar, S. E. 
(2001). Characterization of Wnt gene expression in developing and postnatal 
hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair 
follicle morphogenesis. Mech Dev, 107(1-2), 69-82.  
Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philos Trans R Soc 
Lond B Biol Sci, 361(1473), 1545-1564. doi:10.1098/rstb.2006.1894 
Reiley, W., Zhang, M., & Sun, S. C. (2004). Negative regulation of JNK signaling by the 
tumor suppressor CYLD. J Biol Chem, 279(53), 55161-55167. 
doi:10.1074/jbc.M411049200 
Reiley, W., Zhang, M., Wu, X., Granger, E., & Sun, S. C. (2005). Regulation of the 
deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent 
phosphorylation. Mol Cell Biol, 25(10), 3886-3895. 
doi:10.1128/mcb.25.10.3886-3895.2005 
Reiley, W. W., Jin, W., Lee, A. J., Wright, A., Wu, X., Tewalt, E. F., Leonard, T. O., 
Norbury, C. C., Fitzpatrick, L., Zhang, M., & Sun, S. C. (2007). Deubiquitinating 
enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and 
prevents abnormal T cell responses. J Exp Med, 204(6), 1475-1485. 
doi:10.1084/jem.20062694 
Reiley, W. W., Zhang, M., Jin, W., Losiewicz, M., Donohue, K. B., Norbury, C. C., & Sun, 
S. C. (2006). Regulation of T cell development by the deubiquitinating enzyme 
CYLD. Nat Immunol, 7(4), 411-417. doi:10.1038/ni1315 
Ren, X., Duan, L., He, Q., Zhang, Z., Zhou, Y., Wu, D., Pan, J., Pei, D., & Ding, K. (2010). 
Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 
Signaling Pathway. ACS Med Chem Lett, 1(9), 454-459. doi:10.1021/ml100146z 
Renn, C. L., Leitch, C. C., & Dorsey, S. G. (2009). In vivo evidence that truncated trkB.T1 
participates in nociception. Mol Pain, 5, 61. doi:10.1186/1744-8069-5-61 
Rheinwald, J. G., & Green, H. (1975). Serial cultivation of strains of human epidermal 
keratinocytes: the formation of keratinizing colonies from single cells. Cell, 6(3), 
331-343.  
Ricci, A., Greco, S., Mariotta, S., Felici, L., Bronzetti, E., Cavazzana, A., Cardillo, G., 
Amenta, F., Bisetti, A., & Barbolini, G. (2001). Neurotrophins and neurotrophin 
receptors in human lung cancer. Am J Respir Cell Mol Biol, 25(4), 439-446. 
doi:10.1165/ajrcmb.25.4.4470 
Riccio, A., Ahn, S., Davenport, C. M., Blendy, J. A., & Ginty, D. D. (1999). Mediation by a 
CREB family transcription factor of NGF-dependent survival of sympathetic 
neurons. Science, 286(5448), 2358-2361.  
Rimann, M., & Graf-Hausner, U. (2012). Synthetic 3D multicellular systems for drug 
development. Curr Opin Biotechnol, 23(5), 803-809. 
doi:10.1016/j.copbio.2012.01.011 
Rishikaysh, P., Dev, K., Diaz, D., Qureshi, W. M., Filip, S., & Mokry, J. (2014). Signaling 
involved in hair follicle morphogenesis and development. Int J Mol Sci, 15(1), 
1647-1670. doi:10.3390/ijms15011647 
  287 
Rittinger, K., & Ikeda, F. (2017). Linear ubiquitin chains: enzymes, mechanisms and 
biology. Open Biol, 7(4). doi:10.1098/rsob.170026 
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., 
Waterfield, M. D., & Downward, J. (1994). Phosphatidylinositol-3-OH kinase as 
a direct target of Ras. Nature, 370(6490), 527-532. doi:10.1038/370527a0 
Rose, C. R., Blum, R., Pichler, B., Lepier, A., Kafitz, K. W., & Konnerth, A. (2003). 
Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia 
cells. Nature, 426(6962), 74-78. doi:10.1038/nature01983 
Rossler, O. G., & Thiel, G. (2004). Brain-derived neurotrophic factor-, epidermal growth 
factor-, or A-Raf-induced growth of HaCaT keratinocytes requires extracellular 
signal-regulated kinase. Am J Physiol Cell Physiol, 286(5), C1118-1129. 
doi:10.1152/ajpcell.00301.2003 
Roux, P. P., & Barker, P. A. (2002). Neurotrophin signaling through the p75 
neurotrophin receptor. Prog Neurobiol, 67(3), 203-233.  
Rushton, J. J., Davis, L. M., Lei, W., Mo, X., Leutz, A., & Ness, S. A. (2003). Distinct 
changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins. 
Oncogene, 22(2), 308-313. doi:10.1038/sj.onc.1206131 
Rushton, J. J., & Ness, S. A. (2001). The conserved DNA binding domain mediates 
similar regulatory interactions for A-Myb, B-Myb, and c-Myb transcription 
factors. Blood Cells Mol Dis, 27(2), 459-463. doi:10.1006/bcmd.2001.0405 
Rutter, K. J., & Judge, M. R. (2009). Profuse congenital milia in a family. Pediatr 
Dermatol, 26(1), 62-64. doi:10.1111/j.1525-1470.2008.00824.x 
Saikumar, P., Murali, R., & Reddy, E. P. (1990). Role of tryptophan repeats and flanking 
amino acids in Myb-DNA interactions. Proc Natl Acad Sci U S A, 87(21), 8452-
8456.  
Sakamoto, H., Dai, G., Tsujino, K., Hashimoto, K., Huang, X., Fujimoto, T., Mucenski, M., 
Frampton, J., & Ogawa, M. (2006). Proper levels of c-Myb are discretely defined 
at distinct steps of hematopoietic cell development. Blood, 108(3), 896-903. 
doi:10.1182/blood-2005-09-3846 
Sakura, H., Kanei-Ishii, C., Nagase, T., Nakagoshi, H., Gonda, T. J., & Ishii, S. (1989). 
Delineation of three functional domains of the transcriptional activator 
encoded by the c-myb protooncogene. Proc Natl Acad Sci U S A, 86(15), 5758-
5762.  
Salehi, A. H., Roux, P. P., Kubu, C. J., Zeindler, C., Bhakar, A., Tannis, L. L., Verdi, J. M., & 
Barker, P. A. (2000). NRAGE, a novel MAGE protein, interacts with the p75 
neurotrophin receptor and facilitates nerve growth factor-dependent 
apoptosis. Neuron, 27(2), 279-288.  
Salhi, A., Bornholdt, D., Oeffner, F., Malik, S., Heid, E., Happle, R., & Grzeschik, K. H. 
(2004). Multiple familial trichoepithelioma caused by mutations in the 
cylindromatosis tumor suppressor gene. Cancer Res, 64(15), 5113-5117. 
doi:10.1158/0008-5472.can-04-0307 
Samal, R., Ameling, S., Dhople, V., Sappa, P. K., Wenzel, K., Volker, U., Felix, S. B., 
Hammer, E., & Konemann, S. (2015). Brain derived neurotrophic factor 
contributes to the cardiogenic potential of adult resident progenitor cells in 
failing murine heart. PLoS One, 10(3), e0120360. 
doi:10.1371/journal.pone.0120360 
Sampurno, S., Cross, R., Pearson, H., Kaur, P., Malaterre, J., & Ramsay, R. G. (2015). 
Myb via TGFbeta is required for collagen type 1 production and skin integrity. 
Growth Factors, 33(2), 102-112. doi:10.3109/08977194.2015.1016222 
  288 
Sanchez-Sanchez, J., & Arevalo, J. C. (2017). A Review on Ubiquitination of 
Neurotrophin Receptors: Facts and Perspectives. Int J Mol Sci, 18(3). 
doi:10.3390/ijms18030630 
Sandberg, M. L., Sutton, S. E., Pletcher, M. T., Wiltshire, T., Tarantino, L. M., 
Hogenesch, J. B., & Cooke, M. P. (2005). c-Myb and p300 regulate 
hematopoietic stem cell proliferation and differentiation. Dev Cell, 8(2), 153-
166. doi:10.1016/j.devcel.2004.12.015 
Sandberg, R., & Ernberg, I. (2005). The molecular portrait of in vitro growth by meta-
analysis of gene-expression profiles. Genome Biol, 6(8), R65. doi:10.1186/gb-
2005-6-8-r65 
Sano, Y., & Ishii, S. (2001). Increased affinity of c-Myb for CREB-binding protein (CBP) 
after CBP-induced acetylation. J Biol Chem, 276(5), 3674-3682. 
doi:10.1074/jbc.M006896200 
Saragovi, H. U., Zheng, W., Maliartchouk, S., DiGugliemo, G. M., Mawal, Y. R., Kamen, 
A., Woo, S. B., Cuello, A. C., Debeir, T., & Neet, K. E. (1998). A TrkA-selective, 
fast internalizing nerve growth factor-antibody complex induces trophic but not 
neuritogenic signals. J Biol Chem, 273(52), 34933-34940.  
Sariola, H. (2001). The neurotrophic factors in non-neuronal tissues. Cell Mol Life Sci, 
58(8), 1061-1066. doi:10.1007/pl00000921 
Sato, M., Rodriguez-Barrueco, R., Yu, J., Do, C., Silva, J. M., & Gautier, J. (2015). MYC is 
a critical target of FBXW7. Oncotarget, 6(5), 3292-3305. 
doi:10.18632/oncotarget.3203 
Sato, Y., Goto, E., Shibata, Y., Kubota, Y., Yamagata, A., Goto-Ito, S., Kubota, K., Inoue, 
J., Takekawa, M., Tokunaga, F., & Fukai, S. (2015). Structures of CYLD USP with 
Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity. Nat 
Struct Mol Biol, 22(3), 222-229. doi:10.1038/nsmb.2970 
Scala, S., Wosikowski, K., Giannakakou, P., Valle, P., Biedler, J. L., Spengler, B. A., 
Lucarelli, E., Bates, S. E., & Thiele, C. J. (1996). Brain-derived neurotrophic 
factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res, 
56(16), 3737-3742.  
Schneider, L., Clement, C. A., Teilmann, S. C., Pazour, G. J., Hoffmann, E. K., Satir, P., & 
Christensen, S. T. (2005). PDGFRalphaalpha signaling is regulated through the 
primary cilium in fibroblasts. Curr Biol, 15(20), 1861-1866. 
doi:10.1016/j.cub.2005.09.012 
Schulz, T., Proske, S., Hartschuh, W., Kurzen, H., Paul, E., & Wunsch, P. H. (2005). High-
grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal 
neoplasm often showing metastatic spread. Am J Dermatopathol, 27(1), 9-16.  
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006). Stattic: a small-molecule 
inhibitor of STAT3 activation and dimerization. Chem Biol, 13(11), 1235-1242. 
doi:10.1016/j.chembiol.2006.09.018 
Sclabas, G. M., Fujioka, S., Schmidt, C., Li, Z., Frederick, W. A., Yang, W., Yokoi, K., 
Evans, D. B., Abbruzzese, J. L., Hess, K. R., Zhang, W., Fidler, I. J., & Chiao, P. J. 
(2005). Overexpression of tropomysin-related kinase B in metastatic human 
pancreatic cancer cells. Clin Cancer Res, 11(2 Pt 1), 440-449.  
Sellheyer, K. (2015). Spiradenoma and cylindroma originate from the hair follicle bulge 
and not from the eccrine sweat gland: an immunohistochemical study with 
CD200 and other stem cell markers. J Cutan Pathol, 42(2), 90-101. 
doi:10.1111/cup.12406 
  289 
Serracino, H. S., & Kleinschmidt-Demasters, B. K. (2013). Skull invaders: when surgical 
pathology and neuropathology worlds collide. J Neuropathol Exp Neurol, 72(7), 
600-613. doi:10.1097/NEN.0b013e318299c40f 
Shao, H., Cheng, H. Y., Cook, R. G., & Tweardy, D. J. (2003). Identification and 
characterization of signal transducer and activator of transcription 3 
recruitment sites within the epidermal growth factor receptor. Cancer Res, 
63(14), 3923-3930.  
Shelton, D. L., Sutherland, J., Gripp, J., Camerato, T., Armanini, M. P., Phillips, H. S., 
Carroll, K., Spencer, S. D., & Levinson, A. D. (1995). Human trks: molecular 
cloning, tissue distribution, and expression of extracellular domain 
immunoadhesins. J Neurosci, 15(1 Pt 2), 477-491.  
Shibayama, E., & Koizumi, H. (1996). Cellular localisation of the Trk neurotrophin 
receptor family in human non-neuronal tissues. American Journal of Pathology, 
148(6), 1807-1818.  
Shih, V. F., Tsui, R., Caldwell, A., & Hoffmann, A. (2011). A single NFkappaB system for 
both canonical and non-canonical signaling. Cell Res, 21(1), 86-102. 
doi:10.1038/cr.2010.161 
Shin, D. S., Kim, H. N., Shin, K. D., Yoon, Y. J., Kim, S. J., Han, D. C., & Kwon, B. M. 
(2009). Cryptotanshinone inhibits constitutive signal transducer and activator 
of transcription 3 function through blocking the dimerization in DU145 prostate 
cancer cells. Cancer Res, 69(1), 193-202. doi:10.1158/0008-5472.can-08-2575 
Sicinska, J., Rakowska, A., Czuwara-Ladykowska, J., Mroz, A., Lipinski, M., Nasierowska-
Guttmejer, A., Sikorska, J., Sklinda, K., Slowinska, M., Kowalska-Oledzka, E., 
Walecka, I., Walecki, J., & Rudnicka, L. (2007). Cylindroma transforming into 
basal cell carcinoma in a patient with Brooke-Spiegler syndrome. J Dermatol 
Case Rep, 1(1), 4-9. doi:10.3315/jdcr.2007.1.1002 
Siddiquee, K., Zhang, S., Guida, W. C., Blaskovich, M. A., Greedy, B., Lawrence, H. R., 
Yip, M. L., Jove, R., McLaughlin, M. M., Lawrence, N. J., Sebti, S. M., & Turkson, 
J. (2007). Selective chemical probe inhibitor of Stat3, identified through 
structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci 
U S A, 104(18), 7391-7396. doi:10.1073/pnas.0609757104 
Sinkevicius, K. W., Kriegel, C., Bellaria, K. J., Lee, J., Lau, A. N., Leeman, K. T., Zhou, P., 
Beede, A. M., Fillmore, C. M., Caswell, D., Barrios, J., Wong, K. K., Sholl, L. M., 
Schlaeger, T. M., Bronson, R. T., Chirieac, L. R., Winslow, M. M., Haigis, M. C., & 
Kim, C. F. (2014). Neurotrophin receptor TrkB promotes lung adenocarcinoma 
metastasis. Proc Natl Acad Sci U S A, 111(28), 10299-10304. 
doi:10.1073/pnas.1404399111 
Skaper, S. D. (2012). The neurotrophin family of neurotrophic factors: an overview. 
Methods Mol Biol, 846, 1-12. doi:10.1007/978-1-61779-536-7_1 
Skeldal, S., Sykes, A. M., Glerup, S., Matusica, D., Palstra, N., Autio, H., Boskovic, Z., 
Madsen, P., Castren, E., Nykjaer, A., & Coulson, E. J. (2012). Mapping of the 
interaction site between sortilin and the p75 neurotrophin receptor reveals a 
regulatory role for the sortilin intracellular domain in p75 neurotrophin 
receptor shedding and apoptosis. J Biol Chem, 287(52), 43798-43809. 
doi:10.1074/jbc.M112.374710 
Smeyne, R. J., Klein, R., Schnapp, A., Long, L. K., Bryant, S., Lewin, A., Lira, S. A., & 
Barbacid, M. (1994). Severe sensory and sympathetic neuropathies in mice 
carrying a disrupted Trk/NGF receptor gene. Nature, 368(6468), 246-249. 
doi:10.1038/368246a0 
  290 
Sorrell, J. M., & Caplan, A. I. (2004). Fibroblast heterogeneity: more than skin deep. J 
Cell Sci, 117(Pt 5), 667-675. doi:10.1242/jcs.01005 
Spruck, C. H., Strohmaier, H., Sangfelt, O., Muller, H. M., Hubalek, M., Muller-Holzner, 
E., Marth, C., Widschwendter, M., & Reed, S. I. (2002). hCDC4 gene mutations 
in endometrial cancer. Cancer Res, 62(16), 4535-4539.  
Srokowski, C. C., Masri, J., Hovelmeyer, N., Krembel, A. K., Tertilt, C., Strand, D., 
Mahnke, K., Massoumi, R., Waisman, A., & Schild, H. (2009). Naturally occurring 
short splice variant of CYLD positively regulates dendritic cell function. Blood, 
113(23), 5891-5895. doi:10.1182/blood-2008-08-175489 
Stefanato, C. M., Yaar, M., Bhawan, J., Phillips, T. J., Kosmadaki, M. G., Botchkarev, V., 
& Gilchrest, B. A. (2003). Modulations of nerve growth factor and Bcl-2 in 
ultraviolet-irradiated human epidermis. J Cutan Pathol, 30(6), 351-357.  
Stegmeier, F., Sowa, M. E., Nalepa, G., Gygi, S. P., Harper, J. W., & Elledge, S. J. (2007). 
The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S 
A, 104(21), 8869-8874. doi:10.1073/pnas.0703268104 
Stenman, G., Andersson, M. K., & Andren, Y. (2010). New tricks from an old oncogene: 
gene fusion and copy number alterations of MYB in human cancer. Cell Cycle, 
9(15), 2986-2995. doi:10.4161/cc.9.15.12515 
Stenman, G., Persson, F., & Andersson, M. K. (2014). Diagnostic and therapeutic 
implications of new molecular biomarkers in salivary gland cancers. Oral Oncol, 
50(8), 683-690. doi:10.1016/j.oraloncology.2014.04.008 
Stephens, P. J., Davies, H. R., Mitani, Y., Van Loo, P., Shlien, A., Tarpey, P. S., 
Papaemmanuil, E., Cheverton, A., Bignell, G. R., Butler, A. P., Gamble, J., 
Gamble, S., Hardy, C., Hinton, J., Jia, M., Jayakumar, A., Jones, D., Latimer, C., 
McLaren, S., McBride, D. J., Menzies, A., Mudie, L., Maddison, M., Raine, K., 
Nik-Zainal, S., O'Meara, S., Teague, J. W., Varela, I., Wedge, D. C., Whitmore, I., 
Lippman, S. M., McDermott, U., Stratton, M. R., Campbell, P. J., El-Naggar, A. K., 
& Futreal, P. A. (2013). Whole exome sequencing of adenoid cystic carcinoma. J 
Clin Invest, 123(7), 2965-2968. doi:10.1172/jci67201 
Stoilov, P., Castren, E., & Stamm, S. (2002). Analysis of the human TrkB gene genomic 
organization reveals novel TrkB isoforms, unusual gene length, and splicing 
mechanism. Biochem Biophys Res Commun, 290(3), 1054-1065. 
doi:10.1006/bbrc.2001.6301 
Stokes, A., Wakano, C., Koblan-Huberson, M., Adra, C. N., Fleig, A., & Turner, H. (2006). 
TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell 
Signal, 18(10), 1584-1594. doi:10.1016/j.cellsig.2005.12.009 
Strohmaier, C., Carter, B. D., Urfer, R., Barde, Y. A., & Dechant, G. (1996). A splice 
variant of the neurotrophin receptor trkB with increased specificity for brain-
derived neurotrophic factor. EMBO J, 15(13), 3332-3337.  
Suhasini, M., & Pilz, R. B. (1999). Transcriptional elongation of c-myb is regulated by 
NF-kappaB (p50/RelB). Oncogene, 18(51), 7360-7369. 
doi:10.1038/sj.onc.1203158 
Sun, L., Gao, J., Huo, L., Sun, X., Shi, X., Liu, M., Li, D., Zhang, C., & Zhou, J. (2010). 
Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B. 
J Pathol, 221(4), 425-432. doi:10.1002/path.2723 
Sun, S. C. (2010). CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB 
activation and diverse biological processes. Cell Death Differ, 17(1), 25-34. 
doi:10.1038/cdd.2009.43 
  291 
Swietach, P., Hulikova, A., Patiar, S., Vaughan-Jones, R. D., & Harris, A. L. (2012). 
Importance of intracellular pH in determining the uptake and efficacy of the 
weakly basic chemotherapeutic drug, doxorubicin. PLoS One, 7(4), e35949. 
doi:10.1371/journal.pone.0035949 
Szepietowski, J. C., Wasik, F., Szybejko-Machaj, G., Bieniek, A., & Schwartz, R. A. (2001). 
Brooke-Spiegler syndrome. J Eur Acad Dermatol Venereol, 15(4), 346-349.  
Tacconelli, A., Farina, A. R., Cappabianca, L., Cea, G., Panella, S., Chioda, A., Gallo, R., 
Cinque, B., Sferra, R., Vetuschi, A., Campese, A. F., Screpanti, I., Gulino, A., & 
Mackay, A. R. (2007). TrkAIII expression in the thymus. J Neuroimmunol, 183(1-
2), 151-161. doi:10.1016/j.jneuroim.2006.12.005 
Tacconelli, A., Farina, A. R., Cappabianca, L., Desantis, G., Tessitore, A., Vetuschi, A., 
Sferra, R., Rucci, N., Argenti, B., Screpanti, I., Gulino, A., & Mackay, A. R. (2004). 
TrkA alternative splicing: a regulated tumor-promoting switch in human 
neuroblastoma. Cancer Cell, 6(4), 347-360. doi:10.1016/j.ccr.2004.09.011 
Tahirov, T. H., Sato, K., Ichikawa-Iwata, E., Sasaki, M., Inoue-Bungo, T., Shiina, M., 
Kimura, K., Takata, S., Fujikawa, A., Morii, H., Kumasaka, T., Yamamoto, M., 
Ishii, S., & Ogata, K. (2002). Mechanism of c-Myb-C/EBP beta cooperation from 
separated sites on a promoter. Cell, 108(1), 57-70.  
Takahashi, M., Rapley, E., Biggs, P. J., Lakhani, S. R., Cooke, D., Hansen, J., Blair, E., 
Hofmann, B., Siebert, R., Turner, G., Evans, D. G., Schrander-Stumpel, C., 
Beemer, F. A., van Vloten, W. A., Breuning, M. H., van den Ouweland, A., Halley, 
D., Delpech, B., Cleveland, M., Leigh, I., Chapman, P., Burn, J., Hohl, D., Gorog, J. 
P., Seal, S., & Mangion, J. (2000). Linkage and LOH studies in 19 cylindromatosis 
families show no evidence of genetic heterogeneity and refine the CYLD locus 
on chromosome 16q12-q13. Hum Genet, 106(1), 58-65.  
Takahashi, Y., Shimokawa, N., Esmaeili-Mahani, S., Morita, A., Masuda, H., Iwasaki, T., 
Tamura, J., Haglund, K., & Koibuchi, N. (2011). Ligand-induced downregulation 
of TrkA is partly regulated through ubiquitination by Cbl. FEBS Lett, 585(12), 
1741-1747. doi:10.1016/j.febslet.2011.04.056 
Takeuchi, T., Adachi, Y., & Ohtsuki, Y. (2005). Skeletrophin, a novel ubiquitin ligase to 
the intracellular region of Jagged-2, is aberrantly expressed in multiple 
myeloma. Am J Pathol, 166(6), 1817-1826. doi:10.1016/s0002-9440(10)62491-1 
Tanaka, K., Okugawa, Y., Toiyama, Y., Inoue, Y., Saigusa, S., Kawamura, M., Araki, T., 
Uchida, K., Mohri, Y., & Kusunoki, M. (2014). Brain-derived neurotrophic factor 
(BDNF)-induced tropomyosin-related kinase B (Trk B) signaling is a potential 
therapeutic target for peritoneal carcinomatosis arising from colorectal cancer. 
PLoS One, 9(5), e96410. doi:10.1371/journal.pone.0096410 
Tanaka, Y., Patestos, N. P., Maekawa, T., & Ishii, S. (1999). B-myb is required for inner 
cell mass formation at an early stage of development. J Biol Chem, 274(40), 
28067-28070.  
Tang, A., Gao, K., Chu, L., Zhang, R., Yang, J., & Zheng, J. (2017). Aurora kinases: novel 
therapy targets in cancers. Oncotarget, 8(14), 23937-23954. 
doi:10.18632/oncotarget.14893 
Tauriello, D. V., Haegebarth, A., Kuper, I., Edelmann, M. J., Henraat, M., Canninga-van 
Dijk, M. R., Kessler, B. M., Clevers, H., & Maurice, M. M. (2010). Loss of the 
tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-
linked ubiquitination of Dvl. Mol Cell, 37(5), 607-619. 
doi:10.1016/j.molcel.2010.01.035 
  292 
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, 
R., Chen, Z. Y., Lee, F. S., Kraemer, R. T., Nykjaer, A., & Hempstead, B. L. (2005). 
ProBDNF induces neuronal apoptosis via activation of a receptor complex of 
p75NTR and sortilin. J Neurosci, 25(22), 5455-5463. 
doi:10.1523/jneurosci.5123-04.2005 
Tessarollo, L., Tsoulfas, P., Donovan, M. J., Palko, M. E., Blair-Flynn, J., Hempstead, B. 
L., & Parada, L. F. (1997). Targeted deletion of all isoforms of the trkC gene 
suggests the use of alternate receptors by its ligand neurotrophin-3 in neuronal 
development and implicates trkC in normal cardiogenesis. Proc Natl Acad Sci U 
S A, 94(26), 14776-14781.  
Thiele, C. J., Li, Z., & McKee, A. E. (2009). On Trk--the TrkB signal transduction pathway 
is an increasingly important target in cancer biology. Clin Cancer Res, 15(19), 
5962-5967. doi:10.1158/1078-0432.ccr-08-0651 
Thoenen, H., & Barde, Y. A. (1980). Physiology of nerve growth factor. Physiol Rev, 
60(4), 1284-1335.  
Thompson, M. A., Rosenthal, M. A., Ellis, S. L., Friend, A. J., Zorbas, M. I., Whitehead, R. 
H., & Ramsay, R. G. (1998). c-Myb down-regulation is associated with human 
colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer 
Res, 58(22), 5168-5175.  
Thorner, A. R., Hoadley, K. A., Parker, J. S., Winkel, S., Millikan, R. C., & Perou, C. M. 
(2009). In vitro and in vivo analysis of B-Myb in basal-like breast cancer. 
Oncogene, 28(5), 742-751. doi:10.1038/onc.2008.430 
Thorner, A. R., Parker, J. S., Hoadley, K. A., & Perou, C. M. (2010). Potential tumor 
suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One, 
5(10), e13073. doi:10.1371/journal.pone.0013073 
Thurber, G. M., & Wittrup, K. D. (2008). Quantitative spatiotemporal analysis of 
antibody fragment diffusion and endocytic consumption in tumor spheroids. 
Cancer Res, 68(9), 3334-3341. doi:10.1158/0008-5472.can-07-3018 
Tibbitt, M. W., & Anseth, K. S. (2009). Hydrogels as extracellular matrix mimics for 3D 
cell culture. Biotechnol Bioeng, 103(4), 655-663. doi:10.1002/bit.22361 
Tomita, A., Towatari, M., Tsuzuki, S., Hayakawa, F., Kosugi, H., Tamai, K., Miyazaki, T., 
Kinoshita, T., & Saito, H. (2000). c-Myb acetylation at the carboxyl-terminal 
conserved domain by transcriptional co-activator p300. Oncogene, 19(3), 444-
451. doi:10.1038/sj.onc.1203329 
Tong, X., & Coulombe, P. A. (2006). Keratin 17 modulates hair follicle cycling in a 
TNFalpha-dependent fashion. Genes Dev, 20(10), 1353-1364. 
doi:10.1101/gad.1387406 
Toscani, A., Mettus, R. V., Coupland, R., Simpkins, H., Litvin, J., Orth, J., Hatton, K. S., & 
Reddy, E. P. (1997). Arrest of spermatogenesis and defective breast 
development in mice lacking A-myb. Nature, 386(6626), 713-717. 
doi:10.1038/386713a0 
Tournier, C., Dong, C., Turner, T. K., Jones, S. N., Flavell, R. A., & Davis, R. J. (2001). 
MKK7 is an essential component of the JNK signal transduction pathway 
activated by proinflammatory cytokines. Genes Dev, 15(11), 1419-1426. 
doi:10.1101/gad.888501 
Trauth, K., Mutschler, B., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., & Klempnauer, 
K. H. (1994). Mouse A-myb encodes a trans-activator and is expressed in 
mitotically active cells of the developing central nervous system, adult testis 
and B lymphocytes. EMBO J, 13(24), 5994-6005.  
  293 
Tripathy, S. M., Somu, T. N., Sundaram, M., & Sadhiya, S. (2015). Malignant Cylindroma 
of Post Aural Region Involving the Temporal Bone. J Clin Diagn Res, 9(7), Md01-
02. doi:10.7860/jcdr/2015/13682.6232 
Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., & Mosialos, G. 
(2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB 
activation by TNFR family members. Nature, 424(6950), 793-796. 
doi:10.1038/nature01803 
Trompouki, E., Tsagaratou, A., Kosmidis, S. K., Dolle, P., Qian, J., Kontoyiannis, D. L., 
Cardoso, W. V., & Mosialos, G. (2009). Truncation of the catalytic domain of the 
cylindromatosis tumor suppressor impairs lung maturation. Neoplasia, 11(5), 
469-476.  
Troyanovsky, S. M., Guelstein, V. I., Tchipysheva, T. A., Krutovskikh, V. A., & Bannikov, 
G. A. (1989). Patterns of expression of keratin 17 in human epithelia: 
dependency on cell position. J Cell Sci, 93 ( Pt 3), 419-426.  
Truzzi, F., Marconi, A., Atzei, P., Panza, M. C., Lotti, R., Dallaglio, K., Tiberio, R., Palazzo, 
E., Vaschieri, C., & Pincelli, C. (2011). p75 neurotrophin receptor mediates 
apoptosis in transit-amplifying cells and its overexpression restores cell death 
in psoriatic keratinocytes. Cell Death Differ, 18(6), 948-958. 
doi:10.1038/cdd.2010.162 
Truzzi, F., Marconi, A., Lotti, R., Dallaglio, K., French, L. E., Hempstead, B. L., & Pincelli, 
C. (2008). Neurotrophins and their receptors stimulate melanoma cell 
proliferation and migration. J Invest Dermatol, 128(8), 2031-2040. 
doi:10.1038/jid.2008.21 
Tsai, Y. F., Tseng, L. M., Hsu, C. Y., Yang, M. H., Chiu, J. H., & Shyr, Y. M. (2017). Brain-
derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-
endothelial cells interaction and affects the outcomes of triple negative breast 
cancer. PLoS One, 12(6), e0178173. doi:10.1371/journal.pone.0178173 
Tsao, M. C., Walthall, B. J., & Ham, R. G. (1982). Clonal growth of normal human 
epidermal keratinocytes in a defined medium. J Cell Physiol, 110(2), 219-229. 
doi:10.1002/jcp.1041100217 
Tsoulfas, P., Soppet, D., Escandon, E., Tessarollo, L., Mendoza-Ramirez, J. L., Rosenthal, 
A., Nikolics, K., & Parada, L. F. (1993). The rat trkC locus encodes multiple 
neurogenic receptors that exhibit differential response to neurotrophin-3 in 
PC12 cells. Neuron, 10(5), 975-990.  
Tu, K., Liu, Z., Yao, B., Xue, Y., Xu, M., Dou, C., Yin, G., & Wang, J. (2016). BCL-3 
promotes the tumor growth of hepatocellular carcinoma by regulating cell 
proliferation and the cell cycle through cyclin D1. Oncol Rep, 35(4), 2382-2390. 
doi:10.3892/or.2016.4616 
Tunggal, L., Ravaux, J., Pesch, M., Smola, H., Krieg, T., Gaill, F., Sasaki, T., Timpl, R., 
Mauch, C., & Aumailley, M. (2002). Defective laminin 5 processing in 
cylindroma cells. Am J Pathol, 160(2), 459-468. doi:10.1016/s0002-
9440(10)64865-1 
Uede, K., Yamamoto, Y., & Furukawa, F. (2004). Brooke-Spiegler syndrome associated 
with cylindroma, trichoepithelioma, spiradenoma, and syringoma. J Dermatol, 
31(1), 32-38.  
Ultsch, M. H., Wiesmann, C., Simmons, L. C., Henrich, J., Yang, M., Reilly, D., Bass, S. H., 
& de Vos, A. M. (1999). Crystal structures of the neurotrophin-binding domain 
of TrkA, TrkB and TrkC. J Mol Biol, 290(1), 149-159. doi:10.1006/jmbi.1999.2816 
  294 
Underwood, C. K., & Coulson, E. J. (2008). The p75 neurotrophin receptor. Int J 
Biochem Cell Biol, 40(9), 1664-1668. doi:10.1016/j.biocel.2007.06.010 
Urbanik, T., Kohler, B. C., Boger, R. J., Worns, M. A., Heeger, S., Otto, G., Hovelmeyer, 
N., Galle, P. R., Schuchmann, M., Waisman, A., & Schulze-Bergkamen, H. (2011). 
Down-regulation of CYLD as a trigger for NF-kappaB activation and a 
mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J 
Oncol, 38(1), 121-131.  
Uren, R. T., & Turnley, A. M. (2014). Regulation of neurotrophin receptor (Trk) 
signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player. Front Mol 
Neurosci, 7, 39. doi:10.3389/fnmol.2014.00039 
Urfer, R., Tsoulfas, P., O'Connell, L., Shelton, D. L., Parada, L. F., & Presta, L. G. (1995). 
An immunoglobulin-like domain determines the specificity of neurotrophin 
receptors. EMBO J, 14(12), 2795-2805.  
Uttarkar, S., Dukare, S., Bopp, B., Goblirsch, M., Jose, J., & Klempnauer, K. H. (2015). 
Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb 
by Blocking the Interaction with the KIX Domain of the Coactivator p300. Mol 
Cancer Ther, 14(6), 1276-1285. doi:10.1158/1535-7163.mct-14-0662 
Uttarkar, S., Frampton, J., & Klempnauer, K. H. (2017). Targeting the transcription 
factor Myb by small-molecule inhibitors. Exp Hematol, 47, 31-35. 
doi:10.1016/j.exphem.2016.12.003 
Uttarkar, S., Piontek, T., Dukare, S., Schomburg, C., Schlenke, P., Berdel, W. E., Muller-
Tidow, C., Schmidt, T. J., & Klempnauer, K. H. (2016). Small-Molecule Disruption 
of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. Mol 
Cancer Ther, 15(12), 2905-2915. doi:10.1158/1535-7163.mct-16-0185 
Vaillant, A. R., Mazzoni, I., Tudan, C., Boudreau, M., Kaplan, D. R., & Miller, F. D. (1999). 
Depolarization and neurotrophins converge on the phosphatidylinositol 3-
kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol, 
146(5), 955-966.  
Valdez, G., Akmentin, W., Philippidou, P., Kuruvilla, R., Ginty, D. D., & Halegoua, S. 
(2005). Pincher-mediated macroendocytosis underlies retrograde signaling by 
neurotrophin receptors. J Neurosci, 25(21), 5236-5247. 
doi:10.1523/jneurosci.5104-04.2005 
Valdez, G., Philippidou, P., Rosenbaum, J., Akmentin, W., Shao, Y., & Halegoua, S. 
(2007). Trk-signaling endosomes are generated by Rac-dependent 
macroendocytosis. Proc Natl Acad Sci U S A, 104(30), 12270-12275. 
doi:10.1073/pnas.0702819104 
Valenta, T., Hausmann, G., & Basler, K. (2012). The many faces and functions of beta-
catenin. EMBO J, 31(12), 2714-2736. doi:10.1038/emboj.2012.150 
Valenzuela, D. M., Maisonpierre, P. C., Glass, D. J., Rojas, E., Nunez, L., Kong, Y., Gies, 
D. R., Stitt, T. N., Ip, N. Y., & Yancopoulos, G. D. (1993). Alternative forms of rat 
TrkC with different functional capabilities. Neuron, 10(5), 963-974.  
Valley, M., Zimprich, C. A., & Lazar, D. F. (2014, May 2014). CellTiter-Glo® 3D: A 
Sensitive, Accurate Viability Assay for 3D Cell Cultures.   Retrieved from 
http://www.promega.co.uk/resources/pubhub/a-cell-viability-assay-for-3d-
cultures/  
van Andel, H., Kocemba, K. A., de Haan-Kramer, A., Mellink, C. H., Piwowar, M., Broijl, 
A., van Duin, M., Sonneveld, P., Maurice, M. M., Kersten, M. J., Spaargaren, M., 
& Pals, S. T. (2017). Loss of CYLD expression unleashes Wnt signaling in multiple 
  295 
myeloma and is associated with aggressive disease. Oncogene, 36(15), 2105-
2115. doi:10.1038/onc.2016.368 
van Balkom, I. D., & Hennekam, R. C. (1994). Dermal eccrine cylindromatosis. J Med 
Genet, 31(4), 321-324.  
van der Putte, S. C. (1995). The pathogenesis of familial multiple cylindromas, 
trichoepitheliomas, milia, and spiradenomas. Am J Dermatopathol, 17(3), 271-
280.  
van Dijk, M., Goransson, S. A., & Stromblad, S. (2013). Cell to extracellular matrix 
interactions and their reciprocal nature in cancer. Exp Cell Res, 319(11), 1663-
1670. doi:10.1016/j.yexcr.2013.02.006 
Vanecek, T., Halbhuber, Z., Kacerovska, D., Martinek, P., Sedivcova, M., Carr, R. A., 
Slouka, D., Michal, M., & Kazakov, D. V. (2014). Large germline deletions of the 
CYLD gene in patients with Brooke-Spiegler syndrome and multiple familial 
trichoepithelioma. Am J Dermatopathol, 36(11), 868-874. 
doi:10.1097/dad.0000000000000068 
Vanhecke, E., Adriaenssens, E., Verbeke, S., Meignan, S., Germain, E., Berteaux, N., 
Nurcombe, V., Le Bourhis, X., & Hondermarck, H. (2011). Brain-derived 
neurotrophic factor and neurotrophin-4/5 are expressed in breast cancer and 
can be targeted to inhibit tumor cell survival. Clin Cancer Res, 17(7), 1741-1752. 
doi:10.1158/1078-0432.ccr-10-1890 
Vega, J. A., Garcia-Suarez, O., Hannestad, J., Perez-Perez, M., & Germana, A. (2003). 
Neurotrophins and the immune system. J Anat, 203(1), 1-19.  
Verhoeft, K. R., Ngan, H. L., & Lui, V. W. Y. (2016). The cylindromatosis (CYLD) gene and 
head and neck tumorigenesis. Cancers of the Head & Neck, 1(1), 10. 
doi:10.1186/s41199-016-0012-y 
Vernon, H. J., Olsen, E. A., & Vollmer, R. T. (1988). Autosomal dominant multiple 
cylindromas associated with solitary lung cylindroma. J Am Acad Dermatol, 
19(2 Pt 2), 397-400.  
Vesela, B., Svandova, E., Smarda, J., & Matalova, E. (2014). Mybs in mouse hair follicle 
development. Tissue Cell, 46(5), 352-355. doi:10.1016/j.tice.2014.06.006 
Vicario, A., Kisiswa, L., Tann, J. Y., Kelly, C. E., & Ibanez, C. F. (2015). Neuron-type-
specific signaling by the p75NTR death receptor is regulated by differential 
proteolytic cleavage. J Cell Sci, 128(8), 1507-1517. doi:10.1242/jcs.161745 
Vijg, J., & Dolle, M. E. (2002). Large genome rearrangements as a primary cause of 
aging. Mech Ageing Dev, 123(8), 907-915.  
Vijg, J., & Suh, Y. (2013). Genome instability and aging. Annu Rev Physiol, 75, 645-668. 
doi:10.1146/annurev-physiol-030212-183715 
Vilar, M., Charalampopoulos, I., Kenchappa, R. S., Simi, A., Karaca, E., Reversi, A., Choi, 
S., Bothwell, M., Mingarro, I., Friedman, W. J., Schiavo, G., Bastiaens, P. I., 
Verveer, P. J., Carter, B. D., & Ibanez, C. F. (2009). Activation of the p75 
neurotrophin receptor through conformational rearrangement of disulphide-
linked receptor dimers. Neuron, 62(1), 72-83. 
doi:10.1016/j.neuron.2009.02.020 
Virtanen, C., Ishikawa, Y., Honjoh, D., Kimura, M., Shimane, M., Miyoshi, T., Nomura, 
H., & Jones, M. H. (2002). Integrated classification of lung tumors and cell lines 
by expression profiling. Proc Natl Acad Sci U S A, 99(19), 12357-12362. 
doi:10.1073/pnas.192240599 
Vollmers, A., Wallace, L., Fullard, N., Hoher, T., Alexander, M. D., & Reichelt, J. (2012). 
Two- and three-dimensional culture of keratinocyte stem and precursor cells 
  296 
derived from primary murine epidermal cultures. Stem Cell Rev, 8(2), 402-413. 
doi:10.1007/s12015-011-9314-y 
von Schack, D., Casademunt, E., Schweigreiter, R., Meyer, M., Bibel, M., & Dechant, G. 
(2001). Complete ablation of the neurotrophin receptor p75NTR causes defects 
both in the nervous and the vascular system. Nat Neurosci, 4(10), 977-978. 
doi:10.1038/nn730 
Wagner, N., Wagner, K. D., Theres, H., Englert, C., Schedl, A., & Scholz, H. (2005). 
Coronary vessel development requires activation of the TrkB neurotrophin 
receptor by the Wilms' tumor transcription factor Wt1. Genes Dev, 19(21), 
2631-2642. doi:10.1101/gad.346405 
Wakahara, R., Kunimoto, H., Tanino, K., Kojima, H., Inoue, A., Shintaku, H., & Nakajima, 
K. (2012). Phospho-Ser727 of STAT3 regulates STAT3 activity by enhancing 
dephosphorylation of phospho-Tyr705 largely through TC45. Genes Cells, 17(2), 
132-145. doi:10.1111/j.1365-2443.2011.01575.x 
Wallace, L., & Reichelt, J. (2013). Using 3D culture to investigate the role of mechanical 
signaling in keratinocyte stem cells. Methods Mol Biol, 989, 153-164. 
doi:10.1007/978-1-62703-330-5_13 
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., & Chen, Z. J. (2001). TAK1 is a 
ubiquitin-dependent kinase of MKK and IKK. Nature, 412(6844), 346-351. 
doi:10.1038/35085597 
Wang, L., Baiocchi, R. A., Pal, S., Mosialos, G., Caligiuri, M., & Sif, S. (2005). The BRG1- 
and hBRM-associated factor BAF57 induces apoptosis by stimulating expression 
of the cylindromatosis tumor suppressor gene. Mol Cell Biol, 25(18), 7953-
7965. doi:10.1128/mcb.25.18.7953-7965.2005 
Wang, S., Bray, P., McCaffrey, T., March, K., Hempstead, B. L., & Kraemer, R. (2000). 
p75(NTR) mediates neurotrophin-induced apoptosis of vascular smooth muscle 
cells. Am J Pathol, 157(4), 1247-1258. doi:10.1016/s0002-9440(10)64640-8 
Wang, X., Sun, L., Maffini, M. V., Soto, A., Sonnenschein, C., & Kaplan, D. L. (2010). A 
complex 3D human tissue culture system based on mammary stromal cells and 
silk scaffolds for modeling breast morphogenesis and function. Biomaterials, 
31(14), 3920-3929. doi:10.1016/j.biomaterials.2010.01.118 
Watson, F. L., Heerssen, H. M., Bhattacharyya, A., Klesse, L., Lin, M. Z., & Segal, R. A. 
(2001). Neurotrophins use the Erk5 pathway to mediate a retrograde survival 
response. Nat Neurosci, 4(10), 981-988. doi:10.1038/nn720 
Watt, F. M., Mattey, D. L., & Garrod, D. R. (1984). Calcium-induced reorganization of 
desmosomal components in cultured human keratinocytes. J Cell Biol, 99(6), 
2211-2215.  
Weber, L., Wick, G., Gebhart, W., Krieg, T., & Timpl, R. (1984). Basement membrane 
components outline the tumour islands in cylindroma. Br J Dermatol, 111(1), 
45-51.  
Weber, L. V., Al-Refae, K., Wolk, G., Bonatz, G., Altmuller, J., Becker, C., Gisselmann, G., 
& Hatt, H. (2016). Expression and functionality of TRPV1 in breast cancer cells. 
Breast Cancer (Dove Med Press), 8, 243-252. doi:10.2147/bctt.s121610 
Wei, W., Jin, J., Schlisio, S., Harper, J. W., & Kaelin, W. G., Jr. (2005). The v-Jun point 
mutation allows c-Jun to escape GSK3-dependent recognition and destruction 
by the Fbw7 ubiquitin ligase. Cancer Cell, 8(1), 25-33. 
doi:10.1016/j.ccr.2005.06.005 
  297 
Welch, J. P., Wells, R. S., & Kerr, C. B. (1968). Ancell-Spiegler cylindromas (turban 
tumours) and Brooke-Fordyce Trichoepitheliomas: evidence for a single genetic 
entity. J Med Genet, 5(1), 29-35.  
Welcker, M., & Clurman, B. E. (2008). FBW7 ubiquitin ligase: a tumour suppressor at 
the crossroads of cell division, growth and differentiation. Nat Rev Cancer, 8(2), 
83-93. doi:10.1038/nrc2290 
Wen, Z., Zhong, Z., & Darnell, J. E., Jr. (1995). Maximal activation of transcription by 
Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82(2), 
241-250.  
Weskamp, G., Schlondorff, J., Lum, L., Becherer, J. D., Kim, T. W., Saftig, P., Hartmann, 
D., Murphy, G., & Blobel, C. P. (2004). Evidence for a critical role of the tumor 
necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 
neurotrophin receptor (p75NTR). J Biol Chem, 279(6), 4241-4249. 
doi:10.1074/jbc.M307974200 
Wickstrom, S. A., Masoumi, K. C., Khochbin, S., Fassler, R., & Massoumi, R. (2010). 
CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and 
increasing the levels of acetylated tubulin. EMBO J, 29(1), 131-144. 
doi:10.1038/emboj.2009.317 
Wiedemann, F. R., Siemen, D., Mawrin, C., Horn, T. F., & Dietzmann, K. (2006). The 
neurotrophin receptor TrkB is colocalized to mitochondrial membranes. Int J 
Biochem Cell Biol, 38(4), 610-620. doi:10.1016/j.biocel.2005.10.024 
Wiese, S., Digby, M. R., Gunnersen, J. M., Gotz, R., Pei, G., Holtmann, B., Lowenthal, J., 
& Sendtner, M. (1999). The anti-apoptotic protein ITA is essential for NGF-
mediated survival of embryonic chick neurons. Nat Neurosci, 2(11), 978-983. 
doi:10.1038/14777 
Wiesmann, C., Ultsch, M. H., Bass, S. H., & de Vos, A. M. (1999). Crystal structure of 
nerve growth factor in complex with the ligand-binding domain of the TrkA 
receptor. Nature, 401(6749), 184-188. doi:10.1038/43705 
Wilczek, C., Chayka, O., Plachetka, A., & Klempnauer, K. H. (2009). Myb-induced 
chromatin remodeling at a dual enhancer/promoter element involves non-
coding rna transcription and is disrupted by oncogenic mutations of v-myb. J 
Biol Chem, 284(51), 35314-35324. doi:10.1074/jbc.M109.066175 
Williams, S. E., Beronja, S., Pasolli, H. A., & Fuchs, E. (2011). Asymmetric cell divisions 
promote Notch-dependent epidermal differentiation. Nature, 470(7334), 353-
358. doi:10.1038/nature09793 
Wilson, A., & Radtke, F. (2006). Multiple functions of Notch signaling in self-renewing 
organs and cancer. FEBS Lett, 580(12), 2860-2868. 
doi:10.1016/j.febslet.2006.03.024 
Wilson, W. R., & Hay, M. P. (2011). Targeting hypoxia in cancer therapy. Nat Rev 
Cancer, 11(6), 393-410. doi:10.1038/nrc3064 
Wong, A. L., Soo, R. A., Tan, D. S., Lee, S. C., Lim, J. S., Marban, P. C., Kong, L. R., Lee, Y. 
J., Wang, L. Z., Thuya, W. L., Soong, R., Yee, M. Q., Chin, T. M., Cordero, M. T., 
Asuncion, B. R., Pang, B., Pervaiz, S., Hirpara, J. L., Sinha, A., Xu, W. W., Yuasa, 
M., Tsunoda, T., Motoyama, M., Yamauchi, T., & Goh, B. C. (2015). Phase I and 
biomarker study of OPB-51602, a novel signal transducer and activator of 
transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. 
Ann Oncol, 26(5), 998-1005. doi:10.1093/annonc/mdv026 
  298 
Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J. Q., Sethi, G., & Goh, B. C. (2017). Do 
STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin 
Investig Drugs, 26(8), 883-887. doi:10.1080/13543784.2017.1351941 
Wong, J., & Garner, B. (2012). Evidence that truncated TrkB isoform, TrkB-Shc can 
regulate phosphorylated TrkB protein levels. Biochem Biophys Res Commun, 
420(2), 331-335. doi:10.1016/j.bbrc.2012.02.159 
Woo, C. H., Sopchak, L., & Lipsick, J. S. (1998). Overexpression of an alternatively 
spliced form of c-Myb results in increases in transactivation and transforms 
avian myelomonoblasts. J Virol, 72(8), 6813-6821.  
Wooten, M. W., Seibenhener, M. L., Mamidipudi, V., Diaz-Meco, M. T., Barker, P. A., & 
Moscat, J. (2001). The atypical protein kinase C-interacting protein p62 is a 
scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem, 276(11), 
7709-7712. doi:10.1074/jbc.C000869200 
Wright, A., Reiley, W. W., Chang, M., Jin, W., Lee, A. J., Zhang, M., & Sun, S. C. (2007). 
Regulation of early wave of germ cell apoptosis and spermatogenesis by 
deubiquitinating enzyme CYLD. Dev Cell, 13(5), 705-716. 
doi:10.1016/j.devcel.2007.09.007 
Xia, Z. P., Sun, L., Chen, X., Pineda, G., Jiang, X., Adhikari, A., Zeng, W., & Chen, Z. J. 
(2009). Direct activation of protein kinases by unanchored polyubiquitin chains. 
Nature, 461(7260), 114-119. doi:10.1038/nature08247 
Xie, S., Chen, M., Gao, S., Zhong, T., Zhou, P., Li, D., Zhou, J., Gao, J., & Liu, M. (2017). 
The B-box module of CYLD is responsible for its intermolecular interaction and 
cytoplasmic localization. Oncotarget, 8(31), 50889-50895. 
doi:10.18632/oncotarget.15142 
Yaar, M., Eller, M. S., DiBenedetto, P., Reenstra, W. R., Zhai, S., McQuaid, T., 
Archambault, M., & Gilchrest, B. A. (1994). The trk family of receptors mediates 
nerve growth factor and neurotrophin-3 effects in melanocytes. J Clin Invest, 
94(4), 1550-1562. doi:10.1172/jci117496 
Yacoubian, T. A., & Lo, D. C. (2000). Truncated and full-length TrkB receptors regulate 
distinct modes of dendritic growth. Nat Neurosci, 3(4), 342-349. 
doi:10.1038/73911 
Yamada, M., Ohnishi, H., Sano, S., Nakatani, A., Ikeuchi, T., & Hatanaka, H. (1997). 
Insulin receptor substrate (IRS)-1 and IRS-2 are tyrosine-phosphorylated and 
associated with phosphatidylinositol 3-kinase in response to brain-derived 
neurotrophic factor in cultured cerebral cortical neurons. J Biol Chem, 272(48), 
30334-30339.  
Yamashita, T., & Tohyama, M. (2003). The p75 receptor acts as a displacement factor 
that releases Rho from Rho-GDI. Nat Neurosci, 6(5), 461-467. 
doi:10.1038/nn1045 
Yamashita, T., Tucker, K. L., & Barde, Y. A. (1999). Neurotrophin binding to the p75 
receptor modulates Rho activity and axonal outgrowth. Neuron, 24(3), 585-593.  
Yang, Y., Liu, M., Li, D., Ran, J., Gao, J., Suo, S., Sun, S. C., & Zhou, J. (2014). CYLD 
regulates spindle orientation by stabilizing astral microtubules and promoting 
dishevelled-NuMA-dynein/dynactin complex formation. Proc Natl Acad Sci U S 
A, 111(6), 2158-2163. doi:10.1073/pnas.1319341111 
Yang, Y., Ran, J., Liu, M., Li, D., Li, Y., Shi, X., Meng, D., Pan, J., Ou, G., Aneja, R., Sun, S. 
C., & Zhou, J. (2014). CYLD mediates ciliogenesis in multiple organs by 
deubiquitinating Cep70 and inactivating HDAC6. Cell Res, 24(11), 1342-1353. 
doi:10.1038/cr.2014.136 
  299 
Yang, Y., & Zhou, J. (2016). CYLD - a deubiquitylase that acts to fine-tune microtubule 
properties and functions. J Cell Sci, 129(12), 2289-2295. doi:10.1242/jcs.183319 
Yano, H., Cong, F., Birge, R. B., Goff, S. P., & Chao, M. V. (2000). Association of the Abl 
tyrosine kinase with the Trk nerve growth factor receptor. J Neurosci Res, 59(3), 
356-364.  
Yau, R., & Rape, M. (2016). The increasing complexity of the ubiquitin code. Nat Cell 
Biol, 18(6), 579-586. doi:10.1038/ncb3358 
Yeiser, E. C., Rutkoski, N. J., Naito, A., Inoue, J., & Carter, B. D. (2004). Neurotrophin 
signaling through the p75 receptor is deficient in traf6-/- mice. J Neurosci, 
24(46), 10521-10529. doi:10.1523/jneurosci.1390-04.2004 
Yin, B., Ma, Z. Y., Zhou, Z. W., Gao, W. C., Du, Z. G., Zhao, Z. H., & Li, Q. Q. (2015). The 
TrkB+ cancer stem cells contribute to post-chemotherapy recurrence of triple-
negative breast cancers in an orthotopic mouse model. Oncogene, 34(6), 761-
770. doi:10.1038/onc.2014.8 
Yokouchi, M., Kondo, T., Houghton, A., Bartkiewicz, M., Horne, W. C., Zhang, H., 
Yoshimura, A., & Baron, R. (1999). Ligand-induced ubiquitination of the 
epidermal growth factor receptor involves the interaction of the c-Cbl RING 
finger and UbcH7. J Biol Chem, 274(44), 31707-31712.  
Yoon, S. O., Casaccia-Bonnefil, P., Carter, B., & Chao, M. V. (1998). Competitive 
signaling between TrkA and p75 nerve growth factor receptors determines cell 
survival. J Neurosci, 18(9), 3273-3281.  
York, R. D., Molliver, D. C., Grewal, S. S., Stenberg, P. E., McCleskey, E. W., & Stork, P. J. 
(2000). Role of phosphoinositide 3-kinase and endocytosis in nerve growth 
factor-induced extracellular signal-regulated kinase activation via Ras and Rap1. 
Mol Cell Biol, 20(21), 8069-8083.  
Yoshida, H., Jono, H., Kai, H., & Li, J. D. (2005). The tumor suppressor cylindromatosis 
(CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative 
cross-talk with TRAF6 AND TRAF7. J Biol Chem, 280(49), 41111-41121. 
doi:10.1074/jbc.M509526200 
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014). Revisiting STAT3 signalling 
in cancer: new and unexpected biological functions. Nat Rev Cancer, 14(11), 
736-746. doi:10.1038/nrc3818 
Yu, T., Calvo, L., Anta, B., Lopez-Benito, S., Lopez-Bellido, R., Vicente-Garcia, C., 
Tessarollo, L., Rodriguez, R. E., & Arevalo, J. C. (2014). In vivo regulation of NGF-
mediated functions by Nedd4-2 ubiquitination of TrkA. J Neurosci, 34(17), 
6098-6106. doi:10.1523/jneurosci.4271-13.2014 
Yu, T., Calvo, L., Anta, B., Lopez-Benito, S., Southon, E., Chao, M. V., Tessarollo, L., & 
Arevalo, J. C. (2011). Regulation of trafficking of activated TrkA is critical for 
NGF-mediated functions. Traffic, 12(4), 521-534. doi:10.1111/j.1600-
0854.2010.01156.x 
Yuan, X. B., Jin, M., Xu, X., Song, Y. Q., Wu, C. P., Poo, M. M., & Duan, S. (2003). 
Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell 
Biol, 5(1), 38-45. doi:10.1038/ncb895 
Zamansky, G. B., Nguyen, U., & Chou, I. N. (1991). An immunofluorescence study of the 
calcium-induced coordinated reorganization of microfilaments, keratin 
intermediate filaments, and microtubules in cultured human epidermal 
keratinocytes. J Invest Dermatol, 97(6), 985-994.  
Zanoni, M., Piccinini, F., Arienti, C., Zamagni, A., Santi, S., Polico, R., Bevilacqua, A., & 
Tesei, A. (2016). 3D tumor spheroid models for in vitro therapeutic screening: a 
  300 
systematic approach to enhance the biological relevance of data obtained. Sci 
Rep, 6, 19103. doi:10.1038/srep19103 
Zegers, M. M., O'Brien, L. E., Yu, W., Datta, A., & Mostov, K. E. (2003). Epithelial 
polarity and tubulogenesis in vitro. Trends Cell Biol, 13(4), 169-176.  
Zhan, T., Rindtorff, N., & Boutros, M. (2017). Wnt signaling in cancer. Oncogene, 
36(11), 1461-1473. doi:10.1038/onc.2016.304 
Zhang, J., Stirling, B., Temmerman, S. T., Ma, C. A., Fuss, I. J., Derry, J. M., & Jain, A. 
(2006). Impaired regulation of NF-kappaB and increased susceptibility to colitis-
associated tumorigenesis in CYLD-deficient mice. J Clin Invest, 116(11), 3042-
3049. doi:10.1172/jci28746 
Zhang, M., Wu, X., Lee, A. J., Jin, W., Chang, M., Wright, A., Imaizumi, T., & Sun, S. C. 
(2008). Regulation of IkappaB kinase-related kinases and antiviral responses by 
tumor suppressor CYLD. J Biol Chem, 283(27), 18621-18626. 
doi:10.1074/jbc.M801451200 
Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017). 30 Years of NF-kappaB: A Blossoming 
of Relevance to Human Pathobiology. Cell, 168(1-2), 37-57. 
doi:10.1016/j.cell.2016.12.012 
Zhang, X. J., Liang, Y. H., He, P. P., Yang, S., Wang, H. Y., Chen, J. J., Yuan, W. T., Xu, S. J., 
Cui, Y., & Huang, W. (2004). Identification of the cylindromatosis tumor-
suppressor gene responsible for multiple familial trichoepithelioma. J Invest 
Dermatol, 122(3), 658-664. doi:10.1111/j.0022-202X.2004.22321.x 
Zhang, Y., Moheban, D. B., Conway, B. R., Bhattacharyya, A., & Segal, R. A. (2000). Cell 
surface Trk receptors mediate NGF-induced survival while internalized 
receptors regulate NGF-induced differentiation. J Neurosci, 20(15), 5671-5678.  
Zhao, H., Kalota, A., Jin, S., & Gewirtz, A. M. (2009). The c-myb proto-oncogene and 
microRNA-15a comprise an active autoregulatory feedback loop in human 
hematopoietic cells. Blood, 113(3), 505-516. doi:10.1182/blood-2008-01-
136218 
Zhao, L., Glazov, E. A., Pattabiraman, D. R., Al-Owaidi, F., Zhang, P., Brown, M. A., Leo, 
P. J., & Gonda, T. J. (2011). Integrated genome-wide chromatin occupancy and 
expression analyses identify key myeloid pro-differentiation transcription 
factors repressed by Myb. Nucleic Acids Res, 39(11), 4664-4679. 
doi:10.1093/nar/gkr024 
Zhong, Z., Wen, Z., & Darnell, J. E., Jr. (1994). Stat3: a STAT family member activated by 
tyrosine phosphorylation in response to epidermal growth factor and 
interleukin-6. Science, 264(5155), 95-98.  
Zhou, Y., & Ness, S. A. (2011). Myb proteins: angels and demons in normal and 
transformed cells. Front Biosci (Landmark Ed), 16, 1109-1131.  
Zuo, Y. G., Xu, Y., Wang, B., Liu, Y. H., Qu, T., Fang, K., & Ho, M. G. (2007). A novel 
mutation of CYLD in a Chinese family with multiple familial trichoepithelioma 
and no CYLD protein expression in the tumour tissue. Br J Dermatol, 157(4), 
818-821. doi:10.1111/j.1365-2133.2007.08081.x 
 
